3.4.21.35 Acidosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8662295&form=6&db=m Effect of metabolic alkalosis and metabolic acidosis on urinary kallikrein excretion of anaesthetized rats: evidence for a role of blood pH as regulator of renal kallikrein secretion. causal interaction,ongoing research,unassigned 4,3,0 3.4.21.35 Acquired Immunodeficiency Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11359541&form=6&db=m The potential contribution of decision aids to screening programmes. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,3,0 3.4.21.35 Acquired Immunodeficiency Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16195861&form=6&db=m [Significance of the PSA-concentration for the detection of prostate cancer] causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24595937&form=6&db=m Is there a relationship between acute coronary syndrome and prostate specific antigen level? causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24595938&form=6&db=m Editorial Comment on: Is There a Relationship Between Acute Coronary Syndrome and Prostate Specific Antigen Level? unassigned - 3.4.21.35 Acute Kidney Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1563979&form=6&db=m Evidence for intrarenal kallikrein storage during chromate-induced acute renal failure in rat. causal interaction,unassigned 1,0 3.4.21.35 Acute Kidney Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21679467&form=6&db=m Renal kallikrein excretion and epigenetics in human acute kidney injury: Expression, mechanisms and consequences. causal interaction,ongoing research,unassigned 4,4,0 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1279216&form=6&db=m Recurrent prostate cancer despite undetectable prostate specific antigen. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,3,0 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1279220&form=6&db=m Re: Biopsy after external beam radiation therapy for adenocarcinoma of the prostate: correlation with original histological grade and current prostate specific antigen levels. diagnostic usage,therapeutic application,unassigned 2,4,0 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1370328&form=6&db=m Re: Prostate specific antigen values after radical retropubic prostatectomy for adenocarcinoma of the prostate: impact of adjuvant treatment (hormonal and radiation) causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,4,0 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1371568&form=6&db=m The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,4 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1695690&form=6&db=m Nuclear deoxyribonucleic acid ploidy and serum prostate specific antigen in operable prostatic adenocarcinoma. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1699237&form=6&db=m The relation of prostatic acid phosphatase and prostate specific antigen with tumour grade in prostatic adenocarcinoma: an immunohistochemical study. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,3,1 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1700144&form=6&db=m Prostate specific antigen after irradiation for prostatic carcinoma. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,1,2 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1700159&form=6&db=m Re: Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,4,0 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1703241&form=6&db=m Prostate specific antigen values after radical retropubic prostatectomy for adenocarcinoma of the prostate: impact of adjuvant treatment (hormonal and radiation) causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,1,4 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1707989&form=6&db=m Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,2,0 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1716696&form=6&db=m Prostate specific antigen in the management of patients with localized adenocarcinoma of the prostate treated with primary radiation therapy. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,3,4 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1719244&form=6&db=m Biopsy after external beam radiation therapy for adenocarcinoma of the prostate: correlation with original histological grade and current prostate specific antigen levels. diagnostic usage,therapeutic application,unassigned 2,4,0 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2201434&form=6&db=m Carcinosarcoma of the prostate in combination with adenocarcinoma of the prostate and adenocarcinoma of the seminal vesicles. A case report with immunocytochemical analysis and review of the literature. diagnostic usage,unassigned 2,0 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2434667&form=6&db=m Prospective comparison between serum monoclonal prostate specific antigen and acid phosphatase measurements in metastatic prostatic cancer. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,4,0 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2462648&form=6&db=m [An immunohistological study of metastatic adenocarcinoma of the lymph node: is it useful in diagnosing a primary tumor?] diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2468794&form=6&db=m Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. I. Untreated patients. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,4 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2468795&form=6&db=m Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,4,0 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2468796&form=6&db=m Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. III. Radiation treated patients. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,3,4 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2468797&form=6&db=m Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. IV. Anti-androgen treated patients. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,1,4 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2470927&form=6&db=m The role of prostate specific antigen as a tumor marker in men with advanced adenocarcinoma of the prostate. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,1 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2536589&form=6&db=m Paget's disease primarily involving the scrotum. causal interaction,diagnostic usage,unassigned 3,2,0 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2683969&form=6&db=m New cancer markers. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3946039&form=6&db=m Invasive carcinoma of prostate presenting as rectal carcinoma. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,3,1 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6195357&form=6&db=m Unusual metastatic patterns of prostate adenocarcinoma. causal interaction,diagnostic usage,ongoing research,unassigned 1,2,2,0 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7507278&form=6&db=m Prostate specific antigen and prostate specific acid phosphatase in adenocarcinoma of Skene's paraurethral glands and ducts. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,1,2 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7507783&form=6&db=m Utilization of polyclonal serum prostate specific antigen levels in screening for prostate cancer: a comparison with corresponding monoclonal values. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,3,1 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7508259&form=6&db=m The impact of prostatic manipulation upon serum PSA in patients with adenocarcinoma of the prostate. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7508522&form=6&db=m Radical radiation therapy in the management of prostatic adenocarcinoma: the initial prostate specific antigen value as a predictor of treatment outcome. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,2,3,4 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7523725&form=6&db=m Prostate specific antigen as an outcome variable for T1 and T2 prostate cancer treated by radiation therapy. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,4,0 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7523726&form=6&db=m Radical prostatectomy and radical radiation therapy for clinical stages T1 to 2 adenocarcinoma of the prostate: new insights into outcome from repeat biopsy and prostate specific antigen followup. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,4,0 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7531589&form=6&db=m DNA ploidy, serum prostate specific antigen, histological grade and immunohistochemistry as predictive parameters of lymph node metastases in T1-T3/M0 prostatic adenocarcinoma. causal interaction,diagnostic usage,ongoing research,unassigned 3,4,4,0 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7531783&form=6&db=m Variable histology of anastomotic biopsies with detectable prostate specific antigen after radical prostatectomy. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,1,0 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7536268&form=6&db=m Patterns of positive specimen margins and detectable prostate specific antigen after radical perineal prostatectomy. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,2,0 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7645457&form=6&db=m [A case of clear cell adenocarcinoma of the female urethra] diagnostic usage,ongoing research,unassigned 1,3,0 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8138434&form=6&db=m The prognostic significance of DNA ploidy in clinically localized prostate cancer treated with radiation therapy. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8619388&form=6&db=m [Relationship between pretreatment serum levels of prostate specific antigen and bone metastasis in prostate cancer] diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8625205&form=6&db=m Carcinosarcoma of the prostate. Report of 21 cases. diagnostic usage,unassigned 3,0 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8739470&form=6&db=m Immunohistochemical labelling for prostate specific antigen in non-prostatic tissues. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8879683&form=6&db=m Prostate specific antigen in breast cancer, benign breast disease and normal breast tissue. causal interaction,diagnostic usage,ongoing research,unassigned 3,4,4,0 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8951478&form=6&db=m [The role of prostate specific antigen in diagnosis of localized adenocarcinoma of the prostate. Nara Uro-Oncology Research Group] causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,1,0 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9091086&form=6&db=m [Preliminary data on our laparoscopy experience in urinary pathology] causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9187691&form=6&db=m Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,4,0 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9276358&form=6&db=m Rate of PSA rise predicts metastatic versus local recurrence after definitive radiotherapy. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,3,0 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9302135&form=6&db=m Outcome based staging for clinically localized adenocarcinoma of the prostate. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9302143&form=6&db=m Long-term results of radical retropubic prostatectomy in men with high grade carcinoma of the prostate. causal interaction,diagnostic usage,therapeutic application,unassigned 1,2,4,0 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9382999&form=6&db=m The use of RT-"nested" PCR of prostate specific antigen to detect hematogenous neoplastic cells in patients with prostate adenocarcinoma. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9583887&form=6&db=m Cell proliferation rate by MIB-1 immunohistochemistry predicts postradiation recurrence in prostatic adenocarcinomas. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9708940&form=6&db=m The greatest dimension of prostate carcinoma is a simple, inexpensive predictor of prostate specific antigen failure in radical prostatectomy specimens. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,3,2 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9796260&form=6&db=m [A case of prostatic ductal adenocarcinoma with endometrioid features, associated with rectal invasion and multiple liver metastases] diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10091767&form=6&db=m Prognostic value of plasma prostate specific antigen after megestrol acetate treatment in patients with metastatic breast carcinoma. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,2,1 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10188912&form=6&db=m The promoter and the enhancer region of the KLK 3 (prostate specific antigen) gene is frequently mutated in breast tumours and in breast carcinoma cell lines. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10223487&form=6&db=m Human glandular kallikrein 2 expression in prostate adenocarcinoma and lymph node metastases. diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10470664&form=6&db=m Serum prostate specific antigen levels are not elevated in most of the patients with advanced pancreatic adenocarcinoma. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10851332&form=6&db=m Neoadjuvant Hormonal Therapy in Stage C Adenocarcinoma of the Prostate and Incidence of Biochemical Recurrence. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,2,0 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11060270&form=6&db=m [Bone scintigraphy findings in patients with recently diagnosed adenocarcinoma of the prostate: relationship with prostate specific antigen levels] causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11395558&form=6&db=m A clinicopathologic analysis of urothelial carcinomas diagnosed on prostate needle biopsy. diagnostic usage,unassigned 2,0 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11586207&form=6&db=m Interstitial microwave thermal therapy for prostate cancer: method of treatment and results of a phase I/II trial. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,3,1 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11696440&form=6&db=m A synthetic tissue kallikrein inhibitor suppresses cancer cell invasiveness. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,4 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11720279&form=6&db=m The role of molecular forms of prostate-specific antigen (PSA or hK3) and of human glandular kallikrein 2 (hK2) in the diagnosis and monitoring of prostate cancer and in extra-prostatic disease. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,3,0 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12010595&form=6&db=m Incorrect biochemistry complicates prostate cancer management. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,2,0 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12549643&form=6&db=m Malignant anterior urethral strictures: a rare complication of transurethral resection of malignant prostate. diagnostic usage,therapeutic application,unassigned 2,2,0 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12657938&form=6&db=m MUC6 is a marker of seminal vesicle-ejaculatory duct epithelium and is useful for the differential diagnosis with prostate adenocarcinoma. causal interaction,unassigned 3,0 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12822458&form=6&db=m [Signet ring cell carcinoma of the prostate successfully treated with endocrine therapy: a case report] unassigned - 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12853777&form=6&db=m Correlation of minute (0.5 MM or less) focus of prostate adenocarcinoma on needle biopsy with radical prostatectomy specimen: role of prostate specific antigen density. causal interaction,ongoing research,therapeutic application,unassigned 2,1,1,0 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14765279&form=6&db=m Periprostatic subendothelial intravascular granulomatosis: a mimic of high-grade intravascular prostatic adenocarcinoma. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14968443&form=6&db=m Clinical understaging in patients with prostate adenocarcinoma submitted to radical prostatectomy: predictive value of serum chromogranin A. diagnostic usage,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15008717&form=6&db=m Characterizing prostatic adenocarcinomas in men with a serum prostate specific antigen level of < 4.0 ng/mL. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,1,0 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15032014&form=6&db=m [A case of brain metastasis associated with prostate cancer] causal interaction,unassigned 2,0 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15032020&form=6&db=m [A case of prostate cancer with invasion to the middle ureter] causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,1,0 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15105655&form=6&db=m Prostate carcinoma with squamous differentiation: an analysis of 33 cases. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15371830&form=6&db=m DNA image cytometry on biopsies can help the detection of localized Gleason 3+3 prostate cancers. diagnostic usage,ongoing research,unassigned 4,1,0 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15379952&form=6&db=m Prostatic ductal adenocarcinoma showing Bcl-2 expression. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,1 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15661069&form=6&db=m Female para-urethral adenocarcinoma: histological and immunohistochemical study. diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15707507&form=6&db=m Predictive value of PSA velocity over early clinical and pathological parameters in patients with localized prostate cancer who undergo radical retropubic prostatectomy. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,1,1 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15839912&form=6&db=m Early outcomes of active surveillance for localized prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,4,0 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15885949&form=6&db=m Collet-Sicard syndrome: a rare presentation of metastatic prostate adenocarcinoma. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16093983&form=6&db=m Preoperative prediction of small volume cancer (less than 0.5 ml) in radical prostatectomy specimens. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16646647&form=6&db=m Laparoscopic repair of external iliac-artery transection during laparoscopic radical prostatectomy. ongoing research,unassigned 2,0 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16929604&form=6&db=m Single small focus of prostate adenocarcinoma (< or = 1 mm and too small for grading) and clinical significant disease after radical prostatectomy. diagnostic usage,ongoing research,therapeutic application,unassigned 4,1,1,0 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17085105&form=6&db=m The discovery of prostate specific antigen as a biomarker for the early detection of adenocarcinoma of the prostate. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,4,0 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17201946&form=6&db=m Urothelial-type adenocarcinoma of the prostate mimicking metastatic colorectal adenocarcinoma. diagnostic usage,therapeutic application,unassigned 4,2,0 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17450256&form=6&db=m [Serum testosterone, dihydrotestosterone, luteinizing hormone and follicle-stimulating hormone versus prostate specific antigen in patients with localized prostate adenocarcinoma who underwent radical prostatectomy. Radioimmunoassays measurements] causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,2,0 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17561475&form=6&db=m Metastatic prostatic adenocarcinoma in an inguinal hernia sac in a patient with undetectable serum prostate specific antigen level. causal interaction,diagnostic usage,unassigned 3,1,0 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17642557&form=6&db=m Bullous pemphigoid associated with prostate adenocarcinoma. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,3,1 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17721186&form=6&db=m Primary mucin-producing urothelial-type adenocarcinoma of prostate: report of 15 cases. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,2,0 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17846704&form=6&db=m Weekly docetaxel, zoledronic acid and estramustine in hormone-refractory prostate cancer (HRPC). causal interaction,diagnostic usage,therapeutic application,unassigned 2,2,4,0 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17933147&form=6&db=m [Small cell carcinoma of the prostate: a case report] diagnostic usage,therapeutic application,unassigned 1,4,0 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17963516&form=6&db=m Diagnostic utility of p501s (prostein) in comparison to prostate specific antigen (PSA) for the detection of metastatic prostatic adenocarcinoma. causal interaction,diagnostic usage,unassigned 3,3,0 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18670149&form=6&db=m Eosinophilic pneumonia and thoracic metastases as an initial manifestation of prostatic carcinoma. causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18694507&form=6&db=m Anejaculation as an atypical presentation of prostate cancer: a case report. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19014682&form=6&db=m Metastatic prostate adenocarcinoma presenting with pulmonary symptoms: a case report and review of the literature. causal interaction,therapeutic application,unassigned 1,2,0 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19230915&form=6&db=m Phase II trial of neoadjuvant nab-paclitaxel in high risk patients with prostate cancer undergoing radical prostatectomy. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,3,3 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19524976&form=6&db=m Multifocal high grade prostatic intraepithelial neoplasia is a significant risk factor for prostatic adenocarcinoma. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20003674&form=6&db=m Rectal Hem-o-Lok clip migration after robot-assisted laparoscopic radical prostatectomy. diagnostic usage,ongoing research,therapeutic application,unassigned 2,2,1,0 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20438403&form=6&db=m Is high grade prostatic intraepithelial neoplasia still a risk factor for adenocarcinoma in the era of extended biopsy sampling? causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20473923&form=6&db=m KLK15 is a prognostic marker for progression-free survival in patients with radical prostatectomy. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,4 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20800512&form=6&db=m Dutasteride monotherapy in men with serologic relapse following radical therapy for adenocarcinoma of the prostate: A pilot study. diagnostic usage,ongoing research,therapeutic application,unassigned 4,4,2,0 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20952027&form=6&db=m Ductal Adenocarcinoma of the Prostate: Increased Mortality Risk and Decreased Serum Prostate Specific Antigen. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,3,1 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21070080&form=6&db=m Histopathologic effects of hypofractionated robotic radiation therapy on malignant and benign prostate tissue. causal interaction,diagnostic usage,therapeutic application,unassigned 1,3,2,0 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21227139&form=6&db=m A pharmacoeconomic evaluation of staging modalities for patients with newly diagnosed and occult recurrent adenocarcinoma of the prostate. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,3,0 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21227188&form=6&db=m Review article Salvage surgery for locally recurrent prostate cancer after radiation therapy. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,1,3 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22052183&form=6&db=m Metastasis of Occult Prostatic Carcinoma to the Sphenoid Sinus: Report of a Rare Case and a Review of the Literature. diagnostic usage,unassigned 1,0 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23095654&form=6&db=m [Primary adenocarcinoma of the male urethra]. diagnostic usage,unassigned 2,0 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23227385&form=6&db=m Challenges in diagnosis and treatment of a cervical spinal cord injury patient with melanoma, adenocarcinoma, and hepatic and osteolytic metastases: need to implement strategies for prevention and early detection of cancer in spinal cord injury patients. unassigned - 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23573323&form=6&db=m Mycosis fungoides in plaque stage with pronounced eosinophilic infiltration, folliculotropism, and concomitant invasive squamous cell carcinoma. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,1,0 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25017602&form=6&db=m A case with primary signet ring cell adenocarcinoma of the prostate and review of the literature. causal interaction,therapeutic application,unassigned 3,2,0 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26497864&form=6&db=m [A Case of Rapidly Progressive Metastatic Castration-Resistant Prostate Cancer : Durable Control by Early Induction of Carboplatin and Paclitaxel]. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26881627&form=6&db=m Adenocarcinoma of urinary bladder: A report of two patients. diagnostic usage,unassigned 4,0 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27073671&form=6&db=m Hydronephrosis associated with ureteral metastasis of prostate cancer: A rare case report. diagnostic usage,ongoing research,unassigned 4,1,0 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27124795&form=6&db=m MULTIMODAL IMAGING AND HISTOLOGIC CORRELATION OF ISOLATED METASTASIS OF PROSTATE ADENOCARCINOMA TO THE CHOROID. diagnostic usage,therapeutic application,unassigned 4,2,0 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27408008&form=6&db=m Immunophenotypic Characterization of Benign and Malignant Prostatic Lesions. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27503809&form=6&db=m Metastatic prostatic adenocarcinoma with neuroendocrine differentiation to meningioma. causal interaction,ongoing research,unassigned 1,1,0 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28103659&form=6&db=m [A Case of Giant Prostate Carcinoma Effectively Treated with External-Beam Radiation Therapy]. diagnostic usage,ongoing research,therapeutic application,unassigned 4,1,1,0 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28465852&form=6&db=m Prostate Cancer Presenting as Huge Mediastinal and Retroperitoneal Masses: Case Report and Review of the Literature. causal interaction,diagnostic usage,unassigned 4,2,0 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28638800&form=6&db=m Prostatic adenocarcinoma oncocytic variant: Case report and literature review. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,2,0 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29264210&form=6&db=m A phase 3, double-blind, randomized placebo-controlled efficacy and safety study of abiraterone acetate in chemotherapy-naïve patients with mCRPC in China, Malaysia, Thailand and Russia. diagnostic usage,therapeutic application,unassigned 1,1,0 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29772622&form=6&db=m [Delay in High-Grade Metastatic Prostate Cancer Progression by Dutasteride : A Case Report]. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30859516&form=6&db=m Gleason Score Correlation Between Prostate Needle Biopsy and Radical Prostatectomy Materials. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30882158&form=6&db=m Prognostic Value of Platelet Counts in Patients with Metastatic Prostate Cancer Treated with Endocrine Therapy. diagnostic usage,unassigned 2,0 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31179382&form=6&db=m Diagnosis and Conservative Management of Ureteral Orifice Injury During Robotic Prostatectomy for a Large Prostate with a Prominent Median Lobe. causal interaction,diagnostic usage,unassigned 2,4,0 3.4.21.35 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32316705&form=6&db=m [A Case of Neuroendcrine Carcinoma of the Prostate Diagnosed by Prostate Re-Biopsy during Hormonal Treatment and Effectively Treated by Multidisciplinary Therapy]. diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.35 Adenocarcinoma of Lung http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9815800&form=6&db=m Expression of the prostate specific antigen gene by lung tissue. diagnostic usage,unassigned 1,0 3.4.21.35 Adenocarcinoma, Clear Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7645457&form=6&db=m [A case of clear cell adenocarcinoma of the female urethra] diagnostic usage,ongoing research,unassigned 1,3,0 3.4.21.35 Adenocarcinoma, Mucinous http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1326881&form=6&db=m [Two cases of mucinous adenocarcinoma of the prostate] diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Adenocarcinoma, Mucinous http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12910933&form=6&db=m [Mucinous adenocarcinoma of the prostate: a case report and review of 32 cases on immunohistochemical study of both PSA and CEA] diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Adenocarcinoma, Papillary http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23235280&form=6&db=m [A case of ductal adenocarcinoma of prostate associated with retroperitoneal multiple cysts]. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Adenoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1500840&form=6&db=m Tissue kallikrein is associated with prolactin-secreting cells within human growth hormone-secreting adenomas. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,4,2 3.4.21.35 Adenoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2313220&form=6&db=m Characterization of a tissue kallikrein in human prolactin-secreting adenomas. diagnostic usage,ongoing research,unassigned 1,4,0 3.4.21.35 Adenoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8796264&form=6&db=m Regional distribution of tissue kallikrein in the human brain. diagnostic usage,unassigned 3,0 3.4.21.35 Adenoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9000839&form=6&db=m A comparative study of: long-term alpha-1-blocker, Doxazosin therapy versus surgery in the treatment of benign prostatic hyperplasia. causal interaction,unassigned 3,0 3.4.21.35 Adenoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11395559&form=6&db=m Nephrogenic adenoma of the prostatic urethra: a mimicker of prostate adenocarcinoma. diagnostic usage,therapeutic application,unassigned 1,1,0 3.4.21.35 Adenoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15989443&form=6&db=m Change in serum prostate specific antigen concentration after holmium laser enucleation of the prostate: a marker for completeness of adenoma resection? diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Adenoma, Villous http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14501748&form=6&db=m Villous adenoma of the urachus: a case with prostate specific antigen immunoreactivity. causal interaction,unassigned 1,0 3.4.21.35 Aggressive Periodontitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1088326&form=6&db=m [Role of salivary kallikrein in the pathogenesis of periodontosis] causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.35 Alkalosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8662295&form=6&db=m Effect of metabolic alkalosis and metabolic acidosis on urinary kallikrein excretion of anaesthetized rats: evidence for a role of blood pH as regulator of renal kallikrein secretion. causal interaction,ongoing research,unassigned 4,3,0 3.4.21.35 Alopecia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28743526&form=6&db=m Change in Prostate Specific Antigen Concentration in Men with Prostate Specific Antigen Less than 2.5 ng/ml Taking Low Dose Finasteride or Dutasteride for Male Androgenetic Alopecia. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,3,2 3.4.21.35 Alveolitis, Extrinsic Allergic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26318749&form=6&db=m Induction of proteinase 3-anti-neutrophil cytoplasmic autoantibodies by proteinase 3-homologous bacterial protease in mice. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.35 Alzheimer Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8796264&form=6&db=m Regional distribution of tissue kallikrein in the human brain. diagnostic usage,unassigned 3,0 3.4.21.35 Alzheimer Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10561592&form=6&db=m The amyloid beta-protein precursor of Alzheimer's disease is degraded extracellularly by a Kunitz protease inhibitor domain-sensitive trypsin-like serine protease in cultures of chick sympathetic neurons. causal interaction,unassigned 2,0 3.4.21.35 Alzheimer Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10997858&form=6&db=m Localization of a novel type trypsin-like serine protease, neurosin, in brain tissues of Alzheimer's disease and Parkinson's disease. causal interaction,diagnostic usage,ongoing research,unassigned 3,2,4,0 3.4.21.35 Alzheimer Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30981123&form=6&db=m Increased free prostate specific antigen serum levels in Alzheimer's disease, correlation with Cognitive Decline. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.35 Alzheimer Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32772925&form=6&db=m A top 5 list for French general practice. causal interaction,diagnostic usage,unassigned 3,1,0 3.4.21.35 Anemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12771765&form=6&db=m Laboratory evaluations of erectile dysfunction: an evidence based approach. causal interaction,diagnostic usage,therapeutic application,unassigned 1,3,1,0 3.4.21.35 Anemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31183025&form=6&db=m Leukoerythroblastosis in castration-resistant prostate cancer: A clue to diffuse bone marrow carcinomatosis. causal interaction,diagnostic usage,therapeutic application,unassigned 2,4,1,0 3.4.21.35 Anemia, Sickle Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16679937&form=6&db=m Renal kallikrein: a risk marker for nephropathy in children with sickle cell disease. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,2,3 3.4.21.35 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16054020&form=6&db=m Serine proteases and cardiac function. causal interaction,ongoing research,therapeutic application,unassigned 2,1,3,0 3.4.21.35 Aortic Aneurysm, Abdominal http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21571276&form=6&db=m A single nucleotide polymorphism in exon 3 of the kallikrein 1 gene is associated with large but not small abdominal aortic aneurysm. unassigned - 3.4.21.35 Arthritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10596840&form=6&db=m Plasma and tissue kallikrein in arthritis and inflammatory bowel disease. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,2,4 3.4.21.35 Arthritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27219496&form=6&db=m AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,4,0 3.4.21.35 Arthritis, Psoriatic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1462872&form=6&db=m Determination of tissue kallikrein and alpha 1-antitrypsin-tissue kallikrein complexes in synovial fluid of patients with rheumatoid, osteo and psoriatic arthritis. diagnostic usage,ongoing research,unassigned 2,1,0 3.4.21.35 Arthritis, Psoriatic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32802396&form=6&db=m Granulomatous prostatitis mimicking prostate cancer in a patient with psoriatic arthritis: a case report. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.35 Arthritis, Rheumatoid http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2649023&form=6&db=m A tissue kallikrein in the synovial fluid of patients with rheumatoid arthritis. causal interaction,diagnostic usage,unassigned 4,2,0 3.4.21.35 Arthritis, Rheumatoid http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2692412&form=6&db=m Presence of immunoreactive tissue kallikrein in human polymorphonuclear (PMN) leucocytes. diagnostic usage,ongoing research,unassigned 3,4,0 3.4.21.35 Arthritis, Rheumatoid http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7512421&form=6&db=m Inhibitor regulation of tissue kallikrein activity in the synovial fluid of patients with rheumatoid arthritis. causal interaction,unassigned 2,0 3.4.21.35 Arthritis, Rheumatoid http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9159533&form=6&db=m Immunocytochemical analysis of tissue kallikrein and the kinin moiety in rheumatoid synovial fluid neutrophils. diagnostic usage,ongoing research,therapeutic application,unassigned 3,1,1,0 3.4.21.35 Arthritis, Rheumatoid http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9535704&form=6&db=m Expression and characterization of human tissue kallikrein variants. therapeutic application,unassigned 4,0 3.4.21.35 Arthritis, Rheumatoid http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10596840&form=6&db=m Plasma and tissue kallikrein in arthritis and inflammatory bowel disease. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,2,4 3.4.21.35 Arthritis, Rheumatoid http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11924648&form=6&db=m Kallikreins and kininogens in saliva and plasma of patients presenting with rheumatoid arthritis. diagnostic usage,ongoing research,unassigned 3,2,0 3.4.21.35 Asthma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2557751&form=6&db=m Kinin receptors on epithelial cells and smooth muscle of the trachea. causal interaction,diagnostic usage,unassigned 1,1,0 3.4.21.35 Asthma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8300405&form=6&db=m Localization of immunoreactive tissue kallikrein in the seromucous glands of the human and guinea-pig respiratory tree. causal interaction,unassigned 4,0 3.4.21.35 Asthma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8417752&form=6&db=m Localization of immunoreactive tissue kallikrein in human trachea. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.35 Asthma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9535704&form=6&db=m Expression and characterization of human tissue kallikrein variants. therapeutic application,unassigned 4,0 3.4.21.35 Asthma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11325588&form=6&db=m Bivalent inhibition of human beta-tryptase. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.35 Asthma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14660481&form=6&db=m Leukocytic cell sources of airway tissue kallikrein. causal interaction,unassigned 4,0 3.4.21.35 Asthma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29661938&form=6&db=m Dual functionality of ?-tryptase protomers as both proteases and cofactors in the active tetramer. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.35 Asthma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33353951&form=6&db=m Bivalent antibody pliers inhibit ?-tryptase by an allosteric mechanism dependent on the IgG hinge. causal interaction,ongoing research,therapeutic application,unassigned 3,1,1,0 3.4.21.35 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15662224&form=6&db=m Induction of tissue kallikrein in human carotid atheroma does not lead to kallikrein-kinins pathway activation. diagnostic usage,ongoing research,unassigned 2,4,0 3.4.21.35 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23244723&form=6&db=m Patient selection and counseling before prostatic arterial embolization. diagnostic usage,ongoing research,unassigned 1,1,0 3.4.21.35 Autoimmune Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15545270&form=6&db=m Autoimmunity against a tissue kallikrein in IQI/Jic Mice: a model for Sjogren's syndrome. ongoing research,therapeutic application,unassigned 3,4,0 3.4.21.35 Autoimmune Pancreatitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24349818&form=6&db=m IgG4-Related Autoimmune Prostatitis: Is It an Unusual or Underdiagnosed Manifestation of IgG4-Related Disease? causal interaction,diagnostic usage,ongoing research,unassigned 2,4,1,0 3.4.21.35 Azoospermia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15317189&form=6&db=m Evaluation of three rapid detection methods for the forensic identification of seminal fluid in rape cases. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.35 Bacterial Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22314913&form=6&db=m Characterization and expression analysis of a trypsin-like serine protease from planarian Dugesia japonica. causal interaction,therapeutic application,unassigned 2,1,0 3.4.21.35 Bacteriuria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31067846&form=6&db=m [Granulomatous Prostatitis : Three Cases Report]. diagnostic usage,unassigned 4,0 3.4.21.35 Bartter Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=649033&form=6&db=m [The pathophysiological significance of increased renal kallikrein excretion in Bartter's syndrome (author's transl)] causal interaction,unassigned 2,0 3.4.21.35 Bone Resorption http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11251528&form=6&db=m The serum level of the amino-terminal propeptide of type I procollagen is a sensitive marker for prostate cancer metastasis to bone. diagnostic usage,ongoing research,therapeutic application,unassigned 3,1,1,0 3.4.21.35 Brain Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20180644&form=6&db=m Tissue kallikrein in cardiovascular, cerebrovascular and renal diseases and skin wound healing. causal interaction,ongoing research,therapeutic application,unassigned 4,2,4,0 3.4.21.35 Brain Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29510144&form=6&db=m Intra-arterial human urinary kallidinogenase alleviates brain injury in rats with permanent middle cerebral artery occlusion through PI3K/AKT/FoxO1 signaling pathway. causal interaction,ongoing research,therapeutic application,unassigned 2,4,2,0 3.4.21.35 Brain Injuries, Traumatic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31499021&form=6&db=m Determination of serum tissue kallikrein levels after traumatic brain injury. diagnostic usage,unassigned 3,0 3.4.21.35 Brain Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16368519&form=6&db=m Experimental therapy with tissue kallikrein against cerebral ischemia. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,4,0 3.4.21.35 Brain Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20179726&form=6&db=m Human urinary kallidinogenase suppresses cerebral inflammation in experimental stroke and downregulates nuclear factor-kappaB. ongoing research,therapeutic application,unassigned 4,1,0 3.4.21.35 Brain Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26677174&form=6&db=m Tissue kallikrein promotes survival and ??catenin degradation in SH?SY5Y cells under nutrient stress conditions via autophagy. therapeutic application,unassigned 1,0 3.4.21.35 Brain Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27094522&form=6&db=m Exogenous human urinary kallidinogenase increases cerebral blood flow in patients with acute ischemic stroke. causal interaction,ongoing research,therapeutic application,unassigned 3,4,4,0 3.4.21.35 Brain Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27248356&form=6&db=m Tissue kallikrein protects SH-SY5Y neuronal cells against oxygen and glucose deprivation-induced injury through bradykinin B2 receptor-dependent regulation of autophagy induction. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.35 Brain Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31866331&form=6&db=m Tissue kallikrein: A potential serum biomarker to predict delayed cerebral ischemia in aneurysmal subarachnoid hemorrhage. causal interaction,therapeutic application,unassigned 2,1,0 3.4.21.35 Brain Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12463494&form=6&db=m Brain metastasis from prostate small cell carcinoma: not to be neglected. diagnostic usage,unassigned 4,0 3.4.21.35 Breast Cyst http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8739078&form=6&db=m Prostate specific antigen--a new constituent of breast cyst fluid. causal interaction,ongoing research,therapeutic application,unassigned 3,4,1,0 3.4.21.35 Breast Cyst http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10102136&form=6&db=m Prostate specific antigen molecular forms in breast cyst fluid and serum of women with fibrocystic breast disease. diagnostic usage,ongoing research,unassigned 3,2,0 3.4.21.35 Breast Cyst http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10508124&form=6&db=m Human glandular kallikrein in breast milk, amniotic fluid, and breast cyst fluid. ongoing research,unassigned 4,0 3.4.21.35 Breast Cyst http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11128396&form=6&db=m Prostate specific antigen in the female body: its role in breast cancer prognosis. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,2,2 3.4.21.35 Breast Cyst http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19108401&form=6&db=m Prostatic acid phosphatase in breast cyst fluid. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.35 Breast Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8879683&form=6&db=m Prostate specific antigen in breast cancer, benign breast disease and normal breast tissue. causal interaction,diagnostic usage,ongoing research,unassigned 3,4,4,0 3.4.21.35 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2683969&form=6&db=m New cancer markers. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.35 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7523638&form=6&db=m Ectopic production of prostate specific antigen by a breast tumor metastatic to the ovary. causal interaction,ongoing research,therapeutic application,unassigned 3,2,2,0 3.4.21.35 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7524772&form=6&db=m Quantitative analysis of mutant p53 protein in breast tumor cytosols and study of its association with other biochemical prognostic indicators in breast cancer. causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.35 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7532467&form=6&db=m Induction of prostate specific antigen production by steroids and tamoxifen in breast cancer cell lines. ongoing research,therapeutic application,unassigned 3,1,0 3.4.21.35 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7576230&form=6&db=m Visualization of tissue kallikrein in human breast carcinoma by two-dimensional western blotting and immunohistochemistry. diagnostic usage,ongoing research,unassigned 3,4,0 3.4.21.35 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7860622&form=6&db=m Identification of immunoreactive tissue kallikrein in human ductal breast carcinomas. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,4,0 3.4.21.35 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8879683&form=6&db=m Prostate specific antigen in breast cancer, benign breast disease and normal breast tissue. causal interaction,diagnostic usage,ongoing research,unassigned 3,4,4,0 3.4.21.35 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9094193&form=6&db=m Prostate specific antigen in women with breast cancer: is it amenable to routine immunohistochemical detection? causal interaction,diagnostic usage,ongoing research,unassigned 3,3,2,0 3.4.21.35 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9205072&form=6&db=m Expression of human prostate-specific glandular kallikrein protein (hK2) in the breast cancer cell line T47-D. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,4,0 3.4.21.35 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9252683&form=6&db=m Immunocytochemical detection of prostate specific antigen expression in human breast carcinoma cells. causal interaction,diagnostic usage,ongoing research,unassigned 1,3,4,0 3.4.21.35 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9584052&form=6&db=m Correlation of prostate specific antigen immunoactivity (IR-PSA) to other prognostic factors in female breast cancer. diagnostic usage,unassigned 2,0 3.4.21.35 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9646955&form=6&db=m Prostate specific antigen production by breast tumors after induction with oral contraceptives. causal interaction,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.35 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10069662&form=6&db=m Serum IGF-binding protein-6 and prostate specific antigen in breast cancer. diagnostic usage,ongoing research,unassigned 2,2,0 3.4.21.35 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10091767&form=6&db=m Prognostic value of plasma prostate specific antigen after megestrol acetate treatment in patients with metastatic breast carcinoma. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,2,1 3.4.21.35 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10373425&form=6&db=m Purification and characterization of a complex containing matriptase and a Kunitz-type serine protease inhibitor from human milk. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,4,3 3.4.21.35 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10592443&form=6&db=m IGFs and human cancer: implications regarding the risk of growth hormone therapy. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,1,0 3.4.21.35 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10646889&form=6&db=m Expression of a prostate-associated protein, human glandular kallikrein (hK2), in breast tumours and in normal breast secretions. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,4,0 3.4.21.35 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10832596&form=6&db=m Differential steroid hormone regulation of human glandular kallikrein (hK2) and prostate-specific antigen (PSA) in breast cancer cell lines. diagnostic usage,ongoing research,unassigned 3,4,0 3.4.21.35 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10942096&form=6&db=m Breast cancer prognostic significance of a single nucleotide polymorphism in the proximal androgen response element of the prostate specific antigen gene promoter. causal interaction,diagnostic usage,ongoing research,unassigned 3,3,4,0 3.4.21.35 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10984865&form=6&db=m Unrealistic optimism and the Health Belief Model. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11128396&form=6&db=m Prostate specific antigen in the female body: its role in breast cancer prognosis. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,2,2 3.4.21.35 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11688514&form=6&db=m Immunohistochemical analysis of prostate specific antigen in breast cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,4,1 3.4.21.35 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12040976&form=6&db=m Oral testosterone replacement in Korean patients with PADAM. diagnostic usage,ongoing research,unassigned 2,2,0 3.4.21.35 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12439720&form=6&db=m The androgen-regulated gene human kallikrein 15 (KLK15) is an independent and favourable prognostic marker for breast cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,3,4 3.4.21.35 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14728598&form=6&db=m Ethical issues for cancer screening. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15226029&form=6&db=m Ethical issues for cancer screenings. Five countries--four types of cancer. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15281091&form=6&db=m Mitogenic signalling by B2 bradykinin receptor in epithelial breast cells. causal interaction,ongoing research,unassigned 3,4,0 3.4.21.35 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15623486&form=6&db=m Expression of prostate specific antigen in male breast cancer. causal interaction,diagnostic usage,ongoing research,unassigned 2,3,4,0 3.4.21.35 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16196369&form=6&db=m Effect of cathepsin D and prostate specific antigen on latent transforming growth factor-beta in breast cancer cell lines. diagnostic usage,ongoing research,unassigned 3,4,0 3.4.21.35 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16289388&form=6&db=m Urinary estrogen metabolites, prostate specific antigen, and body mass index among African-American men in South Carolina. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,1,0 3.4.21.35 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16434994&form=6&db=m Expression of human Kallikrein 14 (KLK14) in breast cancer is associated with higher tumour grades and positive nodal status. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,4,0 3.4.21.35 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16934141&form=6&db=m Prevalence of the use of cancer related self-tests by members of the public: a community survey. diagnostic usage,therapeutic application,unassigned 2,1,0 3.4.21.35 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17045982&form=6&db=m Development of an immunofluorometric assay for human kallikrein 15 (KLK15) and identification of KLK15 in tissues and biological fluids. causal interaction,diagnostic usage,ongoing research,unassigned 3,4,2,0 3.4.21.35 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18577888&form=6&db=m Influence of the kallikrein-kinin system on prostate and breast tumour angiogenesis. ongoing research,unassigned 4,0 3.4.21.35 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24086015&form=6&db=m PS3-42: Health Literacy and Cancer Prevention: It's Not What You Say It's What They Hear. diagnostic usage,ongoing research,therapeutic application,unassigned 2,2,2,0 3.4.21.35 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25324037&form=6&db=m Detecting exosomes specifically: a multiplexed device based on alternating current electrohydrodynamic induced nanoshearing. diagnostic usage,ongoing research,unassigned 1,4,0 3.4.21.35 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25503118&form=6&db=m Bioregulation of kallikrein-related peptidases 6, 10 and 11 by the kinin B? receptor in breast cancer cells. causal interaction,ongoing research,therapeutic application,unassigned 1,4,1,0 3.4.21.35 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27903863&form=6&db=m Internalization of secreted antigen-targeted antibodies by the neonatal Fc receptor for precision imaging of the androgen receptor axis. diagnostic usage,ongoing research,unassigned 2,3,0 3.4.21.35 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28511371&form=6&db=m Study of Serum Total PSA and Free PSA as an Oncological Marker in Breast Tumour. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.35 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29078054&form=6&db=m Online, Interactive Option Grid Patient Decision Aids and their Effect on User Preferences. diagnostic usage,therapeutic application,unassigned 3,3,0 3.4.21.35 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29885274&form=6&db=m Overview of tissue kallikrein and kallikrein-related peptidases in breast cancer. causal interaction,diagnostic usage,ongoing research,unassigned 1,2,1,0 3.4.21.35 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29933385&form=6&db=m Testosterone treatment and the risk of aggressive prostate cancer in men with low testosterone levels. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,3,2 3.4.21.35 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30024607&form=6&db=m Prostate specific antigen as a biomarker for breast cancer: a meta-analysis study. diagnostic usage,ongoing research,therapeutic application,unassigned 4,4,3,0 3.4.21.35 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31855293&form=6&db=m Modeling the overdetection of screen-identified cancers in population-based cancer screening with the Coxian phase-type Markov process. diagnostic usage,ongoing research,unassigned 4,1,0 3.4.21.35 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32334022&form=6&db=m Identification of six novel alternative transcripts of the human kallikrein-related peptidase 15 (KLK15), using 3'RACE and high-throughput sequencing. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.35 Breast Neoplasms, Male http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15623486&form=6&db=m Expression of prostate specific antigen in male breast cancer. causal interaction,diagnostic usage,ongoing research,unassigned 2,3,4,0 3.4.21.35 Bronchitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3849314&form=6&db=m [Method for determining kallikrein of tissue origin in blood plasma and its clinical significance] causal interaction,diagnostic usage,ongoing research,unassigned 4,4,2,0 3.4.21.35 Bronchitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32772925&form=6&db=m A top 5 list for French general practice. causal interaction,diagnostic usage,unassigned 3,1,0 3.4.21.35 Carcinoid Tumor http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2235095&form=6&db=m Grossly elevated serum prostatic acid phosphatase in a patient with carcinoid. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.35 Carcinoid Tumor http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2428458&form=6&db=m Flushing in the carcinoid syndrome and plasma kallikrein. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,4,1 3.4.21.35 Carcinoid Tumor http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3026083&form=6&db=m Prostate-specific acid phosphatase in carcinoid tumors. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,1,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1279493&form=6&db=m The efficacy of serum prostate specific antigen as a tumour marker in prostatic carcinoma: a comparison with serum acid phosphatase. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1283504&form=6&db=m [Value of PSA in the staging of prostatic cancer] diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1371021&form=6&db=m [Ultrasonography of the prostate] diagnostic usage,unassigned 2,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1371559&form=6&db=m Screening for prostatic carcinoma with prostate specific antigen. causal interaction,diagnostic usage,unassigned 4,2,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1372378&form=6&db=m Androgen effect on prostate specific antigen secretion. causal interaction,diagnostic usage,therapeutic application,unassigned 3,2,4,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1373666&form=6&db=m Identification of metastatic disease by T category, gleason score and serum PSA level in patients with carcinoma of the prostate. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1374431&form=6&db=m Use of monoclonal antibody E48 in diagnosing transitional cell carcinoma of urinary bladder. diagnostic usage,unassigned 3,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1377289&form=6&db=m False positive prostate specific antigen values in the sera of women with renal cell carcinoma. diagnostic usage,ongoing research,unassigned 3,3,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1379747&form=6&db=m Prostate specific antigen levels during and after external beam radiotherapy for localized carcinoma of the prostate: predictor of therapeutic efficacy. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,3,3 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1380992&form=6&db=m Quantitative estimation of tissue prostate specific antigen, deoxyribonucleic acid ploidy and cytological grade in fine needle aspiration biopsies for prognosis of hormonally treated prostatic carcinoma. diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1695689&form=6&db=m Deoxyribonucleic acid ploidy and the direct assay of prostatic acid phosphatase and prostate specific antigen in fine needle aspiration biopsies as diagnostic methods in prostatic carcinoma. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,3,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1695690&form=6&db=m Nuclear deoxyribonucleic acid ploidy and serum prostate specific antigen in operable prostatic adenocarcinoma. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1697651&form=6&db=m [A comparison between prostate-acid-phosphatase and prostate-specific antigen in the diagnosis of prostatic carcinoma] causal interaction,diagnostic usage,ongoing research,unassigned 4,3,4,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1697917&form=6&db=m Prostate specific antigen and local recurrence after radical prostatectomy. causal interaction,diagnostic usage,unassigned 3,2,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1698754&form=6&db=m A prospective study of prostate specific antigen levels in patients receiving radiotherapy for localized carcinoma of the prostate. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,4 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1700144&form=6&db=m Prostate specific antigen after irradiation for prostatic carcinoma. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,1,2 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1701495&form=6&db=m Screening for prostatic carcinoma. diagnostic usage,unassigned 4,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1707987&form=6&db=m Prostate specific antigen levels after definitive irradiation for carcinoma of the prostate. diagnostic usage,therapeutic application,unassigned 4,2,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1712189&form=6&db=m [Specific prostatic antigen in prostatic carcinoma: its relationship with tumor differentiation and clinical course] diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1712665&form=6&db=m A model of prostatic carcinoma tumor kinetics based on prostate specific antigen levels after radiation therapy. causal interaction,ongoing research,therapeutic application,unassigned 1,3,3,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1716697&form=6&db=m Prostate specific antigen and prostatic acid phosphatase for monitoring therapy of carcinoma of the prostate. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,4 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1718651&form=6&db=m Comparison of phosphatase isoenzymes PAP and PSA with bone scan in patients with prostate carcinoma. diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1723583&form=6&db=m Screening for carcinoma of the prostate with prostate specific antigen. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1723815&form=6&db=m Evaluation of prostate-specific antigen and prostatic acid phosphatase in untreated prostatic carcinoma and benign prostatic hyperplasia. causal interaction,diagnostic usage,ongoing research,unassigned 3,4,3,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1760884&form=6&db=m Phosphatase isoenzymes as bone metastasis markers in prostatic carcinoma. diagnostic usage,unassigned 2,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2430732&form=6&db=m Measurements of serum gamma-seminoprotein and prostate specific antigen evaluated for monitoring carcinoma of the prostate. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,3,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2434667&form=6&db=m Prospective comparison between serum monoclonal prostate specific antigen and acid phosphatase measurements in metastatic prostatic cancer. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,4,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2435927&form=6&db=m An evaluation of prostate specific antigen in prostatic cancer. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,3,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2453920&form=6&db=m Clinical application of prostatic markers. I. Classification of prostatic tumours using immunohistochemical techniques. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,3,1 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2459419&form=6&db=m Comparative experimental study of the serum prostate specific antigen and prostatic acid phosphatase in serially transplantable human prostatic carcinoma lines in nude mice. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,4,1 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2464396&form=6&db=m Comparative study of the clinical usefulness of prostate specific antigen and prostatic acid phosphatase in prostatic disease. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,4,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2472049&form=6&db=m [Changes in tumor markers following cryosurgery of prostate carcinoma] diagnostic usage,ongoing research,unassigned 4,1,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2683969&form=6&db=m New cancer markers. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3521781&form=6&db=m Origin of carcinomas causing bladder neck obstruction demonstrated by immunoperoxidase localisation of specific antigens. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,3,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6192256&form=6&db=m Immunohistologic diagnosis of 2 cases of metastatic prostate cancer to breast. causal interaction,unassigned 4,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6197801&form=6&db=m Evaluation of commercial immunoperoxidase kits in diagnosis of prostate carcinoma. diagnostic usage,ongoing research,therapeutic application,unassigned 3,2,1,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6205496&form=6&db=m Immunoperoxidase localization of prostatic antigens. Comparison of primary and metastatic sites. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,2,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7500474&form=6&db=m The incidence of prostate cancer progression with undetectable serum prostate specific antigen in a series of 394 radical prostatectomies. causal interaction,diagnostic usage,unassigned 3,2,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7505045&form=6&db=m The role of ultrasound in prostate cancer detection in patients with an elevated prostate specific antigen level but no prostatic nodule. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7508520&form=6&db=m Erythrocyte polyamines and prognosis in stage D2 prostatic carcinoma patients. diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7508527&form=6&db=m Re: False-positive prostate specific antigen values in the sera of women with renal cell carcinoma. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,3,3,1 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7512666&form=6&db=m Re: The inability of prostate specific antigen index to enhance the predictive value of prostate specific antigen in the diagnosis of prostatic carcinoma. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7514940&form=6&db=m Correlation of serum prostate specific antigen levels and bone scintigraphy in carcinoma prostate. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7515448&form=6&db=m Tumor volume and stage in carcinoma of the prostate detected by elevations in prostate specific antigen. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,1,1 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7516401&form=6&db=m Prostate specific antigen density: a method for differentiating prostate carcinoma from benign prostatic hypertrophy demonstrates ethnic variation. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,1 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7520597&form=6&db=m [Proper use of prostate specific antigen] causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7523036&form=6&db=m Chest radiography in patients with early stage prostatic carcinoma. Effect on treatment planning and cost analysis. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7523710&form=6&db=m Diagnosis of prostatic carcinoma: the yield of serum prostate specific antigen, digital rectal examination and transrectal ultrasonography. diagnostic usage,unassigned 4,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7524903&form=6&db=m Expression of human prostatic acid phosphatase and prostate specific antigen genes in neoplastic and benign tissues. causal interaction,diagnostic usage,ongoing research,unassigned 3,3,4,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7525040&form=6&db=m The use of prostate specific antigen density to improve the sensitivity of prostate specific antigen in detecting prostate carcinoma. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,4,4 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7525041&form=6&db=m Prostate specific antigen density in patients with histologically proven prostate carcinoma. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,2,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7527916&form=6&db=m [Comparison between 2 techniques of screening for prostatic carcinoma. Rectal exploration and transrectal ultrasonography vs. prostate specific antigen] causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,2,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7531589&form=6&db=m DNA ploidy, serum prostate specific antigen, histological grade and immunohistochemistry as predictive parameters of lymph node metastases in T1-T3/M0 prostatic adenocarcinoma. causal interaction,diagnostic usage,ongoing research,unassigned 3,4,4,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7532238&form=6&db=m Re: The inability of prostate specific antigen index to enhance the predictive value of prostate specific antigen in the diagnosis of prostatic carcinoma. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7538981&form=6&db=m Relationship between histologic grading and serum prostate specific antigen in prostatic carcinoma. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,3,1 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7542133&form=6&db=m The value of prostatic specific antigen in the early diagnosis of prostatic cancer: a Greek view. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,4,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7543606&form=6&db=m Prostate specific antigen based disease control following ultrasound guided 125iodine implantation for stage T1/T2 prostatic carcinoma. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7544841&form=6&db=m Serial prostate specific antigen measurements and progression in untreated confined (stages T0 to 3NxM0, grades 1 to 3) carcinoma of the prostate. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7545754&form=6&db=m Evaluation of serum and seminal plasma markers in the diagnosis of canine prostatic disorders. causal interaction,diagnostic usage,ongoing research,unassigned 3,4,4,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7545844&form=6&db=m [The value of prostate-specific antigen in therapy follow-up of prostatic carcinoma] causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,2,1 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7551844&form=6&db=m Derivation and application of upper limits for prostate specific antigen in men aged 50-74 years with no clinical evidence of prostatic carcinoma. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,1,1 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7563351&form=6&db=m Prostate specific antigen in the expressed prostatic fluid of men with benign prostatic hyperplasia and prostate carcinoma. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,3,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7664987&form=6&db=m Overexpression of a human prostate-specific glandular kallikrein, hK2, in E. coli and generation of antibodies. causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7679758&form=6&db=m Prostate biopsy in patients after proctectomy. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,1,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7683136&form=6&db=m [The role of the absolute value and "density" of the prostate-specific antigen estimated echographically in the selection of patients to undergo a biopsy in suspected prostatic carcinoma. A comparison between PSA, palpation and echography in 95 patients undergoing echo-guided endorectal prostatic biopsy] diagnostic usage,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7683340&form=6&db=m Prostate specific antigen and prostatic acid phosphatase immunoreactivity as prognostic indicators of advanced prostatic carcinoma. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,4,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7685287&form=6&db=m Clinical use of prostate-specific antigen in the staging of patients with prostatic carcinoma. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,3,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7685417&form=6&db=m Screening for prostatic carcinoma with prostate specific antigen: results of the second year. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7686982&form=6&db=m The inability of prostate specific antigen index to enhance the predictive the value of prostate specific antigen in the diagnosis of prostatic carcinoma. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7686984&form=6&db=m Does high grade prostatic intraepithelial neoplasia result in elevated serum prostate specific antigen levels? causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7688112&form=6&db=m [Reliability and use of prostate-specific antigen in the management of patients with prostatic cancer] causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,2,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7689036&form=6&db=m A comparative study on expression of prostatic inhibin peptide, prostate acid phosphatase and prostate specific antigen in androgen independent human and rat prostate carcinoma cell lines. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,4,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7693607&form=6&db=m The value of prostatic acid phosphatase and prostate specific antigen as serum markers in carcinoma of the prostate. causal interaction,diagnostic usage,ongoing research,unassigned 2,4,4,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7693980&form=6&db=m Prostate specific antigen levels in men older than 50 years without clinical evidence of prostatic carcinoma. causal interaction,diagnostic usage,ongoing research,unassigned 4,2,1,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7694265&form=6&db=m Comparison of prostate secretory protein with prostate specific antigen and prostatic acid phosphatase as a serum biomarker for diagnosis and monitoring patients with prostate carcinoma. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7700405&form=6&db=m [Laparoscopic pelvic lymph node dissection valuable in the staging of clinically localized prostate carcinoma] causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,2,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7733886&form=6&db=m Molecular cloning, purification and in situ localization of human colon kallikrein. ongoing research,unassigned 4,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7925066&form=6&db=m Screening for cancer. Is it useful? causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8062519&form=6&db=m Expression of tissue kallikrein in human kidney. diagnostic usage,ongoing research,unassigned 2,4,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8558675&form=6&db=m Characterization of patients with androgen-independent prostatic carcinoma whose serum prostate specific antigen decreased following flutamide withdrawal. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,1,1,1 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8583583&form=6&db=m Prospective characterization of pathological features of prostatic carcinomas detected via serum prostate specific antigen based screening. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8608513&form=6&db=m The fall in incidence of prostate carcinoma. On the down side of a prostate specific antigen induced peak in incidence--data from the Utah Cancer Registry. causal interaction,diagnostic usage,therapeutic application,unassigned 2,4,1,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8608537&form=6&db=m Prostate specific antigen density as a prognostic factor for patients with prostate carcinoma treated with radiotherapy. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,3,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8630883&form=6&db=m Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,3 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8632570&form=6&db=m Preoperative prediction of tumor heterogeneity and recurrence after radical prostatectomy for localized prostatic carcinoma with digital rectal, examination prostate specific antigen and the results of 6 systematic biopsies. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,2,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8635111&form=6&db=m Prostate specific antigen findings and biopsy results following interactive ultrasound guided transperineal brachytherapy for early stage prostate carcinoma. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,4,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8635135&form=6&db=m The proportion of free to total prostate specific antigen: a method of detecting prostate carcinoma. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,2 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8640677&form=6&db=m Do prostate specific antigen and prostate specific antigen density enhance the detection of prostate carcinoma after initial diagnosis of prostatic intraepithelial neoplasia without concurrent carcinoma? causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,2 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8674014&form=6&db=m Current prognostic factors for prostate carcinoma. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8776967&form=6&db=m [Prognostic importance of prostate specific antigen in patients with hormonally treated stage D2 prostate carcinoma] causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,3,2 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8826949&form=6&db=m Trends in the stage specific incidence of prostate carcinoma in the Detroit metropolitan area, 1973-1994. causal interaction,diagnostic usage,unassigned 4,2,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8847816&form=6&db=m [The significance of free-type PSA and complex-type PSA in patients with prostatic carcinoma--the characteristics of ACS-PSA method compared with that of Delfia- and Eiken-PSA method] causal interaction,diagnostic usage,ongoing research,unassigned 1,4,4,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8863571&form=6&db=m Prospective evaluation of prostate specific antigen and prostate specific antigen density in the detection of nonpalpable and stage T1C carcinoma of the prostate. diagnostic usage,ongoing research,therapeutic application,unassigned 4,4,2,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8881955&form=6&db=m The proportional decrease in prostate specific antigen level best predicts the duration of survival after hormonal therapy in patients with metastatic carcinoma of the prostate. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,3 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8898378&form=6&db=m A novel protease homolog differentially expressed in breast and ovarian cancer. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,4,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8941009&form=6&db=m Prostate carcinoma staging. Clinical utility of bone alkaline phosphatase in addition to prostate specific antigen. diagnostic usage,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8984601&form=6&db=m [Prostate-specific antigen in the diagnosis of organ-confined treatable prostate carcinoma] causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8988730&form=6&db=m Evaluation of radiation effect, tumor differentiation, and prostate specific antigen staining in sequential prostate biopsies after external beam radiotherapy for patients with prostate carcinoma. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,2,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8988731&form=6&db=m The ratio of free to total serum prostate specific antigen and its use in differential diagnosis of prostate carcinoma in Japan. causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8988733&form=6&db=m The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,3,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8988746&form=6&db=m The fall in incidence of prostate carcinoma. On the down side of a prostate specific antigen induced peak in incidence--data from the Utah Cancer Registry. causal interaction,unassigned 2,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8996352&form=6&db=m The free-to-total serum prostate specific antigen ratio for staging prostate carcinoma. causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8996358&form=6&db=m Plasma chromogranin A in prostatic carcinoma and neuroendocrine tumors. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9010106&form=6&db=m Radiotherapy for localized prostate carcinoma. The correlation of pretreatment prostate specific antigen and nadir prostate specific antigen with outcome as assessed by systematic biopsy and serum prostate specific antigen. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,2,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9052473&form=6&db=m The significance of serum alkaline phosphatase bone isoenzyme in prostatic carcinoma with bony metastasis. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9069305&form=6&db=m Transperineal ultrasound-guided radioactive seed implantation for organ-confined carcinoma of the prostate. diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9072597&form=6&db=m Prospective evaluation of prostate specific antigen and prostate specific antigen density in the detection of carcinoma of the prostate: ethnic variations. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,4,2 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9083160&form=6&db=m Prognostic factors for clinically localized prostate carcinoma: analysis of 938 patients irradiated in the prostate specific antigen era. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9112516&form=6&db=m The value of serum carboxyterminal propeptide of type 1 procollagen in predicting bone metastases in prostate cancer. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,4,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9120932&form=6&db=m Serum markers as a predictor of response duration and patient survival after hormonal therapy for metastatic carcinoma of the prostate. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,3,2 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9123732&form=6&db=m Combined modality staging of prostate carcinoma and its utility in predicting pathologic stage and postoperative prostate specific antigen failure. diagnostic usage,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9128985&form=6&db=m A phase II study of oral idarubicin as a treatment for metastatic hormone-refractory prostate carcinoma with special focus on prostate specific antigen doubling time. Swiss Group for Clinical Cancer Research, Berne, Switzerland. causal interaction,diagnostic usage,therapeutic application,unassigned 1,2,4,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9132401&form=6&db=m [Quantitative studies of the kallikrein-prokallikrein system in mixed saliva in oral squamous epithelial carcinoma] causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,1,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9146612&form=6&db=m The free-to-total prostate specific antigen ratio improves the specificity of prostate specific antigen in screening for prostate cancer in the general population. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,3,2 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9149025&form=6&db=m Detection of prostate carcinoma using prostate specific antigen, its density, and the density of the transition zone in Japanese men with intermediate serum prostate specific antigen concentrations. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,3,1 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9170832&form=6&db=m Correlation of digital rectal examination, prostate specific antigen, and transrectal ultrasound in prostate carcinoma in African Americans. diagnostic usage,ongoing research,unassigned 4,1,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9191530&form=6&db=m Detection of circulating prostate carcinoma cells via an enhanced reverse transcriptase-polymerase chain reaction assay in patients with early stage prostate carcinoma. Independence from other pretreatment characteristics. causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9224356&form=6&db=m Re: Characterization of patients with androgen independent prostatic carcinoma whose serum prostate specific antigen decreased following flutamide withdrawal. causal interaction,diagnostic usage,ongoing research,unassigned 2,2,2,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9302140&form=6&db=m Serial tissue polypeptide specific antigen determination in the followup of hormone treated carcinoma of the prostate. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9315396&form=6&db=m Prostate specific antigen levels during radical radiation therapy and the prediction of outcome in localized carcinoma of the prostate. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,1,3 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9329580&form=6&db=m Screening for prostatic carcinoma with prostate specific antigen. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9351545&form=6&db=m Serum concentration of type I collagen metabolites as a quantitative marker of bone metastases in patients with prostate carcinoma. diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9351555&form=6&db=m Prostate carcinoma screening in the county of Tyrol, Austria: experience and results. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9351557&form=6&db=m The results of prostate carcinoma screening in the U.S. as reflected in the surveillance, epidemiology, and end results program. causal interaction,diagnostic usage,unassigned 4,2,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9351558&form=6&db=m Eight years of "Prostate Cancer Awareness Week": lessons in screening and early detection. Prostate Cancer Education Council. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,2,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9351559&form=6&db=m The early detection of prostate carcinoma with prostate specific antigen: the Washington University experience. causal interaction,diagnostic usage,unassigned 2,3,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9351561&form=6&db=m Future benefits and cost-effectiveness of prostate carcinoma screening. American Cancer Society. causal interaction,diagnostic usage,unassigned 4,2,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9428494&form=6&db=m Assessment of the biologic markers p53, Ki-67, and apoptotic index as predictive indicators of prostate carcinoma recurrence after surgery. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,1,2 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9445191&form=6&db=m Calculated prostate carcinoma volume: The optimal predictor of 3-year prostate specific antigen (PSA) failure free survival after surgery or radiation therapy of patients with pretreatment PSA levels of 4-20 nanograms per milliliter. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,2,3 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9445192&form=6&db=m Watchful waiting or watchful progression?: Prostate specific antigen doubling times and clinical behavior in patients with early untreated prostate carcinoma. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,1,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9471767&form=6&db=m [Will determination of prostate specific antigen density improve the diagnosis of prostatic carcinoma?] causal interaction,diagnostic usage,ongoing research,unassigned 4,4,3,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9486580&form=6&db=m Pathologic classification of prostate carcinoma: the impact of margin status. diagnostic usage,unassigned 4,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9554362&form=6&db=m Stability of free and total prostate specific antigen in serum from patients with prostate carcinoma and benign hyperplasia. causal interaction,diagnostic usage,ongoing research,unassigned 3,4,4,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9587121&form=6&db=m Assessment of outcome prediction models for patients with localized prostate carcinoma managed with radical prostatectomy or external beam radiation therapy. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,3,4 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9623236&form=6&db=m [The relationship between the serum level of prostate specific antigen and bone and CT scans in the staging of the primary carcinoma of the prostate] causal interaction,diagnostic usage,ongoing research,unassigned 1,4,4,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9628609&form=6&db=m Transition zone prostate specific antigen density: lack of use in prediction of prostatic carcinoma. causal interaction,diagnostic usage,ongoing research,unassigned 1,1,1,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9655302&form=6&db=m Modeling postradiation prostate specific antigen level kinetics: predictors of rising postnadir slope suggest cure in men who remain biochemically free of prostate carcinoma. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,3,2,1 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9679891&form=6&db=m Repeat ultrasound guided prostate needle biopsy: use of free-to-total prostate specific antigen ratio in predicting prostatic carcinoma. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,1,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9708940&form=6&db=m The greatest dimension of prostate carcinoma is a simple, inexpensive predictor of prostate specific antigen failure in radical prostatectomy specimens. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,3,2 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9708941&form=6&db=m Histopathologic review of prostate biopsies from patients referred to a comprehensive cancer center: correlation of pathologic findings, analysis of cost, and impact on treatment. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9731903&form=6&db=m Interphase cytogenetic study of preoperative core biopsies for the prediction of early serum prostate specific antigen recurrence after radical prostatectomy of clinically localized prostate carcinoma. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,2 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9733142&form=6&db=m Detection of human glandular kallikrein, hK2, as its precursor form and in complex with protease inhibitors in prostate carcinoma serum. causal interaction,diagnostic usage,ongoing research,unassigned 3,4,4,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9781951&form=6&db=m Predicting the pathology results of radical prostatectomy from preoperative information: a validation study. diagnostic usage,ongoing research,therapeutic application,unassigned 2,3,1,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9783939&form=6&db=m The effect of prostate volume on the yield of needle biopsy. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9783977&form=6&db=m Expression of matrix metalloproteinase-7 and tissue inhibitor of metalloproteinase-1 in human prostate. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,1 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9787503&form=6&db=m [Adenocarcinoma of the prostate] causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,1,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9806658&form=6&db=m The dynamics of prostate specific antigen in hormone refractory prostate carcinoma: an analysis of cancer and leukemia group B study 9181 of megestrol acetate. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,3,1 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9842633&form=6&db=m Metastatic carcinoma of the prostate mimicking primary carcinoid tumor of the lung and mediastinum. diagnostic usage,unassigned 4,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9874461&form=6&db=m The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma. diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9934801&form=6&db=m Relationship between prostate specific antigen density, microvessel density and prostatic volume in benign prostatic hyperplasia and advanced prostatic carcinoma. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,4,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10091812&form=6&db=m The greatest dimension of prostate carcinoma is a simple, inexpensive predictor of prostate specific antigen failure in radical prostatectomy specimens. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,1,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10233448&form=6&db=m Elevated serum prostate specific antigen levels in conjunction with an initial prostatic biopsy negative for carcinoma: who should undergo a repeat biopsy? causal interaction,diagnostic usage,unassigned 1,2,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10430254&form=6&db=m Observations of prostate specific antigen doubling time in Japanese patients with nonmetastatic prostate carcinoma. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10436698&form=6&db=m [Bone scintigraphy in prostatic cancer. Correlation with clinical and laboratory features and with survival] diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10463983&form=6&db=m A prospective study of the serum prostate specific antigen concentrations and Gleason histologic scores of black and white men with prostate carcinoma. diagnostic usage,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10494319&form=6&db=m [Prostate-specific antigen as a tumor marker of prostate carcinoma] causal interaction,diagnostic usage,ongoing research,unassigned 4,4,2,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10506719&form=6&db=m The age of the urologist affects the postoperative care of prostate carcinoma patients. diagnostic usage,ongoing research,therapeutic application,unassigned 4,2,2,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10596867&form=6&db=m Visualisation of tissue kallikrein and kinin receptors in oesophageal carcinoma. causal interaction,diagnostic usage,unassigned 1,1,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10604330&form=6&db=m Inflammatory infiltrate (prostatitis) in whole mounted radical prostatectomy specimens from black and white patients is not an etiology for racial difference in prostate specific antigen. causal interaction,diagnostic usage,unassigned 4,2,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10638179&form=6&db=m Penile metastasis from carcinoma of the prostate in a patient with high serum prostate specific antigen levels. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,1,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10649255&form=6&db=m Use of complementary health practices by prostate carcinoma patients undergoing radiation therapy. causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10667080&form=6&db=m [Prostatic carcinoma. Screening--when and what?] causal interaction,diagnostic usage,unassigned 3,2,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10751861&form=6&db=m Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,3,2 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10786085&form=6&db=m [Early detection of prostate carcinoma. What diagnosis is of value when?] diagnostic usage,unassigned 4,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10799172&form=6&db=m Correlation of serum prostate specific antigen and quantitative immunohistochemistry. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10813723&form=6&db=m Prostate specific antigen outcome based on the extent of extracapsular extension and margin status in patients with seminal vesicle negative prostate carcinoma of Gleason score < or = 7. diagnostic usage,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10820353&form=6&db=m The correlation of serial prostate specific antigen measurements with clinical outcome after external beam radiation therapy of patients for prostate carcinoma. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,4,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10835758&form=6&db=m [Obstructive jaundice in prostate neoplasm. Case report] causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,2,1 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10869961&form=6&db=m Changes in beta-2 microglobulin expression in prostate cancer. diagnostic usage,unassigned 1,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10882875&form=6&db=m Prostate cancer screening in the Tyrol, Austria: experience and results. diagnostic usage,unassigned 4,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10898343&form=6&db=m Establishment of human prostate carcinoma skeletal metastasis models. diagnostic usage,ongoing research,therapeutic application,unassigned 3,4,2,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10918174&form=6&db=m Loss of tissue transglutaminase as a biomarker for prostate adenocarcinoma. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,1 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10951348&form=6&db=m Prostate specific antigen adjusted for transition zone volume: the most powerful method for detecting prostate carcinoma. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,2,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11002227&form=6&db=m Visual estimate of the percentage of carcinoma is an independent predictor of prostate carcinoma recurrence after radical prostatectomy. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,1,0 3.4.21.35 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11042577&form=6&db=m Pathologic findings and prostate specific antigen outcome after radical prostatectomy for patients diagnosed on the basis of a single microscopic focus of prostate carcinoma with a gleason score /=8. diagnostic usage,unassigned 4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14520710&form=6&db=m Increase of AKT/PKB expression correlates with gleason pattern in human prostate cancer. causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14532778&form=6&db=m Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14532846&form=6&db=m Inhibition of dendropoiesis by tumor derived and purified prostate specific antigen. unassigned - 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14616447&form=6&db=m Immediate dual energy X-ray absorptiometry reveals a high incidence of osteoporosis in patients with advanced prostate cancer before hormonal manipulation. causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14633706&form=6&db=m Genetic signatures of differentiation induced by 1alpha,25-dihydroxyvitamin D3 in human colon cancer cells. unassigned - 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14634374&form=6&db=m Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,2 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14634394&form=6&db=m Total and Gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies. causal interaction,diagnostic usage,ongoing research,unassigned 3,4,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14634399&form=6&db=m Variations among individual surgeons in the rate of positive surgical margins in radical prostatectomy specimens. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14634401&form=6&db=m Serum osteoprotegerin and receptor activator of nuclear factor-kappa B ligand as indicators of disturbed osteoclastogenesis in patients with prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 1,2,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14634402&form=6&db=m The predictors of pelvic lymph node metastasis at radical retropubic prostatectomy. diagnostic usage,ongoing research,therapeutic application,unassigned 4,1,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14635068&form=6&db=m The percentage of prostate needle biopsy cores with carcinoma from the more involved side of the biopsy as a predictor of prostate specific antigen recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14665876&form=6&db=m Assessment of the enhancement in predictive accuracy provided by systematic biopsy in predicting outcome for clinically localized prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 2,2,3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14693270&form=6&db=m Multivariate models to predict clinically important outcomes at prostatectomy for patients with organ-confined disease and needle biopsy Gleason scores of 6 or less. diagnostic usage,unassigned 4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14695222&form=6&db=m Human kallikrein 14: a new potential biomarker for ovarian and breast cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,4,3 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14713754&form=6&db=m Selenium: epidemiology and basic science. diagnostic usage,unassigned 2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14713758&form=6&db=m Prostate cancer chemoprevention agent development: the National Cancer Institute, Division of Cancer Prevention portfolio. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14713783&form=6&db=m Palliative transurethral prostate resection for bladder outlet obstruction in patients with locally advanced prostate cancer. causal interaction,diagnostic usage,unassigned 2,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14713787&form=6&db=m Impact of volume weighted mean nuclear volume on outcomes following salvage radiation therapy after radical prostatectomy. diagnostic usage,ongoing research,unassigned 4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14713792&form=6&db=m Feasibility of radical prostatectomy after neoadjuvant chemohormonal therapy for patients with high risk or locally advanced prostate cancer: results of a phase I/II study. diagnostic usage,therapeutic application,unassigned 4,2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14733999&form=6&db=m Prostate cancer detection is also relevant in low prostate specific antigen ranges. causal interaction,diagnostic usage,ongoing research,unassigned 3,4,2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14761814&form=6&db=m Active surveillance: towards a new paradigm in the management of early prostate cancer. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14767282&form=6&db=m Watchful waiting and factors predictive of secondary treatment of localized prostate cancer. diagnostic usage,unassigned 4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14969807&form=6&db=m PSA relapse prostate cancer: the importance of tailored therapy. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14983963&form=6&db=m The clinical significance of a small focus of well-differentiated carcinoma at prostate biopsy. diagnostic usage,unassigned 4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15008720&form=6&db=m Delayed therapy with curative intent in a contemporary prostate cancer watchful-waiting cohort. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15017206&form=6&db=m Percent of cores positive for cancer is a better preoperative predictor of cancer recurrence after radical prostatectomy than prostate specific antigen. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15017207&form=6&db=m The risk of finding focal cancer (less than 3 mm) remains high on re-biopsy of patients with persistently increased prostate specific antigen but the clinical significance is questionable. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15017210&form=6&db=m Long-term survival probability in men with clinically localized prostate cancer: a case-control, propensity modeling study stratified by race, age, treatment and comorbidities. causal interaction,diagnostic usage,unassigned 2,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15017213&form=6&db=m The impact of polymorphism on prostate specific antigen gene on the risk, tumor volume and pathological stage of prostate cancer. diagnostic usage,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15018076&form=6&db=m [Prostate specific antigen and diagnosis of prostate cancer] causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15065084&form=6&db=m In vivo real-time imaging of TGF-beta-induced transcriptional activation of the RANK ligand gene promoter in intraosseous prostate cancer. diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15076291&form=6&db=m Predicting the presence and side of extracapsular extension: a nomogram for staging prostate cancer. diagnostic usage,unassigned 4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15076292&form=6&db=m Predictors of prostate cancer after initial negative systematic 12 core biopsy. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15080511&form=6&db=m Serum prostate specific antigen levels in men with benign prostatic hyperplasia and cancer of prostate. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15110992&form=6&db=m Tumour metabolites regulate tissue kallikrein in human umbilical vein endothelial cells. ongoing research,unassigned 4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15122737&form=6&db=m Does the Prentice criterion validate surrogate endpoints? diagnostic usage,therapeutic application,unassigned 2,3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15126770&form=6&db=m Baseline staging of newly diagnosed prostate cancer: a summary of the literature. causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15126786&form=6&db=m A comparison of extended biopsy and sextant biopsy schemes for predicting the pathological stage of prostate cancer. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15126788&form=6&db=m Preoperative model for predicting prostate specific antigen recurrence after radical prostatectomy using percent of biopsy tissue with cancer, biopsy Gleason grade and serum prostate specific antigen. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15126794&form=6&db=m Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigen. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,1,1 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15126795&form=6&db=m Prostate cancer detection in the prostate specific antigen range of 2.0 to 3.9 ng/ml: value of percent free prostate specific antigen on tumor detection and tumor aggressiveness. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15126796&form=6&db=m The economic burden of metastatic and prostate specific antigen progression in patients with prostate cancer: findings from a retrospective analysis of health plan data. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,4,1 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15126799&form=6&db=m Transrectal focused ultrasound combined with transurethral resection of the prostate for the treatment of localized prostate cancer: feasibility study. diagnostic usage,ongoing research,unassigned 4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15136399&form=6&db=m Gene expression profiling identifies matriptase overexpression in malignant mesothelioma. causal interaction,unassigned 3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15147545&form=6&db=m Radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation: Five-year results. diagnostic usage,unassigned 4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15164607&form=6&db=m [Tumor markers of urinary tract carcinoma] causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15201750&form=6&db=m Adverse prognostic significance of capsular incision with radical retropubic prostatectomy. diagnostic usage,ongoing research,unassigned 3,2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15201754&form=6&db=m Percent carcinoma in prostatectomy specimen is associated with risk of recurrence after radical prostatectomy in patients with pathologically organ confined prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15204635&form=6&db=m Two constructed antibody-derived delivery vehicles for targeting oligodeoxynucleotides to prostate tumors expressing prostate specific antigen. therapeutic application,unassigned 2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15207005&form=6&db=m A simple computer program for calculating PSA recurrence in prostate cancer patients. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15217431&form=6&db=m 'Vanishing' prostate cancer in radical prostatectomy specimens: incidence and long-term follow-up in 38 cases. diagnostic usage,unassigned 3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15234233&form=6&db=m Are multiple markers the future of prostate cancer diagnostics? diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15247717&form=6&db=m Contemporary impact of transrectal ultrasound lesions for prostate cancer detection. unassigned - 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15249132&form=6&db=m Steroid hormonal regulation of growth, prostate specific antigen secretion, and transcription mediated by the mutated androgen receptor in CWR22Rv1 human prostate carcinoma cells. causal interaction,diagnostic usage,ongoing research,unassigned 1,3,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15271309&form=6&db=m Time trends in pathologic features of radical prostatectomy--impact of family history. diagnostic usage,ongoing research,unassigned 2,3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15283888&form=6&db=m The assessment of PTEN tumor suppressor gene in combination with Gleason scoring and serum PSA to evaluate progression of prostate carcinoma. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,3,1 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15301172&form=6&db=m A systematic review of brachytherapy. Is it an effective and safe treatment for localised prostate cancer? diagnostic usage,unassigned 1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15307634&form=6&db=m The tissue kallikrein family of serine proteases: functional roles in human disease and potential as clinical biomarkers. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15310992&form=6&db=m Phyllodes tumor of the prostate: long-term followup study of 23 cases. diagnostic usage,ongoing research,unassigned 3,3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15333115&form=6&db=m Associations of race, education, and patterns of preventive service use with stage of cancer at time of diagnosis. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15345003&form=6&db=m Cerebellar metastases from prostatic carcinoma. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15371827&form=6&db=m The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? diagnostic usage,ongoing research,therapeutic application,unassigned 2,3,2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15447848&form=6&db=m [Synergistic effects of paclitaxel and gemcitabine on androgen-independent prostate cancer] diagnostic usage,ongoing research,unassigned 2,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15538237&form=6&db=m POTENCY, CONTINENCE AND COMPLICATIONS IN 3,477 CONSECUTIVE RADICAL RETROPUBIC PROSTATECTOMIES. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15538242&form=6&db=m Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: long-term results. therapeutic application,unassigned 3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15540737&form=6&db=m Race is not a predictor of prostate cancer detection on repeat prostate biopsy. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15547720&form=6&db=m Equiguard suppresses androgen-dependent LNCaP prostate cancer cell proliferation by targeting cell cycle control via down regulation of the retinoblastoma protein Rb and induction of apoptosis via the release of cytochrome c. diagnostic usage,ongoing research,unassigned 1,2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15592031&form=6&db=m Prognostic significance of high grade prostatic intraepithelial neoplasia and atypical small acinar proliferation in the contemporary era. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15598315&form=6&db=m Phyllodes tumor of the seminal vesicle: case report and literature review. therapeutic application,unassigned 1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15623486&form=6&db=m Expression of prostate specific antigen in male breast cancer. causal interaction,diagnostic usage,ongoing research,unassigned 2,3,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15625982&form=6&db=m Percent free PSA as an additional measure in a prostate cancer screen. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15643194&form=6&db=m Human kallikrein-2 gene polymorphism is associated with the occurrence of prostate cancer. causal interaction,diagnostic usage,ongoing research,unassigned 3,4,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15643200&form=6&db=m Prediction of extraprostatic extension in the neurovascular bundle based on prostate needle biopsy pathology, serum prostate specific antigen and digital rectal examination. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15672862&form=6&db=m The effect of osteoprotegerin administration on the intra-tibial growth of the osteoblastic LuCaP 23.1 prostate cancer xenograft. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15678849&form=6&db=m Immunohistochemical expression of prostate specific antigen (PSA) in benign and malignant tumors of the prostate. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,4,1 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15711261&form=6&db=m Prostate biopsy following a positive screen in the prostate, lung, colorectal and ovarian cancer screening trial. causal interaction,unassigned 3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15733480&form=6&db=m [Association of polymorphisms in testosterone 5-alpha-reductase II genotype and prognosis factors of prostate cancer] diagnostic usage,unassigned 3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15748366&form=6&db=m Prevalence of high-grade prostatic intraepithelial neoplasia and its relationship to serum prostate specific antigen. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15751649&form=6&db=m [Tumor markers in prostate cancer--clinical significance and future prospect of prostate specific antigen (PSA)] causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,1,4 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15758704&form=6&db=m Laparoscopic radical prostatectomy. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15758718&form=6&db=m Delays in cancer detection using 2 and 4-year screening intervals for prostate cancer screening with initial prostate specific antigen less than 2 ng/ml. causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15758726&form=6&db=m Salvage surgery for radiorecurrent prostate cancer: contemporary outcomes. diagnostic usage,unassigned 4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15783108&form=6&db=m Important preoperative prognostic factors for extracapsular extension, seminal vesicle invasion and lymph node involvement in cases with radical retropubic prostatectomy. diagnostic usage,ongoing research,unassigned 4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15800933&form=6&db=m Presence and specificity of tumor associated lymphocytes from ascites fluid in prostate cancer. diagnostic usage,ongoing research,therapeutic application,unassigned 1,4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15821485&form=6&db=m Treatment of patients with high risk localized prostate cancer: results from cancer of the prostate strategic urological research endeavor (CaPSURE). diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15839837&form=6&db=m Hepatocyte growth factor is a preferred in vitro substrate for human hepsin, a membrane-anchored serine protease implicated in prostate and ovarian cancers. causal interaction,ongoing research,therapeutic application,unassigned 3,1,2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15864591&form=6&db=m Efficacy of an intratumoral controlled release formulation of clusterin antisense oligonucleotide complexed with chitosan containing paclitaxel or docetaxel in prostate cancer xenograft models. diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15899700&form=6&db=m Visualisation of transforming growth factor-beta 1, tissue kallikrein, and kinin and transforming growth factor-beta receptors on human clear-cell renal carcinoma cells. diagnostic usage,ongoing research,unassigned 3,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15911097&form=6&db=m Human tissue kallikrein gene family: applications in cancer. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15912782&form=6&db=m Limited value of perineural invasion in radical prostatectomy specimens as a predictor of biochemical recurrence in Japanese men with clinically localized prostate cancer. diagnostic usage,unassigned 4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15954083&form=6&db=m Does a delay in external beam radiation therapy after tissue diagnosis affect outcome for men with prostate carcinoma? diagnostic usage,ongoing research,therapeutic application,unassigned 2,3,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15955889&form=6&db=m Receptor isoform and ligand-specific modulation of dihydrotestosterone-induced prostate specific antigen gene expression and prostate tumor cell growth by estrogens. causal interaction,diagnostic usage,ongoing research,unassigned 1,3,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15986440&form=6&db=m FTY720, a fungus metabolite, inhibits in vivo growth of androgen-independent prostate cancer. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16006887&form=6&db=m Prostate cancer in men using testosterone supplementation. diagnostic usage,unassigned 4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16006944&form=6&db=m Results of compliance with prostate cancer screening guidelines. diagnostic usage,unassigned 4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16033100&form=6&db=m Heterogeneity in prostate cancer: prostate specific antigen (PSA) and DNA cytophotometry. diagnostic usage,ongoing research,unassigned 2,3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16093983&form=6&db=m Preoperative prediction of small volume cancer (less than 0.5 ml) in radical prostatectomy specimens. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16104904&form=6&db=m A comparison of the biological features between prostate cancers arising in the transition and peripheral zones. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16126870&form=6&db=m Upregulation of tissue kallikrein, kinin B1 receptor, and kinin B2 receptor in mast and giant cells infiltrating oesophageal squamous cell carcinoma. causal interaction,diagnostic usage,ongoing research,unassigned 1,1,3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16138362&form=6&db=m Bayesian neural networks for bivariate binary data: an application to prostate cancer study. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,2,1,1 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16173043&form=6&db=m N-cadherin switching occurs in high Gleason grade prostate cancer. diagnostic usage,unassigned 4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16180322&form=6&db=m [Spermatic cord liposarcoma. Association with prostate cancer. Report of a case and review of literature] therapeutic application,unassigned 1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16195861&form=6&db=m [Significance of the PSA-concentration for the detection of prostate cancer] causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16215709&form=6&db=m [The role of PSA in diagnosis of prostate cancer and its recurrence] causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16217288&form=6&db=m The independent impact of extended pattern biopsy on prostate cancer stage migration. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,2,1 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16219610&form=6&db=m Prostate cancer presenting with normal serum PSA levels and boney metastases treated with zoledronic acid. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16238978&form=6&db=m [Ophthalmoplegia in a patient with prostate cancer and bone metastases] causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16280756&form=6&db=m The relationship between tumor volume and the number of positive cores in men undergoing multisite extended biopsy: implication for expectant management. diagnostic usage,unassigned 3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16287440&form=6&db=m Visual estimation of tumour extent is not an independent predictor of prostate specific antigen recurrence. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16387414&form=6&db=m The magnitude of early castration-induced primary tumour regression in prostate cancer does not predict clinical outcome. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16387739&form=6&db=m Inhibition of CWR22Rnu1 tumor growth and PSA secretion in athymic nude mice by green and black teas. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16406991&form=6&db=m Perioperative complications of laparoscopic and robotic assisted laparoscopic radical prostatectomy. causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16420035&form=6&db=m Insight into the structural requirements of urokinase-type plasminogen activator inhibitors based on 3D QSAR CoMFA/CoMSIA models. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16469085&form=6&db=m A case of Sister Mary Joseph's nodule from prostatic cancer. causal interaction,diagnostic usage,ongoing research,unassigned 1,2,3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16469578&form=6&db=m Prostate specific antigen remains an independent predictor of cancer at prostate biopsy in black american men but not in white men: results from a consecutive series of 914 men. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16469591&form=6&db=m Impact of patient age at treatment on outcome following radical retropubic prostatectomy for prostate cancer. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16497155&form=6&db=m Interplay of human tissue kallikrein 4 (hK4) with the plasminogen activation system: hK4 regulates the structure and functions of the urokinase-type plasminogen activator receptor (uPAR). causal interaction,diagnostic usage,therapeutic application,unassigned 4,1,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16512601&form=6&db=m Immunohistochemistry in diagnostic surgical pathology of the prostate. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16514966&form=6&db=m [PSA in early detection of prostate cancer and course of disease] causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16538643&form=6&db=m Detection of carcinomas in an asymptomatic Chinese population: advantage of screening with multiple tumor markers. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16541764&form=6&db=m [Combined use of PSA density and free to total PSA ratio for cancer detection from patients with PSA elevations] diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16546384&form=6&db=m Inhibition of trypsin and urokinase by Cbz-amino(4-guanidinophenyl)methanephosphonate aromatic ester derivatives: the influence of the ester group on their biological activity. unassigned - 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16600800&form=6&db=m Rh2 synergistically enhances Paclitaxel or mitoxantrone in prostate cancer models. therapeutic application,unassigned 1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16619264&form=6&db=m Androgen receptor action in hormone-dependent and recurrent prostate cancer. diagnostic usage,unassigned 3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16644872&form=6&db=m Serum and urine tissue kallikrein concentrations in male-to-female transsexuals treated with antiandrogens and estrogens. unassigned - 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16681679&form=6&db=m A UK-based investigation of inter- and intra-observer reproducibility of Gleason grading of prostatic biopsies. diagnostic usage,unassigned 1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16697520&form=6&db=m A (-5, -7) proPSA based artificial neural network to detect prostate cancer. diagnostic usage,unassigned 3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16753368&form=6&db=m Impact of increased number of biopsies on the nature of prostate cancer identified. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16753403&form=6&db=m A prospective, randomized trial comparing conventional transurethral prostate resection with PlasmaKinetic vaporization of the prostate: physiological changes, early complications and long-term followup. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16800730&form=6&db=m Kallikrein-related peptidase (KLK) family mRNA variants and protein isoforms in hormone-related cancers: do they have a function? causal interaction,unassigned 4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16813889&form=6&db=m Detectable prostate specific antigen between 60 and 120 days following radical prostatectomy for prostate cancer: natural history and prognostic significance. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,2 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16890642&form=6&db=m The interpretation of serum prostate specific antigen in men receiving 5alpha-reductase inhibitors: a review and clinical recommendations. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,4 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16890675&form=6&db=m Prostate cancers scored as Gleason 6 on prostate biopsy are frequently Gleason 7 tumors at radical prostatectomy: implication on outcome. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16890678&form=6&db=m Poorly differentiated prostate cancer treated with radical prostatectomy: long-term outcome and incidence of pathological downgrading. diagnostic usage,unassigned 1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16890704&form=6&db=m Is race a positive predictor of cancer on repeat prostate biopsy? causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,2 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16894640&form=6&db=m Transrectal ultrasound-guided biopsy of prostate voxels identified as suspicious of malignancy on three-dimensional (1)H MR spectroscopic imaging in patients with abnormal digital rectal examination or raised prostate specific antigen level of 4-10 ng/ml. causal interaction,diagnostic usage,unassigned 1,3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16895483&form=6&db=m Disease processes may be reflected by correlations among tissue kallikrein proteases but not with proteolytic factors uPA and PAI-1 in primary ovarian carcinoma. causal interaction,diagnostic usage,unassigned 4,2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16933059&form=6&db=m High bone density is associated with prostate cancer in older Afro-Caribbean men: Tobago Prostate Survey. causal interaction,unassigned 2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16933710&form=6&db=m Prostate specific antigen ratio: for diagnosis and assessment of aggressiveness of malignancy of prostate. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16934141&form=6&db=m Prevalence of the use of cancer related self-tests by members of the public: a community survey. diagnostic usage,therapeutic application,unassigned 2,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16936091&form=6&db=m Serial analysis of gene expression (SAGE) in the rat limbal and central corneal epithelium. ongoing research,unassigned 1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16952643&form=6&db=m Prediagnosis prostate specific antigen velocity is associated with risk of prostate cancer progression following brachytherapy and external beam radiation therapy. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,3 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16999628&form=6&db=m Focal prostate cryoablation: initial results show cancer control and potency preservation. diagnostic usage,unassigned 1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17070238&form=6&db=m Prostate cancer prevention and finasteride. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,3 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17070313&form=6&db=m Expression of the ubiquitin ligase subunit cyclin kinase subunit 1 and its relationship to S-phase kinase protein 2 and p27Kip1 in prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17084157&form=6&db=m Identifying men diagnosed with clinically localized prostate cancer who are at high risk for death from prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,2 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17084169&form=6&db=m Management of high risk metastatic prostate cancer: defining risk at the time of initial treatment failure. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17084174&form=6&db=m Management of high risk metastatic prostate cancer: the case for novel therapies. therapeutic application,unassigned 2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17085120&form=6&db=m Comparison of methods for calculating prostate specific antigen velocity. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17085123&form=6&db=m Characteristics of patients with familial versus sporadic prostate cancer. diagnostic usage,ongoing research,unassigned 4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17125483&form=6&db=m Early use of a phosphodiesterase inhibitor after brachytherapy restores and preserves erectile function. diagnostic usage,therapeutic application,unassigned 4,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17131055&form=6&db=m Matriptase and its putative role in cancer. causal interaction,ongoing research,therapeutic application,unassigned 4,3,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17162013&form=6&db=m Does body mass index affect preoperative prostate specific antigen velocity or pathological outcomes after radical prostatectomy? causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,2,3 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17162015&form=6&db=m Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17171424&form=6&db=m Free/total PSA ratio can help in the prediction of high gleason score prostate cancer in men with total serum prostate specific antigen (PSA) of 3-10 ng/ml. diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17222602&form=6&db=m Understanding mixed messages about prostate specific antigen: biases in the evaluation of cancer biomarkers. diagnostic usage,unassigned 1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17222618&form=6&db=m Age adjusted prostate specific antigen and prostate specific antigen velocity cut points in prostate cancer screening. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,3,2 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17222621&form=6&db=m Prostate specific antigen density correlates with features of prostate cancer aggressiveness. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,4 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17222676&form=6&db=m Expression of major heat shock proteins in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,1 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17296372&form=6&db=m The relationship between serum prostate specific antigen level and tumor volume persists in the current era. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17296414&form=6&db=m Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. causal interaction,diagnostic usage,unassigned 2,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17322656&form=6&db=m Urinary tissue factor levels in neoplastic diseases. diagnostic usage,unassigned 4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17342201&form=6&db=m Selective alpha-particle mediated depletion of tumor vasculature with vascular normalization. causal interaction,unassigned 3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17352157&form=6&db=m The preliminary results of docetaxel-prednisolone combination therapy for the Japanese patients with hormone-refractory prostate cancer. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17352166&form=6&db=m [Giant prostate carcinoma treated effectively with endocrine therapy: case report] diagnostic usage,unassigned 2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17363527&form=6&db=m Primary tumor levels of human tissue kallikreins affect surgical success and survival in ovarian cancer patients. causal interaction,diagnostic usage,ongoing research,unassigned 1,3,3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17382716&form=6&db=m The association between total prostate specific antigen concentration and prostate specific antigen velocity. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,2 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17382720&form=6&db=m Predictors of overall and cancer-free survival of patients with localized prostate cancer treated with primary androgen suppression therapy: results from the prostate cancer outcomes study. diagnostic usage,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17390539&form=6&db=m Validating a custom multiplex ELISA against individual commercial immunoassays using clinical samples. diagnostic usage,ongoing research,unassigned 3,2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17436344&form=6&db=m Activity and stability of human kallikrein-2-specific linear and cyclic peptide inhibitors. causal interaction,unassigned 2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17437394&form=6&db=m Cancer screening in Queensland men. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17437802&form=6&db=m Influence of prostate volume and percent free prostate specific antigen on prostate cancer detection in men with a total prostate specific antigen of 2.6 to 10.0 ng/ml. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,1 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17437803&form=6&db=m Risk of prostate cancer for young men with a prostate specific antigen less than their age specific median. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,1 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17437804&form=6&db=m Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,3,3 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17437815&form=6&db=m Do tumor volume, tumor volume ratio, type of nerve sparing and surgical experience affect prostate specific antigen recurrence after laparoscopic radical prostatectomy? A matched pair analysis. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17442563&form=6&db=m A novel multi-array immunoassay device for tumor markers based on insert-plug model of piezoelectric immunosensor. diagnostic usage,unassigned 4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17477366&form=6&db=m Expression of the forkhead transcription factor FOXP1 is associated both with hypoxia inducible factors (HIFs) and the androgen receptor in prostate cancer but is not directly regulated by androgens or hypoxia. diagnostic usage,unassigned 3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17479106&form=6&db=m An HSV-1 amplicon system for prostate-specific expression of ICP4 to complement oncolytic viral replication for in vitro and in vivo treatment of prostate cancer cells. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,3,4 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17487371&form=6&db=m Kallikrein 11 expressed in human breast cancer cells releases insulin-like growth factor through degradation of IGFBP-3. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,4,1 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17499288&form=6&db=m Under diagnosis and over diagnosis of prostate cancer in a screening population with serum PSA 2 to 10 ng/ml. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,1,1 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17499289&form=6&db=m Effect of prostate volume on tumor grade in patients undergoing radical prostatectomy in the era of extended prostatic biopsies. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17499293&form=6&db=m Is routine digital rectal examination required for the followup of prostate cancer? causal interaction,unassigned 4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17541843&form=6&db=m Targeting of biotinylated oligonucleotides to prostate tumors with antibody-based delivery vehicles. diagnostic usage,ongoing research,unassigned 3,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17561720&form=6&db=m [Prostate cancer diagnosed through the biopsy of the bone metastatic lesion; a case report] diagnostic usage,unassigned 4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17621876&form=6&db=m Current status of tissue kallikrein inhibitors: importance in cancer. diagnostic usage,unassigned 2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17629406&form=6&db=m Tissue kallikrein proteolytic cascade pathways in normal physiology and cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,3,1 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17631319&form=6&db=m Chromogranin A expression in patients with hormone naïve prostate cancer predicts the development of hormone refractory disease. causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17632144&form=6&db=m The relationship between anxiety and time to treatment for patients with prostate cancer on surveillance. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17644117&form=6&db=m Chemoprevention of prostate cancer: agents and study designs. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17644123&form=6&db=m Assessing and treating patients with increasing prostate specific antigen following radical prostatectomy. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17644125&form=6&db=m Contemporary trends in low risk prostate cancer: risk assessment and treatment. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17674442&form=6&db=m Words of wisdom. Re: Age adjusted prostate specific antigen and prostate specific antigen velocity cut points in prostate cancer screening. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,3,2 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17681059&form=6&db=m Prediction of pathological stages before prostatectomy in prostate cancer patients: Analysis of 12 systematic prostate needle biopsy specimens. unassigned - 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17689069&form=6&db=m PSA and other tissue kallikreins for prostate cancer detection. diagnostic usage,therapeutic application,unassigned 4,2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17698095&form=6&db=m Importance of tumor location in patients with high preoperative prostate specific antigen levels (greater than 20 ng/ml) treated with radical prostatectomy. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,3,2 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17698103&form=6&db=m Higher frequency of familial clustering of prostate cancer in French-Canadian men. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17698107&form=6&db=m Lead time of prostate cancer detected in population based screening for prostate cancer in Japan. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17698121&form=6&db=m Subclassification of clinical stage T1 prostate cancer: impact on biochemical recurrence following radical prostatectomy. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17698131&form=6&db=m Predicting unilateral prostate cancer based on biopsy features: implications for focal ablative therapy--results from the SEARCH database. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17707059&form=6&db=m Clinical safety of a viral vector based prostate cancer vaccine strategy. diagnostic usage,ongoing research,therapeutic application,unassigned 3,3,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17760748&form=6&db=m Significance of the craniocaudal distribution of cancer in radical prostatectomy specimens. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17868719&form=6&db=m Validity of the CAPRA score to predict biochemical recurrence-free survival after radical prostatectomy. Results from a european multicenter survey of 1,296 patients. diagnostic usage,ongoing research,unassigned 4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17868722&form=6&db=m Association of obesity with tumor characteristics and treatment failure of prostate cancer in African-American and European American men. diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17868725&form=6&db=m Predicting the risk of patients with biopsy Gleason score 6 to harbor a higher grade cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17868726&form=6&db=m Prostate cancer risk assessment program: a 10-year update of cancer detection. causal interaction,diagnostic usage,unassigned 2,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17922874&form=6&db=m Patient selection determines the prostate cancer yield of dynamic contrast-enhanced magnetic resonance imaging-guided transrectal biopsies in a closed 3-Tesla scanner. diagnostic usage,unassigned 4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17936844&form=6&db=m Prostate specific antigen velocity in men with total prostate specific antigen less than 4 ng/ml. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,4 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17936849&form=6&db=m A comparison of the incidence and location of positive surgical margins in robotic assisted laparoscopic radical prostatectomy and open retropubic radical prostatectomy. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17947957&form=6&db=m Serum ceruloplasmin as a marker in prostate cancer. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17991322&form=6&db=m Value of tumor markers in diagnosing and monitoring colorectal cancer and strategies for further improvement: analysis of 130 cases. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17997422&form=6&db=m Percent free prostate specific antigen does not enhance the specificity of total prostate specific antigen for the detection of prostate cancer in Korean men 50 to 65 years old: a prospective multicenter study. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,2 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18047963&form=6&db=m Adjuvant radiotherapy for high-risk patients following radical prostatectomy. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18188561&form=6&db=m Using extracellular biomarkers for monitoring efficacy of therapeutics in cancer patients: an update. causal interaction,diagnostic usage,unassigned 1,2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18207180&form=6&db=m Prostate cancer volume at biopsy predicts clinically significant upgrading. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18221963&form=6&db=m Prostate specific antigen kinetics in the management of prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,4 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18279927&form=6&db=m Preoperative prediction of unifocal, unilateral, margin-negative, and small volume prostate cancer. diagnostic usage,unassigned 4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18289590&form=6&db=m Comparison of prostate specific antigen velocity in screened versus referred patients with prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,4 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18304461&form=6&db=m Polymorphisms of GSTM1 and CYP1A1 genes and their genetic susceptibility to prostate cancer in Chinese men. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18336606&form=6&db=m Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18343412&form=6&db=m Saturation technique does not decrease cancer detection during followup after initial prostate biopsy. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,1,1 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18343425&form=6&db=m The performance of prostate specific antigen, prostate specific antigen density and transition zone density in the era of extended biopsy schemes. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,2,3 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18343427&form=6&db=m Prognostic Significance of alpha-Methylacyl-CoA Racemase Among Men With High Grade Prostatic Intraepithelial Neoplasia in Prostate Biopsies. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18343434&form=6&db=m Limitations of Prostate Specific Antigen Doubling Time Following Biochemical Recurrence After Radical Prostatectomy: Results From the SEARCH Database. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18343454&form=6&db=m Central zone carcinoma of the prostate gland: a distinct tumor type with poor prognostic features. causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18353378&form=6&db=m Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18423725&form=6&db=m Circulating tumor cells in peripheral blood samples from patients with increased serum prostate specific antigen: initial results in early prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,1,1 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18423746&form=6&db=m Change in prostate specific antigen following androgen stimulation is an independent predictor of prostate cancer diagnosis. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,3 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18485383&form=6&db=m A novel nomogram to predict the probability of prostate cancer on repeat biopsy. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18507013&form=6&db=m Transforming growth factor-beta1 modulates tumor-stromal cell interactions of prostate cancer through insulin-like growth factor-I. causal interaction,unassigned 2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18512384&form=6&db=m [A preliminar mathematical model for patients with a previous negative prostate biopsy] diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18535913&form=6&db=m Epithelial to mesenchymal transition (EMT) in human prostate cancer: lessons learned from ARCaP model. causal interaction,ongoing research,unassigned 2,2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18542796&form=6&db=m Subsequent prostate cancer detection in patients with prostatic intraepithelial neoplasia or atypical small acinar proliferation. diagnostic usage,unassigned 2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18550097&form=6&db=m The performance of prostate specific antigen for predicting prostate cancer is maintained after a prior negative prostate biopsy. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,3,4 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18550106&form=6&db=m The impact of the 2005 international society of urological pathology consensus conference on standard Gleason grading of prostatic carcinoma in needle biopsies. diagnostic usage,unassigned 4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18550118&form=6&db=m [-2]proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,3,3 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18585845&form=6&db=m Prostate-specific antigen kinetics in clinical decision-making during active surveillance for early prostate cancer--a review. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18594168&form=6&db=m [Establishment of reference intervals of tumor markers in Korean adults] diagnostic usage,ongoing research,therapeutic application,unassigned 2,3,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18621129&form=6&db=m Human prostate stromal cells stimulate increased PSA production in DHEA-treated prostate cancer epithelial cells. diagnostic usage,ongoing research,therapeutic application,unassigned 1,4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18630837&form=6&db=m Correlation of modified Gleason grading of prostate carcinoma with age, serum prostate specific antigen and tumor extent in needle biopsy specimens. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18635219&form=6&db=m Finnish multicenter study comparing intermittent to continuous androgen deprivation for advanced prostate cancer: interim analysis of prognostic markers affecting initial response to androgen deprivation. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18649741&form=6&db=m 25-Hydroxyvitamin D-1 alpha-hydroxylase (CYP27B1) is a new class of tumor suppressor in the prostate. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18694408&form=6&db=m Evaluation of a novel precision template-guided biopsy system for detecting prostate cancer. diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18697492&form=6&db=m [Clinical impact of body mass index on prostate biopsy in patients with intermediate PSA levels] diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18705314&form=6&db=m Evaluation of tumor markers biochip C12 system in the diagnosis of gastric cancer and the strategies for improvement: analysis of 100 cases. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18707699&form=6&db=m Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18707706&form=6&db=m Prostate cancers diagnosed at repeat biopsy are smaller and less likely to be high grade. causal interaction,diagnostic usage,ongoing research,unassigned 3,4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18707710&form=6&db=m Racial variations in the performance of prostate specific antigen and prostate specific antigen density in the era of extended prostate biopsy schemes. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18710459&form=6&db=m Catheter-less robotic radical prostatectomy using a custom-made synchronous anastomotic splint and vesical urinary diversion device: report of the initial series and perioperative outcomes. diagnostic usage,unassigned 4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18788442&form=6&db=m [Examination of prostate biopsy among Japanese with less than 4.0 ng/ml prostate specific antigen--usefulness of free/total PSA ratio] diagnostic usage,unassigned 4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18791963&form=6&db=m [Selective application of tumor markers PSA] causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18794087&form=6&db=m High-throughput screening identifies cardiac glycosides as potent inhibitors of human tissue kallikrein expression: implications for cancer therapies. diagnostic usage,therapeutic application,unassigned 1,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18801515&form=6&db=m Pathological upgrading and up staging with immediate repeat biopsy in patients eligible for active surveillance. diagnostic usage,unassigned 4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18801519&form=6&db=m What are the factors associated with short prostate specific antigen doubling time after radical prostatectomy? A report from the SEARCH database group. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,4 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18801541&form=6&db=m Mass screening for prostate cancer in Korea: a population based study. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18804811&form=6&db=m The significance of monoamine oxidase-A expression in high grade prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,1 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18841439&form=6&db=m Major inter-laboratory variations in PSA testing practices: results from national surveys in Ireland in 2006 and 2007. therapeutic application,unassigned 2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18930283&form=6&db=m Surveillance and deferred treatment for localized prostate cancer. Population based study in the National Prostate Cancer Register of Sweden. diagnostic usage,therapeutic application,unassigned 4,3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18959172&form=6&db=m [Disease relapses after radical radiotherapy of prostate cancer--analysis of prognostic factors] diagnostic usage,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19012935&form=6&db=m Annexin A3 in urine: a highly specific noninvasive marker for prostate cancer early detection. causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19012937&form=6&db=m The impact of discordance between biopsy and pathological Gleason scores on survival after radical prostatectomy. diagnostic usage,unassigned 2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19060997&form=6&db=m Pretreatment tumor volume estimation based on total serum psa in patients with localized prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,2,1 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19080439&form=6&db=m [Effects of anti-gene and antisense therapeutics on human prostate cancer xenograft in nude mice] diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19081465&form=6&db=m Visually directed transrectal high intensity focused ultrasound for the treatment of prostate cancer: a preliminary report on the Italian experience. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19084848&form=6&db=m The clinical significance in healthy men of the association between obesity related plasma hemodilution and tumor marker concentration. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19091347&form=6&db=m Phase II study of Dutasteride for recurrent prostate cancer during androgen deprivation therapy. diagnostic usage,ongoing research,therapeutic application,unassigned 3,4,3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19150091&form=6&db=m Prognostic significance of circulating tumor cells in patients with hormone refractory prostate cancer. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19150092&form=6&db=m Lycopene for advanced hormone refractory prostate cancer: a prospective, open phase II pilot study. causal interaction,diagnostic usage,therapeutic application,unassigned 2,2,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19150546&form=6&db=m The number of cores positive for high grade prostatic intraepithelial neoplasia on initial biopsy is associated with prostate cancer on second biopsy. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19202079&form=6&db=m Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues. causal interaction,diagnostic usage,unassigned 4,2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19216452&form=6&db=m Use of common seric tumor markers in patients with solid cancers. diagnostic usage,therapeutic application,unassigned 2,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19230923&form=6&db=m Sociodemographic predictors of prostate cancer risk category at diagnosis: unique patterns of significant and insignificant disease. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19286200&form=6&db=m Does transrectal ultrasound probe configuration really matter? End fire versus side fire probe prostate cancer detection rates. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19286210&form=6&db=m Association of nonsteroidal anti-inflammatory drugs, prostate specific antigen and prostate volume. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19337394&form=6&db=m PAIII prostate tumors express prostate specific antigen (PSA) in Lobund-Wistar rats. diagnostic usage,ongoing research,unassigned 1,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19348246&form=6&db=m [Application of angiotensin II receptor blocker in prostate cancer] causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19371879&form=6&db=m Characteristics of prostate cancers detected at prostate specific antigen levels less than 2.5 ng/ml. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19371894&form=6&db=m Prostate specific antigen half-time and prostate specific antigen doubling time as predictors of response to androgen deprivation therapy for metastatic prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,4 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19403342&form=6&db=m Designing nanomaterial-enhanced electrochemical immunosensors for cancer biomarker proteins. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19442312&form=6&db=m Cancer screening among migrants in an Australian cohort; cross-sectional analyses from the 45 and Up Study. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19447436&form=6&db=m Factors predicting prostatic biopsy Gleason sum under grading. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19483644&form=6&db=m Vaccination with agonist peptide PSA: 154-163 (155L) derived from prostate specific antigen induced CD8 T-cell response to the native peptide PSA: 154-163 but failed to induce the reactivity against tumor targets expressing PSA: a phase 2 study in patients with recurrent prostate cancer. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19524966&form=6&db=m Chemoprevention of prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19524974&form=6&db=m Body mass index and prostate specific antigen as predictors of adverse pathology and biochemical recurrence after prostatectomy. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,1,2 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19524976&form=6&db=m Multifocal high grade prostatic intraepithelial neoplasia is a significant risk factor for prostatic adenocarcinoma. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19668818&form=6&db=m Electrochemiluminescent immunosensor for detection of protein cancer biomarkers using carbon nanotube forests and [Ru-(bpy)(3)](2+)-doped silica nanoparticles. ongoing research,therapeutic application,unassigned 1,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19683310&form=6&db=m Extensive biopsies and transurethral prostate resection in men with previous negative biopsies and high or increasing prostate specific antigen. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19704337&form=6&db=m A phase I/II study of GTI-2040 plus docetaxel as second-line treatment in advanced non-small cell lung cancer: a study of the PMH phase II consortium. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19751256&form=6&db=m Serum testosterone is associated with aggressive prostate cancer in older men: results from the Baltimore Longitudinal Study of Aging. diagnostic usage,unassigned 4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19752671&form=6&db=m Biological, psychological and behavioral, and social variables influencing colorectal cancer screening in African Americans. diagnostic usage,unassigned 3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19758614&form=6&db=m Natural history of persistently elevated prostate specific antigen after radical prostatectomy: results from the SEARCH database. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19758616&form=6&db=m Men older than 70 years have higher risk prostate cancer and poorer survival in the early and late prostate specific antigen eras. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19758620&form=6&db=m Exercise and prostate cancer risk in a cohort of veterans undergoing prostate needle biopsy. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19778969&form=6&db=m Prostate specific antigen for early detection of prostate cancer: longitudinal study. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,2,4 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19780165&form=6&db=m Proton MRS detects metabolic changes in hormone sensitive and resistant human prostate cancer models CWR22 and CWR22r. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19780325&form=6&db=m Urinary PSA level and relative tumor volume after prostate biopsy. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19836788&form=6&db=m Validation in a Multiple Urology Practice Cohort of the Prostate Cancer Prevention Trial Calculator for Predicting Prostate Cancer Detection. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19913814&form=6&db=m Can prostate specific antigen velocity thresholds decrease insignificant prostate cancer detection? causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,2 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19914651&form=6&db=m The significance of a positive bladder neck margin after radical prostatectomy: the American Joint Committee on Cancer Pathological Stage T4 designation is not warranted. diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19920389&form=6&db=m Decrease in prostate specific antigen secretion correlated with docetaxel-induced growth inhibition and apoptosis in human prostate tumor cells. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19966928&form=6&db=m Early Detection of Cancer: Immunoassays for Plasma Tumor Markers. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19999547&form=6&db=m [Apoptosis in pathologic prostatic processes] causal interaction,unassigned 4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20000326&form=6&db=m Quantitative, label-free detection of five protein biomarkers using multiplexed arrays of silicon photonic microring resonators. diagnostic usage,unassigned 1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20006859&form=6&db=m Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen. causal interaction,diagnostic usage,ongoing research,unassigned 3,4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20006887&form=6&db=m Performance of prostate cancer prevention trial risk calculator in a contemporary cohort screened for prostate cancer and diagnosed by extended prostate biopsy. causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20011088&form=6&db=m Does prostate specific antigen density correlates with aggressiveness of the prostate cancer? causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,4,1 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20047017&form=6&db=m Preclinical evaluation of a monoclonal antibody (3C6) specific for prostate-specific membrane antigen. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,3,4 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20067463&form=6&db=m Expression analysis and study of the KLK15 mRNA splice variants in prostate cancer and benign prostatic hyperplasia. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,4,1 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20083275&form=6&db=m Initial prostate specific antigen 1.5 ng/ml or greater in men 50 years old or younger predicts higher prostate cancer risk. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,1,2 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20089269&form=6&db=m Prostate specific antigen decrease and prostate cancer diagnosis: antibiotic versus placebo prospective randomized clinical trial. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,2,4 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20089281&form=6&db=m Tumor percent involvement predicts prostate specific antigen recurrence after radical prostatectomy only in men with smaller prostate. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,3 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20117878&form=6&db=m Sarcosine in Urine after Digital Rectal Examination Fails as a Marker in Prostate Cancer Detection and Identification of Aggressive Tumours. diagnostic usage,unassigned 4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20129773&form=6&db=m Aligned carbon nanotubes on quartz substrate for liquid gated biosensing. diagnostic usage,therapeutic application,unassigned 1,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20176031&form=6&db=m A cell kinetics model for prostate cancer and its application to clinical data and individual patients. causal interaction,diagnostic usage,unassigned 3,3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20180426&form=6&db=m [Skip metastasis of prostate cancer: diagnosis and treatment] diagnostic usage,unassigned 4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20299498&form=6&db=m Trends of the Primary Therapy for Patients with Prostate Cancer in Nara Uro-oncological Research Group (NUORG): a Comparison Between the CaPSURE Data and the NUORG Data. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,1 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20300365&form=6&db=m Finasteride-its impact on sexual function and prostate cancer. causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20303103&form=6&db=m Tumor volume in radical prostatectomy specimens assessed by digital image analysis software correlates with other prognostic factors. diagnostic usage,unassigned 4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20303104&form=6&db=m Preoperative prostate specific antigen doubling time is not a useful predictor of biochemical progression after radical prostatectomy. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,4 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20459553&form=6&db=m The length of positive surgical margins correlates with biochemical recurrence after radical prostatectomy. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20473923&form=6&db=m KLK15 is a prognostic marker for progression-free survival in patients with radical prostatectomy. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,4 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20483148&form=6&db=m Prostate specific antigen at the initial diagnosis of metastasis to bone in patients after radical prostatectomy. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,1 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20519274&form=6&db=m Differential expression of steroid 5alpha-reductase isozymes and association with disease severity and angiogenic genes predict their biological role in prostate cancer. causal interaction,diagnostic usage,ongoing research,unassigned 4,2,2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20519927&form=6&db=m [A case of prostate cancer that developed following transurethral resection of the prostate: diagnostic efficiency of diffusion-weighted images on magnetic resonance imaging] diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20571134&form=6&db=m Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20585690&form=6&db=m Immunosensor for the detection of cancer biomarker based on percolated graphene thin film. diagnostic usage,therapeutic application,unassigned 2,3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20635444&form=6&db=m Can we predict real T3 stage prostate cancer in patients with clinical T3 (cT3) disease before radical prostatectomy? causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20643434&form=6&db=m Prostate specific antigen velocity does not aid prostate cancer detection in men with prior negative biopsy. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20643449&form=6&db=m Participation of older patients with prostate cancer in Medicare eligible trials. unassigned - 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20646652&form=6&db=m [National external quality assessment and comparability of assays for tumor markers measurements] diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20665692&form=6&db=m Arraying prostate specific antigen PSA and Fab anti-PSA using light assisted molecular immobilization technology. diagnostic usage,ongoing research,therapeutic application,unassigned 4,1,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20677270&form=6&db=m Diffusion-weighted MRI for monitoring tumor response to photodynamic therapy. diagnostic usage,ongoing research,therapeutic application,unassigned 3,1,3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20693148&form=6&db=m Supporting informed decision making for prostate specific antigen (PSA) testing on the web: an online randomized controlled trial. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20708918&form=6&db=m Dumbbell-like Au-Fe3O4 nanoparticles as label for the preparation of electrochemical immunosensors. diagnostic usage,ongoing research,therapeutic application,unassigned 1,1,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20800030&form=6&db=m [Reference values of prostate specific antigen (PSA) in 63926 workers without prostatic symptoms who participated in prostate screening cancer developed by the Ibermutuamur Prevention Society in 2006] causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20824184&form=6&db=m Harnessing naturally occurring tumor immunity: a clinical vaccine trial in prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20836318&form=6&db=m Knowledge of prostate cancer screening among native African urban population in Nigeria. diagnostic usage,unassigned 2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20846685&form=6&db=m Risk grouping versus risk continuum in patients with clinically localized prostate cancer: a taxometric test. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20846692&form=6&db=m Multifocal high grade prostatic intraepithelial neoplasia is a risk factor for subsequent prostate cancer. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20846693&form=6&db=m Disproportionate presentation of high risk prostate cancer in a safety net health system. diagnostic usage,unassigned 4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20854069&form=6&db=m Immunohistochemistry for p16, but not Rb or p21, is an independent predictor of prognosis in conservatively treated, clinically localised prostate cancer. causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20859288&form=6&db=m Role of human tissue kallikrein in gastrointestinal stromal tumour invasion. causal interaction,ongoing research,unassigned 3,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20890424&form=6&db=m Preoperative nomograms for predicting extracapsular extension in Korean men with localized prostate cancer: a multi-institutional clinicopathologic study. diagnostic usage,ongoing research,unassigned 4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20940693&form=6&db=m Personalized approach to prostate cancer prognosis. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20952027&form=6&db=m Ductal Adenocarcinoma of the Prostate: Increased Mortality Risk and Decreased Serum Prostate Specific Antigen. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,3,1 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20980650&form=6&db=m Rye Whole Grain and Bran Intake Compared with Refined Wheat Decreases Urinary C-Peptide, Plasma Insulin, and Prostate Specific Antigen in Men with Prostate Cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,2,1 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21031435&form=6&db=m Differential expression of peroxiredoxins in prostate cancer: Consistent upregulation of PRDX3 and PRDX4. causal interaction,diagnostic usage,unassigned 3,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21053206&form=6&db=m Effect of electroporation-mediated diphtheria toxin A expression on PSA positive human prostate xenograft tumors in SCID mice. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,4,3 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21071102&form=6&db=m Evaluating diagnostic strategy of older patients with unexplained unintentional body weight loss: A hospital-based study. diagnostic usage,unassigned 4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21075385&form=6&db=m Inhibition of aberrant androgen receptor induction of prostate specific antigen gene expression, cell proliferation and tumor growth by 17?-estradiol in prostate cancer. causal interaction,ongoing research,unassigned 4,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21086409&form=6&db=m [Sensitivity and specificity evaluation of endorectal magnetic resonance imaging and transrectal sonography in the staging of prostate cancer.] diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21184521&form=6&db=m Up-regulation and clinical significance of serine protease kallikrein 6 in colon cancer. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21194845&form=6&db=m Life events, cortisol and levels of prostate specific antigen: A story of synergism. diagnostic usage,ongoing research,unassigned 2,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21195601&form=6&db=m Sensitive electrochemical immunosensor for cancer biomarker with signal enhancement based on nitrodopamine-functionalized iron oxide nanoparticles. unassigned - 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21198137&form=6&db=m Hybrid optimal scheduling for intermittent androgen suppression of prostate cancer. unassigned - 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21224096&form=6&db=m Radical prostatectomy in men less than 50 years old. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,3,3 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21227046&form=6&db=m Inhibition of vascular endothelial cell growth factor suppresses the in vivo growth of human prostate tumors. diagnostic usage,unassigned 4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21227198&form=6&db=m The utility of free to total PSA ratio for detecting prostate cancer in Japanese men with total PSA between 2.1 and 10 ng/ml. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21388798&form=6&db=m Electrochemical immunosensors for cancer biomarker with signal amplification based on ferrocene functionalized iron oxide nanoparticles. diagnostic usage,therapeutic application,unassigned 2,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21392961&form=6&db=m Nanoporous gold film based immunosensor for label-free detection of cancer biomarker. therapeutic application,unassigned 1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21419439&form=6&db=m A Multicenter Study of [-2]Pro-Prostate Specific Antigen Combined With Prostate Specific Antigen and Free Prostate Specific Antigen for Prostate Cancer Detection in the 2.0 to 10.0 ng/ml Prostate Specific Antigen Range. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,4 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21419448&form=6&db=m A Contemporary Analysis of Outcomes of Adenocarcinoma of the Prostate With Seminal Vesicle Invasion (pT3b) After Radical Prostatectomy. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21456069&form=6&db=m Effect of electroporation-mediated diphtheria toxin A expression on PSA positive human prostate xenograft tumors in SCID mice. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,4,3 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21482098&form=6&db=m Colorimetric platform for visual detection of cancer biomarker based on intrinsic peroxidase activity of graphene oxide. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21504557&form=6&db=m A novel multiplex assay combining autoantibodies plus PSA has potential implications for classification of prostate cancer from non-malignant cases. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21629784&form=6&db=m A tri-marker proliferation index predicts biochemical recurrence after surgery for prostate cancer. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21629831&form=6&db=m Chemoprevention of prostate cancer with nutrients and supplements. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21630551&form=6&db=m The analysis of some factors that influence on serum PSA level in localized prostate cancer patients: mathematical model. causal interaction,diagnostic usage,ongoing research,unassigned 3,4,3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21632234&form=6&db=m Microfluidic electrochemical immunoarray for ultrasensitive detection of two cancer biomarker proteins in serum. diagnostic usage,unassigned 3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21656738&form=6&db=m Up-regulation and clinical significance of serine protease kallikrein 6 in colon cancer. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21741862&form=6&db=m Common variation in Kallikrein genes KLK5, KLK6, KLK12, and KLK13 and risk of prostate cancer and tumor aggressiveness. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21862072&form=6&db=m Gleason Score 7 Prostate Cancer on Needle Biopsy: Relation of Primary Pattern 3 or 4 to Pathological Stage and Progression After Radical Prostatectomy. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21904690&form=6&db=m Effects of the demethylating agent, 5-azacytidine, on expression of the kallikrein-kinin genes in carcinoma cells of the lung and pleura. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21993700&form=6&db=m Effects of kallikrein-related peptidase 14 gene inhibition by small interfering RNA in ovarian carcinoma cells. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,4 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22052759&form=6&db=m Personalized approach to prostate cancer prognosis. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22095615&form=6&db=m Lipid nanoparticle siRNA systems for silencing the androgen receptor in human prostate cancer In Vivo. unassigned - 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22112489&form=6&db=m Molecular pathology of prostate cancer. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22117828&form=6&db=m High grade intraepithelial neoplasia of prostate is associated with values of prostate specific antigen related parameters intermediate between prostate cancer and normal levels. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22177152&form=6&db=m Prostate size does not predict high grade cancer. causal interaction,ongoing research,unassigned 1,2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22232535&form=6&db=m Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study. diagnostic usage,therapeutic application,unassigned 2,2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22292443&form=6&db=m Tissue Biomarkers for Prostate Cancer Radiation Therapy. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22293265&form=6&db=m Correlation between the preoperative serum prostate specific antigen, Gleason score, and clinical staging with pathological outcome following robot-assisted radical prostatectomy: an Indian experience. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22335871&form=6&db=m Impact of Multiparametric Endorectal Coil Prostate Magnetic Resonance Imaging on Disease Reclassification Among Active Surveillance Candidates: A Prospective Cohort Study. causal interaction,diagnostic usage,unassigned 2,3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22341271&form=6&db=m Antigen Specific T-Cell Responses Against Tumor Antigens are Controlled by Regulatory T Cells in Patients With Prostate Cancer. diagnostic usage,ongoing research,unassigned 3,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22373580&form=6&db=m Upregulation and secretion of kallikrein-related peptidase 6 (KLK6) in gastric cancer. diagnostic usage,ongoing research,therapeutic application,unassigned 1,4,3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22406482&form=6&db=m Microscopic assessment of fresh prostate tumour specimens yields significantly increased rates of correctly annotated samples for downstream analysis. diagnostic usage,ongoing research,therapeutic application,unassigned 4,1,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22413803&form=6&db=m DNA Repair System and Prostate Cancer Progression: The Role of NBS1 Polymorphism (rs1805794). causal interaction,diagnostic usage,unassigned 2,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22467358&form=6&db=m Neighborhood socioeconomic status modifies the association between individual smoking status and PAH-DNA adduct levels in prostate tissue. diagnostic usage,unassigned 4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22502673&form=6&db=m Elevated level of prostate specific antigen among prostate cancer patients and high prevalence in the Gangetic zone of Bihar, India. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22502982&form=6&db=m Combined (18) F-fluorocholine and (18) F-fluoride positron emission tomography/computed tomography imaging for staging of high-risk prostate cancer. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22537761&form=6&db=m Historical prostate cancer screening and treatment outcomes from a single institution. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22542926&form=6&db=m An aptamer based resonance light scattering assay of prostate specific antigen. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22552350&form=6&db=m Soluble E-cadherin and IL-6 serum levels in patients affected by prostate cancer before and after prostatectomy. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22579070&form=6&db=m Insensitivity to the growth inhibitory effects of activin A: an acquired capability in prostate cancer progression. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22663543&form=6&db=m Zyflamend, a combination of herbal extracts, attenuates tumor growth in murine xenograft models of prostate cancer. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22666930&form=6&db=m Kappa statistics in the screening of malignancy of prostate. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22763628&form=6&db=m Circulating free testosterone is an independent predictor of advanced disease in patients with clinically localized prostate cancer. diagnostic usage,ongoing research,unassigned 4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22869146&form=6&db=m Epigenetic-induced repression of microRNA-205 is associated with MED1 activation and a poorer prognosis in localized prostate cancer. causal interaction,diagnostic usage,unassigned 4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22874102&form=6&db=m Quantitative DNA methylation analysis of genes coding for kallikrein-related peptidases 6 and 10 as biomarkers for prostate cancer. therapeutic application,unassigned 1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22883760&form=6&db=m Re: Short Term Outcomes of Prostate Biopsy in Men Tested for Cancer by Prostate Specific Antigen: Prospective Evaluation Within ProtecT Study. diagnostic usage,therapeutic application,unassigned 2,3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23063630&form=6&db=m Prognostic Impact of Subclassification of Radical Prostatectomy Positive Margins by Linear Extent and Gleason Grade. diagnostic usage,therapeutic application,unassigned 2,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23084064&form=6&db=m Multiplex detection platform for tumor markers and glucose in serum based on a microfluidic microparticle array. diagnostic usage,ongoing research,unassigned 4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23087903&form=6&db=m Low incidence of fatigue after hypofractionated stereotactic body radiation therapy for localized prostate cancer. diagnostic usage,therapeutic application,unassigned 2,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23105567&form=6&db=m Prostate specific antigen in patients of benign prostate hypertrophy and carcinoma prostate. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,2 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23105652&form=6&db=m Tumor marker requests in a general teaching Turkish hospital. diagnostic usage,therapeutic application,unassigned 4,3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23159265&form=6&db=m The Impact of Clinical Stage on Prostate Cancer Survival Following Radical Prostatectomy. causal interaction,diagnostic usage,therapeutic application,unassigned 1,2,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23164385&form=6&db=m [11C]choline positron emission tomography/computerized tomography for early detection of prostate cancer recurrence in patients with low increasing prostate specific antigen. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23244723&form=6&db=m Patient selection and counseling before prostatic arterial embolization. diagnostic usage,ongoing research,unassigned 1,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23268329&form=6&db=m High grade prostate intraepithelial neoplasia (PIN) is a PSA-independent risk factor for prostate cancer in African American men: Results from a pilot study. causal interaction,diagnostic usage,therapeutic application,unassigned 2,4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23314541&form=6&db=m Serum levels of cancer biomarkers in diabetic and non-diabetic proteinuric patients: a preliminary study. diagnostic usage,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23337463&form=6&db=m Risk of suicide in men with low-risk prostate cancer. ongoing research,unassigned 2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23391636&form=6&db=m Association of transcript levels of 10 established or candidate-biomarker gene targets with cancerous versus non-cancerous prostate tissue from radical prostatectomy specimens. diagnostic usage,ongoing research,unassigned 3,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23395803&form=6&db=m Testosterone Replacement Therapy in Patients with Prostate Cancer After Radical Prostatectomy. causal interaction,diagnostic usage,therapeutic application,unassigned 3,1,2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23412126&form=6&db=m [A case of prostate cancer presenting as extensive abdominal metastasis]. diagnostic usage,unassigned 1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23459235&form=6&db=m A Cancer-Indicative microRNA Pattern in Normal Prostate Tissue. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23474436&form=6&db=m Effect of finasteride on serum levels of androstenedione, testosterone and their 5?-reduced metabolites in men at risk for prostate cancer. causal interaction,diagnostic usage,unassigned 1,2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23499583&form=6&db=m Clinical significance of kallikrein-related peptidase (KLK10) mRNA expression in colorectal cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,4 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23505134&form=6&db=m Carbon Nanotubes Multifunctionalized by Rolling Circle Amplification and Their Application for Highly Sensitive Detection of Cancer Markers. diagnostic usage,unassigned 4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23529468&form=6&db=m Prostate cancer - Active surveillance as a management option. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23532557&form=6&db=m Cabazitaxel: A Guide to Its Use in Hormone-Refractory Metastatic Prostate Cancer. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23542085&form=6&db=m Detection of cancer biomarkers by piezoelectric biosensor using PZT ceramic resonator as the transducer. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23579402&form=6&db=m 5-alpha reductase inhibitors in patients on active surveillance: do the benefits outweigh the risk? causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23587030&form=6&db=m Correlation of hK6 expression with tumor recurrence and prognosis in advanced gastric cancer. causal interaction,unassigned 3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23608675&form=6&db=m Socioeconomic variation and prostate specific antigen testing in the community: a United kingdom based population study. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23613288&form=6&db=m An evaluation of usefulness of prostate specific antigen and digital rectal examination in the diagnosis of prostate cancer in an unscreened population:experience in a nigerian teaching hospital. diagnostic usage,ongoing research,unassigned 4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23620432&form=6&db=m Quantified KLK15 gene expression levels discriminate prostate cancer from benign tumors and constitute a novel independent predictor of disease progression. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23641775&form=6&db=m Sociodemographic and health-related predictors of self-reported mammogram, faecal occult blood test and prostate specific antigen test use in a large Australian study. diagnostic usage,therapeutic application,unassigned 4,2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23716281&form=6&db=m The "PROCAINA (PROstate CAncer INdication Attitudes) Project" (Part II) - A survey among Italian radiation oncologists on radical radiotherapy in prostate cancer. diagnostic usage,therapeutic application,unassigned 4,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23730101&form=6&db=m A Review on the Clinical Utility of PSA in Cancer Prostate. diagnostic usage,unassigned 4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23763882&form=6&db=m Prognostic factors for newly diagnosed prostate cancer and their role in treatment selection. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23768149&form=6&db=m The modified Glasgow prognostic score in prostate cancer: results from a retrospective clinical series of 744 patients. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23803082&form=6&db=m Susceptibility Loci associations with prostate cancer risk in northern chinese men. causal interaction,diagnostic usage,ongoing research,unassigned 3,4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23811700&form=6&db=m Imaging of prostate carcinoma. diagnostic usage,therapeutic application,unassigned 4,3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23826311&form=6&db=m Seminal plasma as a source of prostate cancer peptide biomarker candidates for detection of indolent and advanced disease. causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23842001&form=6&db=m Identification of a Novel Proteoform of Prostate Specific Antigen (SNP-L132I) in Clinical Samples by Multiple Reaction Monitoring. diagnostic usage,unassigned 4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24008878&form=6&db=m Cellular distribution and heterogeneity of Psa and Psma expression in normal, hyperplasia and human prostate cancer. diagnostic usage,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24027389&form=6&db=m Secondary signet ring cell carcinoma of prostate. diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24072771&form=6&db=m Oral administration of naturally occurring chitosan based nanoformulated green tea polyphenol EGCG effectively inhibits prostate cancer cell growth in a xenograft model. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24078504&form=6&db=m Bilateral cancer in prostate biopsy associates with the presence of extracapsular disease and positive surgical margins in low risk patients: a consideration for bilateral nerve sparing radical prostatectomy decision. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24140827&form=6&db=m Electrochemiluminescence immunosensor for tumor markers based on biological barcode mode with conductive nanospheres. diagnostic usage,unassigned 2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24166498&form=6&db=m MicroRNAs, miR-154, miR-299-5p, miR-376a, miR-376c, miR-377, miR-381, miR-487b, miR-485-3p, miR-495 and miR-654-3p, mapped to the 14q32.31 locus, regulate proliferation, apoptosis, migration and invasion in metastatic prostate cancer cells. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24300729&form=6&db=m Clinical significance of cancer in radical prostatectomy specimens: analysis from a contemporary series of 2900 men. causal interaction,unassigned 3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24333515&form=6&db=m Improving Detection of Clinically Significant Prostate Cancer: Magnetic Resonance Imaging/Transrectal Ultrasound Fusion Guided Prostate Biopsy. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24407206&form=6&db=m Words of wisdom. Re: Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study. diagnostic usage,therapeutic application,unassigned 2,2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24423580&form=6&db=m Androgen deprivation decreases prostate specific antigen in the absence of tumor: implications for interpretation of PSA results. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24430362&form=6&db=m Kallikrein-related peptidase-6 (KLK6) mRNA expression is an independent prognostic tissue biomarker of poor disease-free and overall survival in colorectal adenocarcinoma. diagnostic usage,unassigned 2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24435840&form=6&db=m Association between systemic inflammatory markers and serum prostate-specific antigen in men without prostatic disease - the 2001-2008 National Health and Nutrition Examination Survey. causal interaction,diagnostic usage,unassigned 4,2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24472071&form=6&db=m The fluctuation of PCA3 score in men undergoing first or repeat prostate biopsies. diagnostic usage,ongoing research,unassigned 4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24474708&form=6&db=m Functionalized MoS2 Nanosheet-Based Field-Effect Biosensor for Label-Free Sensitive Detection of Cancer Marker Proteins in Solution. diagnostic usage,therapeutic application,unassigned 1,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24496681&form=6&db=m Improved anti-tumor efficiency against prostate cancer by docetaxel-loaded PEG-PCL micelles. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,4,1 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24523142&form=6&db=m Clinical significance of different types of p53 gene alteration in surgically treated prostate cancer. diagnostic usage,unassigned 3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24571737&form=6&db=m Targeting kallikrein-related peptidases in prostate cancer. causal interaction,unassigned 1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24619900&form=6&db=m Serum tumor markers in hemodialysis patients. diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24646125&form=6&db=m Prostate Cancer and Its Mimics at Multiparametric Prostate MRI. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24680737&form=6&db=m Model predictive control for optimally scheduling intermittent androgen suppression of prostate cancer. ongoing research,unassigned 1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24793632&form=6&db=m [Abiraterone acetate (AA): current guidelines of prescription of abiraterone]. causal interaction,ongoing research,therapeutic application,unassigned 3,3,2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24853012&form=6&db=m The Chance of Small Interfering RNAs as Eligible Candidates for a Personalized Treatment of Prostate Cancer. causal interaction,diagnostic usage,ongoing research,unassigned 2,3,3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24854539&form=6&db=m Low mRNA expression levels of kallikrein-related peptidase 4 (KLK4) predict short-term relapse in patients with laryngeal squamous cell carcinoma. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,1 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24858997&form=6&db=m An enhanced LSPR fiber-optic nanoprobe for ultrasensitive detection of protein biomarkers. therapeutic application,unassigned 1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24870726&form=6&db=m Economic evaluation of prostate cancer screening test as a National Cancer Screening Program in South Korea. unassigned - 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24892731&form=6&db=m Differential detection of tumor cells using a combination of cell rolling, multivalent binding, and multiple antibodies. diagnostic usage,ongoing research,unassigned 3,3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24982776&form=6&db=m Squamous cell carcinoma of the prostate following treatment with an LHRH-agonist: a rare case of transformation of adenocarcinoma of the prostate. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25065587&form=6&db=m Targeting thapsigargin towards tumors. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25124389&form=6&db=m Clear cell urothelial carcinoma of the urinary bladder: a case report and review of the literature. diagnostic usage,ongoing research,therapeutic application,unassigned 2,3,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25127571&form=6&db=m Rapid chemiluminescent sandwich enzyme immunoassay capable of consecutively quantifying multiple tumor markers in a sample. diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25128228&form=6&db=m Prostate cancer with Paneth cell-like neuroendocrine differentiation has recognizable histomorphology and harbors AURKA gene amplification. diagnostic usage,unassigned 4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25157338&form=6&db=m Short-term enzalutamide treatment for the potential remission of active surveillance or intermediate-risk prostate cancer: a case study, review, and the need for a clinical trial. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25199875&form=6&db=m Circulating tumor cells in prostate cancer: a better predictor of survival than prostate specific antigen? causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,3,1 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25208250&form=6&db=m Is anyone listening? Variation in PSA screening among providers for men 75+ before and after United States Preventive Services Task Force recommendations against it: a retrospective cohort study. diagnostic usage,therapeutic application,unassigned 2,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25218798&form=6&db=m Rating general practitioner consultation performance in cancer care: does the specialty of assessors matter? A simulated patient study. diagnostic usage,ongoing research,therapeutic application,unassigned 2,2,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25261558&form=6&db=m Pediatric population reference value distributions for cancer biomarkers and covariate-stratified reference intervals in the CALIPER cohort. diagnostic usage,ongoing research,unassigned 2,3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25318883&form=6&db=m Carbohydrate antigens as potential biomarkers for the malignancy in patients with idiopathic deep venous thrombosis: a retrospective cohort study. diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25328681&form=6&db=m Elucidating immunologic mechanisms of PROSTVAC cancer immunotherapy. ongoing research,therapeutic application,unassigned 1,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25362477&form=6&db=m Detection of cancer biomarkers in serum using a hybrid mechanical and optoplasmonic nanosensor. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25431626&form=6&db=m Paper-based electrochemical immunoassay for rapid, inexpensive cancer biomarker protein detection. diagnostic usage,unassigned 2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25436005&form=6&db=m Sulfur inhibits the growth of androgen-independent prostate cancer in vivo. diagnostic usage,unassigned 1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25463645&form=6&db=m Gel pad array chip for high throughput and multi-analyte microbead-based immunoassays. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25481037&form=6&db=m Impact of the U.S. Preventive Services Task Force Recommendations against Prostate Specific Antigen Screening on Prostate Biopsy and Cancer Detection Rates. diagnostic usage,therapeutic application,unassigned 4,2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25530535&form=6&db=m CuO-induced signal amplification strategy for multiplexed photoelectrochemical immunosensing using CdS sensitized ZnO nanotubes arrays as photoactive material and AuPd alloy nanoparticles as electron sink. diagnostic usage,ongoing research,therapeutic application,unassigned 2,2,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25556099&form=6&db=m Discovery of O-(3-carbamimidoylphenyl)-l-serine amides as matriptase inhibitors using a fragment-linking approach. causal interaction,diagnostic usage,therapeutic application,unassigned 4,1,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25578541&form=6&db=m Electrochemical red-ox therapy of prostate cancer in nude mice. ongoing research,unassigned 1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25602482&form=6&db=m [Docetaxel for small cell carcinoma of the prostate with a metastatic pelvic tumor : a case report]. diagnostic usage,unassigned 4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25799190&form=6&db=m Pathological features of localized prostate cancer in China: a contemporary analysis of radical prostatectomy specimens. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25821749&form=6&db=m Transition zone prostate specific antigen density improves prostate cancer detection in Iranian men. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,2,2 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25825985&form=6&db=m HOXB13 overexpression is an independent predictor of early PSA recurrence in prostate cancer treated by radical prostatectomy. causal interaction,diagnostic usage,unassigned 2,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25863334&form=6&db=m Predicting high-grade cancer at ten-core prostate biopsy using four kallikrein markers measured in blood in the ProtecT study. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,4,1 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25883418&form=6&db=m Reconnoitring the status of prostate specific antigen and its role in women. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25899828&form=6&db=m Weaker ERG expression in patients with ERG-positive prostate cancer is associated with advanced disease and weaker androgen receptor expression: An Indian outlook. causal interaction,diagnostic usage,unassigned 1,3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25983194&form=6&db=m Patterns of Local Failure following Radiation Therapy for Prostate Cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25988518&form=6&db=m Baseline Perineural Invasion is Associated with Shorter Time to Progression in Men with Prostate Cancer Undergoing Active Surveillance: Results from the REDEEM Study. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,1,2 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25996781&form=6&db=m Luminescence energy transfer detection of PSA in red region based on Mn2+-enhanced NaYF4:Yb, Er upconversion nanorods. therapeutic application,unassigned 2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26003206&form=6&db=m Natural History of Pathologically Benign Cancer Suspicious Regions on Multiparametric Magnetic Resonance Imaging Following Targeted Biopsy. diagnostic usage,ongoing research,unassigned 2,3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26052106&form=6&db=m Ultra-sensitive protein detection via Single Molecule Arrays towards early stage cancer monitoring. diagnostic usage,ongoing research,unassigned 3,3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26158863&form=6&db=m Recombinant human alpha fetoprotein synergistically potentiates the anti-cancer effects of 1'-S-1'-acetoxychavicol acetate when used as a complex against human tumours harbouring AFP-receptors. diagnostic usage,ongoing research,unassigned 4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26159154&form=6&db=m A nanoplasmonic biosensor for label-free multiplex detection of cancer biomarkers. diagnostic usage,ongoing research,unassigned 4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26164521&form=6&db=m [A case of metastatic castration-resistant prostate cancer by abiraterone treatment]. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26192253&form=6&db=m The Risk of Distant Metastases and Cancer Specific Survival in Men with Serum Prostate Specific Antigen Values above 100 ng/ml. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,3,1 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26192258&form=6&db=m Can Confirmatory Biopsy be Omitted in Patients with Prostate Cancer Favorable Diagnostic Features on Active Surveillance? unassigned - 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26236756&form=6&db=m Methodology to study the three-dimensional spatial distribution of prostate cancer and their dependence on clinical parameters. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,3,1 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26327354&form=6&db=m Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort. diagnostic usage,unassigned 1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26341575&form=6&db=m African-American Men with Gleason Score 3+3=6 Prostate Cancer Produce Less Prostate Specific Antigen than Caucasian Men: A Potential Impact on Active Surveillance. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,1 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26351937&form=6&db=m mRNA overexpression of kallikrein-related peptidase 14 (KLK14) is an independent predictor of poor overall survival in chronic lymphocytic leukemia patients. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26388370&form=6&db=m Real-time prostate-specific antigen detection with prostate-specific antigen imprinted capacitive biosensors. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26415325&form=6&db=m INITIAL SYMPTOMATIC PITUITARY METASTASIS IN A PATIENT WITH PROSTATE FOAMY GLAND CARCINOMA: TAILORING SAFE AND EFFECTIVE THERAPY. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26429715&form=6&db=m Thapsigargin, Origin, Chemistry, Structure-Activity Relationships and Prodrug Development. diagnostic usage,therapeutic application,unassigned 4,2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26435643&form=6&db=m Validation of revised Epstein's criteria for insignificant prostate cancer prediction in a Greek subpopulation. diagnostic usage,unassigned 3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26452418&form=6&db=m Does larger tumor volume explain the higher prostate specific antigen levels in black men with prostate cancer--Results from the SEARCH database. causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26473941&form=6&db=m Ultrasensitive Detection of Dual Cancer Biomarkers with Integrated CMOS-Compatible Nanowire Arrays. diagnostic usage,unassigned 1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26519653&form=6&db=m Comorbid Disease Burden is Independently Associated with Higher Risk Disease at Prostatectomy in Patients Eligible for Active Surveillance. causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26530362&form=6&db=m Prostate Specific Antigen as a Tumor Marker in Prostate Cancer: Biochemical and Clinical Aspects. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,3 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26581414&form=6&db=m The optimal number of initial prostate biopsy cores in daily practice: a prospective study using the Nara Urological Research and Treatment Group nomogram. diagnostic usage,ongoing research,unassigned 4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26612689&form=6&db=m Virus encoded circulatory miRNAs for early detection of prostate cancer. diagnostic usage,therapeutic application,unassigned 2,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26638190&form=6&db=m Screening for familial and hereditary prostate cancer. causal interaction,diagnostic usage,unassigned 3,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26642698&form=6&db=m Status of External Quality Assessment on Tumor Markers in China. diagnostic usage,unassigned 2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26656266&form=6&db=m Trade-Off between Treatment of Early Prostate Cancer and Incidence of Advanced Prostate Cancer in the Prostate Screening Era. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26666211&form=6&db=m Amplified binding-induced homogeneous assay through catalytic cycling of analyte for ultrasensitive protein detection. diagnostic usage,ongoing research,unassigned 1,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26674305&form=6&db=m Serial Magnetic Resonance Imaging in Active Surveillance of Prostate Cancer: Incremental Value. diagnostic usage,ongoing research,therapeutic application,unassigned 2,1,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26958088&form=6&db=m Immunochemical Assays and Nucleic-Acid Detection Techniques for Clinical Diagnosis of Prostate Cancer. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26964917&form=6&db=m Systemic radioligand therapy with (177)Lu-PSMA-I&T in patients with metastatic castration-resistant prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 3,1,2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26983637&form=6&db=m Radioimmunotherapy of prostate cancer targeting human kallikrein-related peptidase 2. causal interaction,diagnostic usage,ongoing research,unassigned 1,2,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26995770&form=6&db=m Extended pelvic lymphadenectomy in patients with clinically localised prostate cancer: A prospective observational study. diagnostic usage,unassigned 4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27004218&form=6&db=m Comparative study of tumor markers in patients with colorectal carcinoma before and after chemotherapy. diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27121158&form=6&db=m GPs views and understanding of PSA testing, screening and early detection; survey. diagnostic usage,unassigned 3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27281263&form=6&db=m Targeted Prostate Biopsy Gleason Score Heterogeneity and Implications for Risk Stratification. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27343801&form=6&db=m Do Black NonHispanic Men Produce Less Prostate Specific Antigen in Benign Prostate Tissue or Cancer Compared to White NonHispanic Men with Gleason Score 6 Prostate Cancer? causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,3,2 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27408081&form=6&db=m Prostate Cancer - What's New? causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27449263&form=6&db=m Phase II Evaluation of Magnetic Resonance Imaging Guided Focal Laser Ablation of Prostate Cancer. diagnostic usage,unassigned 4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27645821&form=6&db=m The age-specific reference intervals for tPSA, fPSA, and %fPSA in healthy Han ethnic male. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27659411&form=6&db=m The use of (68 ) Ga-PSMA PET CT in men with biochemical recurrence after definitive treatment of acinar prostate cancer. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27689068&form=6&db=m Incidental prostate cancer diagnosed at radical cystoprostatectomy for bladder cancer: disease-specific outcomes and survival. unassigned - 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27693448&form=6&db=m PTEN Loss in Gleason Score 3 + 4 = 7 Prostate Biopsies is Associated with Nonorgan Confined Disease at Radical Prostatectomy. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27693450&form=6&db=m Properties of the 4-Kallikrein Panel Outside the Diagnostic Gray Zone: Meta-Analysis of Patients with Positive Digital Rectal Examination or Prostate Specific Antigen 10 ng/ml and Above. diagnostic usage,ongoing research,unassigned 4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27772702&form=6&db=m PEG-based autonomous capillary system with integrated microbead array for immunoassay. diagnostic usage,ongoing research,unassigned 4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27800298&form=6&db=m Lesion Targeted CT-Guided Transgluteal Prostate Biopsy in Combination With Prebiopsy MRI in Patients Without Rectal Access. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27856226&form=6&db=m Indications, Utilization and Complications Following Prostate Biopsy: New York State Analysis. causal interaction,diagnostic usage,unassigned 2,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27893926&form=6&db=m Estimation of the optimal regime in treatment of prostate cancer recurrence from observational data using flexible weighting models. diagnostic usage,therapeutic application,unassigned 2,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27909617&form=6&db=m Diagnostic value of microRNAs in prostate cancer patients with prostate specific antigen (PSA) levels between 2, and 10 ng/mL. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27916711&form=6&db=m Implementation of a Surgeon-Level Comparative Quality Performance Review to Improve Positive Surgical Margin Rates during Radical Prostatectomy. diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28012768&form=6&db=m Laparoscopic Radical Prostatectomy with a Remote Controlled Robot. diagnostic usage,unassigned 2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28034917&form=6&db=m Active surveillance for low-risk localized prostate cancer: what do men and their partners think? causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28052296&form=6&db=m Clinical and Biochemical Influence of Prostatic Stones. diagnostic usage,ongoing research,unassigned 2,2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28078896&form=6&db=m [The incidence, mortality and risk factors of prostate cancer]. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28098061&form=6&db=m Prostate cancer immunotherapy, particularly in combination with androgen deprivation or radiation treatment. Customized pharmacogenomic approaches to overcome immunotherapy cancer resistance. therapeutic application,unassigned 2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28117816&form=6&db=m A Murine Orthotopic Bladder Tumor Model and Tumor Detection System. ongoing research,unassigned 3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28124526&form=6&db=m Predictive value of [-2]propsa (p2psa) and its derivatives for the prostate cancer detection in the 2.0 to 10.0ng/mL PSA range. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28159676&form=6&db=m Transformation of prostatic adenocarcinoma to well differentiated neuroendocrine tumor after hormonal treatment. diagnostic usage,ongoing research,unassigned 2,2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28201871&form=6&db=m Targeted Contrast Agent Specific to an Oncoprotein in Tumor Microenvironment with the Potential for Detection and Risk Stratification of Prostate Cancer with MRI. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,1,1 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28235549&form=6&db=m Clinical Outcome Following Low Suspicion Multiparametric Prostate Magnetic Resonance Imaging or Benign Magnetic Resonance Imaging Guided Biopsy to Detect Prostate Cancer. diagnostic usage,therapeutic application,unassigned 1,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28245478&form=6&db=m Association between Basal Total Testosterone Levels and Tumor Upgrading in Low and Intermediate Risk Prostate Cancer. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28267056&form=6&db=m Active surveillance for low-risk prostate cancer. diagnostic usage,unassigned 2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28299695&form=6&db=m Development of Novel Piezoelectric Biosensor Using PZT Ceramic Resonator for Detection of Cancer Markers. diagnostic usage,ongoing research,unassigned 4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28300861&form=6&db=m Primary Cribriform Carcinoma of the Eyelid With Neuroendocrine Features: A Case Report. diagnostic usage,ongoing research,therapeutic application,unassigned 3,1,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28322857&form=6&db=m Vascular Targeted Photodynamic Therapy with Padeliporfin for Low Risk Prostate Cancer Treatment: Midterm Oncologic Outcomes. causal interaction,therapeutic application,unassigned 1,3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28325365&form=6&db=m Macrocystic ductal adenocarcinoma of prostate: A rare gross appearance of prostate cancer. diagnostic usage,ongoing research,unassigned 3,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28392705&form=6&db=m Long noncoding RNA LINC01296 is associated with poor prognosis in prostate cancer and promotes cancer-cell proliferation and metastasis. diagnostic usage,ongoing research,unassigned 3,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28417057&form=6&db=m Evaluation of sHLA-G levels in serum of patients with prostate cancer identify as a potential of tumor marker. diagnostic usage,therapeutic application,unassigned 4,2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28420168&form=6&db=m Comparative Study of Blood-Based Biomarkers, ?2,3-Sialic Acid PSA and PHI, for High-Risk Prostate Cancer Detection. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28511371&form=6&db=m Study of Serum Total PSA and Free PSA as an Oncological Marker in Breast Tumour. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28554811&form=6&db=m The Impact of Prostate Cancer Zonal Origin on Pathological Parameters at Radical Prostatectomy and Subsequent Biochemical Failure. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28611361&form=6&db=m Discovery of a novel conformational equilibrium in urokinase-type plasminogen activator. causal interaction,unassigned 4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28616986&form=6&db=m On-a-chip Biosensing Based on All-Dielectric Nanoresonators. diagnostic usage,ongoing research,therapeutic application,unassigned 4,1,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28669765&form=6&db=m Independent Validation of the American Joint Committee on Cancer 8th Edition Prostate Cancer Staging Classification. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28725585&form=6&db=m A critical comparison of techniques for MRI-targeted biopsy of the prostate. diagnostic usage,unassigned 2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28785195&form=6&db=m The Modulating Effects of Benign Prostate Enlargement Medications on Upgrading Predictors in Patients with Gleason 6 at Biopsy. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,2,1 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28872768&form=6&db=m Skene's gland adenocarcinoma with intestinal differentiation: A case report and literature review. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28878593&form=6&db=m Low-Risk Prostate Cancer and Tumor Upgrading in the Surgical Specimen: Analysis of Clinical Factors Predicting Tumor Upgrading in a Contemporary Series of Patients Who were Evaluated According to the Modified Gleason Score Grading System. diagnostic usage,unassigned 3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28919005&form=6&db=m Ex vivo ?H2AX radiation sensitivity assay in prostate cancer: Inter-patient and intra-patient heterogeneity. diagnostic usage,unassigned 2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28935568&form=6&db=m Genetically engineered oncolytic Newcastle disease virus mediates cytolysis of prostate cancer stem like cells. ongoing research,unassigned 3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28939976&form=6&db=m A novel biopsy-related parameter derived from location and relationship of positive cores on standard 12-core trans-rectal ultrasound-guided prostate biopsy: a useful parameter for predicting tumor volume compared to number of positive cores. diagnostic usage,unassigned 3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28949515&form=6&db=m Single Molecule Upconversion-Linked Immunosorbent Assay with Extended Dynamic Range for the Sensitive Detection of Diagnostic Biomarkers. diagnostic usage,unassigned 2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28988599&form=6&db=m Pathological outcomes in men with prostate cancer who are eligible for active surveillance. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29128577&form=6&db=m Pathological and 3 Tesla Volumetric Magnetic Resonance Imaging Predictors of Biochemical Recurrence after Robotic Assisted Radical Prostatectomy: Correlation with Whole Mount Histopathology. causal interaction,diagnostic usage,unassigned 4,2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29138196&form=6&db=m Cross-sectional study evaluating data quality of the National Cancer Registration and Analysis Service (NCRAS) prostate cancer registry data using the Cluster randomised trial of PSA testing for Prostate cancer (CAP). diagnostic usage,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29174667&form=6&db=m Metal-organic gel enhanced fluorescence anisotropy for sensitive detection of prostate specific antigen. diagnostic usage,unassigned 4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29190897&form=6&db=m Biomarkers identified for prostate cancer patients through genome-scale screening. diagnostic usage,therapeutic application,unassigned 4,2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29264132&form=6&db=m The older the better: The characteristic of localized prostate cancer in Chinese men. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29264144&form=6&db=m Contemporary outcomes in the detection of prostate cancer using transrectal ultrasound-guided 12-core biopsy in Singaporean men with elevated prostate specific antigen and/or abnormal digital rectal examination. diagnostic usage,unassigned 4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29366641&form=6&db=m Subcutaneous Fat Distribution Is a Prognostic Biomarker for Men with Castration Resistant Prostate Cancer. diagnostic usage,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29410888&form=6&db=m What should be done to minimize pain without any sexual function deterioration in transrectal prostate biopsy? causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29524974&form=6&db=m African-American men with prostate cancer have larger tumor volume than Caucasian men despite no difference in serum prostate specific antigen. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29533522&form=6&db=m Repeat prostate-specific antigen test before prostate biopsy: a 20% decrease in prostate specific antigen values is associated with a reduced risk of cancer and particularly of high-grade cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29594019&form=6&db=m Stopping screening, when and how? causal interaction,unassigned 3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29614347&form=6&db=m Discovery of novel transcripts of the human tissue kallikrein (KLK1) and kallikrein-related peptidase 2 (KLK2) in human cancer cells, exploiting Next-Generation Sequencing technology. ongoing research,unassigned 4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29630980&form=6&db=m The Research Implications of Prostate Specific Antigen Registry Errors: Data from the Veterans Health Administration. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29657651&form=6&db=m Role of Magnetic Resonance Imaging, Magnetic Resonance Spectroscopy and Transrectal Ultrasound in Evaluation of Prostatic Pathologies with Focus on Prostate Cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29672311&form=6&db=m Inverse Association of Prostatic Chronic Inflammation among Prostate Cancer Tumor Grade Groups: Retrospective Study of 738 Consecutive Cases Elected to a First Random Biopsy Set. causal interaction,unassigned 2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29679618&form=6&db=m Is it Time to Perform Only Magnetic Resonance Imaging Targeted Cores? Our Experience with 1,032 Men Who Underwent Prostate Biopsy. diagnostic usage,ongoing research,unassigned 2,2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29709664&form=6&db=m Outcomes and Prognostic Factors in Men Receiving Androgen Deprivation Therapy for Prostate Cancer Recurrence after Radical Prostatectomy. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29730198&form=6&db=m Long-Term Outcomes after Deferred Radical Prostatectomy in Men Initially Treated with Active Surveillance. causal interaction,diagnostic usage,therapeutic application,unassigned 2,2,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29758219&form=6&db=m Prostate Specific Antigen Density as a Predictor of Clinically Significant Prostate Cancer When the Prostate Specific Antigen is in the Diagnostic Gray Zone: Defining the Optimum Cutoff Point Stratified by Race and Body Mass Index. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,4,1 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29758220&form=6&db=m Evaluation of an Aggressive Prostate Biopsy Strategy in Men Younger than 50 Years. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,2 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29885274&form=6&db=m Overview of tissue kallikrein and kallikrein-related peptidases in breast cancer. causal interaction,diagnostic usage,ongoing research,unassigned 1,2,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29887239&form=6&db=m Effect of multimodal analgesia with paravertebral blocks on biochemical recurrence in men undergoing open radical prostatectomy. causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29906406&form=6&db=m The malignancy index in plasma samples as a prostate cancer biomarker. causal interaction,diagnostic usage,unassigned 3,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29928615&form=6&db=m The impact of intra-operative cell salvage during open radical prostatectomy. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29928903&form=6&db=m Biochemical characterization of human tissue kallikrein 15 and examination of its potential role in cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,4,1 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29934309&form=6&db=m A potent, proteolysis-resistant inhibitor of kallikrein-related peptidase 6 (KLK6) for cancer therapy, developed by combinatorial engineering. therapeutic application,unassigned 4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30094987&form=6&db=m Robust, Highly Visible, and Facile Bioconjugation Colloidal Crystal Beads for Bioassay. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30179617&form=6&db=m Coffee, Caffeine Metabolism Genotype and Disease Progression in Patients with Localized Prostate Cancer Managed with Active Surveillance. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30363462&form=6&db=m Prostate imaging features that indicate benign or malignant pathology on biopsy. diagnostic usage,therapeutic application,unassigned 2,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30365107&form=6&db=m Exploration of the diagnostic value and molecular mechanism of miR?1 in prostate cancer: A study based on meta?analyses and bioinformatics. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30520109&form=6&db=m Ex vivo treatment of prostate tumor tissue recapitulates in vivo therapy response. diagnostic usage,ongoing research,therapeutic application,unassigned 3,1,3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30529422&form=6&db=m Evaluation of the therapeutic effect against benign prostatic hyperplasia and the active constituents from Epilobium angustifolium L. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30545489&form=6&db=m Extracting tumour prognostic factors from a diverse electronic record dataset in genito-urinary oncology. diagnostic usage,unassigned 2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30546938&form=6&db=m Genetic associations of T cell cancer immune response with tumor aggressiveness in localized prostate cancer patients and disease reclassification in an active surveillance cohort. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30577402&form=6&db=m Oncologic and Functional Outcomes of Partial Gland Ablation with High Intensity Focused Ultrasound for Localized Prostate Cancer. unassigned - 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30598160&form=6&db=m Rolling circle amplification integrated with suspension bead array for ultrasensitive multiplex immunodetection of tumor markers. diagnostic usage,unassigned 4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30662360&form=6&db=m Establishing a prediction model for prostate cancer bone metastasis. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30759692&form=6&db=m Comparison of Prostate Biopsy with or without Prebiopsy Multiparametric Magnetic Resonance Imaging for Prostate Cancer Detection: An Observational Cohort Study. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30802065&form=6&db=m Intracellular Activation of a Prostate Specific Antigen-Cleavable Doxorubicin Prodrug: a Key Feature Towards Prodrug-Nanomedicine Design. unassigned - 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30810464&form=6&db=m Clinical Validation of IsoPSA™, a Single Parameter, Structure Based Assay for Improved Detection of High Grade Prostate Cancer. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30835628&form=6&db=m The Ratio of the Number of Biopsy Specimens to Prostate Volume (Biopsy Density) Greater Than 1.5 Improves the Prostate Cancer Detection Rate in Men Undergoing Transperineal Biopsy of the Prostate. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30848745&form=6&db=m [Conventional serum tumor markers in liver cancer. Retrospective analysis of 118 patients]. diagnostic usage,unassigned 4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30885200&form=6&db=m Literature review of the burden of prostate cancer in Germany, France, the United Kingdom and Canada. causal interaction,unassigned 3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30954471&form=6&db=m Functional Organotypic Cultures of Prostate Tissues: A Relevant Preclinical Model that Preserves Hypoxia Sensitivity and Calcium Signaling. causal interaction,ongoing research,unassigned 1,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30971069&form=6&db=m Rectal Invasion by Prostatic Adenocarcinoma That Was Initially Diagnosed in a Rectal Polyp on Colonoscopy. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30973040&form=6&db=m TGF-?/PI3K/AKT/mTOR/NF-kB pathway. Clinicopathological features in prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31035335&form=6&db=m Targeting Tumor Markers with Antisense Peptides: An Example of Human Prostate Specific Antigen. diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31060606&form=6&db=m Similar incidence of DNA damage response pathway alterations between clinically localized and metastatic prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,3,4 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31067848&form=6&db=m [A Case Report : Primary Urothelial Carcinoma of the Prostate Producing Interleukin-6 Detected from a Fever]. diagnostic usage,unassigned 4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31112106&form=6&db=m Personalized Risks of Over Diagnosis for Screen Detected Prostate Cancer Incorporating Patient Comorbidities: Estimation and Communication. diagnostic usage,unassigned 2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31144590&form=6&db=m Combined External Beam Radiation Therapy and Brachytherapy versus Radical Prostatectomy with Adjuvant Radiation Therapy of Gleason 9-10 Prostate Cancer. diagnostic usage,ongoing research,therapeutic application,unassigned 3,3,3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31347953&form=6&db=m Hemigland Cryoablation of Localized Low, Intermediate and High Risk Prostate Cancer: Oncologic and Functional Outcomes at 5 Years. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31383015&form=6&db=m Is there any association between prostate-specific antigen screening frequency and uptake of active surveillance in men with low or very low risk prostate cancer? causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31384885&form=6&db=m The role of modelling in the policy decision making process for cancer screening: example of prostate specific antigen screening. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,2,2,3 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31414747&form=6&db=m Evaluation of MARK BTM for Quantitative Measurement of Three Tumor Markers: Prostate Specific Antigen, Alpha Fetoprotein, and Carcinoembryonic Antigen. causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31569672&form=6&db=m Increased Plasmatic Levels of PSA-Expressing Exosomes Distinguish Prostate Cancer Patients from Benign Prostatic Hyperplasia: A Prospective Study. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31577907&form=6&db=m Clinical utility of emerging biomarkers in prostate cancer liquid biopsies. ongoing research,unassigned 1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31614271&form=6&db=m A novel label-free colorimetric aptasensor for sensitive determination of PSA biomarker using gold nanoparticles and a cationic polymer in human serum. diagnostic usage,ongoing research,unassigned 4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31679971&form=6&db=m 6-Substituted amiloride derivatives as inhibitors of the urokinase-type plasminogen activator for use in metastatic disease. unassigned - 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31718396&form=6&db=m Development and External Validation of a Multiparametric Magnetic Resonance Imaging and International Society of Urological Pathology Based Add-On Prediction Tool to Identify Prostate Cancer Candidates for Pelvic Lymph Node Dissection. diagnostic usage,unassigned 4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31734078&form=6&db=m Prevalence and correlates of non-tissue prostate cancer diagnosis in the United States. diagnostic usage,ongoing research,unassigned 2,3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31785151&form=6&db=m Circulating ensembles of tumor-associated cells: A redoubtable new systemic hallmark of cancer. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31794085&form=6&db=m The clinical predictive factors and postoperative histopathological parameters associated with upgrading after radical prostatectomy: A contemporary analysis with grade groups. diagnostic usage,unassigned 3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31802056&form=6&db=m Impact of pre-treatment variables on the completion of 223radium-dichloride therapy in mCRPC patients with bone metastases. diagnostic usage,ongoing research,therapeutic application,unassigned 3,2,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31845840&form=6&db=m Association between Postoperative Detection of Circulating Tumor Cells and Recurrence in Patients with Prostate Cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31860754&form=6&db=m Response of intraductal carcinoma of the prostate to androgen deprivation therapy predicts prostate cancer prognosis in radical prostatectomy patients. diagnostic usage,unassigned 4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31928408&form=6&db=m Prostate Specific Antigen Criteria to Diagnose Failure of Cancer Control following Focal Therapy of Nonmetastatic Prostate Cancer Using High Intensity Focused Ultrasound. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31933772&form=6&db=m Expression of ARHGAP10 correlates with prognosis of prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31956215&form=6&db=m [TROUSSEAU'S SYNDROME ACCOMPANIED BY ADVANCED PROSTATE CANCER THAT DEVELOPED ISCHEMIC STROKE; A CASE REPORT]. diagnostic usage,unassigned 4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31988233&form=6&db=m Pharmacodynamics effects of CDK4/6 inhibitor LEE011 (ribociclib) in high-risk, localised prostate cancer: a study protocol for a randomised controlled phase II trial (LEEP study: LEE011 in high-risk, localised Prostate cancer). diagnostic usage,unassigned 2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32019501&form=6&db=m Development and validation of a preoperative nomogram for predicting survival of patients with locally advanced prostate cancer after radical prostatectomy. diagnostic usage,unassigned 4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32053990&form=6&db=m Beyond PSA: The Role of Prostate Health Index (phi). causal interaction,diagnostic usage,therapeutic application,unassigned 2,4,3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32057646&form=6&db=m [Indications and outlooks of radiohormonal therapy of high-risk prostate cancers]. diagnostic usage,unassigned 4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32069024&form=6&db=m Simultaneous Detection of Multiple Tumor Markers in Blood by Functional Liquid Crystal Sensors Assisted with Target-Induced Dissociation of Aptamer. diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32213206&form=6&db=m Overall survival prediction in metastatic castration-resistant prostate cancer treated with radium-223. diagnostic usage,therapeutic application,unassigned 2,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32243242&form=6&db=m Competing Risks of Mortality among Men with Biochemical Recurrence after Radical Prostatectomy. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32257976&form=6&db=m Cyclooxygenase-2 inhibitors delay relapse and reduce Prostate Specific Antigen (PSA) velocity in patients treated with radiotherapy for nonmetastatic prostate cancer: a pilot study. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,2,4 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32327702&form=6&db=m African-American men with low-risk prostate cancer treated with radical prostatectomy in an equal-access health care system: implications for active surveillance. diagnostic usage,ongoing research,therapeutic application,unassigned 3,2,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32334022&form=6&db=m Identification of six novel alternative transcripts of the human kallikrein-related peptidase 15 (KLK15), using 3'RACE and high-throughput sequencing. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32420205&form=6&db=m Single port robotic radical prostatectomy: a systematic review. diagnostic usage,unassigned 3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32446432&form=6&db=m Imaging and Management of Prostate Cancer. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32496160&form=6&db=m Does the Visibility of Grade Group 1 Prostate Cancer on Baseline Multiparametric Magnetic Resonance Imaging Impact Clinical Outcomes? diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32671252&form=6&db=m A novel immunosensor for the monitoring of PSA using binding of biotinylated antibody to the prostate specific antigen based on nano-ink modified flexible paper substrate: efficient method for diagnosis of cancer using biosensing technology. diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32673683&form=6&db=m Quantification of perineural invasion focus after radical prostatectomy could improve predictive power of recurrence. diagnostic usage,ongoing research,unassigned 4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32773789&form=6&db=m [A clinical analysis of 14 cases of prostatic stromal tumor of uncertain malignant potential]. diagnostic usage,unassigned 3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32796451&form=6&db=m Is there a utility of adding skeletal imaging to 68-Ga-prostate-specific membrane antigen-PET/computed tomography in initial staging of patients with high-risk prostate cancer? causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32821294&form=6&db=m Vibrational spectroscopy of liquid biopsies for prostate cancer diagnosis. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32826248&form=6&db=m Unique Features of Prostate Cancer in African American and West Indian Patients Including Diagnosis of High Grade Cancers Using Only Elevated Serum Levels of Prostate Specific Antigen. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32843956&form=6&db=m Increases in tumor markers are associated with primary Sjögren's syndrome-associated interstitial lung disease. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32950271&form=6&db=m Impact of organ confined prostate cancer treatment on quality of life. causal interaction,diagnostic usage,unassigned 1,2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33026934&form=6&db=m Predicting Pathological Tumor Size in Prostate Cancer Based on Multiparametric Prostate Magnetic Resonance Imaging and Preoperative Findings. diagnostic usage,unassigned 3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33032306&form=6&db=m Prostate cancer screening in New Zealand: lessons from the past to shape the future in the light of changing evidence. diagnostic usage,unassigned 4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33035140&form=6&db=m Does Baseline Serum Testosterone Influence Androgen Deprivation Therapy Outcomes in Hormone Naïve Patients with Advanced Prostate Cancer? diagnostic usage,unassigned 3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33160844&form=6&db=m "Robotic fatigue?" - The impact of case order on positive surgical margins in robotic-assisted laparoscopic prostatectomy. causal interaction,diagnostic usage,unassigned 2,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33198555&form=6&db=m The Clinical Significance of Multiple Negative Surveillance Prostate Biopsies for Men on Active Surveillance-Does Cancer Vanish or Simply Hide? causal interaction,diagnostic usage,therapeutic application,unassigned 2,2,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33207140&form=6&db=m Can 68Ga-PSMA-11 Positron Emission Tomography/Computerized Tomography Predict Pathological Response of Primary Prostate Cancer to Neoadjuvant Androgen Deprivation Therapy? A Pilot Study. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33263957&form=6&db=m [Early detection of prostate cancer: a summary of the past 10 years]. therapeutic application,unassigned 1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33324607&form=6&db=m Highly Selective Optical Sensor Eu (TTA)3 Phen Embedded in Poly Methylmethacrylate for Assessment of Total Prostate Specific Antigen Tumor Marker in Male Serum Suffering Prostate Diseases. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33350857&form=6&db=m Therapies for Clinically Localized Prostate Cancer: A Comparative Effectiveness Review. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33351846&form=6&db=m Association between prostate cancer characteristics and BRCA1/2-associated family cancer history in a Japanese cohort. causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33402973&form=6&db=m Prostate hyperplasia in St Mary's Hospital Lacor: utility of prostate specific antigen in screening for prostate malignancy. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33407381&form=6&db=m Predicting Gleason sum upgrading from biopsy to radical prostatectomy pathology: a new nomogram and its internal validation. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33490732&form=6&db=m Markers of Toxicity and Response to Radiation Therapy in Patients With Prostate Cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,4,2 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33539897&form=6&db=m Photoselective Vaporization of the Prostate in the Management of Lower Urinary Tract Symptoms in Prostate Cancer Patients on Active Surveillance. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33550581&form=6&db=m A Modified Partin Table to Better Predict Extracapsular Extension in Clinically Localized Prostate Cancer. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33671134&form=6&db=m p38 MAPK Inhibition Mitigates Hypoxia-Induced AR Signaling in Castration-Resistant Prostate Cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,4,4 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33718631&form=6&db=m Screening for new peptide substrates for the development of albumin binding anticancer pro-drugs that are cleaved by prostate-specific antigen (PSA) to improve the anti tumor efficacy. causal interaction,diagnostic usage,therapeutic application,unassigned 1,2,4,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33789930&form=6&db=m Tumor detection of 18F-PSMA-1007 in the prostate gland in patients with prostate cancer using prostatectomy specimens as reference method. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33804289&form=6&db=m Screening of 5- and 6-Substituted Amiloride Libraries Identifies Dual-uPA/NHE1 Active and Single Target-Selective Inhibitors. therapeutic application,unassigned 2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33834977&form=6&db=m [The predictive value of medical big data for the prognosis of elderly patients with pneumonia: based on the result of clinical database of a Beijing Chaoyang Hospital Consortium Chaoyang Emergency Ward]. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33890485&form=6&db=m Association between Lesion Location and Oncologic Outcomes after Focal Therapy for Localized Prostate Cancer Using Either High Intensity Focused Ultrasound or Cryotherapy. diagnostic usage,therapeutic application,unassigned 4,2,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33934962&form=6&db=m Prostate cancer and microfluids. causal interaction,diagnostic usage,therapeutic application,unassigned 1,3,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33941976&form=6&db=m Giant dumbbell-shaped prostatic cystadenoma presenting as pelvic and scrotal mass. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,1,1 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34311541&form=6&db=m Emerging impact of quercetin in the treatment of prostate cancer. causal interaction,unassigned 3,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34375129&form=6&db=m Comparing Revo-i and da Vinci in Retzius-sparing robot-assisted radical prostatectomy: a preliminary propensity score analysis of outcomes. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,1,1 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34452888&form=6&db=m N-Butylphthalide vs. Human Urinary Kallidinogenase for the Treatment of Acute Ischemic Stroke: Functional Outcome and Impact on Serum VEGF and TNF-? Expressions. causal interaction,ongoing research,therapeutic application,unassigned 2,4,1,0 3.4.21.35 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34503355&form=6&db=m Factors Associated with Time to Conversion from Active Surveillance to Treatment for Prostate Cancer in a Multi-Institutional Cohort. causal interaction,diagnostic usage,unassigned 2,3,0 3.4.21.35 Neoplasms, Germ Cell and Embryonal http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12752266&form=6&db=m Human tissue kallikreins and testicular cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 2,2,1,0 3.4.21.35 Neoplasms, Second Primary http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15879786&form=6&db=m The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. diagnostic usage,ongoing research,therapeutic application,unassigned 4,2,2,0 3.4.21.35 Neoplastic Cells, Circulating http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11432343&form=6&db=m [Clinical significance of detecting circulating cancer cells in patients with solid malignancies] diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Neoplastic Cells, Circulating http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12210484&form=6&db=m Linkage between polymorphisms in the prostate specific antigen ARE1 gene region, prostate cancer risk, and circulating tumor cells. causal interaction,diagnostic usage,ongoing research,unassigned 1,3,2,0 3.4.21.35 Neoplastic Cells, Circulating http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18423725&form=6&db=m Circulating tumor cells in peripheral blood samples from patients with increased serum prostate specific antigen: initial results in early prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,1,1 3.4.21.35 Neoplastic Cells, Circulating http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18707699&form=6&db=m Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,4,0 3.4.21.35 Neoplastic Cells, Circulating http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19150091&form=6&db=m Prognostic significance of circulating tumor cells in patients with hormone refractory prostate cancer. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.35 Neoplastic Cells, Circulating http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24793632&form=6&db=m [Abiraterone acetate (AA): current guidelines of prescription of abiraterone]. causal interaction,ongoing research,therapeutic application,unassigned 3,3,2,0 3.4.21.35 Neoplastic Cells, Circulating http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25199875&form=6&db=m Circulating tumor cells in prostate cancer: a better predictor of survival than prostate specific antigen? causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,3,1 3.4.21.35 Neoplastic Cells, Circulating http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31845840&form=6&db=m Association between Postoperative Detection of Circulating Tumor Cells and Recurrence in Patients with Prostate Cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,3,0 3.4.21.35 Neoplastic Cells, Circulating http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33934962&form=6&db=m Prostate cancer and microfluids. causal interaction,diagnostic usage,therapeutic application,unassigned 1,3,1,0 3.4.21.35 Nervous System Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18591930&form=6&db=m Treatment options for benign prostatic hyperplasia in older men. causal interaction,diagnostic usage,therapeutic application,unassigned 1,3,3,0 3.4.21.35 Neuroblastoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3360206&form=6&db=m Identification of latent tissue kallikrein, prolactin and growth hormone secretion in GH3 pituitary cells using modified radioimmunoassays. ongoing research,unassigned 2,0 3.4.21.35 Neuroblastoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16865540&form=6&db=m Tissue kallikrein and kinin receptor expression in an angiogenic co-culture neuroblastoma model. diagnostic usage,ongoing research,therapeutic application,unassigned 1,3,1,0 3.4.21.35 Neuroendocrine Tumors http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8996358&form=6&db=m Plasma chromogranin A in prostatic carcinoma and neuroendocrine tumors. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.35 Neuroendocrine Tumors http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9448972&form=6&db=m Pure small cell carcinoma of the prostate. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,2,0 3.4.21.35 Neuroendocrine Tumors http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28034291&form=6&db=m Radiopharmaceuticals for the Diagnosis and Therapy of Neuroendocrine Differentiated Prostate Cancer. causal interaction,diagnostic usage,unassigned 3,3,0 3.4.21.35 Neuroinflammatory Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31428213&form=6&db=m Human Urinary Kallidinogenase Reduces Lipopolysaccharide-Induced Neuroinflammation and Oxidative Stress in BV-2 Cells. ongoing research,unassigned 4,0 3.4.21.35 Newcastle Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28935568&form=6&db=m Genetically engineered oncolytic Newcastle disease virus mediates cytolysis of prostate cancer stem like cells. ongoing research,unassigned 3,0 3.4.21.35 Non-alcoholic Fatty Liver Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27219496&form=6&db=m AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,4,0 3.4.21.35 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14691120&form=6&db=m Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,1,0 3.4.21.35 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15247719&form=6&db=m Obesity and biochemical outcome following radical prostatectomy for organ confined disease with negative surgical margins. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15586023&form=6&db=m Obesity and prostate cancer. diagnostic usage,unassigned 4,0 3.4.21.35 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15711258&form=6&db=m Obesity and prostate cancer clinical risk factors at presentation: data from CaPSURE. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.35 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16406980&form=6&db=m Obesity, serum prostate specific antigen and prostate size: implications for prostate cancer detection. diagnostic usage,therapeutic application,unassigned 4,2,0 3.4.21.35 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16753415&form=6&db=m Obesity adversely affects health related quality of life before and after radical retropubic prostatectomy. causal interaction,therapeutic application,unassigned 2,1,0 3.4.21.35 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16890735&form=6&db=m Re: Obesity, serum prostate specific antigen and prostate size: implications for prostate cancer detection. S. J. Freedland, E. A. Platz, J. C. Presti Jr., W. J. Aronson, C. L. Amling, C. J. Kane and M. K. Terris. J Urol, 175: 500-504, 2006. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.35 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16981964&form=6&db=m Renal functional reserve in obesity hypertension. ongoing research,unassigned 4,0 3.4.21.35 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17162013&form=6&db=m Does body mass index affect preoperative prostate specific antigen velocity or pathological outcomes after radical prostatectomy? causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,2,3 3.4.21.35 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17936811&form=6&db=m The ratio of oleic-to-stearic acid in the prostate predicts biochemical failure after radical prostatectomy for localized prostate cancer. diagnostic usage,unassigned 4,0 3.4.21.35 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18207169&form=6&db=m Association of obesity with prostate specific antigen and prostate specific antigen velocity in healthy young men. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,2 3.4.21.35 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18554651&form=6&db=m Health risk behaviors and prostate specific antigen awareness among men in California. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,1,1 3.4.21.35 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19450837&form=6&db=m Effect of body mass index and waist circumference on prostate specific antigen and prostate volume in a generally healthy Korean population. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.35 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19524974&form=6&db=m Body mass index and prostate specific antigen as predictors of adverse pathology and biochemical recurrence after prostatectomy. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,1,2 3.4.21.35 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19581922&form=6&db=m Obese men have higher-grade and larger tumors: an analysis of the duke prostate center database. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19836806&form=6&db=m Should Prostate Specific Antigen be Adjusted for Body Mass Index? Data From the Baltimore Longitudinal Study of Aging. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,1 3.4.21.35 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20399465&form=6&db=m Association of Body Mass Index With Prostate Cancer Biochemical Failure. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.35 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20620404&form=6&db=m Prostate specific antigen mass ratio potential as a prostate cancer screening tool. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,3,0 3.4.21.35 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25218922&form=6&db=m Poor glycemic control is associated with reduced prostate specific antigen concentrations in men with type 1 diabetes. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,1 3.4.21.35 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25916673&form=6&db=m Age and Obesity Promote Methylation and Suppression of 5?-Reductase 2: Implications for Personalized Therapy of Benign Prostatic Hyperplasia. causal interaction,diagnostic usage,unassigned 3,2,0 3.4.21.35 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26714904&form=6&db=m [Association between obesity-related plasma hemodilution and the concentration of prostate specific antigen]. causal interaction,ongoing research,unassigned 1,3,0 3.4.21.35 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27219496&form=6&db=m AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,4,0 3.4.21.35 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29941675&form=6&db=m The inverse relationship between prostate specific antigen (PSA) and obesity. causal interaction,diagnostic usage,ongoing research,unassigned 1,2,2,0 3.4.21.35 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30306787&form=6&db=m The inverse relationship between prostate specific antigen (PSA) and obesity causal interaction,diagnostic usage,ongoing research,unassigned 1,2,2,0 3.4.21.35 Obesity, Abdominal http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22425083&form=6&db=m Effect of central obesity on prostate specific antigen measured by computerized tomography: related markers and prostate volume. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Oligospermia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15317189&form=6&db=m Evaluation of three rapid detection methods for the forensic identification of seminal fluid in rape cases. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.35 Osteoarthritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2649023&form=6&db=m A tissue kallikrein in the synovial fluid of patients with rheumatoid arthritis. causal interaction,diagnostic usage,unassigned 4,2,0 3.4.21.35 Osteoarthritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27219496&form=6&db=m AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,4,0 3.4.21.35 Osteoporosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14616447&form=6&db=m Immediate dual energy X-ray absorptiometry reveals a high incidence of osteoporosis in patients with advanced prostate cancer before hormonal manipulation. causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.35 Otitis Media http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32772925&form=6&db=m A top 5 list for French general practice. causal interaction,diagnostic usage,unassigned 3,1,0 3.4.21.35 Otitis Media with Effusion http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32772925&form=6&db=m A top 5 list for French general practice. causal interaction,diagnostic usage,unassigned 3,1,0 3.4.21.35 Ovarian Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7523735&form=6&db=m Prostate cancer screening in the prostate, lung, colorectal and ovarian cancer screening trial of the National Cancer Institute. diagnostic usage,ongoing research,therapeutic application,unassigned 2,1,1,0 3.4.21.35 Ovarian Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8898378&form=6&db=m A novel protease homolog differentially expressed in breast and ovarian cancer. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,4,0 3.4.21.35 Ovarian Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9494598&form=6&db=m Prostate specific antigen (PSA) in breast and ovarian cancer. diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.35 Ovarian Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12915603&form=6&db=m Prognostic value of the human kallikrein gene 15 expression in ovarian cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,1 3.4.21.35 Ovarian Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16515981&form=6&db=m Prostate specific antigen changes as related to the initial prostate specific antigen: data from the prostate, lung, colorectal and ovarian cancer screening trial. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,2 3.4.21.35 Ovarian Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16800744&form=6&db=m Overexpression of the human tissue kallikrein genes KLK4, 5, 6, and 7 increases the malignant phenotype of ovarian cancer cells. causal interaction,diagnostic usage,ongoing research,unassigned 1,3,3,0 3.4.21.35 Ovarian Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16895483&form=6&db=m Disease processes may be reflected by correlations among tissue kallikrein proteases but not with proteolytic factors uPA and PAI-1 in primary ovarian carcinoma. causal interaction,diagnostic usage,unassigned 4,2,0 3.4.21.35 Ovarian Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16950394&form=6&db=m Crystal structures of human tissue kallikrein 4: activity modulation by a specific zinc binding site. causal interaction,diagnostic usage,unassigned 3,2,0 3.4.21.35 Ovarian Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19383346&form=6&db=m Impact of cytogenetic and genomic aberrations of the kallikrein locus in ovarian cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,3,0 3.4.21.35 Ovarian Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20800559&form=6&db=m Genomic instability and copy-number heterogeneity of chromosome 19q, including the kallikrein locus, in ovarian carcinomas. causal interaction,diagnostic usage,unassigned 2,4,0 3.4.21.35 Ovarian Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21457553&form=6&db=m A Kallikrein 15 (KLK15) single nucleotide polymorphism located close to a novel exon shows evidence of association with poor ovarian cancer survival. causal interaction,diagnostic usage,unassigned 3,3,0 3.4.21.35 Ovarian Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21604935&form=6&db=m The Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial: the prostate cancer screening results in context. diagnostic usage,unassigned 4,0 3.4.21.35 Ovarian Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27569432&form=6&db=m Prognostic Significance of Digital Rectal Examination and Prostate Specific Antigen in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Arm. causal interaction,diagnostic usage,ongoing research,unassigned 3,4,3,0 3.4.21.35 Overweight http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15711258&form=6&db=m Obesity and prostate cancer clinical risk factors at presentation: data from CaPSURE. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.35 Overweight http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27219496&form=6&db=m AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,4,0 3.4.21.35 Pancreatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1725573&form=6&db=m Urinary kallikrein excretion in chronic pancreatic diseases. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,4,0 3.4.21.35 Pancreatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12933515&form=6&db=m Combining diagnostic test results to increase accuracy. diagnostic usage,unassigned 4,0 3.4.21.35 Pancreatitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=375113&form=6&db=m Kallikrein, kininogen and kinins in control of blood pressure. causal interaction,diagnostic usage,therapeutic application,unassigned 3,2,1,0 3.4.21.35 Pancreatitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1725573&form=6&db=m Urinary kallikrein excretion in chronic pancreatic diseases. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,4,0 3.4.21.35 Pancreatitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2481954&form=6&db=m Role of the kallikrein-kinin system in human pancreatitis. causal interaction,diagnostic usage,ongoing research,unassigned 3,3,1,0 3.4.21.35 Pancreatitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8005167&form=6&db=m Studies on the release of tissue kallikrein in experimental pancreatitis in the pig. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,3,1 3.4.21.35 Pancreatitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8326807&form=6&db=m [Enzyme liberation and activation of the kallikrein-kinin system in experimental pancreatitis. Studies of portal vein blood, pancreatic lymph and peritoneal effusion] causal interaction,unassigned 4,0 3.4.21.35 Pancreatitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9535704&form=6&db=m Expression and characterization of human tissue kallikrein variants. therapeutic application,unassigned 4,0 3.4.21.35 Pancreatitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10547191&form=6&db=m Tissue kallikrein in severe acute pancreatitis in patients treated with high-dose intraperitoneal aprotinin. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,4,3 3.4.21.35 Pancreatitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12381683&form=6&db=m Involvement of tissue kallikrein but not plasma kallikrein in the development of symptoms mediated by endogenous kinins in acute pancreatitis in rats. therapeutic application,unassigned 3,0 3.4.21.35 Pancreatitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12770935&form=6&db=m Mechanism of kinin release during experimental acute pancreatitis in rats: evidence for pro- as well as anti-inflammatory roles of oedema formation. causal interaction,therapeutic application,unassigned 2,1,0 3.4.21.35 Pancreatitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18695645&form=6&db=m Kallikrein inhibitors limit kinin B(2) antagonist-induced progression of oedematous to haemorrhagic pancreatitis in rats. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.35 Pancreatitis, Acute Necrotizing http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10547191&form=6&db=m Tissue kallikrein in severe acute pancreatitis in patients treated with high-dose intraperitoneal aprotinin. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,4,3 3.4.21.35 Pancytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22767279&form=6&db=m [Prostate cancer with disseminated carcinomatosis of bone marrow initially presenting with disseminated intravascular coagulation syndrome: a case report]. causal interaction,diagnostic usage,unassigned 2,3,0 3.4.21.35 Paralysis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12439671&form=6&db=m Bilateral third and unilateral sixth nerve palsies as early presenting signs of metastatic prostatic carcinoma. causal interaction,unassigned 4,0 3.4.21.35 Parkinson Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10997858&form=6&db=m Localization of a novel type trypsin-like serine protease, neurosin, in brain tissues of Alzheimer's disease and Parkinson's disease. causal interaction,diagnostic usage,ongoing research,unassigned 3,2,4,0 3.4.21.35 Parotitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2416305&form=6&db=m New concepts in the treatment of chronic recurrent parotitis. diagnostic usage,ongoing research,therapeutic application,unassigned 1,3,4,0 3.4.21.35 Parotitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2423832&form=6&db=m [Treatment of chronic recurring parotitis with the protease inhibitor aprotinin (trasylol)] causal interaction,ongoing research,therapeutic application,unassigned 3,3,4,0 3.4.21.35 Parotitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3495094&form=6&db=m Effect of radioactive iodine therapy on parotid gland function. diagnostic usage,unassigned 2,0 3.4.21.35 Parotitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6569964&form=6&db=m [Glandular kallikrein in chronic recurrent parotitis] causal interaction,diagnostic usage,ongoing research,unassigned 3,4,2,0 3.4.21.35 Parotitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21449659&form=6&db=m Effect of radioactive iodine therapy on parotid gland function. diagnostic usage,unassigned 2,0 3.4.21.35 Pemphigus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15840094&form=6&db=m Increased activity of plasma and tissue kallikreins, plasma kininase II and salivary kallikrein in pemphigus foliaceus (fogo selvagem). diagnostic usage,ongoing research,unassigned 1,2,0 3.4.21.35 Periodontal Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=618762&form=6&db=m Blood flow, collagen components of oral tissue and salivary kallikrein in young to senescent, germfree and conventional rats. A study on the etiologic factors of periodontal disease. ongoing research,unassigned 4,0 3.4.21.35 Periodontal Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1088326&form=6&db=m [Role of salivary kallikrein in the pathogenesis of periodontosis] causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.35 Periodontal Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3028080&form=6&db=m Salivary kallikrein and kininase activities in periodontal diseases. unassigned - 3.4.21.35 Periodontal Pocket http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7628782&form=6&db=m [Experimental periodontitis in rats] diagnostic usage,ongoing research,unassigned 3,3,0 3.4.21.35 Peripheral Arterial Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28426464&form=6&db=m Comparative effectiveness in urology: a state of the art review utilizing a systematic approach. causal interaction,diagnostic usage,therapeutic application,unassigned 3,2,2,0 3.4.21.35 Pheochromocytoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15598314&form=6&db=m Autopsy case of prostate cancer with multiple endocrine neoplasia 2A. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,3,0 3.4.21.35 Pituitary Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26415325&form=6&db=m INITIAL SYMPTOMATIC PITUITARY METASTASIS IN A PATIENT WITH PROSTATE FOAMY GLAND CARCINOMA: TAILORING SAFE AND EFFECTIVE THERAPY. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,1,0 3.4.21.35 Pituitary Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1462825&form=6&db=m Tissue kallikrein and the effect of bromocriptine in human prolactin and growth hormone-secreting pituitary adenomas. causal interaction,ongoing research,therapeutic application,unassigned 1,2,1,0 3.4.21.35 Pituitary Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1492535&form=6&db=m Bioregulatory role of the kallikrein-kinin system in the normal pituitary gland and its tumours. causal interaction,ongoing research,unassigned 4,3,0 3.4.21.35 Pituitary Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1500840&form=6&db=m Tissue kallikrein is associated with prolactin-secreting cells within human growth hormone-secreting adenomas. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,4,2 3.4.21.35 Pituitary Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3390808&form=6&db=m Glandular kallikrein in estrogen-induced pituitary tumors: time course of induction and correlation with prolactin. causal interaction,ongoing research,unassigned 4,2,0 3.4.21.35 Pituitary Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3640707&form=6&db=m Elevated glandular kallikrein in estrogen-induced pituitary tumors. causal interaction,unassigned 4,0 3.4.21.35 Pituitary Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12050526&form=6&db=m Decreasing prostate specific antigen value leading to the diagnosis of a pituitary adenoma. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.35 plasma kallikrein deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23324381&form=6&db=m Tissue kallikrein, blood pressure regulation, and hypertension: insight from genetic kallikrein deficiency. causal interaction,ongoing research,therapeutic application,unassigned 4,2,2,0 3.4.21.35 Pleural Effusion, Malignant http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12224436&form=6&db=m [Utility of prostate-specific antigen in pleural fluid for the diagnosis of metastatic effusion secondary to prostate cancer] causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.35 Pneumonia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15333115&form=6&db=m Associations of race, education, and patterns of preventive service use with stage of cancer at time of diagnosis. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Pneumonia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21760880&form=6&db=m Granzyme K activates protease-activated receptor-1. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.35 Pneumonia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33834977&form=6&db=m [The predictive value of medical big data for the prognosis of elderly patients with pneumonia: based on the result of clinical database of a Beijing Chaoyang Hospital Consortium Chaoyang Emergency Ward]. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,1,0 3.4.21.35 Polycystic Ovary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11297583&form=6&db=m Prostate-specific antigen and human glandular kallikrein 2 are markedly elevated in urine of patients with polycystic ovary syndrome. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,1,0 3.4.21.35 Polycystic Ovary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15233555&form=6&db=m Serum prostate specific antigen levels in women with polycystic ovary syndrome and the effect of flutamide+desogestrel/ethinyl estradiol combination. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.35 Polycystic Ovary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19009369&form=6&db=m Diagnostic value of prostate-specific antigen (PSA) and free prostate specific antigen (fPSA) in women with ovulatory and anovulatory polycystic ovary syndrome. diagnostic usage,unassigned 3,0 3.4.21.35 Polycystic Ovary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24965976&form=6&db=m The combination of ovarian volume and outline has better diagnostic accuracy than prostate-specific antigen (PSA) concentrations in women with polycystic ovarian syndrome (PCOs). causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,3,1 3.4.21.35 Polycystic Ovary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27219496&form=6&db=m AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,4,0 3.4.21.35 Polycystic Ovary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27426018&form=6&db=m Prostate specific antigen (PSA) in diagnosis of polycystic ovarian syndrome - a new insight. causal interaction,diagnostic usage,therapeutic application,unassigned 2,4,3,0 3.4.21.35 Polycystic Ovary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30728681&form=6&db=m A Study on Omentin-1 and Prostate Specific Antigen in Women on Treatment for Polycystic Ovary Syndrome. diagnostic usage,therapeutic application,unassigned 2,4,0 3.4.21.35 Polycythemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17767032&form=6&db=m [Hormone replacement Up-to-date. Clinical practice of androgen replacement therapy] causal interaction,diagnostic usage,therapeutic application,unassigned 1,3,4,0 3.4.21.35 Pre-Eclampsia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9228554&form=6&db=m Localisation of tissue kallikrein in the kidney of black African women with early onset pre-eclampsia: a pilot study. therapeutic application,unassigned 2,0 3.4.21.35 Pre-Eclampsia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10203299&form=6&db=m Urinary tissue kallikrein excretion in black African women with severe pre-eclampsia. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.35 Pre-Eclampsia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11194435&form=6&db=m Tissue kallikrein activity in pregnancy. causal interaction,unassigned 4,0 3.4.21.35 Pre-Eclampsia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31880472&form=6&db=m Plasma concentrations of tissue kallikrein in normal and preeclamptic pregnancies. diagnostic usage,ongoing research,unassigned 2,3,0 3.4.21.35 Proctitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25218798&form=6&db=m Rating general practitioner consultation performance in cancer care: does the specialty of assessors matter? A simulated patient study. diagnostic usage,ongoing research,therapeutic application,unassigned 2,2,1,0 3.4.21.35 Prolactinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1462825&form=6&db=m Tissue kallikrein and the effect of bromocriptine in human prolactin and growth hormone-secreting pituitary adenomas. causal interaction,ongoing research,therapeutic application,unassigned 1,2,1,0 3.4.21.35 Prolactinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1492535&form=6&db=m Bioregulatory role of the kallikrein-kinin system in the normal pituitary gland and its tumours. causal interaction,ongoing research,unassigned 4,3,0 3.4.21.35 Prolactinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1500840&form=6&db=m Tissue kallikrein is associated with prolactin-secreting cells within human growth hormone-secreting adenomas. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,4,2 3.4.21.35 Prolactinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2313220&form=6&db=m Characterization of a tissue kallikrein in human prolactin-secreting adenomas. diagnostic usage,ongoing research,unassigned 1,4,0 3.4.21.35 Prostatic Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1693867&form=6&db=m Gamma-seminoprotein--a new tumour marker in prostatic cancer? Results of a pilot study. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,4,0 3.4.21.35 Prostatic Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1720276&form=6&db=m [A mass screening of the prostatic diseases and serum prostate specific antigen] diagnostic usage,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.35 Prostatic Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1720942&form=6&db=m [Prostate-specific antigen. Interpretation of the results in relation to the sampling method] diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2464396&form=6&db=m Comparative study of the clinical usefulness of prostate specific antigen and prostatic acid phosphatase in prostatic disease. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,4,0 3.4.21.35 Prostatic Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7538598&form=6&db=m Prostate specific antigen density is not an independent predictor of response for prostate cancer treated by conformal radiotherapy. causal interaction,diagnostic usage,therapeutic application,unassigned 3,2,3,0 3.4.21.35 Prostatic Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7685140&form=6&db=m [Examination of serum prostate specific antigen (PSA) in the mass screening for prostatic diseases] causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.35 Prostatic Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7690018&form=6&db=m Prostate-specific antigen density: a new prognostic indicator for prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,4,0 3.4.21.35 Prostatic Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9161183&form=6&db=m Case report. Two contrasting radiological presentations of prostatic adenocarcinoma in the jaws. causal interaction,diagnostic usage,unassigned 3,2,0 3.4.21.35 Prostatic Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9594181&form=6&db=m [Influence of age on serum prostate specific antigen concentration] diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Prostatic Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9772876&form=6&db=m Influence of free-to-total prostate specific antigen variability on the early diagnosis of prostate cancer: a comparative study of three immunoassays. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,2 3.4.21.35 Prostatic Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10351981&form=6&db=m New ultrasensitive assays facilitate studies on the role of human glandular kallikrein (hK2) as a marker for prostatic disease. diagnostic usage,ongoing research,unassigned 3,3,0 3.4.21.35 Prostatic Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10759667&form=6&db=m Differential response of prostate specific antigen to testosterone surge after luteinizing hormone-releasing hormone analogue in prostate cancer and benign prostatic hyperplasia. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,3,2 3.4.21.35 Prostatic Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11107529&form=6&db=m [Screening for prostatic diseases in one-day total health check-up by using prostate specific antigen, international prostate symptom score and QOL index] diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11570874&form=6&db=m Modulation of recombinant human prostate-specific antigen: activation by Hofmeister salts and inhibition by azapeptides. Appendix: thermodynamic interpretation of the activation by concentrated salts. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.35 Prostatic Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11720279&form=6&db=m The role of molecular forms of prostate-specific antigen (PSA or hK3) and of human glandular kallikrein 2 (hK2) in the diagnosis and monitoring of prostate cancer and in extra-prostatic disease. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,3,0 3.4.21.35 Prostatic Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12394676&form=6&db=m Discrimination of benign from malignant prostatic disease by selective measurements of single chain, intact free prostate specific antigen. diagnostic usage,ongoing research,unassigned 3,2,0 3.4.21.35 Prostatic Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14665872&form=6&db=m Clinical usefulness of serum antip53 antibodies for prostate cancer detection: a comparative study with prostate specific antigen parameters. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15378521&form=6&db=m Association of free-prostate specific antigen subfractions and human glandular kallikrein 2 with volume of benign and malignant prostatic tissue. diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.35 Prostatic Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15623486&form=6&db=m Expression of prostate specific antigen in male breast cancer. causal interaction,diagnostic usage,ongoing research,unassigned 2,3,4,0 3.4.21.35 Prostatic Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16502049&form=6&db=m Relationship between Serum Prostate Specific Antigen and the Pattern of Inflammation in Both Benign and Malignant Prostatic Disease in Middle Eastern Men. causal interaction,diagnostic usage,ongoing research,unassigned 4,1,2,0 3.4.21.35 Prostatic Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17571482&form=6&db=m Significance of prostate specific antigen in prostate cancer patients and in non cancerous prostatic disease patients. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,2 3.4.21.35 Prostatic Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17997422&form=6&db=m Percent free prostate specific antigen does not enhance the specificity of total prostate specific antigen for the detection of prostate cancer in Korean men 50 to 65 years old: a prospective multicenter study. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,2 3.4.21.35 Prostatic Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18668524&form=6&db=m Nonhuman primates as models for studies of prostate specific antigen and prostatic diseases. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Prostatic Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18686378&form=6&db=m [Differentiation of prostate cancer from benign prostatic disease by total prostate specific antigen dynamic profiles after transrectal prostate biopsy] diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.35 Prostatic Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19012935&form=6&db=m Annexin A3 in urine: a highly specific noninvasive marker for prostate cancer early detection. causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.35 Prostatic Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19486654&form=6&db=m Psychological Distress and Prostate Specific Antigen Levels in Men with and without Prostate Cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,1 3.4.21.35 Prostatic Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21394741&form=6&db=m Enzymatically active prostate-specific antigen promotes growth of human prostate cancers. causal interaction,ongoing research,unassigned 3,4,0 3.4.21.35 Prostatic Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22292649&form=6&db=m The lady with raised prostate specific antigen: do we need to worry? causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Prostatic Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22666930&form=6&db=m Kappa statistics in the screening of malignancy of prostate. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Prostatic Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26328140&form=6&db=m The impact of educational sessions provided on prostate cancer, and its screening tests on the knowledge level, and participation behavior of the individuals in questionnaire surveys. diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1326881&form=6&db=m [Two cases of mucinous adenocarcinoma of the prostate] diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1371554&form=6&db=m Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,2,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1374178&form=6&db=m Volume of normal prostate, of prostate cancer, and of benign prostatic hyperplasia: are correlations with prostate specific antigen clinically useful? causal interaction,diagnostic usage,ongoing research,unassigned 3,4,1,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1376190&form=6&db=m Predicted prostate specific antigen results using transrectal ultrasound gland volume. Differentiation of benign prostatic hyperplasia and prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,1,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1690309&form=6&db=m Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,3,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1700143&form=6&db=m The relationship of prostate specific antigen levels and residual tumor volume in stage A prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,1 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1700150&form=6&db=m Serum prostate specific antigen levels during hyperthermia treatment of benign prostatic hyperplasia. causal interaction,unassigned 3,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1714969&form=6&db=m Effect of the addition of estrogen to medical castration on prostatic size, symptoms, histology and serum prostate specific antigen in 4 men with benign prostatic hypertrophy. causal interaction,diagnostic usage,ongoing research,unassigned 2,1,3,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1716409&form=6&db=m [Clinical and pathological study of tumor marker in benign prostatic hypertrophy and incidental prostatic cancer] causal interaction,diagnostic usage,ongoing research,unassigned 1,4,3,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1723815&form=6&db=m Evaluation of prostate-specific antigen and prostatic acid phosphatase in untreated prostatic carcinoma and benign prostatic hyperplasia. causal interaction,diagnostic usage,ongoing research,unassigned 3,4,3,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2435927&form=6&db=m An evaluation of prostate specific antigen in prostatic cancer. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,3,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2461644&form=6&db=m [Prostatic acid phosphatase (PAP), gamma-seminoprotein (gamma-Sm) and prostate specific antigen (PA) in prostatic cancer] causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,3,3 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2464396&form=6&db=m Comparative study of the clinical usefulness of prostate specific antigen and prostatic acid phosphatase in prostatic disease. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,4,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2464397&form=6&db=m The value of the measurement of serum prostate specific antigen in patients with benign prostatic hyperplasia and untreated prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,3,1 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2467544&form=6&db=m [Benign prostatic hypertrophy with high levels of gamma-seminoprotein (gamma-Sm), prostate specific antigen: report of two cases] causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,1,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2468794&form=6&db=m Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. I. Untreated patients. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,4 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2477559&form=6&db=m Clinical use of prostate specific antigen in patients with prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,3 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6206524&form=6&db=m [Purification and determination of human prostate specific antigen in the serum] causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,4 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7474621&form=6&db=m [Value of PSA/gamma-Sm ratio (P/S ratio) for diagnosis of prostate cancer in patients with urinary retention] causal interaction,diagnostic usage,ongoing research,unassigned 4,4,1,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7479388&form=6&db=m Serum free prostate specific antigen: isoenzymes in benign hyperplasia and cancer of the prostate. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,2,1 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7490873&form=6&db=m The effect of finasteride on prostate specific antigen: review of available data. diagnostic usage,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7512660&form=6&db=m Prostate specific antigen cannot distinguish stage T1a (A1) prostate cancer from benign prostatic hyperplasia. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,3,1 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7516401&form=6&db=m Prostate specific antigen density: a method for differentiating prostate carcinoma from benign prostatic hypertrophy demonstrates ethnic variation. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,1 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7517027&form=6&db=m [Significance of various examination methods in the management of prostatic cancer] diagnostic usage,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7518599&form=6&db=m Relationship between serum prostate specific antigen and histological prostatitis in patients with benign prostatic hyperplasia. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,3,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7524903&form=6&db=m Expression of human prostatic acid phosphatase and prostate specific antigen genes in neoplastic and benign tissues. causal interaction,diagnostic usage,ongoing research,unassigned 3,3,4,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7526007&form=6&db=m Using repeated measures of symptom score, uroflowmetry and prostate specific antigen in the clinical management of prostate disease. Benign Prostatic Hyperplasia Treatment Outcomes Study Group. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,2,2 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7527470&form=6&db=m [Prostate specific antigen in patients with prostatic cancer--clinical usefulness of its measurement with sensitive enzyme immunoassay, TOSOH II PA assay] diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7533925&form=6&db=m Influence of benign prostatic hyperplasia, testosterone and age on serum levels of prostate specific antigen. causal interaction,diagnostic usage,ongoing research,unassigned 2,4,3,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7541857&form=6&db=m Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,3,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7543596&form=6&db=m Autoantibodies to prostate specific antigen in patients with benign prostatic hyperplasia. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,4,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7545754&form=6&db=m Evaluation of serum and seminal plasma markers in the diagnosis of canine prostatic disorders. causal interaction,diagnostic usage,ongoing research,unassigned 3,4,4,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7563351&form=6&db=m Prostate specific antigen in the expressed prostatic fluid of men with benign prostatic hyperplasia and prostate carcinoma. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,3,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7684650&form=6&db=m Relationship between prostate specific antigen, prostate volume and age in the benign prostate. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7686979&form=6&db=m Changing trends in the management of prostatic disease in a single private practice: a 5-year followup. causal interaction,diagnostic usage,therapeutic application,unassigned 3,1,3,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7686984&form=6&db=m Does high grade prostatic intraepithelial neoplasia result in elevated serum prostate specific antigen levels? causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7688112&form=6&db=m [Reliability and use of prostate-specific antigen in the management of patients with prostatic cancer] causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,2,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7692111&form=6&db=m Measurement of prostate specific antigen and gamma-seminoprotein ratio: a new means of distinguishing benign prostatic hyperplasia and prostate cancer. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,3,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8632566&form=6&db=m The effects of ejaculation on serum prostate specific antigen. causal interaction,diagnostic usage,ongoing research,unassigned 2,2,4,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8683677&form=6&db=m A comparison of the free fraction of serum prostate specific antigen in men with benign and cancerous prostates: the best case scenario. diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8709302&form=6&db=m Serum prostate specific antigen levels after transurethral resection of prostate: a longitudinal characterization in men with benign prostatic hyperplasia. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,4,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8709303&form=6&db=m Symptom scores, watchful waiting and prostate specific antigen levels in benign prostatic hyperplasia. causal interaction,unassigned 1,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8847816&form=6&db=m [The significance of free-type PSA and complex-type PSA in patients with prostatic carcinoma--the characteristics of ACS-PSA method compared with that of Delfia- and Eiken-PSA method] causal interaction,diagnostic usage,ongoing research,unassigned 1,4,4,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8851481&form=6&db=m The efficacy of finasteride in the treatment of symptomatic benign prostatic hyperplasia. diagnostic usage,unassigned 3,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8973696&form=6&db=m Comparison of three assays for total serum prostate-specific antigen and percentage of free prostate-specific antigen in predicting prostate histology. diagnostic usage,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8976247&form=6&db=m Serum-to-urinary prostate specific antigen ratio: its impact in distinguishing prostate cancer when serum prostate specific antigen level is 4 to 10 ng./ml. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9023130&form=6&db=m Human prostate-specific glandular kallikrein is expressed as an active and an inactive protein. ongoing research,unassigned 4,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9072591&form=6&db=m The impact of systematic prostate biopsy on prostate cancer incidence in men with symptomatic benign prostatic hyperplasia undergoing transurethral resection of the prostate. causal interaction,diagnostic usage,ongoing research,unassigned 2,4,3,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9120926&form=6&db=m Inflammation in benign prostatic hyperplasia: correlation with prostate specific antigen value. causal interaction,unassigned 3,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9146608&form=6&db=m Prostate specific antigen in benign prostatic hyperplasia: purification and characterization. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,2,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9186314&form=6&db=m The relationship between prostatic intraepithelial neoplasia and prostate cancer: critical issues. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9329548&form=6&db=m First clinical results with Enzymun-Test for free PSA. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9334615&form=6&db=m Trends in diagnosis of stage T1a-b prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 2,4,3,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9351545&form=6&db=m Serum concentration of type I collagen metabolites as a quantitative marker of bone metastases in patients with prostate carcinoma. diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9366341&form=6&db=m Prostatic volume and ratio of free-to-total prostate specific antigen in patients with prostatic cancer or benign prostatic hyperplasia. causal interaction,diagnostic usage,ongoing research,unassigned 4,2,3,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9474173&form=6&db=m Elevation of prostate specific antigen in cardiac surgery with extracorporeal cardiopulmonary circulation. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,2,3,2 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9554361&form=6&db=m Ratio of free-to-total prostate specific antigen in serum cannot distinguish patients with prostate cancer from those with chronic inflammation of the prostate. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,3,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9649261&form=6&db=m Influence of finasteride on free and total serum prostate specific antigen levels in men with benign prostatic hyperplasia. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,1 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9702110&form=6&db=m [Prostate carcinoma: prostate-specific antigen--and then what?] causal interaction,diagnostic usage,unassigned 1,2,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9750496&form=6&db=m [Clinical significance of prostate specific antigen and gamma-seminoprotein ratio for diagnosing prostate cancer] causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,2 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9772876&form=6&db=m Influence of free-to-total prostate specific antigen variability on the early diagnosis of prostate cancer: a comparative study of three immunoassays. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,2 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9805668&form=6&db=m [Clinical significance of prostate specific antigen (PSA) and PSA density in the detection of T1a and T1b prostate cancer] causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,3,1 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9817329&form=6&db=m Free and complexed prostate specific antigen in the differentiation of benign prostatic hyperplasia and prostate cancer: studies in serum and plasma samples. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,4,1 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9817333&form=6&db=m Prostate cancer detection in candidates for open prostatectomy. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,3,1 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9849420&form=6&db=m Longitudinal evaluation of the complexed-to-total prostate specific antigen ratio in men with prostate disease. Effect of treatment. causal interaction,diagnostic usage,ongoing research,unassigned 2,4,4,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9934801&form=6&db=m Relationship between prostate specific antigen density, microvessel density and prostatic volume in benign prostatic hyperplasia and advanced prostatic carcinoma. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,4,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10368241&form=6&db=m Bleeding and activation of coagulation during and after transurethral prostatectomy: importance of the acute-phase response and prostate specific antigen? diagnostic usage,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10408309&form=6&db=m Evaluation of serum arginase activity in benign prostatic hypertrophy and prostatic cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,4 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10411077&form=6&db=m Re: Free and complexed prostate specific antigen in the differentiation of benign prostatic hyperplasia and prostate cancer: studies in serum and plasma samples. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,3,1 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10466060&form=6&db=m Prostate specific antigen density for discriminating prostate cancer from benign prostatic hyperplasia in the gray zone of prostate-specific antigen. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,3,2 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10492183&form=6&db=m Chronic treatment with finasteride daily does not affect spermatogenesis or semen production in young men. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,2,2,4 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10545066&form=6&db=m The combination of human glandular kallikrein and free prostate-specific antigen (PSA) enhances discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately increased total PSA. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,3,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10604304&form=6&db=m Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety study. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,1,2 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10650506&form=6&db=m Prostate specific antigen and benign prostatic hyperplasia. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,3,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10737484&form=6&db=m Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men. diagnostic usage,ongoing research,unassigned 2,3,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10759667&form=6&db=m Differential response of prostate specific antigen to testosterone surge after luteinizing hormone-releasing hormone analogue in prostate cancer and benign prostatic hyperplasia. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,3,2 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10841600&form=6&db=m Determination of transition zone volume by transrectal ultrasound in patients with clinically benign prostatic hyperplasia: agreement with enucleated prostate adenoma weight. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11107528&form=6&db=m [Rebound of prostate specific antigen after discontinuation of antiandrogen therapy for benign prostatic hyperplasia] causal interaction,ongoing research,therapeutic application,unassigned 4,2,4,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11173940&form=6&db=m Comparison of the clinical validity of free prostate-specific antigen, alpha-1 antichymotrypsin-bound prostate-specific antigen and complexed prostate-specific antigen in prostate cancer diagnosis. diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11326657&form=6&db=m Ratio of alpha 1-antichymotrypsin--prostate specific antigen to total prostate specific antigen in prostate cancer diagnosis. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,3,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11490716&form=6&db=m [Differential diagnostic value of prostate-specific antigen in prostatic hyperplasia] causal interaction,diagnostic usage,ongoing research,unassigned 1,4,3,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11507733&form=6&db=m A study of prostane in the treatment of benign prostatic hyperplasia. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11746262&form=6&db=m Plasma membrane association of cathepsin B in human prostate cancer: biochemical and immunogold electron microscopic analysis. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,3,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11753974&form=6&db=m Comparison of human prostate specific glandular kallikrein 2 and prostate specific antigen gene expression in prostate with gene amplification and overexpression of prostate specific glandular kallikrein 2 in tumor tissue. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,4,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11920529&form=6&db=m Prostate specific antigen complexed to alpha-1-antichymotrypsin in patients with intermediate prostate specific antigen levels. causal interaction,diagnostic usage,ongoing research,unassigned 3,4,2,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12197626&form=6&db=m Inflammation and glandular proliferation in hyperplastic prostates: association with prostate specific antigen value. causal interaction,diagnostic usage,unassigned 3,1,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12497098&form=6&db=m Prostate specific antigen measurements after minimally invasive surgery of the prostate in men with benign prostatic hypertrophy. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,2,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12518327&form=6&db=m Serum human glandular kallikrein (hK2) and insulin-like growth factor 1 (IGF-1) improve the discrimination between prostate cancer and benign prostatic hyperplasia in combination with total and %free PSA. diagnostic usage,ongoing research,unassigned 3,3,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12756494&form=6&db=m Increased discrimination between benign prostatic hyperplasia and prostate cancer with equimolar total prostate specific antigen measurement. diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14567353&form=6&db=m Serum human glandular kallikrein (hK2) and insulin-like growth factor 1 (IGF-1) improve the discrimination between prostate cancer and benign prostatic hyperplasia in combination with total and %free PSA. diagnostic usage,ongoing research,unassigned 3,3,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14634394&form=6&db=m Total and Gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies. causal interaction,diagnostic usage,ongoing research,unassigned 3,4,4,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14644122&form=6&db=m Prostate-specific antigen as an estimator of prostate volume in the management of patients with symptomatic benign prostatic hyperplasia. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,1 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15080511&form=6&db=m Serum prostate specific antigen levels in men with benign prostatic hyperplasia and cancer of prostate. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,3,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15091041&form=6&db=m A rational approach to benign prostatic hyperplasia evaluation: recent advances. causal interaction,diagnostic usage,therapeutic application,unassigned 3,2,1,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15126790&form=6&db=m Differentiation of benign prostatic hyperplasia from prostate cancer using prostate specific antigen dynamic profile after transrectal prostate biopsy. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15201794&form=6&db=m Development and initial evaluation of a novel urology curriculum for medical students. ongoing research,unassigned 2,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15201795&form=6&db=m Development of validated instrument to measure medical student learning in clinical urology: a step toward evidence based education. causal interaction,diagnostic usage,ongoing research,unassigned 1,2,2,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15310993&form=6&db=m Effects of systematic 12-core biopsy on the performance of percent free prostate specific antigen for prostate cancer detection. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,3,2 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15653444&form=6&db=m The effects of extracorporeal cardiopulmonary circulation on serum total and free prostate specific antigen levels. diagnostic usage,ongoing research,unassigned 2,4,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15711315&form=6&db=m The relationship among lower urinary tract symptoms, prostate specific antigen and erectile dysfunction in men with benign prostatic hyperplasia: results from the proscar long-term efficacy and safety study. causal interaction,diagnostic usage,ongoing research,unassigned 4,2,3,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16104903&form=6&db=m Clinical utility of human glandular kallikrein 2 within a neural network for prostate cancer detection. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,4,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16502048&form=6&db=m Effects of chronic bacterial prostatitis on prostate specific antigen levels total and free in patients with benign prostatic hyperplasia and prostate cancer. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,4,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16536765&form=6&db=m Relationship between serum prostate-specific antigen and prostate volume in Korean men with benign prostatic hyperplasia: a multicentre study. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,1 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16545295&form=6&db=m [Validity of digital rectal examination of prostate specific antigen] diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16545296&form=6&db=m Validity of digital rectal examination in the era of prostate specific antigen. diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16753400&form=6&db=m Correlation between serum prostate specific antigen and prostate volume in Taiwanese men with biopsy proven benign prostatic hyperplasia. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,1 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16890690&form=6&db=m Response to daily 10 mg alfuzosin predicts acute urinary retention and benign prostatic hyperplasia related surgery in men with lower urinary tract symptoms. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16910584&form=6&db=m Recovery of serum prostate specific antigen value after interruption of antiandrogen therapy with allylestrenol for benign prostatic hyperplasia. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,2,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16952616&form=6&db=m Prevention of benign prostatic hyperplasia disease. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17058611&form=6&db=m [Validity of tests for initial diagnosis and its concordance with final diagnosis in patients with suspected benign prostatic hyperplasia] diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17070238&form=6&db=m Prostate cancer prevention and finasteride. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,3 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17382742&form=6&db=m The effect of dutasteride on the peripheral and transition zones of the prostate and the value of the transition zone index in predicting treatment response. diagnostic usage,ongoing research,therapeutic application,unassigned 2,2,1,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17537216&form=6&db=m Determinants of ejaculatory dysfunction in a community-based longitudinal study. diagnostic usage,unassigned 2,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17666305&form=6&db=m Effect of chronic prostatitis on angiogenic activity and serum prostate specific antigen level in benign prostatic hyperplasia. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,4,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18082216&form=6&db=m The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18423715&form=6&db=m Interactive spaced education versus web based modules for teaching urology to medical students: a randomized controlled trial. therapeutic application,unassigned 1,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18542821&form=6&db=m Urinary PSA: a potential useful marker when serum PSA is between 2.5 ng/mL and 10 ng/mL. diagnostic usage,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18616708&form=6&db=m Effects of aromatase inhibition in hypogonadal older men: a randomized, double-blind, placebo-controlled trial. diagnostic usage,unassigned 2,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18668524&form=6&db=m Nonhuman primates as models for studies of prostate specific antigen and prostatic diseases. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18930490&form=6&db=m Holmium laser enucleation of the prostate--outcomes independent of prostate size? causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,1,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18986558&form=6&db=m The effects of lovastatin on conventional medical treatment of lower urinary tract symptoms with finasteride. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,3,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19002120&form=6&db=m The utility of serum prostatic-specific antigen in the management of men with benign prostatic hyperplasia. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,1,1 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19955594&form=6&db=m MOLECULAR MARKERS ASSOCIATED WITH PROSTATE CANCER: 3-NITROTYROSINE AND GENETIC AND PROTEIC EXPRESSION OF MN-SUPEROXIDE DISMUTASA (MN-SOD). causal interaction,diagnostic usage,ongoing research,unassigned 2,2,3,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20022032&form=6&db=m Adaptive spaced education improves learning efficiency: a randomized controlled trial. unassigned - 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20067463&form=6&db=m Expression analysis and study of the KLK15 mRNA splice variants in prostate cancer and benign prostatic hyperplasia. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,4,1 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20708609&form=6&db=m A sensitive assay to measure biomarker glycosylation demonstrates increased fucosylation of prostate specific antigen (PSA) in patients with prostate cancer compared with benign prostatic hyperplasia. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21129846&form=6&db=m Phase 1 and 2 Studies Demonstrate the Safety and Efficacy of Intraprostatic Injection of PRX302 for the Targeted Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. causal interaction,unassigned 4,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21575967&form=6&db=m Dutasteride reduces prostate size and prostate specific antigen in older hypogonadal men with benign prostatic hyperplasia undergoing testosterone replacement therapy. causal interaction,ongoing research,unassigned 4,2,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21646847&form=6&db=m [Changes in serum prostate specific antigen and testosterone levels after chlormadinone acetate treatment in patients with benign prostatic hyperplasia : a prospective multicenter clinical study]. causal interaction,ongoing research,therapeutic application,unassigned 4,4,2,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22146597&form=6&db=m Autoantibody signatures as biomarkers to distinguish prostate cancer from benign prostatic hyperplasia in patients with increased serum prostate specific antigen. causal interaction,diagnostic usage,ongoing research,unassigned 3,4,3,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22589648&form=6&db=m A pilot study on percent free prostate specific antigen as an additional tool in prostate cancer screening. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,1,4 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22831945&form=6&db=m Plasma sarcosine does not distinguish early and advanced stages of prostate cancer. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23070385&form=6&db=m [Add-on effect of dutasteride in patients with benign prostatic hyperplasia treated with alpha blocker : its effect on overactive bladder]. causal interaction,diagnostic usage,ongoing research,unassigned 2,2,2,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23142202&form=6&db=m Prospective, Randomized, Double-Blind, Vehicle Controlled, Multicenter Phase IIb Clinical Trial of the Pore Forming Protein PRX302 for Targeted Treatment of Symptomatic Benign Prostatic Hyperplasia. therapeutic application,unassigned 2,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23693096&form=6&db=m [Prostate-specific antigen. The role in the prostate cancer diagnosis]. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24008878&form=6&db=m Cellular distribution and heterogeneity of Psa and Psma expression in normal, hyperplasia and human prostate cancer. diagnostic usage,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24012146&form=6&db=m Use of selenium-silymarin mix reduces lower urinary tract symptoms and prostate specific antigen in men. diagnostic usage,ongoing research,unassigned 2,3,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24246211&form=6&db=m Adding Cyclooxygenase-2 inhibitor to alpha blocker for patients with benign prostate hyperplasia and elevated serum prostate specific antigen could not improve prostate biopsy detection rate but improve lower urinary tract symptoms. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,1,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24349818&form=6&db=m IgG4-Related Autoimmune Prostatitis: Is It an Unusual or Underdiagnosed Manifestation of IgG4-Related Disease? causal interaction,diagnostic usage,ongoing research,unassigned 2,4,1,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24472071&form=6&db=m The fluctuation of PCA3 score in men undergoing first or repeat prostate biopsies. diagnostic usage,ongoing research,unassigned 4,1,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25427836&form=6&db=m Quantitative analysis of prostate specific antigen isoforms using immunoprecipitation and stable isotope labeling mass spectrometry. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,1,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26017879&form=6&db=m Augmented immunoexpression of survivin correlates with parameters of aggressiveness in prostate cancer. diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26545398&form=6&db=m Integration of Metabolomics and Transcriptomics Reveals Major Metabolic Pathways and Potential Biomarker Involved in Prostate Cancer. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,2,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26714904&form=6&db=m [Association between obesity-related plasma hemodilution and the concentration of prostate specific antigen]. causal interaction,ongoing research,unassigned 1,3,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27175628&form=6&db=m The Association Between Metabolic Syndrome and Characteristics of Benign Prostatic Hyperplasia: A Systematic Review and Meta-Analysis. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,1,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27358842&form=6&db=m Relationship of age, prostate-specific antigen, and prostate volume in Indonesian men with benign prostatic hyperplasia. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,1 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28168057&form=6&db=m Biomarkers of Prostatic Cancer: An Attempt to Categorize Patients into Prostatic Carcinoma, Benign Prostatic Hyperplasia, or Prostatitis Based on Serum Prostate Specific Antigen, Prostatic Acid Phosphatase, Calcium, and Phosphorus. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,4,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28430620&form=6&db=m Genetic association between PSA-158G/A polymorphism and the susceptibility of benign prostatic hyperplasia: a meta-analysis. causal interaction,unassigned 3,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28495148&form=6&db=m Analysis of urinary PSA glycosylation is not indicative of high-risk prostate cancer. diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28785195&form=6&db=m The Modulating Effects of Benign Prostate Enlargement Medications on Upgrading Predictors in Patients with Gleason 6 at Biopsy. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,2,1 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30197922&form=6&db=m Prostate specific antigen and relative prostate weight data on effect of Tetracarpidium conophorum leaf extract on testosterone-induced benign prostatic hyperplasia. diagnostic usage,ongoing research,therapeutic application,unassigned 3,3,1,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30529422&form=6&db=m Evaluation of the therapeutic effect against benign prostatic hyperplasia and the active constituents from Epilobium angustifolium L. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31569672&form=6&db=m Increased Plasmatic Levels of PSA-Expressing Exosomes Distinguish Prostate Cancer Patients from Benign Prostatic Hyperplasia: A Prospective Study. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33274871&form=6&db=m Impact of Prostate Specific Antigen and Testosterone Hormone Levels in Patients of Benign Prostatic Hyperplasia in Khartoum State-Sudan. causal interaction,diagnostic usage,ongoing research,unassigned 4,2,2,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33539321&form=6&db=m GV1001 interacts with androgen receptor to inhibit prostate cell proliferation in benign prostatic hyperplasia by regulating expression of molecules related to epithelial-mesenchymal transition. diagnostic usage,ongoing research,therapeutic application,unassigned 1,3,2,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33754606&form=6&db=m Is there a PSA cut-off value indicating incidental prostate cancer in patients undergoing surgery for benign prostatic hyperplasia? diagnostic usage,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33883082&form=6&db=m Relationship among lymphocytes, free/total prostate specific antigen, lower urinary tract symptoms and prostatic inflammation in benign prostatic hyperplasia patients. causal interaction,unassigned 4,0 3.4.21.35 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34212237&form=6&db=m Are all procedures for benign prostatic hyperplasia created equal? A systematic review on post-procedural PSA dynamics and its correlation with relief of bladder outlet obstruction. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,2,2,1 3.4.21.35 Prostatic Intraepithelial Neoplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7529857&form=6&db=m The most promising surrogate endpoint biomarkers for screening candidate chemopreventive compounds for prostatic adenocarcinoma in short-term phase II clinical trials. causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.35 Prostatic Intraepithelial Neoplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7541850&form=6&db=m Morphometric analysis and clinical followup of isolated prostatic intraepithelial neoplasia in needle biopsy of the prostate. diagnostic usage,ongoing research,therapeutic application,unassigned 4,4,3,0 3.4.21.35 Prostatic Intraepithelial Neoplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7544835&form=6&db=m Prostatic intraepithelial neoplasia is a risk factor for adenocarcinoma: predictive accuracy in needle biopsies. causal interaction,diagnostic usage,ongoing research,unassigned 2,4,3,0 3.4.21.35 Prostatic Intraepithelial Neoplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7563348&form=6&db=m The incidence of high grade prostatic intraepithelial neoplasia in needle biopsies. diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Intraepithelial Neoplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7686984&form=6&db=m Does high grade prostatic intraepithelial neoplasia result in elevated serum prostate specific antigen levels? causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.35 Prostatic Intraepithelial Neoplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8606866&form=6&db=m The extent and zonal location of prostatic intraepithelial neoplasia and atypical adenomatous hyperplasia: relationship with carcinoma in radical prostatectomy specimens. causal interaction,diagnostic usage,unassigned 2,2,0 3.4.21.35 Prostatic Intraepithelial Neoplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8640677&form=6&db=m Do prostate specific antigen and prostate specific antigen density enhance the detection of prostate carcinoma after initial diagnosis of prostatic intraepithelial neoplasia without concurrent carcinoma? causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,2 3.4.21.35 Prostatic Intraepithelial Neoplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8709305&form=6&db=m Prostatic intraepithelial neoplasia: influence of clinical and pathological data on the detection of prostate cancer. diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Intraepithelial Neoplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9187691&form=6&db=m Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,4,0 3.4.21.35 Prostatic Intraepithelial Neoplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10081875&form=6&db=m Androgen receptor expression in prostatic intraepithelial neoplasia and cancer. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,3,0 3.4.21.35 Prostatic Intraepithelial Neoplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10458359&form=6&db=m Effect of neoadjuvant hormonal therapy on prostatic intraepithelial neoplasia and its prognostic significance. diagnostic usage,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Prostatic Intraepithelial Neoplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10524873&form=6&db=m The effect of high grade prostatic intraepithelial neoplasia on serum total and percentage of free prostate specific antigen levels. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,2,1 3.4.21.35 Prostatic Intraepithelial Neoplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10687983&form=6&db=m Predictors of first repeat biopsy cancer detection with suspected local stage prostate cancer. diagnostic usage,ongoing research,unassigned 3,2,0 3.4.21.35 Prostatic Intraepithelial Neoplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11257656&form=6&db=m Predictive value of total and percent free prostate specific antigen in high grade prostatic intraepithelial neoplasia lesions: results of the Tyrol Prostate Specific Antigen Screening Project. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.35 Prostatic Intraepithelial Neoplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11283929&form=6&db=m Prospective study of correlations between biopsy-detected high grade prostatic intraepithelial neoplasia, serum prostate specific antigen concentration, and race. causal interaction,diagnostic usage,unassigned 1,2,0 3.4.21.35 Prostatic Intraepithelial Neoplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11342920&form=6&db=m Systematic transperineal ultrasound guided template biopsy of the prostate in patients at high risk. causal interaction,diagnostic usage,unassigned 2,2,0 3.4.21.35 Prostatic Intraepithelial Neoplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11435830&form=6&db=m Prostate cancer diagnosis using a saturation needle biopsy technique after previous negative sextant biopsies. causal interaction,diagnostic usage,unassigned 2,4,0 3.4.21.35 Prostatic Intraepithelial Neoplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12094135&form=6&db=m Prostatic intraepithelial neoplasia and prostate cancer. causal interaction,ongoing research,unassigned 4,1,0 3.4.21.35 Prostatic Intraepithelial Neoplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12352407&form=6&db=m Followup interval prostate biopsy 3 years after diagnosis of high grade prostatic intraepithelial neoplasia is associated with high likelihood of prostate cancer, independent of change in prostate specific antigen levels. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Prostatic Intraepithelial Neoplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14501721&form=6&db=m A nomogram for predicting a positive repeat prostate biopsy in patients with a previous negative biopsy session. diagnostic usage,ongoing research,unassigned 4,1,0 3.4.21.35 Prostatic Intraepithelial Neoplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14713758&form=6&db=m Prostate cancer chemoprevention agent development: the National Cancer Institute, Division of Cancer Prevention portfolio. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Prostatic Intraepithelial Neoplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15748366&form=6&db=m Prevalence of high-grade prostatic intraepithelial neoplasia and its relationship to serum prostate specific antigen. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,3,0 3.4.21.35 Prostatic Intraepithelial Neoplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17644117&form=6&db=m Chemoprevention of prostate cancer: agents and study designs. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.35 Prostatic Intraepithelial Neoplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18343412&form=6&db=m Saturation technique does not decrease cancer detection during followup after initial prostate biopsy. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,1,1 3.4.21.35 Prostatic Intraepithelial Neoplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18343427&form=6&db=m Prognostic Significance of alpha-Methylacyl-CoA Racemase Among Men With High Grade Prostatic Intraepithelial Neoplasia in Prostate Biopsies. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,2,0 3.4.21.35 Prostatic Intraepithelial Neoplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18485383&form=6&db=m A novel nomogram to predict the probability of prostate cancer on repeat biopsy. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,3,0 3.4.21.35 Prostatic Intraepithelial Neoplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19150546&form=6&db=m The number of cores positive for high grade prostatic intraepithelial neoplasia on initial biopsy is associated with prostate cancer on second biopsy. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,4,0 3.4.21.35 Prostatic Intraepithelial Neoplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19286210&form=6&db=m Association of nonsteroidal anti-inflammatory drugs, prostate specific antigen and prostate volume. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.35 Prostatic Intraepithelial Neoplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19524976&form=6&db=m Multifocal high grade prostatic intraepithelial neoplasia is a significant risk factor for prostatic adenocarcinoma. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.35 Prostatic Intraepithelial Neoplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20473923&form=6&db=m KLK15 is a prognostic marker for progression-free survival in patients with radical prostatectomy. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,4 3.4.21.35 Prostatic Intraepithelial Neoplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20846692&form=6&db=m Multifocal high grade prostatic intraepithelial neoplasia is a risk factor for subsequent prostate cancer. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,3,0 3.4.21.35 Prostatic Intraepithelial Neoplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21629831&form=6&db=m Chemoprevention of prostate cancer with nutrients and supplements. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,2,0 3.4.21.35 Prostatic Intraepithelial Neoplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23268329&form=6&db=m High grade prostate intraepithelial neoplasia (PIN) is a PSA-independent risk factor for prostate cancer in African American men: Results from a pilot study. causal interaction,diagnostic usage,therapeutic application,unassigned 2,4,1,0 3.4.21.35 Prostatic Intraepithelial Neoplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23474436&form=6&db=m Effect of finasteride on serum levels of androstenedione, testosterone and their 5?-reduced metabolites in men at risk for prostate cancer. causal interaction,diagnostic usage,unassigned 1,2,0 3.4.21.35 Prostatic Intraepithelial Neoplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25899828&form=6&db=m Weaker ERG expression in patients with ERG-positive prostate cancer is associated with advanced disease and weaker androgen receptor expression: An Indian outlook. causal interaction,diagnostic usage,unassigned 1,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1279216&form=6&db=m Recurrent prostate cancer despite undetectable prostate specific antigen. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1279493&form=6&db=m The efficacy of serum prostate specific antigen as a tumour marker in prostatic carcinoma: a comparison with serum acid phosphatase. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1283894&form=6&db=m Chemoprevention strategies for prostate cancer: the role of 5 alpha-reductase inhibitors. diagnostic usage,unassigned 2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1283897&form=6&db=m The role of digital rectal examination, transrectal ultrasound, and prostate specific antigen for the detection of confined and clinically relevant prostate cancer. diagnostic usage,ongoing research,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1289680&form=6&db=m Human prostate cancer model: roles of growth factors and extracellular matrices. diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1370699&form=6&db=m Re: Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters. causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1371554&form=6&db=m Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1371558&form=6&db=m The distribution of prostate specific antigen in men without clinical or pathological evidence of prostate cancer: relationship to gland volume and age. diagnostic usage,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1371560&form=6&db=m Serum prostate specific antigen as pre-screening test for prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1371564&form=6&db=m Estramustine and vinblastine: use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer. therapeutic application,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1371565&form=6&db=m Prostate specific antigen levels after radical prostatectomy in patients with organ confined and locally extensive prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,1,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1371566&form=6&db=m Urinary prostate specific antigen levels: role in monitoring the response of prostate cancer to therapy. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1371568&form=6&db=m The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,4 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1372426&form=6&db=m Prostate specific antigen and prostatitis. I. Effect of prostatitis on serum PSA in the human and nonhuman primate. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,3 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1373781&form=6&db=m The detection of prostate specific antigen, MHS-5, and other markers in invasive prostate cancer and seminal vesicle. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1374175&form=6&db=m Prostate specific antigen in diagnosis, staging, and follow-up of prostate cancer. diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1374178&form=6&db=m Volume of normal prostate, of prostate cancer, and of benign prostatic hyperplasia: are correlations with prostate specific antigen clinically useful? causal interaction,diagnostic usage,ongoing research,unassigned 3,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1374678&form=6&db=m Circulating prostate specific antigen-positive cells correlate with metastatic prostate cancer. diagnostic usage,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1376190&form=6&db=m Predicted prostate specific antigen results using transrectal ultrasound gland volume. Differentiation of benign prostatic hyperplasia and prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1376191&form=6&db=m Clinical diagnosis of prostate cancer. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1379059&form=6&db=m The prognostic significance of prostate specific antigen in metastatic hormone-resistant prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,3,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1380223&form=6&db=m Prostate specific antigen and prostatic acid phosphatase measurements for the follow-up of patients with prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,3,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1380941&form=6&db=m Prostate specific antigen: clinical use in the diagnosis and management of prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1382383&form=6&db=m [Measurement of serum PSA values by DELFIA PSA and its clinical significance on diagnosis and follow-up of prostate cancer patients] diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1384920&form=6&db=m Prostate specific antigen and bone scan correlation in the staging and monitoring of patients with prostatic cancer. diagnostic usage,ongoing research,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1384921&form=6&db=m Levels of prostate specific antigen that predict skeletal spread in prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1492625&form=6&db=m Hormone therapy of prostatic bone metastases. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1690309&form=6&db=m Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1692497&form=6&db=m Prostate tumour markers as an aid in the staging of prostatic cancer. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1692885&form=6&db=m Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1692886&form=6&db=m Prostate cancer: correlation of digital rectal examination, transrectal ultrasound and prostate specific antigen levels with tumor volumes in radical prostatectomy specimens. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1698754&form=6&db=m A prospective study of prostate specific antigen levels in patients receiving radiotherapy for localized carcinoma of the prostate. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,4 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1700143&form=6&db=m The relationship of prostate specific antigen levels and residual tumor volume in stage A prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1700145&form=6&db=m Prostate specific antigen for assessing response to ketoconazole and prednisone in patients with hormone refractory metastatic prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,2,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1700155&form=6&db=m Prognostic significance of prostate specific antigen in endocrine treatment for prostatic cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,4 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1700588&form=6&db=m [Changes in prostatic acid phosphatase, gamma-seminoprotein and prostate specific antigen after endocrine therapy for stage D2 prostate cancer] causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,4 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1702339&form=6&db=m Prostate tumour markers and differentiation grade in prostatic cancer. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1703240&form=6&db=m Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,3,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1706439&form=6&db=m Prostate specific antigen in patients with clinical stage C prostate cancer: relation to lymph node status and grade. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1706440&form=6&db=m Prostate specific antigen in hormonally treated stage D2 prostate cancer: is it always an accurate indicator of disease status? causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,3,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1709357&form=6&db=m Digital rectal examination versus transrectal ultrasound in detection of prostate cancer. Preliminary results from a study of a randomly selected population. diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1710531&form=6&db=m The American Cancer Society National Prostate Cancer Detection Project. Findings on the detection of early prostate cancer in 2425 men. diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1712190&form=6&db=m [Occult cancer in patients with symptomatic benign prostatic hyperplasia] diagnostic usage,therapeutic application,unassigned 4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1712873&form=6&db=m [Clinical evaluation of serum basic fetoprotein for prostatic cancer--comparative study with PAP, gamma-Sm and PSA] diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1716409&form=6&db=m [Clinical and pathological study of tumor marker in benign prostatic hypertrophy and incidental prostatic cancer] causal interaction,diagnostic usage,ongoing research,unassigned 1,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1716696&form=6&db=m Prostate specific antigen in the management of patients with localized adenocarcinoma of the prostate treated with primary radiation therapy. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,3,4 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1716697&form=6&db=m Prostate specific antigen and prostatic acid phosphatase for monitoring therapy of carcinoma of the prostate. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,4 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1717096&form=6&db=m Screening for prostate cancer. Comparison of transrectal ultrasound, prostate specific antigen and rectal examination. diagnostic usage,ongoing research,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1719250&form=6&db=m Re: Prostate specific antigen for assessing response to ketoconazole and prednisone in patients with hormone refractory metastatic prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,2,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1719610&form=6&db=m Tumour markers in prostatic cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1726790&form=6&db=m Reciprocal mesenchymal-epithelial interaction affecting prostate tumour growth and hormonal responsiveness. diagnostic usage,ongoing research,unassigned 3,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1830713&form=6&db=m Laparoscopic pelvic lymph node dissection. therapeutic application,unassigned 1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1964496&form=6&db=m [Prostate cancer with an unusual course] diagnostic usage,ongoing research,unassigned 3,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2416371&form=6&db=m [Prostatic carcinoma: immunoperoxidase study with antisera against prostatic acid phosphatase and the prostate-specific antigen] ongoing research,therapeutic application,unassigned 3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2430732&form=6&db=m Measurements of serum gamma-seminoprotein and prostate specific antigen evaluated for monitoring carcinoma of the prostate. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2434667&form=6&db=m Prospective comparison between serum monoclonal prostate specific antigen and acid phosphatase measurements in metastatic prostatic cancer. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2435927&form=6&db=m An evaluation of prostate specific antigen in prostatic cancer. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2440170&form=6&db=m [Clinical relevance of radioimmunologic determination of prostate specific antigen in prostate cancer] causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,1,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2443922&form=6&db=m An evaluation of five tests to diagnose prostate cancer. diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2445000&form=6&db=m Critical-laboratoristic correlation of the diagnostic importance of prostate specific antigen compared with prostatic acid phosphatase and carcinoembryonic antigen in the prostatic cancer. diagnostic usage,ongoing research,unassigned 2,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2447997&form=6&db=m The role of prostate specific antigen in the baseline assessment of patients undergoing hormone therapy for advanced prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,1,4 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2449722&form=6&db=m Prostate specific antigen. Experimental and clinical observations. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,1,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2449758&form=6&db=m Spontaneous circadian fluctuations of prostate specific antigen and prostatic acid phosphatase serum activities in patients with prostatic cancer. causal interaction,diagnostic usage,ongoing research,unassigned 1,1,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2451035&form=6&db=m Clinical application of transrectal ultrasonography and prostate specific antigen in the search for prostate cancer. diagnostic usage,therapeutic application,unassigned 4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2451037&form=6&db=m Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2452559&form=6&db=m [Clinical significance of tumor markers in prostatic carcinoma--comparative study of prostatic acid phosphatase, prostate specific antigen and gamma-seminoprotein] causal interaction,diagnostic usage,ongoing research,unassigned 1,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2456678&form=6&db=m [Prostate specific antigen in serum of the patients with prostatic cancer] causal interaction,diagnostic usage,ongoing research,unassigned 4,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2461644&form=6&db=m [Prostatic acid phosphatase (PAP), gamma-seminoprotein (gamma-Sm) and prostate specific antigen (PA) in prostatic cancer] causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,3,3 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2461921&form=6&db=m Transrectal ultrasound in the diagnosis and staging of local disease after I125 seed implantation for prostate cancer. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2464397&form=6&db=m The value of the measurement of serum prostate specific antigen in patients with benign prostatic hyperplasia and untreated prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,3,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2467543&form=6&db=m [Comparison of 3 assay kits of prostate specific antigen in serum of prostatic cancer] diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2468795&form=6&db=m Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2470373&form=6&db=m cDNA coding for the entire human prostate specific antigen shows high homologies to the human tissue kallikrein genes. diagnostic usage,unassigned 2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2470661&form=6&db=m [Purification of prostatic acid phosphatase and prostate specific antigen from human seminal plasma] causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2470927&form=6&db=m The role of prostate specific antigen as a tumor marker in men with advanced adenocarcinoma of the prostate. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2473962&form=6&db=m Clinical application of transrectal ultrasonography and prostate specific antigen in the search for prostate cancer. diagnostic usage,therapeutic application,unassigned 4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2477559&form=6&db=m Clinical use of prostate specific antigen in patients with prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,3 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2477560&form=6&db=m Prostate specific antigen: not detectable despite tumor progression after radical prostatectomy. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,1,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3800301&form=6&db=m Preliminary evaluation of measurement of serum prostate-specific antigen level in detection of prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,3,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6339742&form=6&db=m Evaluation of prostate specific acid phosphatase and prostate specific antigen in identification of prostatic cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,3,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6389940&form=6&db=m [Studies on prostate specific antigen, gamma-seminoprotein (gamma-Sm) as a tumor marker of prostatic cancer] diagnostic usage,ongoing research,unassigned 1,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7479385&form=6&db=m Molecular mass and carbohydrate structure of prostate specific antigen: studies for establishment of an international PSA standard. diagnostic usage,therapeutic application,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7479388&form=6&db=m Serum free prostate specific antigen: isoenzymes in benign hyperplasia and cancer of the prostate. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,2,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7479391&form=6&db=m Prostate specific antigen in a community-based sample of men without prostate cancer: correlations with prostate volume, age, body mass index, and symptoms of prostatism. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,1,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7487134&form=6&db=m [Prognostic factors of prostatic cancer] causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7490842&form=6&db=m Limitations of serum prostate specific antigen in predicting peripheral and transition zone cancer volumes as measured by correlation coefficients. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7490873&form=6&db=m The effect of finasteride on prostate specific antigen: review of available data. diagnostic usage,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7496284&form=6&db=m Prospective observational study to assess value of prostate specific antigen as screening test for prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,3,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7500474&form=6&db=m The incidence of prostate cancer progression with undetectable serum prostate specific antigen in a series of 394 radical prostatectomies. causal interaction,diagnostic usage,unassigned 3,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7504748&form=6&db=m The use of prostate specific antigen and prostate specific antigen density in the diagnosis of prostate cancer in a community based urology practice. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7504750&form=6&db=m Systematic sextant biopsies in 651 patients referred for prostate evaluation. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7505045&form=6&db=m The role of ultrasound in prostate cancer detection in patients with an elevated prostate specific antigen level but no prostatic nodule. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7505544&form=6&db=m The role of lipid-associated sialic acid (LSA) and prostate specific antigen (PSA) in the follow-up of prostatic cancer. ongoing research,unassigned 3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7505775&form=6&db=m Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. diagnostic usage,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7505885&form=6&db=m Screening for prostate cancer. Does it make a difference? causal interaction,diagnostic usage,therapeutic application,unassigned 1,3,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7505969&form=6&db=m PSA in benign prostatic hyperplasia and prostatic intraepithelial neoplasia. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7505973&form=6&db=m PSA density (PSAD). Role in patient evaluation and management. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7507783&form=6&db=m Utilization of polyclonal serum prostate specific antigen levels in screening for prostate cancer: a comparison with corresponding monoclonal values. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,3,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7508522&form=6&db=m Radical radiation therapy in the management of prostatic adenocarcinoma: the initial prostate specific antigen value as a predictor of treatment outcome. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,2,3,4 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7508631&form=6&db=m [Prostate-specific antigen: the most useful marker for prostate cancer] causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7508792&form=6&db=m False positive values of PAP and PSA in complicated and non-complicated benign prostatic hypertrophy. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7509485&form=6&db=m A more objective staging of advanced prostate cancer--routine recognition of malignant endocrine structures: the assessment of serum TPS, PSA, and NSE values. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7510346&form=6&db=m Collagen cross-link metabolites in urine as markers of bone metastases in prostatic carcinoma. causal interaction,diagnostic usage,therapeutic application,unassigned 3,2,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7511971&form=6&db=m Prostate specific antigen in screening for recurrence following radical prostatectomy for localised prostatic cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7512659&form=6&db=m Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,3,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7512660&form=6&db=m Prostate specific antigen cannot distinguish stage T1a (A1) prostate cancer from benign prostatic hyperplasia. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,3,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7512661&form=6&db=m Clinical experience of the detection of prostate cancer in patients with benign prostate hyperplasia treated with finasteride. The Finasteride Study Group. diagnostic usage,ongoing research,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7512662&form=6&db=m Eliminating the need for bilateral pelvic lymphadenectomy in select patients with prostate cancer. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7513021&form=6&db=m Assay for prostate specific antigen (PSA): problems and possible solutions. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7514688&form=6&db=m Prostate specific antigen and gleason grade: an immunohistochemical study of prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,4,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7514689&form=6&db=m Combining prostate specific antigen with cancer and gland volume to predict more reliably pathological stage: the influence of prostate specific antigen cancer density. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7514690&form=6&db=m Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7514691&form=6&db=m Effect of radiation therapy on detectable serum prostate specific antigen levels following radical prostatectomy: early versus delayed treatment. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7514692&form=6&db=m The effect of pelvic radiation therapy on serum levels of prostate specific antigen. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7514940&form=6&db=m Correlation of serum prostate specific antigen levels and bone scintigraphy in carcinoma prostate. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7515197&form=6&db=m Prostate cancer screening before and after abdominoperineal resection: recommendations, biopsy, and therapeutic techniques. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7515211&form=6&db=m Management of hormone resistant prostate cancer. diagnostic usage,ongoing research,therapeutic application,unassigned 3,1,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7515212&form=6&db=m Octreotide in advanced prostatic cancer relapsing under hormonal treatment. diagnostic usage,therapeutic application,unassigned 3,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7515447&form=6&db=m Comparison of prostate specific antigen with prostate specific antigen density for 3 clinical applications. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,3,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7515448&form=6&db=m Tumor volume and stage in carcinoma of the prostate detected by elevations in prostate specific antigen. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,1,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7515450&form=6&db=m Re: The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. diagnostic usage,ongoing research,therapeutic application,unassigned 4,2,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7516262&form=6&db=m The New American Joint Committee on Cancer and International Union Against Cancer TNM classification of prostate cancer. Clinicopathologic correlations. causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7516389&form=6&db=m [Therapy by endoscopic laser for prostatic obstruction] diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7516445&form=6&db=m Clinical significance of prostate specific antigen for early stage prostate cancer detection. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7517027&form=6&db=m [Significance of various examination methods in the management of prostatic cancer] diagnostic usage,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7518341&form=6&db=m Prostate specific antigen doubling time and disease relapse after radiotherapy for prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,3 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7519115&form=6&db=m Screening for carcinoma of the prostate: a GP based study. diagnostic usage,ongoing research,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7519363&form=6&db=m Prostate specific antigen progression rates after radical prostatectomy or radiation therapy for localized prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,3,4 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7520346&form=6&db=m Comparison of different serum prostate specific antigen measures for early prostate cancer detection. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7520352&form=6&db=m Relative sensitivity and specificity of serum prostate specific antigen (PSA) level compared with age-referenced PSA, PSA density, and PSA change. Data from the American Cancer Society National Prostate Cancer Detection Project. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7520949&form=6&db=m Rate of change in serum prostate specific antigen levels as a method for prostate cancer detection. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7521783&form=6&db=m Prostate specific antigen and prostate specific antigen density. Roles in patient evaluation and management. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7522000&form=6&db=m [Screening test for prostate cancer] diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7522122&form=6&db=m Prostate cancer screening. Appropriate choices? Investigators of the American Cancer Society National Prostate Cancer Detection Project. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7523342&form=6&db=m Preoperative serum prostate-specific antigen and Gleason grade as predictors of pathologic stage in clinically organ confined prostate cancer: implications for the choice of primary treatment. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7523343&form=6&db=m Indications for and the significance of seminal vesicle irradiation during 3D conformal radiotherapy for localized prostate cancer. diagnostic usage,ongoing research,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7523704&form=6&db=m Radioimmunoscintigraphy with 111indium labeled CYT-356 for the detection of occult prostate cancer recurrence. diagnostic usage,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7523707&form=6&db=m Accuracy of digital rectal examination and transrectal ultrasonography in localizing prostate cancer. diagnostic usage,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7523716&form=6&db=m The use of prostate specific antigen for prostate cancer screening: a managed care perspective. diagnostic usage,therapeutic application,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7523720&form=6&db=m The nature of prostate cancer detected through prostate specific antigen based screening. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7523722&form=6&db=m Natural history of changes in prostate specific antigen in early stage prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7523725&form=6&db=m Prostate specific antigen as an outcome variable for T1 and T2 prostate cancer treated by radiation therapy. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7523726&form=6&db=m Radical prostatectomy and radical radiation therapy for clinical stages T1 to 2 adenocarcinoma of the prostate: new insights into outcome from repeat biopsy and prostate specific antigen followup. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7523731&form=6&db=m 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. causal interaction,diagnostic usage,ongoing research,unassigned 2,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7523734&form=6&db=m Cost analyses of prostate cancer screening: frameworks for discussion. Investigators of the American Cancer Society-National Prostate Cancer Detection Project. diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7523735&form=6&db=m Prostate cancer screening in the prostate, lung, colorectal and ovarian cancer screening trial of the National Cancer Institute. diagnostic usage,ongoing research,therapeutic application,unassigned 2,1,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7525040&form=6&db=m The use of prostate specific antigen density to improve the sensitivity of prostate specific antigen in detecting prostate carcinoma. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,4,4 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7525994&form=6&db=m Comparison of prostate specific antigen concentration versus prostate specific antigen density in the early detection of prostate cancer: receiver operating characteristic curves. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,3,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7525995&form=6&db=m Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: receiver operating characteristic curves. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,2,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7526003&form=6&db=m Correlation between serum prostate specific antigen levels and the volume of the individual glandular zones of the human prostate. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7526969&form=6&db=m Cost-effective prostate cancer detection. Reduction of low-yield biopsies. Investigators of the American Cancer Society National Prostate Cancer Detection Project. diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7527116&form=6&db=m Serum concentrations of prostate specific antigen and its complex with alpha 1-antichymotrypsin before diagnosis of prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7527470&form=6&db=m [Prostate specific antigen in patients with prostatic cancer--clinical usefulness of its measurement with sensitive enzyme immunoassay, TOSOH II PA assay] diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7529857&form=6&db=m The most promising surrogate endpoint biomarkers for screening candidate chemopreventive compounds for prostatic adenocarcinoma in short-term phase II clinical trials. causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7531781&form=6&db=m Measurement of serum prostate specific antigen levels in women and in prostatectomized men with an ultrasensitive immunoassay technique. diagnostic usage,ongoing research,therapeutic application,unassigned 4,1,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7534843&form=6&db=m [Usefulness of hyper sensitive PSA assay kits for determination on low range of prostate specific antigen in prostate cancer] causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,3,4 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7534845&form=6&db=m [Prostate specific antigen (PSA)/gamma-seminoprotein ratio in the cases with PSA levels less than or equal to 10.0 ng/ml] causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7534919&form=6&db=m Comparison of prostate specific antigen, prostate specific membrane antigen, and LNCaP-based enzyme-linked immunosorbent assays in prostatic cancer patients and patients with benign prostatic enlargement. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,3,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7535185&form=6&db=m Detection of residual prostate cancer after external radiotherapy. Role of prostate specific antigen and transrectal ultrasonography. diagnostic usage,ongoing research,therapeutic application,unassigned 4,1,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7535978&form=6&db=m Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer. diagnostic usage,ongoing research,therapeutic application,unassigned 4,1,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7536252&form=6&db=m Molecular staging of prostate cancer. II. A comparison of the application of an enhanced reverse transcriptase polymerase chain reaction assay for prostate specific antigen versus prostate specific membrane antigen. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7536267&form=6&db=m Prostate specific antigen following radiotherapy for local prostate cancer. diagnostic usage,therapeutic application,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7537989&form=6&db=m [Pilot study of screening of prostate cancer by the assay of prostate specific antigen in occupational milieu] diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7538598&form=6&db=m Prostate specific antigen density is not an independent predictor of response for prostate cancer treated by conformal radiotherapy. causal interaction,diagnostic usage,therapeutic application,unassigned 3,2,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7538599&form=6&db=m Prostate specific antigen regression and progression after androgen deprivation for localized and metastatic prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7538601&form=6&db=m Dramatic prostate specific antigen decrease in response to discontinuation of megestrol acetate in advanced prostate cancer: expansion of the antiandrogen withdrawal syndrome. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,1,3,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7538749&form=6&db=m [The digital rectal exam, prostate-specific antigen and transrectal echography in the diagnosis of prostatic cancer] diagnostic usage,ongoing research,therapeutic application,unassigned 4,1,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7539300&form=6&db=m Evaluating multiple diagnostic tests with partial verification. diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7539572&form=6&db=m [Is it possible to do without bone gammagraphy in the staging of prostatic cancer?] diagnostic usage,therapeutic application,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7539857&form=6&db=m A multivariate analysis of clinical and pathological factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7539862&form=6&db=m Practice trends in the diagnosis and management of prostate cancer in the United States. causal interaction,diagnostic usage,therapeutic application,unassigned 3,2,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7540965&form=6&db=m Design of the Prostate Cancer Prevention Trial (PCPT). causal interaction,diagnostic usage,unassigned 2,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7541850&form=6&db=m Morphometric analysis and clinical followup of isolated prostatic intraepithelial neoplasia in needle biopsy of the prostate. diagnostic usage,ongoing research,therapeutic application,unassigned 4,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7541859&form=6&db=m Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. The Lupron Depot Neoadjuvant Prostate Cancer Study Group. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7541863&form=6&db=m Clinical and biochemical evidence of control of prostate cancer at 5 years after external beam radiation. diagnostic usage,therapeutic application,unassigned 4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7541925&form=6&db=m [Status of PSA determination for early detection of prostate carcinoma] causal interaction,diagnostic usage,therapeutic application,unassigned 2,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7542133&form=6&db=m The value of prostatic specific antigen in the early diagnosis of prostatic cancer: a Greek view. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7542158&form=6&db=m Prostate specific antigen and prostate acid phosphatase declines after estramustine phosphate withdrawal: a case report. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7542562&form=6&db=m Tumour markers in patients on deferred treatment: prostate specific antigen doubling times. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7542565&form=6&db=m Screening strategies: a clinical perspective. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7543601&form=6&db=m The lack of predictive value of prostate specific antigen density in the detection of prostate cancer in patients with normal rectal examinations and intermediate prostate specific antigen levels. causal interaction,diagnostic usage,ongoing research,unassigned 2,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7543602&form=6&db=m Failure of focal prostate cancer on biopsy to predict focal prostate cancer: the importance of prevalence. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7543604&form=6&db=m Diagnostic significance of prostate specific antigen and the development of a mass screening system for prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,4,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7543610&form=6&db=m Re: Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: receiver operating characteristic curves. causal interaction,diagnostic usage,therapeutic application,unassigned 2,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7543756&form=6&db=m PSA screening: a public health dilemma. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7544063&form=6&db=m [Value of serum PSA and PAP measurement with newly developed latex turbidimetric immunoassay] causal interaction,diagnostic usage,ongoing research,unassigned 3,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7544484&form=6&db=m Standardization of PSA determinations. causal interaction,diagnostic usage,therapeutic application,unassigned 1,2,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7544569&form=6&db=m Comparison of prostate specific membrane antigen, and prostate specific antigen levels in prostatic cancer patients. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7544840&form=6&db=m The value of prostate specific antigen in early diagnosis of prostate cancer: the study of men born in 1913. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,3,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7544842&form=6&db=m Seminal vesicle biopsy in prostate cancer staging. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7544843&form=6&db=m Prostate specific antigen after radiotherapy for prostate cancer: a reevaluation of long-term biochemical control and the kinetics of recurrence in patients treated at Stanford University. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,4,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7544844&form=6&db=m The central role of prostate specific antigen in diagnosis and progression of prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7544968&form=6&db=m [Yield of ultrasonography-guided transrectal biopsy in the diagnosis of carcinoma of the prostate] diagnostic usage,ongoing research,therapeutic application,unassigned 4,1,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7563353&form=6&db=m Tumor volume and prostate specific antigen: implications for early detection and defining a window of curability. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,2,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7621454&form=6&db=m Radical prostatectomy, radiotherapy or deferred treatment for localized prostate cancer? causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7621458&form=6&db=m Intermittent endocrine therapy and its potential for chemoprevention of prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7645452&form=6&db=m [Clinical study of prostatic cancer--statistical analysis of 184 cases in the latest 21 years] causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7679042&form=6&db=m American Cancer Society--National Prostate Cancer Detection Project. Results from multiple examinations using transrectal ultrasound, digital rectal examination, and prostate specific antigen. causal interaction,diagnostic usage,therapeutic application,unassigned 2,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7679753&form=6&db=m Prevalence and pathological extent of prostate cancer in men with prostate specific antigen levels of 2.9 to 4.0 ng./ml. diagnostic usage,unassigned 2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7679754&form=6&db=m Large, organ confined, impalpable transition zone prostate cancer: association with metastatic levels of prostate specific antigen. diagnostic usage,unassigned 1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7679756&form=6&db=m Prostate specific antigen after external beam radiotherapy for prostatic cancer: followup. causal interaction,diagnostic usage,therapeutic application,unassigned 1,2,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7679759&form=6&db=m Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. causal interaction,diagnostic usage,therapeutic application,unassigned 4,1,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7681119&form=6&db=m Early detection of residual prostate cancer after radical prostatectomy by an ultrasensitive assay for prostate specific antigen. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,2,3 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7683342&form=6&db=m Re: Serum prostate specific antigen as prescreening test for prostate cancer. diagnostic usage,therapeutic application,unassigned 4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7684650&form=6&db=m Relationship between prostate specific antigen, prostate volume and age in the benign prostate. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7685140&form=6&db=m [Examination of serum prostate specific antigen (PSA) in the mass screening for prostatic diseases] causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7685416&form=6&db=m Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 2,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7685418&form=6&db=m The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7685834&form=6&db=m Use of a new hypersensitive assay for the detection of prostate specific antigen in prostate cancer. diagnostic usage,therapeutic application,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7685840&form=6&db=m [Determination of tumor marker doubling time in the patients with prostate cancer relapsed from endocrine therapy] diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7688442&form=6&db=m [Usefulness of prostate specific antigen/gamma-seminoprotein ratio for diagnosis of prostate cancer] causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,2,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7688658&form=6&db=m Characteristics of prostate cancers detected in a multimodality early detection program. The Investigators of the American Cancer Society-National Prostate Cancer Detection Project. diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7689121&form=6&db=m [Current status and problems of a screening for prostatic cancer in the health facilities in Fukuoka Prefecture] causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7689122&form=6&db=m [Role of prostate specific antigen, transrectal ultrasonography, and digital rectal examination in the search for clinical prostate cancer] causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,1,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7690016&form=6&db=m Clinical relevance of trans-rectal ultrasound, biopsy, and serum prostate-specific antigen following external beam radiotherapy for carcinoma of the prostate. causal interaction,diagnostic usage,therapeutic application,unassigned 2,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7690176&form=6&db=m [Diagnosis of cancer of the prostate by determining the blood levels of specific prostatic antigen, rectal examination, and transrectal echography] diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7691505&form=6&db=m Finasteride. A review of its potential in the treatment of benign prostatic hyperplasia. causal interaction,diagnostic usage,unassigned 3,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7692096&form=6&db=m Visual laser ablation of the prostate: clinical experience in 108 patients. diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7692111&form=6&db=m Measurement of prostate specific antigen and gamma-seminoprotein ratio: a new means of distinguishing benign prostatic hyperplasia and prostate cancer. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7692709&form=6&db=m [Measurement of serum PSA by DELFIA PSA kit and its application for mass screening. The Gunma Urological Oncology Study Group] diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7693556&form=6&db=m [Value of determining prostate specific antigen in follow-up of prostatic cancer] diagnostic usage,ongoing research,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7693984&form=6&db=m Re: The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. diagnostic usage,ongoing research,therapeutic application,unassigned 4,2,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7694349&form=6&db=m Multiple imputation for threshold-crossing data with interval censoring. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7773944&form=6&db=m Phase I study of phenylacetate administered twice daily to patients with cancer. diagnostic usage,unassigned 3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7925066&form=6&db=m Screening for cancer. Is it useful? causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7928457&form=6&db=m A multivariable analysis of clinical factors predicting for pathological features associated with local failure after radical prostatectomy for prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7976715&form=6&db=m [Non-specific granulomatous prostatitis. Relationship and differential diagnosis with prostatic cancer] causal interaction,diagnostic usage,ongoing research,unassigned 1,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7979213&form=6&db=m [Cancer of the prostate stage T1. Incidental carcinoma. Review of the literature and an appraisal of the classification] unassigned - 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7990303&form=6&db=m [Comparison of tumor markers versus their relative values to prostatic volume in detecting prostate cancer] causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8511115&form=6&db=m [Biological markers of cancer. Critical study] causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8533671&form=6&db=m [Change in serum prostate specific antigen values in men who had no evidence of prostate cancer on initial biopsy] diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8545399&form=6&db=m [Prostate specific antigen. Clinical applications of ultrasensitive assay] causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8551705&form=6&db=m [Transrectal ultrasound guided biopsies in 266 patients] diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8561077&form=6&db=m Multivariate statistical analysis for pathologist. Part I, The logistic model. diagnostic usage,unassigned 2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8583584&form=6&db=m Prostate specific antigen detected prostate cancer (clinical stage T1c): an interim analysis. causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8583585&form=6&db=m Prostate specific antigen detected prostate cancer. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8597764&form=6&db=m Measurement of prostate specific antigen as screening test for prostate cancer. False positive results cast doubt on conclusion. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8597765&form=6&db=m Measurement of prostate specific antigen as screening test for prostate cancer. Paper gives misleadingly optimistic view. diagnostic usage,therapeutic application,unassigned 4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8597766&form=6&db=m Measurement of prostate specific antigen as screening test for prostate cancer. Trials of treatment are needed before trials of screening. diagnostic usage,therapeutic application,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8597767&form=6&db=m Measurement of prostate specific antigen as screening test for prostate cancer. Measurement presents technical difficulties. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8608486&form=6&db=m The results of radical prostatectomy at a community hospital during the prostate specific antigen era. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8619388&form=6&db=m [Relationship between pretreatment serum levels of prostate specific antigen and bone metastasis in prostate cancer] diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8620419&form=6&db=m The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 3,1,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8624498&form=6&db=m Prostate specific antigen-alpha 2-macroglobulin complexes in prostate cancer patient sera. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8625081&form=6&db=m Distant metastasis after radical prostatectomy in patients without an elevated serum prostate specific antigen level. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8625128&form=6&db=m Early detection of prostate cancer. Results of a prostate specific antigen-based detection program in Japan. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8627846&form=6&db=m Pitfalls in interpreting prostate specific antigen velocity. diagnostic usage,therapeutic application,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8630923&form=6&db=m The results of a five-year early prostate cancer detection intervention. Investigators of the American Cancer Society National Prostate Cancer Detection Project. diagnostic usage,therapeutic application,unassigned 2,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8632568&form=6&db=m Standard versus age-specific prostate specific antigen reference ranges among men with clinically localized prostate cancer: A pathological analysis. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8632571&form=6&db=m Clinical efficacy of bone alkaline phosphatase and prostate specific antigen in the diagnosis of bone metastasis in prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,4,3 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8632594&form=6&db=m Re: Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: receiver operating characteristic curves. causal interaction,diagnostic usage,therapeutic application,unassigned 2,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8648771&form=6&db=m Cryosurgical treatment of localized prostate cancer (stages T1 to T4): preliminary results. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,1,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8649207&form=6&db=m Polyamine deprivation provokes an antalgic effect. diagnostic usage,unassigned 2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8657671&form=6&db=m [Effects of digital rectal examination on serum prostate specific antigen] diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8659273&form=6&db=m [The relationship of PSA to age and prostatic volume in patients with benign prostatic hypertrophy] diagnostic usage,therapeutic application,unassigned 4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8678489&form=6&db=m [Etiology of prostate cancer and significance of screening for early prostate cancer] causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8683677&form=6&db=m A comparison of the free fraction of serum prostate specific antigen in men with benign and cancerous prostates: the best case scenario. diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8683695&form=6&db=m Prostate specific antigen density versus prostate specific antigen slope as predictors of prostate cancer in men with initially negative prostatic biopsies. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,3,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8683696&form=6&db=m Comparative analysis of prostate specific antigen and its indexes in the detection of prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,2,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8683700&form=6&db=m Prostate specific antigen nadir following external beam radiation therapy for clinically localized prostate cancer: the relationship between nadir level and disease-free survival. diagnostic usage,ongoing research,therapeutic application,unassigned 4,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8683704&form=6&db=m Detection of prostate specific antigen in pancreas and salivary glands: a potential impact on prostate cancer overestimation. diagnostic usage,ongoing research,therapeutic application,unassigned 4,1,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8683715&form=6&db=m Re: Editorial: the central role of prostate specific antigen in diagnosis and progression of prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8689502&form=6&db=m Prostate screening--the Singapore experience. diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8689505&form=6&db=m Serum prostate specific antigen and prostate specific antigen density in patients receiving radical prostatectomy. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8707772&form=6&db=m The prostate specific antigen. Its use as a tumor marker for prostate cancer. diagnostic usage,therapeutic application,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8709304&form=6&db=m Free-to-total prostate specific antigen ratio as a single test for detection of significant stage T1c prostate cancer. diagnostic usage,ongoing research,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8709306&form=6&db=m Pathological characteristics and prognosis of nonpalpable and palpable prostate cancers with a Hybritech prostate specific antigen of 4 to 10 ng./ml. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8709448&form=6&db=m [Detection of prostate cancer in urological practice: clinical establishment of serum PSA reference values by age] diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8717457&form=6&db=m Screening and early detection of prostate cancer will decrease morbidity and mortality from prostate cancer: the argument against. diagnostic usage,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8717462&form=6&db=m Supportive care is not the only option in prostate cancer patients resistant to hormone therapy: the argument for. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8725045&form=6&db=m Changes in serum levels of prostatic acid phosphatase and prostate specific antigen after luteinizing hormone-releasing hormone analogue administration in patients with metastatic prostatic cancer in relation to glandular differentiation. causal interaction,diagnostic usage,ongoing research,unassigned 4,2,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8774111&form=6&db=m Human prostatic acid phosphatase and prostate specific antigen: protein structure, gene organization, and expression in neoplastic and benign tissues. diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8791983&form=6&db=m Comparison between equimolar- and skewed-response assays of prostate specific antigen: is there an influence on the clinical significance when measuring total serum prostate specific antigen? causal interaction,diagnostic usage,ongoing research,unassigned 3,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8808875&form=6&db=m An algorithm for predicting nonorgan confined prostate cancer using the results obtained from sextant core biopsies with prostate specific antigen level. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8809195&form=6&db=m Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,1,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8814852&form=6&db=m Dihydrotestosterone and testosterone levels in men screened for prostate cancer: a study of a randomized population. diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8826922&form=6&db=m Enhanced reverse transcriptase-polymerase chain reaction for prostate specific antigen as an indicator of true pathologic stage in patients with prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,2,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8849187&form=6&db=m Use of prostate specific antigen (PSA) and transrectal ultrasound (TRUS) in the diagnosis of prostate cancer--a local experience. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8863571&form=6&db=m Prospective evaluation of prostate specific antigen and prostate specific antigen density in the detection of nonpalpable and stage T1C carcinoma of the prostate. diagnostic usage,ongoing research,therapeutic application,unassigned 4,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8881953&form=6&db=m Abnormal prostatic cells in ejaculates from men with prostatic cancer--a preliminary report. diagnostic usage,unassigned 2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8881955&form=6&db=m The proportional decrease in prostate specific antigen level best predicts the duration of survival after hormonal therapy in patients with metastatic carcinoma of the prostate. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,3 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8891526&form=6&db=m Problems in the determination of prostate specific antigen. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8907816&form=6&db=m Results of a study to correlate serum prostate specific antigen and reproductive hormone levels in patients with localized prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,4,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8911366&form=6&db=m Significance of serum free prostate specific antigen in the screening of prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8918662&form=6&db=m [Serum prostate specific antigen for the early detection of prostate cancer in outpatients of internal medicine] causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8927956&form=6&db=m [Early diagnosis of prostate carcinoma with reference to the density of prostate-specific antigen] causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8939292&form=6&db=m Colocalization of immunoglobulin binding factor and prostate specific antigen in human prostate gland. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8946774&form=6&db=m Prostate specific antigen in the diagnosis and staging of prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8948340&form=6&db=m Assessing the variability of outcome for patients treated with localized prostate irradiation using different definitions of biochemical control. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8951471&form=6&db=m [Diagnosis and treatment of localized prostate cancer] diagnostic usage,therapeutic application,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8951477&form=6&db=m [Molecular staging of hematogenous microdissemination of prostate cancer cells] diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8951479&form=6&db=m [Usefulness of ultrasound-guided prostate biopsy in the diagnosis and treatment of localized prostate cancer] causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8965375&form=6&db=m [Diagnosis and treatment of bladder and prostate cancer in early stages] diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8972247&form=6&db=m Liarozole. ongoing research,therapeutic application,unassigned 3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8973693&form=6&db=m Longitudinal analysis of serial measurements of free and total PSA among men with and without prostatic cancer. diagnostic usage,ongoing research,therapeutic application,unassigned 4,1,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8973696&form=6&db=m Comparison of three assays for total serum prostate-specific antigen and percentage of free prostate-specific antigen in predicting prostate histology. diagnostic usage,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8976247&form=6&db=m Serum-to-urinary prostate specific antigen ratio: its impact in distinguishing prostate cancer when serum prostate specific antigen level is 4 to 10 ng./ml. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8976249&form=6&db=m Effect of digital rectal examination and needle biopsy on serum total and percentage of free prostate specific antigen levels. diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8996351&form=6&db=m Correlation between bone metabolic markers and bone scan in prostatic cancer. diagnostic usage,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9014718&form=6&db=m Anti-androgenic effects of combination finasteride plus flutamide in patients with prostatic carcinoma. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9019610&form=6&db=m [Clinical usefulness of the free and total prostate specific antigen ratio in the diagnosis of cancer of the prostate] causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9023130&form=6&db=m Human prostate-specific glandular kallikrein is expressed as an active and an inactive protein. ongoing research,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9038119&form=6&db=m Has ultrasonography a role in screening for prostatic cancer? diagnostic usage,therapeutic application,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9046415&form=6&db=m [Utility of prostate specific antigen (PSA) density in detecting prostate cancer in men showing gray zone serum PSA levels] causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,2,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9064384&form=6&db=m [Role of prostate specific antigen in the early diagnosis of prostatic cancer. New criteria based on its blood determination] causal interaction,diagnostic usage,unassigned 1,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9072591&form=6&db=m The impact of systematic prostate biopsy on prostate cancer incidence in men with symptomatic benign prostatic hyperplasia undergoing transurethral resection of the prostate. causal interaction,diagnostic usage,ongoing research,unassigned 2,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9072598&form=6&db=m Detection of prostate cancer relapse with prostate specific antigen monitoring at levels of 0.001 to 0.1 microG./L. diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9111601&form=6&db=m Improvement of prostate cancer screening by determination of the ratio free/total PSA in addition to PSA levels. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9112515&form=6&db=m Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,3,3 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9112516&form=6&db=m The value of serum carboxyterminal propeptide of type 1 procollagen in predicting bone metastases in prostate cancer. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9112517&form=6&db=m Prospective longitudinal evaluation of men with initial prostate specific antigen levels of 4.0 ng./ml. or less. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9112521&form=6&db=m Outcome for surgically staged localized prostate cancer treated with external beam radiation therapy. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9120930&form=6&db=m Prostate specific antigen density of the transition zone: a new effective parameter for prostate cancer prediction. causal interaction,diagnostic usage,therapeutic application,unassigned 2,4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9120931&form=6&db=m Sensitive prostate specific antigen measurements identify men with long disease-free intervals and differentiate aggressive from indolent cancer recurrences within 2 years after radical prostatectomy. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,2,3 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9120957&form=6&db=m Re: Detection of prostate specific antigen in pancreas and salivary glands: a potential impact on prostate cancer overestimation. diagnostic usage,ongoing research,therapeutic application,unassigned 4,1,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9120958&form=6&db=m Re: Detection of prostate specific antigen in pancreas and salivary glands: a potential impact on prostate cancer overestimation. diagnostic usage,ongoing research,therapeutic application,unassigned 4,1,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9123732&form=6&db=m Combined modality staging of prostate carcinoma and its utility in predicting pathologic stage and postoperative prostate specific antigen failure. diagnostic usage,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9125863&form=6&db=m [A pilot study of mass screening program for prostatic cancer by means of prostate specific antigen (PSA) filter paper method] diagnostic usage,ongoing research,unassigned 2,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9146608&form=6&db=m Prostate specific antigen in benign prostatic hyperplasia: purification and characterization. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9146612&form=6&db=m The free-to-total prostate specific antigen ratio improves the specificity of prostate specific antigen in screening for prostate cancer in the general population. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,3,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9146618&form=6&db=m Has there been a recent shift in the pathological features and prognosis of patients treated with radical prostatectomy? causal interaction,diagnostic usage,ongoing research,unassigned 2,1,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9150700&form=6&db=m Prostate specific antigen in boys with precocious puberty before and during gonadal suppression by GnRH agonist treatment. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9158517&form=6&db=m When is bone scintigraphy necessary in the assessment of newly diagnosed, untreated prostate cancer? diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9178589&form=6&db=m Diagnosis of prostate cancer: comparison of serum prostate specific antigen, digital rectal examination and transrectal ultrasonography. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9186314&form=6&db=m The relationship between prostatic intraepithelial neoplasia and prostate cancer: critical issues. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9186343&form=6&db=m Prostate specific antigen in black and white men after hormonal therapies for prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,3,3 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9186345&form=6&db=m Long-term efficacy and safety of nilutamide plus castration in advanced prostate cancer, and the significance of early prostate specific antigen normalization. International Anandron Study Group. diagnostic usage,therapeutic application,unassigned 3,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9187691&form=6&db=m Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9201202&form=6&db=m Screening for prostate cancer: what do general practitioners think? causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9209795&form=6&db=m Prostatic cancer: hospital-based prostate specific antigen screening. diagnostic usage,unassigned 2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9215399&form=6&db=m Effects of retinoid X receptor-selective ligands on proliferation of prostate cancer cells. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9224296&form=6&db=m Treatment options for localized prostate cancer based on pretreatment serum prostate specific antigen levels. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9224297&form=6&db=m Reverse transcriptase polymerase chain reaction for prostate specific antigen in the management of prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,3,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9224333&form=6&db=m Comparison of percent free prostate specific antigen and prostate specific antigen density as methods to enhance prostate specific antigen specificity in early prostate cancer detection in men with normal rectal examination and prostate specific antigen between 4.1 and 10 ng./ml. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,3,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9224334&form=6&db=m Prevalence and predictors of a positive repeat transrectal ultrasound guided needle biopsy of the prostate. diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9228549&form=6&db=m Tissue kallikrein and the bradykinin B2 receptor are expressed in endometrial and prostate cancers. causal interaction,ongoing research,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9231681&form=6&db=m Early stage prostate cancer treated with radiation therapy: stratifying an intermediate risk group. diagnostic usage,therapeutic application,unassigned 1,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9234618&form=6&db=m [Serum prostate-specific antigen in a urological outpatient clinic. Efficacy of age-specific and prostate volume-specific reference range in detection of prostate cancer] causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9245203&form=6&db=m [PSA level of the transitional zone: a new marker especially reliable for the detection of prostatic cancer] causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9250498&form=6&db=m [Diagnosis and follow-up of prostate cancer patients using prostate specific antigen (PSA)] diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9256325&form=6&db=m Evaluation of prostate specific antigen density and transrectal ultrasonography-guided biopsies in 100 consecutive patients with a negative digital rectal examination and intermediate serum prostate specific antigen levels. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9258099&form=6&db=m Prospective evaluation of prostate specific antigen density and systematic biopsy for detecting prostate cancer in Japanese patients with normal rectal examinations and intermediate prostate specific antigen levels. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,3,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9264766&form=6&db=m [Value of free/total prostate specific antigen in the early diagnosis of prostate cancer (study of 105 patients)] causal interaction,diagnostic usage,therapeutic application,unassigned 2,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9275269&form=6&db=m Randomised trial of prostate cancer screening in The Netherlands: assessment of acceptance and motives for attendance. causal interaction,diagnostic usage,unassigned 1,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9302135&form=6&db=m Outcome based staging for clinically localized adenocarcinoma of the prostate. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9302183&form=6&db=m Isolation and characterization of free form prostate specific antigen (f-PSA) in sera of men with prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,3,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9308936&form=6&db=m Equivalent 5-year bNED in select prostate cancer patients managed with surgery or radiation therapy despite exclusion of the seminal vesicles from the CTV. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,3,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9329548&form=6&db=m First clinical results with Enzymun-Test for free PSA. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9334615&form=6&db=m Trends in diagnosis of stage T1a-b prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 2,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9334618&form=6&db=m Racial differences in operating characteristics of prostate cancer screening tests. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,2,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9334620&form=6&db=m Prostate specific antigen reverse transcriptase-polymerase chain reaction assay in preoperative staging of prostate cancer. diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9366336&form=6&db=m Serum free prostate specific antigen and prostate specific antigen density measurements for predicting cancer in men with prior negative prostatic biopsies. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9366340&form=6&db=m Stability of serum total and free prostate specific antigen under varying storage intervals and temperatures. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9366341&form=6&db=m Prostatic volume and ratio of free-to-total prostate specific antigen in patients with prostatic cancer or benign prostatic hyperplasia. causal interaction,diagnostic usage,ongoing research,unassigned 4,2,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9366342&form=6&db=m Prostate specific antigen adjusted for the transition zone volume as an indicator of prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,2,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9366345&form=6&db=m Cryosurgical ablation of prostate cancer: patterns of cancer recurrence. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,3,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9374953&form=6&db=m Common cancers--genetics, origin, prevention, screening: Parts I and II. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9400426&form=6&db=m Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,3,3 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9401168&form=6&db=m Prostate cancer screening in the midst of controversy: Canadian men's knowledge, beliefs, utilization, and future intentions. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9406055&form=6&db=m Application of immunomagnetic beads in combination with RT-PCR for the detection of circulating prostate cancer cells. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9414541&form=6&db=m Diagnosis, management and screening of early localised prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 4,1,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9422445&form=6&db=m Color Doppler sonography of the prostate. diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9428387&form=6&db=m Human glandular kallikrein, hK2, shows arginine-restricted specificity and forms complexes with plasma protease inhibitors. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9436285&form=6&db=m Prediction of significant cancer in men with stage T1c adenocarcinoma of the prostate. diagnostic usage,therapeutic application,unassigned 4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9454283&form=6&db=m [Surgical therapy of locally confined prostate carcinoma] causal interaction,diagnostic usage,therapeutic application,unassigned 4,1,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9467484&form=6&db=m Prostate specific antigen velocity as a measure of the natural history of prostate cancer: defining a 'rapid riser' subset. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9474178&form=6&db=m Characteristics of screening detected prostate cancer in men 50 to 66 years old with 3 to 4 ng./ml. Prostate specific antigen. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,1,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9474185&form=6&db=m Biostatistical modeling using traditional preoperative and pathological prognostic variables in the selection of men at high risk for disease recurrence after radical prostatectomy for prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 3,2,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9474187&form=6&db=m The contemporary value of pretreatment prostatic acid phosphatase to predict pathological stage and recurrence in radical prostatectomy cases. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,3,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9474213&form=6&db=m Re: The free-to-total prostate specific antigen ratio improves the specificity of prostate specific antigen in screening for prostate cancer in the general population. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,3,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9484666&form=6&db=m Monitoring percent free PSA in serial specimens: improvement of test specificity, early detection, and identification of occult tumors. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9492543&form=6&db=m [Enzyme-linked immunosorbent assay for serum prostate specific antigen (PSA) using monoclonal antibodies] diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9507843&form=6&db=m The effect of prostate volume, age, total prostate specific antigen level and acute inflammation on the percentage of free serum prostate specific antigen levels in men without clinically detectable prostate cancer. causal interaction,diagnostic usage,ongoing research,unassigned 3,4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9507844&form=6&db=m The use of percent free prostate specific antigen for staging clinically localized prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9507845&form=6&db=m Evaluation of changes in prostate specific antigen in clinically localized prostate cancer managed without initial therapy. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,2,4 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9516590&form=6&db=m Androgen ablation in addition to radiation therapy for prostate cancer: is there true benefit? causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9523660&form=6&db=m Transforming growth factor-beta1 serum concentration in patients with prostatic cancer and benign prostatic hyperplasia. diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9523661&form=6&db=m Expression of E-cadherin in primary prostate cancer: correlation with clinical features. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9523662&form=6&db=m Prediction of pathological stage and clinical outcome in prostate cancer: an improved pre-operative model incorporating biopsy-determined intraductal carcinoma. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9554361&form=6&db=m Ratio of free-to-total prostate specific antigen in serum cannot distinguish patients with prostate cancer from those with chronic inflammation of the prostate. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9554383&form=6&db=m Re: reverse transcriptase polymerase chain reaction for prostate specific antigen in the management of prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9568607&form=6&db=m The impact of prostate cancer knowledge on cancer screening. causal interaction,diagnostic usage,unassigned 2,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9568677&form=6&db=m LNCaP produces both putative zymogen and inactive, free form of prostate-specific antigen. diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9579381&form=6&db=m Prostate-specific antigen (hK3) and human prostatic glandular kallikrein (hK2) in the detection of early stage human prostate cancer. causal interaction,diagnostic usage,ongoing research,unassigned 2,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9586435&form=6&db=m [Radiotherapy of localized cancer of the prostate: current status and new strategies] diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9589875&form=6&db=m [Prostate cancer screening using prostate specific antigen (PSA) in Tokatsu Hospital--examination of lost-to-followup cases] diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9594181&form=6&db=m [Influence of age on serum prostate specific antigen concentration] diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9598505&form=6&db=m Androgen deprivation therapy for asymptomatic advanced prostate cancer in the prostate specific antigen era: a national survey of urologist beliefs and practices. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9598507&form=6&db=m The value of the ratio of free-to-total prostate specific antigen for staging purposes in previously untreated prostate cancer. diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9598514&form=6&db=m 111Indium-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy. The ProstaScint Study Group. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9607395&form=6&db=m Significance of measurement of prostate specific antigen (PSA) in familial prostate cancer lines. diagnostic usage,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9622078&form=6&db=m Increased UDP-glucuronosyltransferase activity and decreased prostate specific antigen production by biochanin A in prostate cancer cells. causal interaction,diagnostic usage,unassigned 3,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9628610&form=6&db=m Serum levels of total and free prostate specific antigen in men on hemodialysis. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9628654&form=6&db=m Development of prostate-specific antigen promoter-based gene therapy for androgen-independent human prostate cancer. causal interaction,ongoing research,therapeutic application,unassigned 2,3,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9649265&form=6&db=m Two consecutive sets of transrectal ultrasound guided sextant biopsies of the prostate for the detection of prostate cancer. diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9649289&form=6&db=m Immunolocalization of apolipoprotein D, androgen receptor and prostate specific antigen in early stage prostate cancers. causal interaction,diagnostic usage,ongoing research,unassigned 2,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9656100&form=6&db=m Free-to-total prostate specific antigen ratio in clinical staging of prostate cancer. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9679889&form=6&db=m Prostate specific antigen density of the transition zone for early detection of prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,2,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9679890&form=6&db=m Comparison of 3 investigational assays for the free form of prostate specific antigen. diagnostic usage,therapeutic application,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9679891&form=6&db=m Repeat ultrasound guided prostate needle biopsy: use of free-to-total prostate specific antigen ratio in predicting prostatic carcinoma. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9679892&form=6&db=m Novel staging tool for localized prostate cancer: a pilot study using genetic adaptive neural networks. diagnostic usage,ongoing research,therapeutic application,unassigned 2,3,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9679893&form=6&db=m Prostate specific antigen and pathological features of prostate cancer in black and white patients: a comparative study based on radical prostatectomy specimens. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9679898&form=6&db=m CD34 immunohistochemical assessment of angiogenesis as a prognostic marker for prostate cancer recurrence after radical prostatectomy. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9697393&form=6&db=m [Use of transrectal ultrasonography in prostate pathology: determination and clinical usefulness of the prostate transition zone] causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9700305&form=6&db=m [Use of prostate specific antigen. A review] causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9707970&form=6&db=m [The role of prostate specific antigen and its derivatives (age-specific PSA, PSA density, velocity, free/total PSA) in the diagnosis of prostate cancer] causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9710944&form=6&db=m Kinetic analysis of prostatic volume and prostate specific antigen (PSA) in patients with advanced prostatic cancer treated by castration. causal interaction,diagnostic usage,ongoing research,unassigned 2,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9712442&form=6&db=m Value of the free to total prostate specific antigen ratio and prostate specific antigen density for detecting prostate cancer in Japanese patients. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,3,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9712443&form=6&db=m Molecular staging of prostate cancer: comparison of nested reverse transcription polymerase chain reaction assay using prostate specific antigen versus prostate specific membrane antigen as primer. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9720554&form=6&db=m Trends in poorly differentiated prostate cancer 1973 to 1994: observations from the Surveillance, Epidemiology and End Results database. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9722757&form=6&db=m Prostate specific antigen (PSA) value adjusted for transition zone volume and free PSA (gamma-seminoprotein)/PSA ratio in the diagnosis of prostate cancer in patients with intermediate PSA levels. causal interaction,diagnostic usage,ongoing research,unassigned 3,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9722758&form=6&db=m The percentage of free prostate specific antigen is an age-independent tumour marker for prostate cancer: establishment of reference ranges in a large population of healthy men. diagnostic usage,ongoing research,therapeutic application,unassigned 4,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9725044&form=6&db=m [Characteristics of screening-detected prostate cancer on health checkup] diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9730444&form=6&db=m In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/mL. diagnostic usage,ongoing research,unassigned 3,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9750494&form=6&db=m [The significance and limitation of prostate specific antigen in the mass screening for prostate cancer] causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,1,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9750496&form=6&db=m [Clinical significance of prostate specific antigen and gamma-seminoprotein ratio for diagnosing prostate cancer] causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9750498&form=6&db=m [The efficacy of PSA density for the early detection of prostate cancer] diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9750499&form=6&db=m [PSATZ (prostate specific antigen adjusted for the transition zone volume)] diagnostic usage,ongoing research,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9750501&form=6&db=m [Prostate specific antigen doubling time in prostate cancer before treatment and in refractory status] causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9750522&form=6&db=m [Antiandrogen withdrawal syndrome] causal interaction,diagnostic usage,therapeutic application,unassigned 1,1,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9751384&form=6&db=m Re: Detection of prostate specific antigen in pancreas and salivary glands: a potential impact on prostate cancer overestimation. diagnostic usage,ongoing research,therapeutic application,unassigned 4,1,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9752600&form=6&db=m [Clinical evaluation of chemiluminescence immunoassay PSA (ACS-PSA) for detection of prostate cancer] diagnostic usage,ongoing research,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9761243&form=6&db=m The precursor form of the human kallikrein 2, a kallikrein homologous to prostate-specific antigen, is present in human sera and is increased in prostate cancer and benign prostatic hyperplasia. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9772875&form=6&db=m The role of power Doppler ultrasonography in the diagnosis of prostate cancer: a preliminary study. diagnostic usage,ongoing research,unassigned 3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9772876&form=6&db=m Influence of free-to-total prostate specific antigen variability on the early diagnosis of prostate cancer: a comparative study of three immunoassays. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9783940&form=6&db=m Perineural invasion and seminal vesicle involvement predict pelvic lymph node metastasis in men with localized carcinoma of the prostate. diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9783942&form=6&db=m Use of lower prostate specific antigen cutoffs for prostate cancer screening in black and white men. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9793832&form=6&db=m Prostate cancer screening--a physician survey in Missouri. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9800488&form=6&db=m [Prostate-specific antigen in the follow-up of conservatively treated prostatic cancer] diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9805668&form=6&db=m [Clinical significance of prostate specific antigen (PSA) and PSA density in the detection of T1a and T1b prostate cancer] causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,3,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9817329&form=6&db=m Free and complexed prostate specific antigen in the differentiation of benign prostatic hyperplasia and prostate cancer: studies in serum and plasma samples. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,4,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9817330&form=6&db=m Prostate specific antigen density of the transition zone for predicting pathological stage of localized prostate cancer in patients with serum prostate specific antigen less than 10 ng./ml. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9817331&form=6&db=m The combination of preoperative prostate specific antigen and postoperative pathological findings to predict prostate specific antigen outcome in clinically localized prostate cancer. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9817333&form=6&db=m Prostate cancer detection in candidates for open prostatectomy. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,3,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9817336&form=6&db=m Repeat screening for prostate cancer after 1-year followup in 984 biopsied men: clinical and pathological features of detected cancer. causal interaction,diagnostic usage,ongoing research,unassigned 3,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9817393&form=6&db=m Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. diagnostic usage,ongoing research,therapeutic application,unassigned 4,1,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9819842&form=6&db=m Assessing uncertainty in microsimulation modelling with application to cancer screening interventions. diagnostic usage,ongoing research,therapeutic application,unassigned 4,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9828800&form=6&db=m Is prostate specific antigen density an important prognostic indicator for patients with prostate cancer treated with external beam therapy? causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,3,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9835085&form=6&db=m [Antiandrogen suppression syndrome in patients with hormone-resistant cancer of the prostate] diagnostic usage,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9849420&form=6&db=m Longitudinal evaluation of the complexed-to-total prostate specific antigen ratio in men with prostate disease. Effect of treatment. causal interaction,diagnostic usage,ongoing research,unassigned 2,4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9850833&form=6&db=m [Clinical studies on the prognostic factors in prostate cancer] diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9850846&form=6&db=m [Clinical utility of the free prostate specific antigen (PSA), alpha 1-antichymotrypsin-complexed PSA, and free/total PSA ratio using the specific and sensitive enzyme-linked immunosorbent assay "E-plate EIKEN PSA"] causal interaction,diagnostic usage,ongoing research,unassigned 1,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9851894&form=6&db=m alpha2-macroglobulin and C1-inactivator are plasma inhibitors of human glandular kallikrein. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9879324&form=6&db=m [Treatment of metastatic prostate cancer: certainty and doubts] causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9915439&form=6&db=m Current followup strategies after radical prostatectomy: a survey of American Urological Association urologists. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9915441&form=6&db=m Decline in prostate cancer mortality from 1980 to 1997, and an update on incidence trends in Olmsted County, Minnesota. diagnostic usage,ongoing research,therapeutic application,unassigned 1,2,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9932152&form=6&db=m Prostate specific antigen (PSA) testing as screening for prostate cancer: the current controversy. causal interaction,diagnostic usage,therapeutic application,unassigned 2,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9951132&form=6&db=m A long follow-up on prostate specific antigen density and prostate biopsy. diagnostic usage,ongoing research,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10022696&form=6&db=m Digital rectal examination for detecting prostate cancer at prostate specific antigen levels of 4 ng./ml. or less. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10022701&form=6&db=m Deoxyribonucleic acid ploidy and serum prostate specific antigen predict outcome following salvage prostatectomy for radiation refractory prostate cancer. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10024471&form=6&db=m Large-scale propagation of recombinant adherent cells that secrete a stable form of human glandular kallikrein, hK2. unassigned - 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10030104&form=6&db=m Evaluation of prostate specific antigen in the prognosis of patients with advanced prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10037390&form=6&db=m Radical perineal prostatectomy: oncological outcome during a 20-year period. causal interaction,diagnostic usage,therapeutic application,unassigned 1,2,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10037393&form=6&db=m Changes in free and free-to-total prostate specific antigen after androgen deprivation or chemotherapy in patients with advanced prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,4 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10037394&form=6&db=m Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10071549&form=6&db=m Plasma sialic acid in patients with prostate cancer. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10078642&form=6&db=m Defining the implant treatment volume for patients with low risk prostate cancer: does the anterior base need to be treated? diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10081867&form=6&db=m Downward trend in prostate cancer mortality in Quebec and Canada. causal interaction,diagnostic usage,therapeutic application,unassigned 3,2,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10081868&form=6&db=m The changing pattern of prostate cancer at the time of diagnosis: characteristics of screen detected prostate cancer in a population based screening study. diagnostic usage,ongoing research,therapeutic application,unassigned 4,1,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10081869&form=6&db=m Prostate specific antigen nadir achieved by men apparently cured of prostate cancer by radiotherapy. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,2,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10081870&form=6&db=m Ultrasensitive detection of prostate specific antigen in the followup of 422 patients after radical prostatectomy. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10086262&form=6&db=m [RT-PCR assay for detecting PSA mRNA in peripheral blood of prostate cancer patients] diagnostic usage,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10087319&form=6&db=m Anti-tumor effects of PC-SPES, an herbal formulation in prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10093628&form=6&db=m Quebec prostate cancer mortality dropped in 1996. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10151084&form=6&db=m Use of the prostate specific antigen (P.S.A.) in early detection of prostate cancer in males over the age of 50. causal interaction,diagnostic usage,therapeutic application,unassigned 2,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10210369&form=6&db=m Molecular determination of surgical margins using fossa biopsies at radical prostatectomy. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,1,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10210419&form=6&db=m Re: Use of lower prostate specific antigen cutoffs for prostate cancer screening in black and white men. diagnostic usage,therapeutic application,unassigned 4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10223487&form=6&db=m Human glandular kallikrein 2 expression in prostate adenocarcinoma and lymph node metastases. diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10231930&form=6&db=m [Early recognition of prostate carcinoma. Initial results of a prospective multicenter study in Germany. Project Group for Early Detection DGU-BDU Laboratory diagnosis Professional Circle] diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10349301&form=6&db=m [Histological characteristics and clinical significance of Japanese prostate cancer with low levels of prostate specific antigen of 4.0 ng/ml or lower] causal interaction,diagnostic usage,ongoing research,unassigned 1,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10351987&form=6&db=m Development of an ultrasensitive immunoassay for human glandular kallikrein with no cross-reactivity from prostate-specific antigen. causal interaction,diagnostic usage,unassigned 3,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10368242&form=6&db=m Serum insulin-like growth factor-1 is not a useful marker of prostate cancer. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10369948&form=6&db=m Serum bone alkaline phosphatase levels enhance the clinical utility of prostate specific antigen in the staging of newly diagnosed prostate cancer patients. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10404306&form=6&db=m The value of gamma-seminoprotein in combination with prostate specific antigen in detecting prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10408309&form=6&db=m Evaluation of serum arginase activity in benign prostatic hypertrophy and prostatic cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,4 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10411025&form=6&db=m Prostate specific antigen: a decade of discovery--what we have learned and where we are going. diagnostic usage,ongoing research,therapeutic application,unassigned 4,1,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10411045&form=6&db=m Racial differences in tumor volume and prostate specific antigen among radical prostatectomy patients. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10411047&form=6&db=m Early quality of life assessment in men treated with permanent source interstitial brachytherapy for clinically localized prostate cancer. diagnostic usage,ongoing research,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10411051&form=6&db=m The efficacy of cryosurgical ablation of prostate cancer: the University of California, San Francisco experience. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10411077&form=6&db=m Re: Free and complexed prostate specific antigen in the differentiation of benign prostatic hyperplasia and prostate cancer: studies in serum and plasma samples. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,3,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10422433&form=6&db=m [Digital rectal examination, transrectal ultrasonography and prostate specific antigen for diagnosis of prostate cancer in clinical urological practice-detection of impalpable cancer] diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10434906&form=6&db=m Prostate specific antigen level and Gleason score in predicting the stage of newly diagnosed prostate cancer. diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10436694&form=6&db=m [Usefulness of free prostate specific antigen in the detection of prostate cancer] causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,1,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10448269&form=6&db=m Rationale for randomised trials of prostate cancer screening. The International Prostate Screening Trial Evaluation Group. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10452935&form=6&db=m Prostate cancer: A challenge for screening. diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10458357&form=6&db=m Serial prostate specific antigen screening for prostate cancer: a computer model evaluates competing strategies. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10465403&form=6&db=m Thapsigargin analogues for targeting programmed death of androgen-independent prostate cancer cells. diagnostic usage,therapeutic application,unassigned 4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10466060&form=6&db=m Prostate specific antigen density for discriminating prostate cancer from benign prostatic hyperplasia in the gray zone of prostate-specific antigen. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,3,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10470206&form=6&db=m The biologic lower detection limit of six ultrasensitive PSA assays. diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10492186&form=6&db=m Prostate specific antigen variation in patients without clinically evident prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,4,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10492189&form=6&db=m Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,1,4 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10492194&form=6&db=m Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate specific antigen: a prospective multicenter clinical trial. diagnostic usage,therapeutic application,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10492600&form=6&db=m Prostate cancer and prostate specific antigen. A Jamaican perspective. diagnostic usage,unassigned 1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10523893&form=6&db=m [Cancer of the prostate: advances in the use of PSA and its derived indices--new tumor markers] diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10524873&form=6&db=m The effect of high grade prostatic intraepithelial neoplasia on serum total and percentage of free prostate specific antigen levels. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,2,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10532984&form=6&db=m Effects of a phytotherapeutic agent, PC-SPES, on prostate cancer: a preliminary investigation on human cell lines and patients. diagnostic usage,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10545066&form=6&db=m The combination of human glandular kallikrein and free prostate-specific antigen (PSA) enhances discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately increased total PSA. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10565744&form=6&db=m Use of human glandular kallikrein 2 for the detection of prostate cancer: preliminary analysis. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10569561&form=6&db=m Neoadjuvant hormonal therapy before radical prostatectomy and risk of prostate specific antigen failure. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,2,4 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10569562&form=6&db=m Significance and metabolism of complexed and noncomplexed prostate specific antigen forms, and human glandular kallikrein 2 in clinically localized prostate cancer before and after radical prostatectomy. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,4,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10571627&form=6&db=m The prognostic value of different forms of prostate specific antigen and their ratios in patients with prostate cancer. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10579073&form=6&db=m The necessity of a second prostate biopsy cannot be predicted by PSA or PSA derivatives (density or free:total ratio) in men with prior negative prostatic biopsies. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10583401&form=6&db=m Production and activation of recombinant hK2 with propeptide mutations resulting in high expression levels. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10586358&form=6&db=m [Serum alkaline phosphatase flare in prostate cancer accompanied by bone metastases and treated with hormonal therapy. TEKK Study Group] causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,3,4 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10604382&form=6&db=m Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10638179&form=6&db=m Penile metastasis from carcinoma of the prostate in a patient with high serum prostate specific antigen levels. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10642608&form=6&db=m Glycotyping of prostate specific antigen. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10647666&form=6&db=m Trends in mortality rates in patients with prostate cancer during the era of prostate specific antigen screening. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10647669&form=6&db=m A comparison of cause of death determination in men previously diagnosed with prostate cancer who died in 1985 or 1995. diagnostic usage,ongoing research,unassigned 2,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10650506&form=6&db=m Prostate specific antigen and benign prostatic hyperplasia. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10657376&form=6&db=m Sensitive and specific immunodetection of human glandular kallikrein 2 in serum. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10668943&form=6&db=m The value of serum prostate specific antigen and other parameters in detecting bone metastases in prostate cancer. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10668945&form=6&db=m Prospective evaluation of prostate specific antigen (PSA), PSA density, free-to-total PSA ratio and a new formula (prostate malignancy index) for detecting prostate cancer and preventing negative biopsies in patients with normal rectal examinations and intermediate PSA levels. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10680732&form=6&db=m Prostate cancer in Saskatchewan Canada, before and during the PSA era. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10687982&form=6&db=m Prostate cancer detection at low prostate specific antigen. causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10687988&form=6&db=m Dexamethasone does not significantly contribute to the response rate of docetaxel and estramustine in androgen independent prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,4,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10687990&form=6&db=m Radiotherapy for isolated serum prostate specific antigen elevation after prostatectomy for prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10689876&form=6&db=m [The result of mass screening of 1997 for prostatic cancer in Isesaki City] diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10692784&form=6&db=m [General features and strategy in the diagnosis of prostatic carcinoma] causal interaction,diagnostic usage,therapeutic application,unassigned 2,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10692785&form=6&db=m [Staging and therapeutic options in local prostatic carcinoma] causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10694554&form=6&db=m Serum human glandular kallikrein-2 protease levels predict the presence of prostate cancer among men with elevated prostate-specific antigen. causal interaction,diagnostic usage,ongoing research,unassigned 3,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10694740&form=6&db=m Statistical models for longitudinal biomarkers of disease onset. diagnostic usage,ongoing research,therapeutic application,unassigned 4,1,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10711851&form=6&db=m Oral chemotherapy in the treatment of hormone-refractory prostate cancer. causal interaction,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10736487&form=6&db=m Human glandular kallikrein as a tool to improve discrimination of poorly differentiated and non-organ-confined prostate cancer compared with prostate-specific antigen. diagnostic usage,ongoing research,unassigned 3,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10737471&form=6&db=m Prostate specific antigen bounce after radioactive seed implantation followed by external beam radiation for prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,1,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10737489&form=6&db=m Impact of positive surgical margins on prostate cancer recurrence and the use of secondary cancer treatment: data from the CaPSURE database. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10737491&form=6&db=m Detection of micrometastatic prostate cancer cells in the lymph nodes by reverse transcriptase polymerase chain reaction is predictive of biochemical recurrence in pathological stage T2 prostate cancer. diagnostic usage,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10751589&form=6&db=m Relapse and cure rates of prostate cancer patients after radical prostatectomy and 5 years of follow-up. diagnostic usage,ongoing research,therapeutic application,unassigned 3,3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10751859&form=6&db=m Percent free prostate specific antigen and cancer detection in black and white men with total prostate specific antigen 2.5 to 9.9 ng./ml. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,2,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10751861&form=6&db=m Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,3,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10751862&form=6&db=m Prostate specific antigen response to mitoxantrone and prednisone in patients with refractory prostate cancer: prognostic factors and generalizability of a multicenter trial to clinical practice. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,4,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10751863&form=6&db=m Patients with abnormal ultrasound of the prostate but normal digital rectal examination should be classified as having clinical stage T2 tumors. diagnostic usage,ongoing research,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10751864&form=6&db=m Human glandular kallikrein 2: a potential serum marker for predicting the organ confined versus non-organ confined growth of prostate cancer. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10759666&form=6&db=m A comparison of six commercial assays for total and free prostate specific antigen (PSA): the predictive value of the ratio of free to total PSA. diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10759667&form=6&db=m Differential response of prostate specific antigen to testosterone surge after luteinizing hormone-releasing hormone analogue in prostate cancer and benign prostatic hyperplasia. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,3,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10759669&form=6&db=m Deferred treatment of localized prostate cancer in the elderly: the impact of the age and stage at the time of diagnosis on the treatment decision. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10759671&form=6&db=m The significance of the free-to-complexed prostate-specific antigen (PSA) ratio in prostate cancer detection in patients with a PSA level of 4.1-10.0 ng/mL. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10760426&form=6&db=m Follow-up costs after external radiation for low risk prostate cancer. diagnostic usage,ongoing research,therapeutic application,unassigned 2,3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10765019&form=6&db=m Expression of the multidrug resistance gene in human prostate cancer. diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10769689&form=6&db=m Development of a new plasmid vector with PSA-promoter and enhancer expressing tissue-specificity in prostate carcinoma cell lines. diagnostic usage,ongoing research,therapeutic application,unassigned 2,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10769794&form=6&db=m [Clinical profiles of prostate cancer in our hospital: association between primary symptoms and clinical stage] diagnostic usage,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10785932&form=6&db=m [Opportunity for a systematic screening of prostatic cancer by determining prostate specific antigen levels] diagnostic usage,unassigned 2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10792083&form=6&db=m Clinical value of human glandular kallikrein 2 and free and total prostate-specific antigen in serum from a population of men with prostate-specific antigen levels 3.0 ng/mL or greater. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10799151&form=6&db=m Prostate specific antigen only progression of prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10799171&form=6&db=m Detection rate of histologically insignificant prostate cancer with systematic sextant biopsies and fine needle aspiration cytology. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10799173&form=6&db=m Quality of life of asymptomatic men with nonmetastatic prostate cancer on androgen deprivation therapy. ongoing research,therapeutic application,unassigned 3,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10799185&form=6&db=m Comparing prostate specific antigen outcomes after different types of radiotherapy management of clinically localized prostate cancer highlights the importance of controlling for established prognostic factors. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,3,3 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10799186&form=6&db=m Radical prostatectomy for localized prostate cancer provides durable cancer control with excellent quality of life: a structured debate. causal interaction,therapeutic application,unassigned 3,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10803192&form=6&db=m [Multiple prostatic biopsies in the "gray zone" of the specific prostatic antigen] diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10803835&form=6&db=m Prostate specific antigen: a useful screening test? causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10808195&form=6&db=m The role of prostate specific antigen measurement in the detection and management of prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,3,3 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10811979&form=6&db=m Inhibition of prostate specific antigen expression by genistein in prostate cancer cells. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,3,4 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10814979&form=6&db=m A latent class mixed model for analysing biomarker trajectories with irregularly scheduled observations. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10848693&form=6&db=m Transrectal power Doppler imaging in the detection of prostate cancer. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10848695&form=6&db=m Mean time to cancer-specific death of apparently clinically localized prostate cancer: policy implications for threshold ages in prostate-specific antigen screening and ablative therapy. causal interaction,diagnostic usage,therapeutic application,unassigned 2,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10851317&form=6&db=m Differential Glycosylation of Cellular Prostate Specific Antigen and the Regulatory Mechanism of Its Secretion. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10851331&form=6&db=m Neoadjuvant Hormone Therapy Before Radical Prostatectomy: Update on the Memorial Sloan-Kettering Cancer Center Trials. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,3,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10854562&form=6&db=m Expression of soluble urokinase plasminogen activator receptor may be related to outcome in prostate cancer patients. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10860092&form=6&db=m Prostate cancer in Victoria in 1993: patterns of reported management. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,1,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10893591&form=6&db=m Transperineal magnetic resonance image guided prostate biopsy. causal interaction,diagnostic usage,therapeutic application,unassigned 3,2,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10893598&form=6&db=m Histopathological prostate cancer characteristics at radical prostatectomy after population based screening. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10893618&form=6&db=m Use of pleural fluid prostate specific antigen in the diagnosis of malignant effusion from metastatic prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10910153&form=6&db=m Real-time magnetic resonance imaging-guided brachytherapy in the treatment of selected patients with clinically localized prostate cancer. diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10928069&form=6&db=m Construction and in vivo evaluation of an anti-PSA x anti-CD3 bispecific antibody for the immunotherapy of prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 1,2,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10953133&form=6&db=m Cytokine variations in patients with hormone treated prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 3,2,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10953141&form=6&db=m Endorectal magnetic resonance imaging as a predictor of biochemical outcome after radical prostatectomy in men with clinically localized prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,3,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10957776&form=6&db=m [Improvement of transrectal ultrasound. Artificial neural network analysis (ANNA) in detection and staging of prostatic carcinoma] causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10971271&form=6&db=m Inactive free : total prostate specific antigen ratios in ejaculate from men with suspected and known prostate cancer, compared with young control men. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,4,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10984865&form=6&db=m Unrealistic optimism and the Health Belief Model. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10992369&form=6&db=m Prostate specific antigen testing and digital rectal examination before and during a randomized trial of screening for prostate cancer: European randomized study of screening for prostate cancer, Rotterdam. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10992405&form=6&db=m Re: radiotherapy for isolated serum prostate specific antigen elevation after prostatectomy for prostate cancer. unassigned - 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10998759&form=6&db=m Markers of undiagnosed incidental cancer in comparison with clinical prostatic cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11008095&form=6&db=m Clinical trials of immunotherapy for advanced prostate cancer. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11010966&form=6&db=m Molecular cloning of the human kallikrein 15 gene (KLK15). Up-regulation in prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,2,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11022692&form=6&db=m [Prostate specific antigen: a role of PSA in the diagnosis of prostate cancer] causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11025710&form=6&db=m Predicting pathological stage of localized prostate cancer using volume weighted mean nuclear volume. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11025776&form=6&db=m PSP94 expression after androgen deprivation therapy: a comparative study with prostate specific antigen in benign prostate and prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,3,4 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11025777&form=6&db=m Antibody immunity to prostate cancer associated antigens can be detected in the serum of patients with prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,4,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11028151&form=6&db=m The value of free and total prostate specific antigen in identifying patients for prostatic biopsy and its relationship to Gleason score and number of positive cores. diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11036336&form=6&db=m [Treatment of localized prostatic cancer--different alternatives. Patients with localized prostatic cancer must actively participate in the choice of therapy] diagnostic usage,therapeutic application,unassigned 4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11061890&form=6&db=m Use of the complex between prostate specific antigen and alpha 1-protease inhibitor for screening prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11061891&form=6&db=m Prostate cancer detection in Black and White men with abnormal digital rectal examination and prostate specific antigen less then 4 ng./ml. causal interaction,diagnostic usage,unassigned 2,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11061900&form=6&db=m Salvage radical prostatectomy for radiorecurrent prostate cancer: morbidity revisited. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11061919&form=6&db=m Re: Prostate specific antigen bounce after radioactive seed implantation followed by external beam radiation for prostate cancer. diagnostic usage,therapeutic application,unassigned 2,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11062371&form=6&db=m Clinical utility of percent-positive prostate biopsies in predicting biochemical outcome after radical prostatectomy or external-beam radiation therapy for patients with clinically localized prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,3,3 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11062383&form=6&db=m Hormonal therapy options for biochemical recurrence of prostate cancer after local therapy. causal interaction,diagnostic usage,therapeutic application,unassigned 3,2,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11064155&form=6&db=m An androgen response element mediates LNCaP cell dependent androgen induction of the hK2 gene. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11080790&form=6&db=m Prostate tissue and serum markers. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11089880&form=6&db=m Repetitive and site-specific molecular staging of prostate cancer using nested reverse transcriptase polymerase chain reaction for prostate specific antigen and prostate specific membrane antigen. diagnostic usage,ongoing research,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11125361&form=6&db=m De novo muscle invasive bladder cancer: is there a change in trend? causal interaction,diagnostic usage,unassigned 4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11156423&form=6&db=m Detection of metastatic prostate cancer using a splice variant-specific reverse transcriptase-polymerase chain reaction assay for human glandular kallikrein. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11166529&form=6&db=m Potential selection bias in a community-based study of PSA levels in African-American men. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11173940&form=6&db=m Comparison of the clinical validity of free prostate-specific antigen, alpha-1 antichymotrypsin-bound prostate-specific antigen and complexed prostate-specific antigen in prostate cancer diagnosis. diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11176395&form=6&db=m Ratio of free-to-total prostate specific antigen correlates with tumor volume in patients with increased prostate specific antigen. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11176461&form=6&db=m The incidence of prostate cancer in a screening population with a serum prostate specific antigen between 2.5 and 4.0 ng/ml: relation to biopsy strategy. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11176484&form=6&db=m Trends in Gleason score for prostate cancer diagnosed between 1983 and 1993. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11186321&form=6&db=m [Model of screening for prostatic cancer among patients with prostate specific antigen concentration of 4-10 ng/ml in blood] causal interaction,diagnostic usage,ongoing research,unassigned 1,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11196384&form=6&db=m [Usefulness of PSA-complex in the diagnosis of prostatic carcinoma] diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11201129&form=6&db=m [Study of free to total prostate specific antigen ratio in the detection of patients with prostate cancer] diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11203074&form=6&db=m Re: Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,3,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11221033&form=6&db=m [Does PSA density of the transition zone represent a useful parameter in the diagnosis of prostate carcinoma?] causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11221036&form=6&db=m [Repeated ultrasound-guided transrectal prostate biopsy in patients with negative histologic test] diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11227122&form=6&db=m Comparative study of alkaline phosphatase and prostate specific antigen in prostate cancer. diagnostic usage,ongoing research,therapeutic application,unassigned 4,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11235139&form=6&db=m [The significance of early detection for prostate cancer in mass screening] causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,3,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11235226&form=6&db=m [Successful complete androgen blockade (CAB) therapy for prostatic cancer detected from multiple lung metastases: a case report] causal interaction,diagnostic usage,unassigned 3,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11257710&form=6&db=m Scatter factor-hepatocyte growth factor elevation in the serum of patients with prostate cancer. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11268287&form=6&db=m Robust prostate-specific expression for targeted gene therapy based on the human kallikrein 2 promoter. diagnostic usage,unassigned 2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11297583&form=6&db=m Prostate-specific antigen and human glandular kallikrein 2 are markedly elevated in urine of patients with polycystic ovary syndrome. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11299734&form=6&db=m Novel polymorphisms in prostate specific antigen gene and its association with prostate cancer. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11304725&form=6&db=m Similar rates of exponential decrease in serum concentrations of free prostate-specific antigen (PSA), PSA complexed to alpha-1-antichymotrypsin, and human glandular kallikrein 2 (hK2) in prostate cancer patients treated with GnRH-analogues. diagnostic usage,ongoing research,unassigned 3,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11305966&form=6&db=m Progression of prostate cancer despite undetectable serum prostate specific antigen. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11326653&form=6&db=m Prostate specific antigen in as a dynamic model in advanced prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,1,4 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11326657&form=6&db=m Ratio of alpha 1-antichymotrypsin--prostate specific antigen to total prostate specific antigen in prostate cancer diagnosis. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11326693&form=6&db=m Serum levels of prostate specific antigen in men on hemodialysis. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11329957&form=6&db=m [Predictive value of prostate specific antigen density in the detection of prostate cancer in patients with elevated prostate specific antigen levels and normal digital rectal findings or stage A prostate cancer] causal interaction,diagnostic usage,ongoing research,unassigned 3,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11342915&form=6&db=m A prospective study to evaluate the role of complexed prostate specific antigen and free/total prostate specific antigen ratio for the diagnosis of prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,3,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11342919&form=6&db=m Predictors of biological aggressiveness of prostate specific antigen screening detected prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,1,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11371884&form=6&db=m Can complexed prostate specific antigen and prostatic volume enhance prostate cancer detection in men with total prostate specific antigen between 2.5 and 4.0 ng./ml. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11381196&form=6&db=m The significance of PSA/IGF-1 ratio in differentiating benign prostate hyperplasia from prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 2,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11392495&form=6&db=m Pre- and post-analytical factors that may influence use of serum prostate specific antigen and its isoforms in a screening programme for prostate cancer. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11394329&form=6&db=m Racial variation in prostate specific antigen in a large cohort of men without prostate cancer. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11395559&form=6&db=m Nephrogenic adenoma of the prostatic urethra: a mimicker of prostate adenocarcinoma. diagnostic usage,therapeutic application,unassigned 1,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11400919&form=6&db=m Prostate specific antigen and screening for early prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11432019&form=6&db=m Markedly raised serum prostate specific antigen levels. Prostatic infarction rather than malignancy? causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11435831&form=6&db=m Serial prostate specific antigen, free-to-total prostate specific antigen ratio and complexed prostate specific antigen for the diagnosis of prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,3,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11435832&form=6&db=m Prostate cancer detection in veterans with a history of Agent Orange exposure. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11435833&form=6&db=m Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: lack of prediction of tumor significance for men with nonpalpable prostate cancer. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11435864&form=6&db=m High dose hook effect in serum total and free prostate specific antigen in a patient with metastatic prostate cancer. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11474294&form=6&db=m Predicting cancer following a diagnosis of high-grade prostatic intraepithelial neoplasia on needle biopsy: data on men with more than one follow-up biopsy. causal interaction,diagnostic usage,unassigned 1,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11483332&form=6&db=m Serum PSA evaluations during salvage radiotherapy for post-prostatectomy biochemical failures as prognosticators for treatment outcomes. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11486050&form=6&db=m Simultaneous quantification of human glandular kallikrein 2 and prostate-specific antigen mRNAs in peripheral blood from prostate cancer patients. diagnostic usage,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11490231&form=6&db=m The value of a single biopsy with 12 transperineal cores for detecting prostate cancer in patients with elevated prostate specific antigen. diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11490232&form=6&db=m Prospective detection of clinically relevant prostate cancer in the prostate specific antigen range 1 to 3 ng./ml. combined with free-to-total ratio 20% or less: the Aarau experience. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11490233&form=6&db=m Safety and morbidity of first and repeat transrectal ultrasound guided prostate needle biopsies: results of a prospective European prostate cancer detection study. diagnostic usage,ongoing research,therapeutic application,unassigned 1,3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11490234&form=6&db=m Interval after prostate specific antigen testing and subsequent risk of incurable prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11490269&form=6&db=m Undetectable prostate specific antigen in disseminated prostate cancer. diagnostic usage,ongoing research,therapeutic application,unassigned 4,1,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11490307&form=6&db=m Pyridinoline cross-linked carboxyterminal telopeptide of type I collagen as a useful marker for monitoring metastatic bone activity in men with prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,3,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11494145&form=6&db=m Induction of immune responses and safety profiles in rhesus macaques immunized with a DNA vaccine expressing human prostate specific antigen. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11531246&form=6&db=m Survey of the rate of PSA testing in general practice. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11533789&form=6&db=m A guideline to clinical utility of prostate specific antigen. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,3,4 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11536307&form=6&db=m Ratio of cathepsin B to stefin A identifies heterogeneity within Gleason histologic scores for human prostate cancer. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11547066&form=6&db=m Predicting risk of prostate specific antigen recurrence after radical prostatectomy with the Center for Prostate Disease Research and Cancer of the Prostate Strategic Urologic Research Endeavor databases. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,2,3 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11547069&form=6&db=m Prostate cancer screening within a prostate specific antigen range of 3 to 3.9 ng./ml.: a comparison of digital rectal examination and free prostate specific antigen as supplemental screening tests. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11558210&form=6&db=m Prostate cancer in general practice. Results of a five year prospective clinical study in one practice. diagnostic usage,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11564273&form=6&db=m Rising prostate specific antigen after radical prostatectomy: a case based review. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11569319&form=6&db=m Promoting informed decision making about prostate cancer screening. causal interaction,diagnostic usage,unassigned 4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11579594&form=6&db=m [Intermittent androgen deprivation treatment of prostate cancer restarted at low level of serum prostate specific antigen: a pilot study] causal interaction,diagnostic usage,therapeutic application,unassigned 1,2,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11582588&form=6&db=m Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11586201&form=6&db=m Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop? diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11586206&form=6&db=m Conservative management of prostate cancer in the prostate specific antigen era: the incidence and time course of subsequent therapy. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11593702&form=6&db=m [Retrospective evaluation of PSA density for selection of biopsy candidates with prostate specific antigen in the gray zone] causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,3,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11603136&form=6&db=m Spectrum of prostate cancer in the Singapore General Hospital (1980 to 1985). causal interaction,diagnostic usage,therapeutic application,unassigned 2,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11681260&form=6&db=m [Prostate cancer] diagnostic usage,therapeutic application,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11692595&form=6&db=m [Significance of PSA-density: analysis in PSA gray zone cases] diagnostic usage,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11696729&form=6&db=m Molecular genetic profiling of Gleason grade 4/5 prostate cancers compared to benign prostatic hyperplasia. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11696732&form=6&db=m Predicting prostate specific antigen outcome preoperatively in the prostate specific antigen era. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11696733&form=6&db=m Validity of the prostate specific antigen test for prostate cancer screening: followup study with a bank of 21,000 sera in Finland. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11696737&form=6&db=m Role of early adjuvant hormonal therapy after radical prostatectomy for prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11696766&form=6&db=m Serum heterophile antibodies interfere with prostate specific antigen test and result in over treatment in a patient with prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,2,3 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11696820&form=6&db=m Low expression of Galpha protein subunits in human prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,4,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11698338&form=6&db=m Testosterone and prostate specific antigen stimulate generation of reactive oxygen species in prostate cancer cells. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,3,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11712084&form=6&db=m Early reduction in the aneuploidy at chromosomes 7 and 8 are significantly correlated with clinical effect in high-dose rate brachytherapy with external beam radiotherapy in localized prostate cancer. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11720279&form=6&db=m The role of molecular forms of prostate-specific antigen (PSA or hK3) and of human glandular kallikrein 2 (hK2) in the diagnosis and monitoring of prostate cancer and in extra-prostatic disease. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11732646&form=6&db=m Prostate specific antigen: biology, biochemistry and available commercial assays. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11743284&form=6&db=m Prospective evaluation of prostate cancer detection by prostate specific antigen related parameters: comparison in serum and plasma samples. diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11743285&form=6&db=m Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml. causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11743329&form=6&db=m Re: a prospective study to evaluate the role of complexed prostate specific antigen and free/total prostate specific antigen ratio for the diagnosis of prostate cancer. I.D.C. Mitchell, B.L. Croal, A. Dickie, N.P. Cohen and I. Ross. J Urol, 165: 1549-1553, 2001. diagnostic usage,ongoing research,therapeutic application,unassigned 4,2,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11746269&form=6&db=m Proliferation of prostate cancer cells in the bone marrow predicts recurrence in patients with localized prostate cancer. diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11769472&form=6&db=m [Prostate specific antigen: a role of PSA in the diagnosis of prostate cancer] causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11769475&form=6&db=m [Prostate cancer test and medical reimbursement] causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11771167&form=6&db=m [Mass screening for prostate cancer in Nagano] diagnostic usage,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11790277&form=6&db=m Artificial neural network model to predict biochemical failure after radical prostatectomy. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11792934&form=6&db=m A technique of bladder neck closure combining prostatectomy and intestinal interposition for unsalvageable urethral disease. diagnostic usage,ongoing research,therapeutic application,unassigned 2,1,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11813228&form=6&db=m Discovering subpopulation structure with latent class mixed models. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11817252&form=6&db=m [Diseases of the prostate in elderly patients. Benign prostate hyperplasia and prostate carcinoma] diagnostic usage,therapeutic application,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11817562&form=6&db=m Autoantibodies to prostasomes as new markers for prostate cancer. diagnostic usage,therapeutic application,unassigned 4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11829778&form=6&db=m [The percentage of free prostate specific antigen used in detecting prostate cancer] causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,3,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11832703&form=6&db=m Expectant management of nonpalpable prostate cancer with curative intent: preliminary results. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11832718&form=6&db=m Prostate cancer screening with prostate specific antigen in spinal cord injured men. causal interaction,diagnostic usage,unassigned 4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11832719&form=6&db=m Percent free prostate specific antigen is not an independent predictor of organ confinement or prostate specific antigen recurrence in unscreened patients with localized prostate cancer treated with radical prostatectomy. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,4,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11832720&form=6&db=m A standard definition of disease freedom is needed for prostate cancer: undetectable prostate specific antigen compared with the American Society of Therapeutic Radiology and Oncology consensus definition. diagnostic usage,therapeutic application,unassigned 2,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11847879&form=6&db=m [Early detection and follow-up of prostatic carcinoma. Responsibilities of the general practitioner] causal interaction,diagnostic usage,unassigned 2,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11848613&form=6&db=m Diagnostic approach to prostate cancer using total prostate specific antigen-based parameters together. diagnostic usage,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11851777&form=6&db=m Embryonal carcinoma of the testis associated with prostate cancer in a 72-year-old man. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11856107&form=6&db=m Prevalence of undiagnosed prostate cancer in men with erectile dysfunction. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11868378&form=6&db=m [Clinical study on prostatic cancer detected incidentally by transurethral resection of the prostate] causal interaction,diagnostic usage,ongoing research,unassigned 1,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11894110&form=6&db=m Effects of herbal preparation Equiguard on hormone-responsive and hormone-refractory prostate carcinoma cells: mechanistic studies. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,3,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11903683&form=6&db=m Value of prostate specific antigen alpha1-antichymotrypsin complex for the detection of prostate cancer in patients with a PSA level of 4.1-10.0 ng/mL: comparison with PSA-related parameters. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11905926&form=6&db=m Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. 1990. diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11912383&form=6&db=m Early onset prostate cancer: predictors of clinical grade. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,3,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11912384&form=6&db=m Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11914620&form=6&db=m Perineural invasion and MIB-1 positivity in addition to Gleason score are significant preoperative predictors of progression after radical retropubic prostatectomy for prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,2,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11942515&form=6&db=m Evaluation of the BioSign PSA membrane test for the identification of semen stains in forensic casework. diagnostic usage,ongoing research,therapeutic application,unassigned 4,2,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11942961&form=6&db=m Does site-specific labelling and individual processing of sextant biopsies improve the accuracy of prostate biopsy in predicting pathological stage in patients with T1c prostate cancer? diagnostic usage,ongoing research,therapeutic application,unassigned 4,1,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11948967&form=6&db=m Down-regulation of the human kallikrein gene 5 (KLK5) in prostate cancer tissues. causal interaction,diagnostic usage,ongoing research,unassigned 4,2,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11956430&form=6&db=m Comparative analysis of complexed prostate specific antigen, free prostate specific antigen and their ratio in detecting prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,3,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11956481&form=6&db=m Pan-cadherin as a high level phenotypic biomarker for prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11966628&form=6&db=m The role of serial free/total prostate-specific antigen ratios in a watchful observation protocol for men with localized prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,1,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11992051&form=6&db=m Strategies combining total and percent free prostate specific antigen for detecting prostate cancer: a prospective evaluation. diagnostic usage,ongoing research,therapeutic application,unassigned 4,2,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11996805&form=6&db=m Amperometric biosensors for detection of the prostate cancer marker (PSA). causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11999465&form=6&db=m Correlation of initial PSA level and biopsy features with PSA-doubling time in early stage prostate cancers in Japanese men. diagnostic usage,therapeutic application,unassigned 2,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12022203&form=6&db=m The usefulness of prostate specific antigen density as a screening method for prostatic carcinoma. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12047384&form=6&db=m Substrate specificity of human kallikrein 2 (hK2) as determined by phage display technology. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12048932&form=6&db=m [A low-fat and high soybean protein diet for patients with elevated serum PSA level: alteration of QOL and serum PSA level after the dietary intervention] causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12050499&form=6&db=m Evaluation of a new serum testing method for detection of prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12050500&form=6&db=m Prediction of pathological stage in patients with clinical stage T1c prostate cancer: the new challenge. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12053924&form=6&db=m Storm over screening for prostate specific antigen. Give men facts on prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,1,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12056041&form=6&db=m [Evaluation of transrectal power-Doppler ultrasonography and effect of contrast-enhancement for detecting prostate cancer] diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12074805&form=6&db=m Prognostic factors in localised prostate cancer with emphasis on the application of molecular techniques. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12081758&form=6&db=m Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part I: international comparisons. unassigned - 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12110098&form=6&db=m Annual PSA tests are not necessary for men with a PSA level below 2 ng/mL: findings of the Imari prostate cancer screening program. diagnostic usage,ongoing research,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12110102&form=6&db=m Failure to maintain the suppressed level of serum testosterone during luteinizing hormone-releasing hormone agonist therapy in a patient with prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 1,2,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12111703&form=6&db=m Stat3 enhances the growth of LNCaP human prostate cancer cells in intact and castrated male nude mice. causal interaction,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12111706&form=6&db=m Using multiple cutpoints for the free-to-total prostate specific antigen ratio improves the accuracy of prostate cancer detection. diagnostic usage,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12118499&form=6&db=m The prevalence of prostate cancer screening in Thai elderly. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12124826&form=6&db=m Initial decline in hemoglobin during neoadjuvant hormonal therapy predicts for early prostate specific antigen failure following radiation and hormonal therapy for patients with intermediate and high-risk prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12131292&form=6&db=m Prostate cancer stage shift has eliminated the gap in disease-free survival in black and white American men after radical prostatectomy. causal interaction,diagnostic usage,therapeutic application,unassigned 2,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12131293&form=6&db=m Targeted screening for prostate cancer in high risk families: early onset is a significant risk factor for disease in first degree relatives. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12131298&form=6&db=m Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. range. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12131362&form=6&db=m Prostate specific antigen inhibits immune responses in vitro: a potential role in prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,3,3 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12142373&form=6&db=m Human tissue kallikreins: a family of new cancer biomarkers. causal interaction,diagnostic usage,ongoing research,unassigned 3,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12142383&form=6&db=m Simultaneous quantification of prostate-specific antigen and human glandular kallikrein 2 mRNA in blood samples from patients with prostate cancer and benign disease. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12187189&form=6&db=m Hereditary prostate cancer: clinical aspects. causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12187205&form=6&db=m Clinical value of prostate specific antigen based parameters for the detection of prostate cancer on repeat biopsy: the usefulness of complexed prostate specific antigen adjusted for transition zone volume. causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12187206&form=6&db=m A centralized comparison of radical perineal and retropubic prostatectomy specimens: is there a difference according to the surgical approach? diagnostic usage,therapeutic application,unassigned 3,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12187207&form=6&db=m Prognostic significance of the nadir prostate specific antigen level after hormone therapy for prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,4 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12187269&form=6&db=m Receptor gene messenger RNA expression in metastatic lesions of prostate cancer. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12210484&form=6&db=m Linkage between polymorphisms in the prostate specific antigen ARE1 gene region, prostate cancer risk, and circulating tumor cells. causal interaction,diagnostic usage,ongoing research,unassigned 1,3,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12218299&form=6&db=m Expanded human tissue kallikrein family--a novel panel of cancer biomarkers. causal interaction,diagnostic usage,ongoing research,unassigned 3,3,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12224436&form=6&db=m [Utility of prostate-specific antigen in pleural fluid for the diagnosis of metastatic effusion secondary to prostate cancer] causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12232754&form=6&db=m Serum insulin level, disease stage, prostate specific antigen (PSA) and Gleason score in prostate cancer. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12242725&form=6&db=m Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,3,3 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12243426&form=6&db=m Cancer screening for the primary care physician. diagnostic usage,ongoing research,therapeutic application,unassigned 4,1,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12243659&form=6&db=m Preperitoneal mesh-plug herniorraphy during radical retropubic prostatectomy. causal interaction,therapeutic application,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12352405&form=6&db=m Vasectomy and prostate cancer characteristics of patients referred for prostate biopsy. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12352407&form=6&db=m Followup interval prostate biopsy 3 years after diagnosis of high grade prostatic intraepithelial neoplasia is associated with high likelihood of prostate cancer, independent of change in prostate specific antigen levels. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12364286&form=6&db=m Prostate specific antigen testing for prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,3,3 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12364299&form=6&db=m Why men with prostate cancer want wider access to prostate specific antigen testing: qualitative study. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,2,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12382001&form=6&db=m Neoadjuvant hormonal therapy prior to radical prostatectomy: evaluation of pathological downstaging and biochemical relapse. diagnostic usage,ongoing research,therapeutic application,unassigned 4,1,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12384565&form=6&db=m Preoperative blood reverse transcriptase-PCR assays for prostate-specific antigen and human glandular kallikrein for prediction of prostate cancer progression after radical prostatectomy. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,2,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12394692&form=6&db=m The accuracy of the increased prostate specific antigen level (greater than or equal to 20 ng./ml.) in predicting prostate cancer: is biopsy always required? diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12394695&form=6&db=m Prostate specific antigen bounce phenomenon after external beam radiation for clinically localized prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,1,3 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12394716&form=6&db=m Sociodemographic characteristics and health related quality of life in men attending prostate cancer support groups. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12431818&form=6&db=m Angiogenesis in prostate cancer: its role in disease progression and possible therapeutic approaches. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12439720&form=6&db=m The androgen-regulated gene human kallikrein 15 (KLK15) is an independent and favourable prognostic marker for breast cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,3,4 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12441934&form=6&db=m Time to achieve a prostate specific antigen nadir of 0.2 ng./ml. after simultaneous irradiation for prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12441935&form=6&db=m Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12441952&form=6&db=m "PSA-itis": knowledge of serum prostate specific antigen and other causes of anxiety in men with metaststic prostate cancer. causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12466122&form=6&db=m Anti-thrombin is expressed in the benign prostatic epithelium and in prostate cancer and is capable of forming complexes with prostate-specific antigen and human glandular kallikrein 2. causal interaction,diagnostic usage,unassigned 2,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12469637&form=6&db=m [Diagnostic and prognostic value of quantitative monitoring of prostate specific antigen in blood serum and urine from patients with prostate cancer after radical prostatectomy] causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,3,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12477151&form=6&db=m Prostate cancer risk is three-fold higher among men, aged 50-64, of African descent compared with men of Asian-Indian descent in Trinidad and Tobago. diagnostic usage,ongoing research,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12478120&form=6&db=m The relationship of prostate gland volume to extended needle biopsy on prostate cancer detection. diagnostic usage,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12478126&form=6&db=m Predicting recurrence after radical prostatectomy for patients with high risk prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12478190&form=6&db=m Quantitative analysis of kallikrein 15 gene expression in prostate tissue. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12481254&form=6&db=m Inhibition of the enzymatic activity of prostate-specific antigen by boric acid and 3-nitrophenyl boronic acid. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12491689&form=6&db=m [The relationships of PSA, FPSAR, clinical and pathological stage in patients with prostate cancer] diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12496317&form=6&db=m Improving the utility of prostate specific antigen (PSA) in the diagnosis of prostate cancer: the use of PSA derivatives and novel markers. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12496825&form=6&db=m Prostate specific antigen levels in the follow up of localised prostate cancer: how does radiotherapy compare to radical prostatectomy? diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12496845&form=6&db=m Characterization and processing of prostate specific antigen (hK3) and human glandular kallikrein (hK2) secreted by LNCaP cells. diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12496851&form=6&db=m Early Diagnosis and Staging. diagnostic usage,unassigned 3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12496928&form=6&db=m Epitope mapping of human prostate specific antigen and glandular kallikrein expressed in insect cells. diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12496985&form=6&db=m Multimodality radiotherapy and androgen ablation in the treatment of clinically localized prostate cancer: early results in high risk patients. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12496998&form=6&db=m Clearance rates of total prostate specific antigen (PSA) after radical prostatectomy in African-Americans and Caucasians. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12496999&form=6&db=m Probability of prostate cancer at various levels of per cent free prostate specific antigen in Japanese men with total PSA of 4.1-10.0 ng/ml. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12497004&form=6&db=m Initiation of salvage therapy for prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12497006&form=6&db=m Primary hormonal therapy for prostate cancer: experience with 135 consecutive PSA-ERA patients from a tertiary care military medical center. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12497031&form=6&db=m A quantitative analysis of the costs and benefits of prostate cancer screening. diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12497046&form=6&db=m A pilot study analyzing PSA, serum testosterone, lipid profile, body mass index and race in a small sample of patients with and without carcinoma of the prostate. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12497119&form=6&db=m Correlation of serum prostate specific antigen and semi quantitative tissue RT-PCR from prostate cancer samples. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12499419&form=6&db=m Salvage external beam radiotherapy for local recurrence without systemic progression or prostate specific antigen recurrence of prostate cancer after initial hormonal therapy: is it possible to identify patients likely to have good treatment outcomes? causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12516040&form=6&db=m Complementary and alternative therapies in prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12518009&form=6&db=m Estimate of population coverage with the prostate specific antigen (PSA) test to screen for prostate cancer in a metropolitan area of northern Italy. diagnostic usage,therapeutic application,unassigned 4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12518322&form=6&db=m The role of human glandular kallikrein 2 for prediction of pathologically organ confined prostate cancer. diagnostic usage,ongoing research,unassigned 2,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12518327&form=6&db=m Serum human glandular kallikrein (hK2) and insulin-like growth factor 1 (IGF-1) improve the discrimination between prostate cancer and benign prostatic hyperplasia in combination with total and %free PSA. diagnostic usage,ongoing research,unassigned 3,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12526217&form=6&db=m [Correlation and significance of E-cadherin and N-cadherin expression in prostate cancer] diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12544286&form=6&db=m Prostate specific antigen and human glandular kallikrein 2 in early detection of prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,4,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12544298&form=6&db=m Soy consumption and phytoestrogens: effect on serum prostate specific antigen when blood lipids and oxidized low-density lipoprotein are reduced in hyperlipidemic men. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12576840&form=6&db=m A prospective, randomized pilot trial of acupuncture of the kidney-bladder distinct meridian for lower urinary tract symptoms. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12578903&form=6&db=m Predicting prostate specific antigen failure after radical retropubic prostatectomy for T1c prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 2,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12584285&form=6&db=m Percent-free prostate specific antigen is elevated in men on haemodialysis or peritoneal dialysis treatment. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,3,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12587805&form=6&db=m 2-Methoxyestradiol, a promising anticancer agent. therapeutic application,unassigned 1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12590170&form=6&db=m Bioassays based on molecular nanomechanics. diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12593864&form=6&db=m The second largest subunit of RNA polymerase II interacts with and enhances transactivation of androgen receptor. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12600412&form=6&db=m The efficacy of a serum carboxyterminal pyridinoline cross-linked telopeptide of type I collagen as a quantitative screening marker for bone metastases in patients with urological malignancies. causal interaction,diagnostic usage,ongoing research,unassigned 2,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12621851&form=6&db=m [Prostatic carcinoma: current status of diagnostic imaging] causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12627213&form=6&db=m Outcome and complications of radical prostatectomy in patients with PSA <10 ng/ml: comparison between the retropubic, perineal and laparoscopic approach. diagnostic usage,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12629349&form=6&db=m Leptin influences cellular differentiation and progression in prostate cancer. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12629352&form=6&db=m Pretreatment predictors of time to cancer specific death after prostate specific antigen failure. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,3,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12629773&form=6&db=m The significance of prostate-specific antigen alpha-1-antichymotrypsin complex and its indices for the detection of prostate cancer. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12663708&form=6&db=m Detection of clinically significant, occult prostate cancer metastases in lymph nodes using a splice variant-specific rt-PCR assay for human glandular kallikrein. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,4,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12672024&form=6&db=m Novel stimulatory role for insulin-like growth factor binding protein-2 in prostate cancer cells. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12672026&form=6&db=m 55 kDa nuclear matrix protein (nmt55) mRNA is expressed in human prostate cancer tissue and is associated with the androgen receptor. diagnostic usage,ongoing research,unassigned 3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12686817&form=6&db=m Prostate specific antigen based biennial screening is sufficient to detect almost all prostate cancers while still curable. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12686818&form=6&db=m An artificial neural network for prostate cancer staging when serum prostate specific antigen is 10 ng./ml. or less. diagnostic usage,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12686822&form=6&db=m Nilutamide as second line hormone therapy for prostate cancer after androgen ablation fails. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,3,3 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12694223&form=6&db=m Genetic counseling for prostate cancer risk. unassigned - 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12719039&form=6&db=m Fractionated perineal high-dose-rate temporary brachytherapy combined with external beam radiation in the treatment of localized prostate cancer: is lymph node sampling necessary? diagnostic usage,therapeutic application,unassigned 2,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12735828&form=6&db=m Enhancing PSA performance in the diagnosis of prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12735836&form=6&db=m Surgical approaches to local failure after definitive therapy. diagnostic usage,therapeutic application,unassigned 2,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12741345&form=6&db=m [Questionnaire based evaluation of prostate biopsy complication comparing different bioptic schemes] diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12743632&form=6&db=m New serum tests for the diagnosis of prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12746834&form=6&db=m Possible mechanism of dexamethasone therapy for prostate cancer: suppression of circulating level of interleukin-6. diagnostic usage,ongoing research,therapeutic application,unassigned 2,1,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12746838&form=6&db=m Three immunoassays based on monoclonal antibodies specific for prostate specific antigen (PSA), alpha-1-antichymotrypsin (ACT), and the PSA-ACT complex. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12746843&form=6&db=m Prediction of extraprostatic cancer by prostate specific antigen density, endorectal MRI, and biopsy Gleason score in clinically localized prostate cancer. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12756494&form=6&db=m Increased discrimination between benign prostatic hyperplasia and prostate cancer with equimolar total prostate specific antigen measurement. diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12767107&form=6&db=m The memorial anxiety scale for prostate cancer: validation of a new scale to measure anxiety in men with with prostate cancer. diagnostic usage,unassigned 1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12772191&form=6&db=m Recombinant prostate specific antigen inhibits angiogenesis in vitro and in vivo. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12775281&form=6&db=m MRI of the skeleton in prostate cancer staging. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12780832&form=6&db=m Problems with prostate specific antigen screening for prostate cancer in the primary healthcare setting in South Africa. diagnostic usage,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12787710&form=6&db=m Early diagnosis and surgical management of prostate cancer. diagnostic usage,therapeutic application,unassigned 4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12796648&form=6&db=m Radical prostatectomy nomograms in black American men: accuracy and applicability. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,3,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12796672&form=6&db=m Clinical, demographic and psychosocial correlates of complementary and alternative medicine use by men diagnosed with localized prostate cancer. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12810209&form=6&db=m Contemporary preoperative parameters predict cancer-free survival after radical prostatectomy: a tool to facilitate treatment decisions. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12828605&form=6&db=m Distribution and secretory pathways of prostate specific antigen, alpha1-antichymotrypsin and prostate secretory granules in prostate cancers. causal interaction,diagnostic usage,ongoing research,unassigned 2,2,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12835804&form=6&db=m Screening for prostate cancer: a survey of New Zealand general practitioners. diagnostic usage,therapeutic application,unassigned 2,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12853795&form=6&db=m Diagnostic potential of serum proteomic patterns in prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12853797&form=6&db=m Comparison of the predictive accuracy of serum prostate specific antigen levels and prostate specific antigen density in the detection of prostate cancer in Hispanic-American and white men. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,3,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12853798&form=6&db=m More information on prostate specific antigen and prostate cancer. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12858354&form=6&db=m Quantitative PSA RT-PCR for preoperative staging of prostate cancer. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12862359&form=6&db=m Pro PSA: a more cancer specific form of prostate specific antigen for the early detection of prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 2,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12875939&form=6&db=m The value of endorectal MRI in the early diagnosis of prostate cancer. diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12890079&form=6&db=m Metastatic prostate cancer: complications and treatment. causal interaction,diagnostic usage,unassigned 2,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12894737&form=6&db=m [A case of primary transitional cell carcinoma of the prostate] causal interaction,diagnostic usage,unassigned 2,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12904256&form=6&db=m Stat3 enhances transactivation of steroid hormone receptors. causal interaction,diagnostic usage,unassigned 3,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12913682&form=6&db=m Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/ml. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12913688&form=6&db=m Prostatic calculi do not influence the level of serum prostate specific antigen in men without clinically detectable prostate cancer or prostatitis. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,3,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12918151&form=6&db=m [Value of prostate-specific antigen density and transitional-zone prostate-specific antigen density in the diagnosis of prostate cancer] causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,3,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12930424&form=6&db=m Quantitative evaluation of bone metastases in patients with advanced prostate cancer during systemic treatment. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12930681&form=6&db=m [Pathological features of prostate cancer in Chinese cohort detected through mass screening and their relationships with serum prostate specific antigen] diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12932112&form=6&db=m A comparative study of prostate specific antigen (PSA), C-terminal propeptide of blood type I procollagen (PICP) and urine type I collagen-crosslinked N telopeptide (NTx) levels using bone scintigraphy in prostate cancer patients. diagnostic usage,ongoing research,therapeutic application,unassigned 3,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12954500&form=6&db=m Variables in predicting survival based on treating "PSA-only" relapse. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12955893&form=6&db=m Comparison of digital rectal examination and prostate specific antigen in early detection of prostate cancer. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12956448&form=6&db=m PSA density and PSA transition zone density in the diagnosis of prostate cancer in PSA gray zone cases. diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14499149&form=6&db=m Using positron emission tomography 2-deoxy-2-[18F]fluoro-D-glucose, 11CO, and 15O-water for monitoring androgen independent prostate cancer. diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14501718&form=6&db=m Testing in serum for human glandular kallikrein 2, and free and total prostate specific antigen in biannual screening for prostate cancer. causal interaction,diagnostic usage,ongoing research,unassigned 3,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14501719&form=6&db=m A multicenter clinical trial on the use of complexed prostate specific antigen in low prostate specific antigen concentrations. diagnostic usage,therapeutic application,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14501720&form=6&db=m No increased prostate cancer incidence after negative transrectal ultrasound guided multiple biopsies in men with increased prostate specific antigen and/or abnormal digital rectal examination. diagnostic usage,therapeutic application,unassigned 2,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14501721&form=6&db=m A nomogram for predicting a positive repeat prostate biopsy in patients with a previous negative biopsy session. diagnostic usage,ongoing research,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14501750&form=6&db=m Overtreatment of a patient with presumed recurrent prostate cancer based on false-positive prostate specific antigen results. causal interaction,diagnostic usage,unassigned 3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14504750&form=6&db=m [Serum markers for early detection and staging of prostate cancer. Status report on current and future markers] causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14532777&form=6&db=m Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14532778&form=6&db=m Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14532780&form=6&db=m Time trends and characteristics of men choosing watchful waiting for initial treatment of localized prostate cancer: results from CaPSURE. causal interaction,diagnostic usage,therapeutic application,unassigned 1,2,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14532781&form=6&db=m The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14532783&form=6&db=m Androgen receptor gene amplification and protein expression in recurrent prostate cancer. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14532785&form=6&db=m Improved biochemical disease-free survival of men younger than 60 years with prostate cancer treated with high dose conformal external beam radiotherapy. causal interaction,diagnostic usage,ongoing research,unassigned 2,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14532794&form=6&db=m Prostate specific antigen bounce after simultaneous irradiation for prostate cancer: the relationship to patient age. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,4,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14532991&form=6&db=m PC-SPES: Molecular mechanism to induce apoptosis and down-regulate expression of PSA in LNCaP human prostate cancer cells. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,4,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14567353&form=6&db=m Serum human glandular kallikrein (hK2) and insulin-like growth factor 1 (IGF-1) improve the discrimination between prostate cancer and benign prostatic hyperplasia in combination with total and %free PSA. diagnostic usage,ongoing research,unassigned 3,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14610406&form=6&db=m Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE). diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14610407&form=6&db=m The evolving role of chemotherapy and other systemic therapies for managing localized prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14610409&form=6&db=m Determinants of prostate cancer specific survival following radiation therapy during the prostate specific antigen era. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,2,3 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14612600&form=6&db=m Prostate cancer management: (1) an update on localised disease. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14616446&form=6&db=m Broadening the criteria for avoiding staging bone scans in prostate cancer: a retrospective study of patients at the Royal Marsden Hospital. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14620298&form=6&db=m The role of prostate specific antigen in screening and management of clinically localized prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14620963&form=6&db=m Cultural sensitivity and informed decision making about prostate cancer screening. diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14634374&form=6&db=m Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14634392&form=6&db=m Prostatic zinc and prostate specific antigen: an experimental evaluation of their combined diagnostic value. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,3,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14634394&form=6&db=m Total and Gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies. causal interaction,diagnostic usage,ongoing research,unassigned 3,4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14653195&form=6&db=m [Free/total prostate specific antigen ratio (%PSA) to predict probability of prostate cancer] causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,1,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14665871&form=6&db=m Comparison of accuracy between the Partin tables of 1997 and 2001 to predict final pathological stage in clinically localized prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14665872&form=6&db=m Clinical usefulness of serum antip53 antibodies for prostate cancer detection: a comparative study with prostate specific antigen parameters. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14665875&form=6&db=m The incidence of prostate cancer in men with prostate specific antigen greater than 4.0 ng/ml: a randomized study of 6 versus 12 core transperineal prostate biopsy. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14665876&form=6&db=m Assessment of the enhancement in predictive accuracy provided by systematic biopsy in predicting outcome for clinically localized prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 2,2,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14689882&form=6&db=m [Mass screening for prostate cancer is the best approach to early diagnosis and treatment of prostate cancer] causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14710248&form=6&db=m [Use of biopsy results to predict capsular perforation and seminal vesicle invasion in prostate cancer] diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14713758&form=6&db=m Prostate cancer chemoprevention agent development: the National Cancer Institute, Division of Cancer Prevention portfolio. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14713781&form=6&db=m Clinical value of longitudinal free-to-total prostate specific antigen ratio slope to diagnosis of prostate cancer. diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14713783&form=6&db=m Palliative transurethral prostate resection for bladder outlet obstruction in patients with locally advanced prostate cancer. causal interaction,diagnostic usage,unassigned 2,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14728598&form=6&db=m Ethical issues for cancer screening. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14733999&form=6&db=m Prostate cancer detection is also relevant in low prostate specific antigen ranges. causal interaction,diagnostic usage,ongoing research,unassigned 3,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14734000&form=6&db=m Cumulative prostate cancer risk assessment with the aid of the free-to-total prostate specific antigen ratio. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14751679&form=6&db=m Antiandrogenic activity of extracts of diesel exhaust particles emitted from diesel-engine truck under different engine loads and speeds. diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14753257&form=6&db=m A new luciferase reporter gene assay for the detection of androgenic and antiandrogenic effects based on a human prostate specific antigen promoter and PC3/AR human prostate cancer cells. diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14765014&form=6&db=m Prostate biopsy. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14767285&form=6&db=m Lymph node positive prostate cancer: long-term survival data after radical prostatectomy. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14767286&form=6&db=m Prostate cancer radiotherapy dose response: an update of the fox chase experience. diagnostic usage,ongoing research,therapeutic application,unassigned 4,1,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14767288&form=6&db=m Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14767320&form=6&db=m Re: prostate specific antigen based biennial screening is sufficient to detect almost all prostate cancers while still curable. causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14769536&form=6&db=m Effects of tomato sauce consumption on apoptotic cell death in prostate benign hyperplasia and carcinoma. causal interaction,diagnostic usage,unassigned 4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14770085&form=6&db=m CD4 and CD8 T-lymphocyte recognition of prostate specific antigen in granulomatous prostatitis. causal interaction,diagnostic usage,therapeutic application,unassigned 1,1,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14969803&form=6&db=m Pathologic characterization of prostate cancers with a very low serum prostate specific antigen (0-2 ng/mL) incidental to cystoprostatectomy: is PSA a useful indicator of clinical significance? causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14969806&form=6&db=m Radiotherapy for a rising PSA following radical prostatectomy. causal interaction,diagnostic usage,therapeutic application,unassigned 3,2,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14969807&form=6&db=m PSA relapse prostate cancer: the importance of tailored therapy. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14971088&form=6&db=m Recurrent PSA after prostatectomy for prostate cancer: implications of PSA doubling time. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14988224&form=6&db=m Multigene reverse transcription-PCR profiling of circulating tumor cells in hormone-refractory prostate cancer. diagnostic usage,ongoing research,unassigned 3,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14997781&form=6&db=m Metastatic prostate cancer to lung with normal prostate specific antigen levels. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15007379&form=6&db=m Early detection of prostate cancer in African-American men through use of multiple biomarkers: human kallikrein 2 (hK2), prostate-specific antigen (PSA), and free PSA (fPSA). diagnostic usage,ongoing research,therapeutic application,unassigned 3,2,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15017184&form=6&db=m The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15017188&form=6&db=m Early identification of individuals with prostate cancer in negative biopsies. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15017207&form=6&db=m The risk of finding focal cancer (less than 3 mm) remains high on re-biopsy of patients with persistently increased prostate specific antigen but the clinical significance is questionable. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15017212&form=6&db=m Survival of patients with hormone refractory prostate cancer in the prostate specific antigen era. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15017213&form=6&db=m The impact of polymorphism on prostate specific antigen gene on the risk, tumor volume and pathological stage of prostate cancer. diagnostic usage,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15018076&form=6&db=m [Prostate specific antigen and diagnosis of prostate cancer] causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15041924&form=6&db=m [Prostate cancer and prostate specific antigen screening] causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15044396&form=6&db=m Carbohydrate structure and differential binding of prostate specific antigen to Maackia amurensis lectin between prostate cancer and benign prostate hypertrophy. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15049913&form=6&db=m Prostate specific antigen (PSA) and prostate specific acid phosphatase (PSAP) immunoreactivity in benign seminal vesicle\ejaculatory duct epithelium: a potential pitfall in the diagnosis of prostate cancer in needle biopsy specimens. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15069304&form=6&db=m Update on chemoprevention of prostate cancer. causal interaction,diagnostic usage,unassigned 4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15076292&form=6&db=m Predictors of prostate cancer after initial negative systematic 12 core biopsy. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15076315&form=6&db=m Inhibition of telomerase activity and secretion of prostate specific antigen by silibinin in prostate cancer cells. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15080511&form=6&db=m Serum prostate specific antigen levels in men with benign prostatic hyperplasia and cancer of prostate. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15100735&form=6&db=m Study of PSA, PSMA and hK2 mRNA in peripheral blood of prostate cancer patients and its clinical implications. diagnostic usage,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15101295&form=6&db=m [Diagnostic value of tissue and serum prostate specific antigen in prostate cancer] diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15103921&form=6&db=m [Systematic prostate biopsy before transurethral resection of the prostate] diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15103922&form=6&db=m [Mass screening for prostate cancer in Tokushima City: the results of 2001] diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15126786&form=6&db=m A comparison of extended biopsy and sextant biopsy schemes for predicting the pathological stage of prostate cancer. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15126789&form=6&db=m Validation of increasing prostate specific antigen as a predictor of prostate cancer death after treatment of localized prostate cancer with surgery or radiation. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15126790&form=6&db=m Differentiation of benign prostatic hyperplasia from prostate cancer using prostate specific antigen dynamic profile after transrectal prostate biopsy. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15126793&form=6&db=m Variation in prostate specific antigen results from 2 different assay platforms: clinical impact on 2304 patients undergoing prostate cancer screening. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,2,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15126794&form=6&db=m Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigen. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,1,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15126795&form=6&db=m Prostate cancer detection in the prostate specific antigen range of 2.0 to 3.9 ng/ml: value of percent free prostate specific antigen on tumor detection and tumor aggressiveness. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15126796&form=6&db=m The economic burden of metastatic and prostate specific antigen progression in patients with prostate cancer: findings from a retrospective analysis of health plan data. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,4,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15126799&form=6&db=m Transrectal focused ultrasound combined with transurethral resection of the prostate for the treatment of localized prostate cancer: feasibility study. diagnostic usage,ongoing research,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15126840&form=6&db=m Re: complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,3,4 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15137320&form=6&db=m Tumor-associated forms of prostate specific antigen improve the discrimination of prostate cancer from benign disease. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15142145&form=6&db=m Comparative evaluation of various prostate specific antigen ratios for the early detection of prostate cancer. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15148765&form=6&db=m Clinicopathological outcome of radical retropubic prostatectomy for 200 men with prostate cancer in a single institution in Japan. causal interaction,diagnostic usage,unassigned 2,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15157207&form=6&db=m Does transrectal ultrasound guided eight-core prostate biopsy improve cancer detection rates in patients with prostate-specific antigen levels of 4.1-10 ng/mL? diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15159306&form=6&db=m Factors predicting prostate specific antigen testing among first-degree relatives of prostate cancer patients. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15161573&form=6&db=m Prostate-specific antigen and related isoforms in the diagnosis and management of prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15166746&form=6&db=m Diagnosis of malignant ascites in prostate cancer by measurement of prostate specific antigen. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15180606&form=6&db=m Comparison of clinical and pathological features in African-American and Caucasian patients with localized prostate cancer. diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15183548&form=6&db=m Can complexed prostate specific antigen enhance prostate cancer detection in Japanese men? diagnostic usage,therapeutic application,unassigned 4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15195124&form=6&db=m PC-SPES: a herbal therapy for the treatment of hormone refractory prostate cancer. diagnostic usage,therapeutic application,unassigned 2,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15195130&form=6&db=m The role of external radiotherapy in patients treated with permanent prostate brachytherapy. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,1,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15201741&form=6&db=m Seminal sparing cystectomy and ileocapsuloplasty: long-term followup results. diagnostic usage,ongoing research,therapeutic application,unassigned 4,1,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15201744&form=6&db=m Relationship between initial prostate specific antigen level and subsequent prostate cancer detection in a longitudinal screening study. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15201755&form=6&db=m The natural history of androgen independent prostate cancer. causal interaction,diagnostic usage,ongoing research,unassigned 2,2,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15201794&form=6&db=m Development and initial evaluation of a novel urology curriculum for medical students. ongoing research,unassigned 2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15201795&form=6&db=m Development of validated instrument to measure medical student learning in clinical urology: a step toward evidence based education. causal interaction,diagnostic usage,ongoing research,unassigned 1,2,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15201819&form=6&db=m Re: no increased prostate cancer incidence after negative transrectal ultrasound guided multiple biopsies in men with increased prostate specific antigen and/or abnormal digital rectal examination. causal interaction,diagnostic usage,unassigned 2,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15226029&form=6&db=m Ethical issues for cancer screenings. Five countries--four types of cancer. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15228865&form=6&db=m Free and total prostate specific antigen in benign prostate hyperplasia and prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,3,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15242358&form=6&db=m Effectiveness of percent free prostate specific antigen as a predictor of prostate cancer detection on repeat biopsy. diagnostic usage,ongoing research,therapeutic application,unassigned 4,2,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15244076&form=6&db=m [Screening for prostate cancer in Yahata, Kitakyushu] diagnostic usage,unassigned 3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15251421&form=6&db=m Characterization of monoclonal antibodies against prostate specific antigen produced by genetic immunization. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15264241&form=6&db=m RNA interference targeting Stat3 inhibits growth and induces apoptosis of human prostate cancer cells. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,3,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15265401&form=6&db=m [Significance and limitations of f/tPSA in differential diagnosis of prostate cancer with tPSA levels between 4 and 10 ng/ml] diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15280622&form=6&db=m Lifestyle and prostate cancer among older African-American and Caucasian men in South Carolina. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15307634&form=6&db=m The tissue kallikrein family of serine proteases: functional roles in human disease and potential as clinical biomarkers. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15310993&form=6&db=m Effects of systematic 12-core biopsy on the performance of percent free prostate specific antigen for prostate cancer detection. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,3,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15344209&form=6&db=m Can a 12 core prostate biopsy increase the detection rate of prostate cancer versus 6 core?: a prospective randomized study in Korea. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15363559&form=6&db=m Can Power Doppler enhanced transrectal ultrasound guided biopsy improve prostate cancer detection on first and repeat prostate biopsy? diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15371827&form=6&db=m The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? diagnostic usage,ongoing research,therapeutic application,unassigned 2,3,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15371828&form=6&db=m Serum proteomic profiling can discriminate prostate cancer from benign prostates in men with total prostate specific antigen levels between 2.5 and 15.0 ng/ml. diagnostic usage,ongoing research,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15371829&form=6&db=m Preoperative neural network using combined magnetic resonance imaging variables, prostate specific antigen and Gleason score to predict prostate cancer stage. diagnostic usage,ongoing research,therapeutic application,unassigned 4,1,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15371879&form=6&db=m Prostate cancer detection on urinalysis for alpha methylacyl coenzyme a racemase protein. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,1,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15378521&form=6&db=m Association of free-prostate specific antigen subfractions and human glandular kallikrein 2 with volume of benign and malignant prostatic tissue. diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15389580&form=6&db=m Preferential production of latent transforming growth factor beta-2 by primary prostatic epithelial cells and its activation by prostate-specific antigen. diagnostic usage,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15389797&form=6&db=m A phase II trial of imatinib mesylate in patients with prostate specific antigen progression after local therapy for prostate cancer. diagnostic usage,ongoing research,therapeutic application,unassigned 4,4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15447848&form=6&db=m [Synergistic effects of paclitaxel and gemcitabine on androgen-independent prostate cancer] diagnostic usage,ongoing research,unassigned 2,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15471072&form=6&db=m [A prostatic duct carcinoma difficult to distinguish from transitional cell carcinoma: a case report] diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15474265&form=6&db=m Preoperative neural network using combined magnetic resonance imaging variables, prostate specific antigen, and Gleason score to predict prostate cancer recurrence after radical prostatectomy. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,1,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15485154&form=6&db=m [Early diagnosis and surgical management of prostate cancer] diagnostic usage,therapeutic application,unassigned 4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15515198&form=6&db=m Proper cut-off value of free to total PSA ratio for detection of prostate cancer in Korean men. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15535437&form=6&db=m Using molecular markers to predict outcome. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15535440&form=6&db=m An overview of chemotherapy trials in localized and recurrent nonmetastatic prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15535442&form=6&db=m Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15538229&form=6&db=m ASSOCIATION OF HEMOSPERMIA WITH PROSTATE CANCER. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15538230&form=6&db=m Prostate cancer characteristics and prostate specific antigen changes in screening detected patients initially treated with a watchful waiting policy. causal interaction,diagnostic usage,unassigned 1,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15538231&form=6&db=m Ferromagnetic thermal ablation of locally recurrent prostate cancer: prostate specific antigen results and immediate/intermediate morbidities. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15538240&form=6&db=m Prostate specific antigen doubling time subsequent to radical prostatectomy as a prognosticator of outcome following salvage radiotherapy. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15538268&form=6&db=m GEOGRAPHIC VARIATION ACROSS VETERANS AFFAIRS MEDICAL CENTERS IN THE TREATMENT OF EARLY STAGE PROSTATE CANCER. diagnostic usage,therapeutic application,unassigned 1,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15538302&form=6&db=m Re: the economic burden of metastatic and prostate specific antigen progression in patients with prostate cancer: findings from a retrospective analysis of health plan data. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,1,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15540729&form=6&db=m Controversies in prostate cancer screening. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15540783&form=6&db=m Identifying the combination of the transcriptional regulatory sequences on prostate specific antigen and human glandular kallikrein genes. diagnostic usage,ongoing research,therapeutic application,unassigned 4,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15540784&form=6&db=m Down-regulation of the prostate specific antigen promoter by p53 in human prostate cancer cells. diagnostic usage,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15541106&form=6&db=m The era of serum prostate specific antigen as a marker for biopsy of the prostate and detecting prostate cancer is now over in the USA. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15542264&form=6&db=m Prostate cancer mortality in Connecticut, Iowa and New Mexico African American men. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15542783&form=6&db=m Screening a combinatorial peptide library to develop a human glandular kallikrein 2-activated prodrug as targeted therapy for prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,3,3,4 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15546246&form=6&db=m Prostate specific antigen for screening for prostate cancer: an appraisal of Thai reports. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15570705&form=6&db=m [Prostate cancer: Diagnosis and staging] diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15570706&form=6&db=m [Prostate cancer. Treatment] causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15572727&form=6&db=m Long-term survival rates of patients with prostate cancer in the prostate-specific antigen screening era: population-based estimates for the year 2000 by period analysis. causal interaction,diagnostic usage,therapeutic application,unassigned 2,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15577296&form=6&db=m Prostate cancer incidence and survival in relation to education (United States). causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15586023&form=6&db=m Obesity and prostate cancer. diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15592030&form=6&db=m Detection of prostate cancer with 11C-methionine positron emission tomography. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15592033&form=6&db=m Prostate cancer in a large prostate is associated with a decreased prostate specific antigen failure rate after brachytherapy. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15599941&form=6&db=m Polymorphic forms of prostate specific antigen and their interaction with androgen receptor trinucleotide repeats in prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15625982&form=6&db=m Percent free PSA as an additional measure in a prostate cancer screen. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15643192&form=6&db=m Validation of a nomogram for predicting positive repeat biopsy for prostate cancer. diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15643193&form=6&db=m Predictors of prostate cancer evaluated by receiver operating characteristics partial area index: a prospective institutional study. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,1,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15643194&form=6&db=m Human kallikrein-2 gene polymorphism is associated with the occurrence of prostate cancer. causal interaction,diagnostic usage,ongoing research,unassigned 3,4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15643197&form=6&db=m Angiotensin II blocker decreases serum prostate specific antigen in hormone refractory prostate cancer. diagnostic usage,ongoing research,therapeutic application,unassigned 4,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15646301&form=6&db=m Intracranial metastasis of prostate cancer: report of two cases. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,1,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15650036&form=6&db=m Intron retention: a common splicing event within the human kallikrein gene family. causal interaction,diagnostic usage,ongoing research,unassigned 1,1,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15651071&form=6&db=m Identification of an immunodominant H-2D(b)-restricted CTL epitope of human PSA. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15651090&form=6&db=m Decreasing age at prostate cancer diagnosis over successive generations in prostate cancer families. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15651277&form=6&db=m [A case of solitary endobronchial metastasis of prostatic cancer] causal interaction,diagnostic usage,therapeutic application,unassigned 2,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15661414&form=6&db=m Trends in reporting Gleason score 1991 to 2001: changes in the pathologist's practice. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15688673&form=6&db=m Statewide analysis of serum prostate specific antigen levels in Louisiana men without prostate cancer. diagnostic usage,ongoing research,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15705077&form=6&db=m Prostate cancer detection with digital rectal examination, prostate-specific antigen, transrectal ultrasonography and biopsy in clinical urological practice. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15711261&form=6&db=m Prostate biopsy following a positive screen in the prostate, lung, colorectal and ovarian cancer screening trial. causal interaction,unassigned 3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15711262&form=6&db=m Comparison of predictive accuracy for pathologically organ confined clinical stage T1c prostate cancer using human glandular kallikrein 2 and prostate specific antigen combined with clinical stage and Gleason grade. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15714966&form=6&db=m [Summary of 'General Rule for Clinical and Pathological Studies on Prostate Cancer (the 3rd Edition)'] diagnostic usage,therapeutic application,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15714973&form=6&db=m [PSA-based parameters] causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15714975&form=6&db=m [Prostate biopsy] causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15716190&form=6&db=m Complexed prostate specific antigen density is better than the other PSA derivatives for detection of prostate cancer in men with total PSA between 2.5 and 20 ng/ml: results of a prospective multicenter study. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15741060&form=6&db=m Novel electrical detection of label-free disease marker proteins using piezoresistive self-sensing micro-cantilevers. diagnostic usage,therapeutic application,unassigned 4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15745494&form=6&db=m Value of prostate specific antigen in predicting the existence of bone metastasis in scintigraphy. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15749642&form=6&db=m [Preclinical models of prostate cancer] causal interaction,diagnostic usage,ongoing research,unassigned 1,2,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15751649&form=6&db=m [Tumor markers in prostate cancer--clinical significance and future prospect of prostate specific antigen (PSA)] causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,1,4 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15755329&form=6&db=m Differences between men with screening-detected versus clinically diagnosed prostate cancers in the USA. causal interaction,diagnostic usage,therapeutic application,unassigned 4,1,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15758718&form=6&db=m Delays in cancer detection using 2 and 4-year screening intervals for prostate cancer screening with initial prostate specific antigen less than 2 ng/ml. causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15758719&form=6&db=m The extent of lymphadenectomy for pTXNO prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era. diagnostic usage,ongoing research,therapeutic application,unassigned 3,3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15787333&form=6&db=m Mass screening of prostate cancer in Changchun City of China. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15821460&form=6&db=m Limitations in the use of serum prostate specific antigen levels to monitor patients after treatment for prostate cancer. diagnostic usage,therapeutic application,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15821482&form=6&db=m Prostate specific antigen adjusted for transition zone epithelial volume: the powerful predictor for the detection of prostate cancer on repeat biopsy. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15821483&form=6&db=m Prostate cancer in patients with screening serum prostate specific antigen values less than 4.0 ng/dl: results from the cooperative prostate cancer tissue resource. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15821485&form=6&db=m Treatment of patients with high risk localized prostate cancer: results from cancer of the prostate strategic urological research endeavor (CaPSURE). diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15821488&form=6&db=m Surrogate end point for prostate cancer specific mortality in patients with nonmetastatic hormone refractory prostate cancer. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15828595&form=6&db=m Learning to improve safety: false-positive pathology report results in wrongful surgery. diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15841288&form=6&db=m [Diagnostic and prognostic value of serum prostate specific antigen in prostate carcinoma] diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15841291&form=6&db=m [Correlation of procollagen (I) with prostate specific antigen and bone scan for the diagnosis of bone metastases in patients with prostate carcinoma] causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,4,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15846084&form=6&db=m Prostate Specific Antigen as a Clinical Biomarker for Prostate Cancer: What's the Take Home Message? causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15879766&form=6&db=m Defining recurrence after radiation for prostate cancer. diagnostic usage,therapeutic application,unassigned 1,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15879782&form=6&db=m The effect of statins on serum prostate specific antigen levels in a cohort of airline pilots: a preliminary report. diagnostic usage,ongoing research,therapeutic application,unassigned 3,1,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15879783&form=6&db=m Prostate cancer detection in men with prostate specific antigen 4 to 10 ng/ml using a combined approach of contrast enhanced color Doppler targeted and systematic biopsy. causal interaction,diagnostic usage,therapeutic application,unassigned 1,2,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15879823&form=6&db=m A population based study of incidence and treatment of benign prostatic hyperplasia among residents of Olmsted County, Minnesota: 1987 to 1997. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15879895&form=6&db=m Re: The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? causal interaction,diagnostic usage,therapeutic application,unassigned 1,2,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15883615&form=6&db=m Prostate biopsy in the diagnosis of prostate cancer: current trends and techniques. causal interaction,diagnostic usage,therapeutic application,unassigned 2,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15897972&form=6&db=m Mass screening of prostate cancer in a Chinese population: the relationship between pathological features of prostate cancer and serum prostate specific antigen. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15907715&form=6&db=m Relationships between reverse transcriptase-polymerase chain reaction for prostate specific antigen, survival, and various prognostic laboratory factors in patients with hormone refractory prostate cancer. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15946386&form=6&db=m PSA testing for prostate cancer: an online survey of the views and reported practice of General Practitioners in the UK. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15947596&form=6&db=m Intermediate term biochemical progression rates after radical prostatectomy and radiotherapy in patients with screen detected prostate cancer. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15947599&form=6&db=m Effectiveness of cyproterone acetate in achieving castration and preventing luteinizing hormone releasing hormone analogue induced testosterone surge in patients with prostate cancer. diagnostic usage,ongoing research,therapeutic application,unassigned 2,1,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15947662&form=6&db=m Robotic radical prostatectomy in the community setting--the learning curve and beyond: initial 200 cases. diagnostic usage,therapeutic application,unassigned 2,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15948407&form=6&db=m [Comparison of value of free-to total prostate specific antigen, prostate specific antigen density and prostate specific antigen density of transition zone for diagnosis of prostate cancer in patients with a PSA level of 4.1-10 ng/ml] diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15967249&form=6&db=m Insulin-like growth factor 1, chromogranin A and prostate specific antigen serum levels in prostate cancer patients and controls. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15999603&form=6&db=m [An experience of individual and early diagnosis of prostate cancer in a Tunisian centre] diagnostic usage,therapeutic application,unassigned 4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16006854&form=6&db=m Prostate specific antigen based prostate cancer screening: accumulating evidence of efficacy but persistent uncertainty. causal interaction,diagnostic usage,therapeutic application,unassigned 1,3,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16006878&form=6&db=m 4-year prostate specific antigen progression and diagnosis of prostate cancer in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16006879&form=6&db=m Screening with prostate specific antigen and metastatic prostate cancer risk: a population based case-control study. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16006880&form=6&db=m Predictors of subsequent prostate cancer in men with a prostate specific antigen of 2.6 to 4.0 ng/ml and an initially negative biopsy. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,3,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16006888&form=6&db=m Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16006944&form=6&db=m Results of compliance with prostate cancer screening guidelines. diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16006970&form=6&db=m Interleukin-6 polymorphism is associated with more aggressive prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16013794&form=6&db=m [Evaluation of prostate specific antigen (PSA) adjusted to transition zone in prostatic cancer detection] diagnostic usage,ongoing research,unassigned 3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16024317&form=6&db=m Review of clinical manifestations of biochemically-advanced prostate cancer cases. diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16033100&form=6&db=m Heterogeneity in prostate cancer: prostate specific antigen (PSA) and DNA cytophotometry. diagnostic usage,ongoing research,unassigned 2,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16047142&form=6&db=m Induction of Th1-type immunity and tumor protection with a prostate-specific antigen DNA vaccine. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16076698&form=6&db=m Is screening for prostate cancer with prostate specific antigen an appropriate public health measure? causal interaction,diagnostic usage,unassigned 3,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16080472&form=6&db=m Free / total prostate specific antigen ratio for prostate cancer detection: a prospective blind study. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16093978&form=6&db=m Prostate specific antigen levels in young adulthood predict prostate cancer risk: results from a cohort of Black and White Americans. diagnostic usage,therapeutic application,unassigned 4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16093979&form=6&db=m Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,2,4,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16093980&form=6&db=m A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16093983&form=6&db=m Preoperative prediction of small volume cancer (less than 0.5 ml) in radical prostatectomy specimens. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16094059&form=6&db=m Intensive lifestyle changes may affect the progression of prostate cancer. diagnostic usage,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16094093&form=6&db=m Re: The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? causal interaction,diagnostic usage,therapeutic application,unassigned 1,2,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16094096&form=6&db=m Re: The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? causal interaction,diagnostic usage,therapeutic application,unassigned 1,2,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16101380&form=6&db=m Antiproliferative efficacy of angiotensin II receptor blockers in prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16104903&form=6&db=m Clinical utility of human glandular kallikrein 2 within a neural network for prostate cancer detection. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16138582&form=6&db=m [Advances in researches on the relationship between single nucleotide polymorphism and prostate cancer] ongoing research,unassigned 3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16142560&form=6&db=m Population standards of prostate specific antigen values in men over 40: community based study in Turkey. diagnostic usage,ongoing research,therapeutic application,unassigned 4,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16145388&form=6&db=m The Vienna nomogram: validation of a novel biopsy strategy defining the optimal number of cores based on patient age and total prostate volume. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16145392&form=6&db=m The prostatic specific antigen era is alive and well: prostatic specific antigen and biochemical progression following radical prostatectomy. diagnostic usage,therapeutic application,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16164156&form=6&db=m Evaluation of the diagnostic use of free prostate specific antigen/total prostate specific antigen ratio in detecting prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16172228&form=6&db=m Role of androgen metabolism genes CYP1B1, PSA/KLK3, and CYP11alpha in prostate cancer risk and aggressiveness. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,1,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16174045&form=6&db=m Measurement of prostate specific antigen complexed to alpha1-antichymotrypsin to avoid unnecessary biopsy in patients with serum prostate specific antigen levels 4-20 ng/mL. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16195861&form=6&db=m [Significance of the PSA-concentration for the detection of prostate cancer] causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16209214&form=6&db=m [Diagnosis and treatment of early prostate cancer] causal interaction,diagnostic usage,therapeutic application,unassigned 2,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16215709&form=6&db=m [The role of PSA in diagnosis of prostate cancer and its recurrence] causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16217287&form=6&db=m Comparison of the incidence of latent prostate cancer detected at autopsy before and after the prostate specific antigen era. diagnostic usage,unassigned 2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16219610&form=6&db=m Prostate cancer presenting with normal serum PSA levels and boney metastases treated with zoledronic acid. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16255309&form=6&db=m African-American men and their reflections and thoughts on prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 2,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16280736&form=6&db=m The effects of 5alpha-reductase inhibitors on the natural history, detection and grading of prostate cancer: current state of knowledge. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16280753&form=6&db=m A multicenter clinical trial on the use of (-5, -7) pro prostate specific antigen. diagnostic usage,therapeutic application,unassigned 4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16280754&form=6&db=m Use of 2.6 ng/ml prostate specific antigen prompt for biopsy in men older than 60 years. diagnostic usage,therapeutic application,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16280762&form=6&db=m Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16289388&form=6&db=m Urinary estrogen metabolites, prostate specific antigen, and body mass index among African-American men in South Carolina. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16302264&form=6&db=m Establishing normal reference ranges for PSA change with age in a population-based study: The Krimpen study. causal interaction,diagnostic usage,ongoing research,unassigned 3,3,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16302271&form=6&db=m Pharmacokinetics, biodistribution, and antitumor efficacy of a human glandular kallikrein 2 (hK2)-activated thapsigargin prodrug. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16327094&form=6&db=m Prostate cancer screening perceptions, knowledge and behaviors among African American men: focus group findings. diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16345027&form=6&db=m A simple and general change-point identifier. causal interaction,diagnostic usage,unassigned 2,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16362587&form=6&db=m Utility of volume adjusted prostate specific antigen density in the diagnosis of prostate cancer in arab men. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,1,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16362588&form=6&db=m Cerebrospinal fluid prostate specific antigen (CSF PSA) in prostate cancer patients with lower spine metastasis. causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16363654&form=6&db=m [Prognostic factors for PSA relapse of prostate cancer after endocrine therapy] causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,2,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16372512&form=6&db=m Trends in prostate cancer epidemiology in the year 2000. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16387412&form=6&db=m Pre-operative Percent Free PSA Predicts Clinical Outcomes in Patients Treated with Radical Prostatectomy with Total PSA Levels below 10ng/ml. diagnostic usage,ongoing research,therapeutic application,unassigned 4,2,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16398367&form=6&db=m [Cloning and expression of androgen response elements of prostate specific antigen promoter] diagnostic usage,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16398372&form=6&db=m [Recent advances in proPSA on early detection in prostate cancer] diagnostic usage,unassigned 1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16406882&form=6&db=m Prostate specific antigen isoforms and human glandular kallikrein 2--which offers the best screening performance in a predominantly black population? diagnostic usage,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16406980&form=6&db=m Obesity, serum prostate specific antigen and prostate size: implications for prostate cancer detection. diagnostic usage,therapeutic application,unassigned 4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16406983&form=6&db=m Relationship among initial serum prostate specific antigen, prostate specific antigen progression and prostate cancer detection at repeat screening visits. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16425536&form=6&db=m The relationship between the serum prostate specific antigen and whole body scintigraphy in prostate cancer patients after prostatectomy. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16429649&form=6&db=m [PSA doubling time and method of calculation] causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16430626&form=6&db=m The increased rate of prostate specific antigen testing has not affected prostate cancer presentation in an inner city population in the UK. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16444931&form=6&db=m Could the sextant prostate biopsy be replaced by transurethral resection? diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16455210&form=6&db=m Disseminated, lethal prostate cancer during human immunodeficiency virus infection presenting with non-specific features. Open questions for urologists, oncologists, and infectious disease specialists. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16469085&form=6&db=m A case of Sister Mary Joseph's nodule from prostatic cancer. causal interaction,diagnostic usage,ongoing research,unassigned 1,2,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16469576&form=6&db=m Pathological characteristics of prostate cancer detected through prostate specific antigen based screening. diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16484852&form=6&db=m [Advancement of treatment for prostate cancer] causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16485553&form=6&db=m [The utility of prostate specific antigen doubling time in repeat biopsy for prostate cancer] causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16502048&form=6&db=m Effects of chronic bacterial prostatitis on prostate specific antigen levels total and free in patients with benign prostatic hyperplasia and prostate cancer. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16502049&form=6&db=m Relationship between Serum Prostate Specific Antigen and the Pattern of Inflammation in Both Benign and Malignant Prostatic Disease in Middle Eastern Men. causal interaction,diagnostic usage,ongoing research,unassigned 4,1,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16515495&form=6&db=m Treatment of PSA only recurrence of prostate cancer after prior local therapy. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16515959&form=6&db=m Prostate specific antigen and other markers for prostate cancer. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16515980&form=6&db=m Prostate cancer detection among men with prostate specific antigen levels of 2.5 to 4.0 ng/ml in a Japanese urological referral population. diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16515989&form=6&db=m The association between total and positive lymph node counts, and disease progression in clinically localized prostate cancer. diagnostic usage,therapeutic application,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16523454&form=6&db=m High-speed biomarker identification utilizing porous silicon nanovial arrays and MALDI-TOF mass spectrometry. unassigned - 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16545295&form=6&db=m [Validity of digital rectal examination of prostate specific antigen] diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16545296&form=6&db=m Validity of digital rectal examination in the era of prostate specific antigen. diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16552242&form=6&db=m Prostate cancer update: 2005. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16581345&form=6&db=m Correlation between serum prostate-specific antigen and alpha-1-antitrypsin in men without and with prostate cancer. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16598740&form=6&db=m Fast and novel purification method to obtain the prostate specific antigen (PSA) from human seminal plasma. diagnostic usage,therapeutic application,unassigned 4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16600723&form=6&db=m Clinical Usefulness of Serum Prostate Specific Antigen for the Detection of Prostate Cancer is Preserved in Men Receiving the Dual 5alpha-Reductase Inhibitor Dutasteride. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,4 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16604995&form=6&db=m Prostate cancer: diagnostic and therapeutic strategies with emphasis on the role of PSA. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16619264&form=6&db=m Androgen receptor action in hormone-dependent and recurrent prostate cancer. diagnostic usage,unassigned 3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16638344&form=6&db=m [Relationship between screening by stratifying cases into groups on prostate specific antigen level and the positive rate of transrectal ultrasound guided systematic sextant prostate biopsy] diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16638345&form=6&db=m [Prediction of the stage of patients with prostate cancer by the combination of serum prostate specific antigen and Gleason score] diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16638346&form=6&db=m [The usefulness of percentage of free prostate specific antigen/prostate specific antigen density in the diagnosis of prostate cancer] diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16643613&form=6&db=m Is interval from an initial biopsy a significant predictor of prostate cancer at repeat biopsies? diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16643616&form=6&db=m Serum human glandular kallikrein 2 (hK2) for distinguishing stage and grade of prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,3,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16672122&form=6&db=m Nomogram prediction for prostate cancer and aggressive prostate cancer at time of biopsy: utilizing all risk factors and tumor markers for prostate cancer. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16673587&form=6&db=m Clinical correlation, ecographic and levels of prostate specific antigen in patients with prostate cancer. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16673588&form=6&db=m Screening for prostate cancer--how to manage in 2006? diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16673599&form=6&db=m Urinary prostate specific antigen: is the clinical use likely? diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16679855&form=6&db=m Recent progress in hormonal therapy for advanced prostate cancer. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16683569&form=6&db=m [Clinical value of CK34BE12 combining the expression of protein P53 gene and prostate specific antigen for the differential diagnosis of prostate carcinoma] causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,4,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16697520&form=6&db=m A (-5, -7) proPSA based artificial neural network to detect prostate cancer. diagnostic usage,unassigned 3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16697807&form=6&db=m Prevalence of prostate specific antigen testing for prostate cancer in elderly men. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16708371&form=6&db=m Association of vitamin D receptor FokI polymorphism with prostate cancer risk, clinicopathological features and recurrence of prostate specific antigen after radical prostatectomy. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16720000&form=6&db=m PSA testing: are patients aware of what lies ahead? diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16750292&form=6&db=m Single-dose antibiotic prophylaxis in core prostate biopsy: impact of timing and identification of risk factors. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,4,4 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16753368&form=6&db=m Impact of increased number of biopsies on the nature of prostate cancer identified. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16753371&form=6&db=m Are bone scans necessary in men with low prostate specific antigen levels following localized therapy? causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16753443&form=6&db=m Prostate specific antigen expression does not necessarily correlate with prostate cancer cell growth. diagnostic usage,ongoing research,therapeutic application,unassigned 3,3,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16753454&form=6&db=m Re: Long-term effects of finasteride on prostate specific antigen levels: results from the Prostate Cancer Prevention Trial. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,2,4,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16813862&form=6&db=m Continuing controversy over monitoring men with localized prostate cancer: a systematic review of programs in the prostate specific antigen era. causal interaction,diagnostic usage,therapeutic application,unassigned 2,1,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16813879&form=6&db=m Prostate specific antigen testing in men older than 75 years in the United States. diagnostic usage,ongoing research,unassigned 2,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16813888&form=6&db=m Pathological outcomes and biochemical progression in men with T1c prostate cancer undergoing radical prostatectomy with prostate specific antigen 2.6 to 4.0 vs 4.1 to 6.0 ng/ml. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16813889&form=6&db=m Detectable prostate specific antigen between 60 and 120 days following radical prostatectomy for prostate cancer: natural history and prognostic significance. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16813891&form=6&db=m 25-year prostate cancer control and survival outcomes: a 40-year radical prostatectomy single institution series. diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16818008&form=6&db=m Does prolonging the time to prostate cancer surgery impact long-term cancer control: a systematic review of the literature. diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16819092&form=6&db=m Environmental Exposure to Trace Elements and Prostate Cancer in Three New Zealand Ethnic Groups. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16827400&form=6&db=m Lifetime and recent prostate specific antigen (PSA) screening of men for prostate cancer in Canada. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,3,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16834663&form=6&db=m Evaluation of an adrenal mass in a patient with progressive prostate cancer reveals pheochromocytoma. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16844319&form=6&db=m The value of digital rectal examination as a predictor of prostate cancer diagnosis among United States Veterans referred for prostate biopsy. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16844459&form=6&db=m Free and total human glandular kallikrein 2 in patients with prostate cancer. diagnostic usage,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16857310&form=6&db=m Control of prostate cancer by transrectal HIFU in 227 patients. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16875796&form=6&db=m Informed decision making and prostate specific antigen (PSA) testing for prostate cancer: a randomised controlled trial exploring the impact of a brief patient decision aid on men's knowledge, attitudes and intention to be tested. diagnostic usage,ongoing research,unassigned 2,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16890642&form=6&db=m The interpretation of serum prostate specific antigen in men receiving 5alpha-reductase inhibitors: a review and clinical recommendations. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,4 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16890668&form=6&db=m Prostate saturation biopsy in the reevaluation of microfocal prostate cancer. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16890677&form=6&db=m Salvage radiotherapy for isolated prostate specific antigen increase after radical prostatectomy: evaluation of prognostic factors and creation of a prognostic scoring system. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16890703&form=6&db=m Sexual behavior, sexually transmitted diseases and prostatitis: the risk of prostate cancer in black men. causal interaction,diagnostic usage,therapeutic application,unassigned 2,3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16890704&form=6&db=m Is race a positive predictor of cancer on repeat prostate biopsy? causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16890705&form=6&db=m Impact of familial and hereditary prostate cancer on cancer specific survival after radical retropubic prostatectomy. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,1,3 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16890735&form=6&db=m Re: Obesity, serum prostate specific antigen and prostate size: implications for prostate cancer detection. S. J. Freedland, E. A. Platz, J. C. Presti Jr., W. J. Aronson, C. L. Amling, C. J. Kane and M. K. Terris. J Urol, 175: 500-504, 2006. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16903936&form=6&db=m Lower urinary tract symptoms and risk of prostate cancer in Japanese men. diagnostic usage,ongoing research,therapeutic application,unassigned 4,1,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16910582&form=6&db=m Bisphosphonate and low-dose dexamethasone treatment for patients with hormone-refractory prostate cancer. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16910584&form=6&db=m Recovery of serum prostate specific antigen value after interruption of antiandrogen therapy with allylestrenol for benign prostatic hyperplasia. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16952616&form=6&db=m Prevention of benign prostatic hyperplasia disease. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16952643&form=6&db=m Prediagnosis prostate specific antigen velocity is associated with risk of prostate cancer progression following brachytherapy and external beam radiation therapy. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,3 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16952644&form=6&db=m Time to prostate specific antigen recurrence after radical prostatectomy and risk of prostate cancer specific mortality. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,3 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16998833&form=6&db=m Soluble N-cadherin in human biological fluids. causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17001152&form=6&db=m Immunohistochemical Staining of Precursor Forms of Prostate-specific Antigen (proPSA) in Metastatic Prostate Cancer. causal interaction,diagnostic usage,ongoing research,unassigned 3,4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17023779&form=6&db=m A prostate specific antigen (PSA) bounce greater than 1.4 ng/mL Is clinically significant after external beam radiotherapy for prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17025212&form=6&db=m [Mass screening for prostate cancer in Ikeda City Osaka] diagnostic usage,ongoing research,therapeutic application,unassigned 4,1,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17045982&form=6&db=m Development of an immunofluorometric assay for human kallikrein 15 (KLK15) and identification of KLK15 in tissues and biological fluids. causal interaction,diagnostic usage,ongoing research,unassigned 3,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17070213&form=6&db=m Prostate specific antigen doubling time calculation: not as easy as 1, 2, 4. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,3,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17070238&form=6&db=m Prostate cancer prevention and finasteride. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,3 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17070241&form=6&db=m Detection of pelvic lymph node metastases in patients with clinically localized prostate cancer: comparison of [18F]fluorocholine positron emission tomography-computerized tomography and laparoscopic radioisotope guided sentinel lymph node dissection. diagnostic usage,therapeutic application,unassigned 2,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17070311&form=6&db=m Citrate concentrations in human seminal fluid and expressed prostatic fluid determined via 1H nuclear magnetic resonance spectroscopy outperform prostate specific antigen in prostate cancer detection. causal interaction,diagnostic usage,ongoing research,unassigned 2,4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17084157&form=6&db=m Identifying men diagnosed with clinically localized prostate cancer who are at high risk for death from prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17084158&form=6&db=m Defining high risk prostate cancer with risk groups and nomograms: implications for designing clinical trials. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17084163&form=6&db=m The case for adjuvant therapy for prostate cancer. diagnostic usage,therapeutic application,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17084169&form=6&db=m Management of high risk metastatic prostate cancer: defining risk at the time of initial treatment failure. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17085105&form=6&db=m The discovery of prostate specific antigen as a biomarker for the early detection of adenocarcinoma of the prostate. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17085120&form=6&db=m Comparison of methods for calculating prostate specific antigen velocity. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17121020&form=6&db=m [Combined assay of serum prostate specific antigen and chromogranin A helps diagnosis of prostate cancer] diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17151093&form=6&db=m PSA/KLK3 AREI promoter polymorphism alters androgen receptor binding and is associated with prostate cancer susceptibility. causal interaction,diagnostic usage,unassigned 3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17162013&form=6&db=m Does body mass index affect preoperative prostate specific antigen velocity or pathological outcomes after radical prostatectomy? causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,2,3 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17162015&form=6&db=m Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17171424&form=6&db=m Free/total PSA ratio can help in the prediction of high gleason score prostate cancer in men with total serum prostate specific antigen (PSA) of 3-10 ng/ml. diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17171425&form=6&db=m The prognostic importance of prostate specific antigen in the monitorisation of patients undergoing maximum androgen blockade for metastatic prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,1,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17201105&form=6&db=m [Neuroendocrine differentiation and markers of cell proliferation in a group of patients with prostate adenocarcinoma and normal or high serum prostate-specific antigen levels] causal interaction,diagnostic usage,ongoing research,unassigned 3,4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17214230&form=6&db=m [Biological markers of prostate cancer] causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17214231&form=6&db=m [Prostate cancer in the elderly patient] causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17222618&form=6&db=m Age adjusted prostate specific antigen and prostate specific antigen velocity cut points in prostate cancer screening. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,3,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17222621&form=6&db=m Prostate specific antigen density correlates with features of prostate cancer aggressiveness. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,4 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17222622&form=6&db=m Development and external validation of an extended repeat biopsy nomogram. diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17222676&form=6&db=m Expression of major heat shock proteins in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17235222&form=6&db=m The impact of inadequate knowledge on patient and spouse experience of prostate cancer. diagnostic usage,unassigned 3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17257635&form=6&db=m Is there an inter-relationship between prostate specific antigen, kallikrein-2 and androgen receptor gene polymorphisms with risk of prostate cancer in north Indian population? causal interaction,diagnostic usage,unassigned 3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17259162&form=6&db=m [Value of prostate specific antigen in early diagnosis of prostatic cancer] causal interaction,diagnostic usage,ongoing research,unassigned 4,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17292604&form=6&db=m Body mass index does not predict prostate-specific antigen or percent free prostate-specific antigen in men undergoing prostate cancer screening. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,3,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17296371&form=6&db=m Prostate specific antigen velocity threshold for predicting prostate cancer in young men. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17296379&form=6&db=m 13-year outcomes following treatment for clinically localized prostate cancer in a population based cohort. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17345087&form=6&db=m Circulating biomarkers for prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17345593&form=6&db=m Serum insulin-like growth factor I/free prostate specific antigen (IGF-I/fPSA) ratio enhances prostate cancer detection in men with total PSA 4.0-10.0 ng/ml. diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17382696&form=6&db=m Conference report and review: current status of biomarkers potentially associated with prostate cancer outcomes. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17382716&form=6&db=m The association between total prostate specific antigen concentration and prostate specific antigen velocity. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17410539&form=6&db=m SELDI-TOF MS versus prostate specific antigen analysis of prospective plasma samples in a nested case-control study of prostate cancer. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17414641&form=6&db=m Prostate cancer update: 2006. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17437802&form=6&db=m Influence of prostate volume and percent free prostate specific antigen on prostate cancer detection in men with a total prostate specific antigen of 2.6 to 10.0 ng/ml. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17437803&form=6&db=m Risk of prostate cancer for young men with a prostate specific antigen less than their age specific median. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17437804&form=6&db=m Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,3,3 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17479106&form=6&db=m An HSV-1 amplicon system for prostate-specific expression of ICP4 to complement oncolytic viral replication for in vitro and in vivo treatment of prostate cancer cells. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,3,4 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17488305&form=6&db=m Distribution of prostate specific antigen (PSA) and percentage free PSA in a contemporary screening cohort with no evidence of prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,3,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17489968&form=6&db=m Evaluating the predictiveness of a continuous marker. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17492070&form=6&db=m Diagnosing prostate cancer - what GPs need to know. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,1,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17499284&form=6&db=m Finasteride decreases the risk of prostatic intraepithelial neoplasia. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17499288&form=6&db=m Under diagnosis and over diagnosis of prostate cancer in a screening population with serum PSA 2 to 10 ng/ml. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,1,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17503469&form=6&db=m Androgen receptor or estrogen receptor-beta blockade alters DHEA-, DHT-, and E(2)-induced proliferation and PSA production in human prostate cancer cells. diagnostic usage,ongoing research,unassigned 2,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17509282&form=6&db=m Prostate cancer. causal interaction,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17509304&form=6&db=m Phase II study of low dose and high dose conjugated estrogen for androgen independent prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17509368&form=6&db=m Re: Prediagnosis prostate specific antigen velocity is associated with risk of prostate cancer progression following brachytherapy and external beam radiation therapy. S. E. Eggener, K. A. Roehl, O. Yossepowitch and W. J. Catalona, J Urol 2006; 176: 1399-1403. causal interaction,diagnostic usage,therapeutic application,unassigned 2,1,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17552952&form=6&db=m Real-time elastography for detecting prostate cancer: preliminary experience. diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17553369&form=6&db=m [Rising Prostate Specific Antigen following treatment with curative intention] diagnostic usage,therapeutic application,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17561137&form=6&db=m Comparison of contrast enhanced color Doppler targeted biopsy to conventional systematic biopsy: impact on Gleason score. causal interaction,diagnostic usage,unassigned 1,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17564105&form=6&db=m [Prostate cancer screening at Tatebayashi City in Gunma prefecture--results of screening with PSA alone between 2003 and 2005] causal interaction,diagnostic usage,unassigned 2,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17571482&form=6&db=m Significance of prostate specific antigen in prostate cancer patients and in non cancerous prostatic disease patients. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17571945&form=6&db=m A randomized trial of lycopene supplementation in Tobago men with high prostate cancer risk. diagnostic usage,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17587816&form=6&db=m Epithelial-mesenchymal transition in prostate cancer and the potential role of kallikrein serine proteases. causal interaction,diagnostic usage,unassigned 2,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17593640&form=6&db=m [Who works in the prevention and early detection of benign prostatic hyperplasia and prostate cancer in Croatia?] diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17631330&form=6&db=m Serum bone turnover markers (PINP and ICTP) for the early detection of bone metastases in patients with prostate cancer: a longitudinal approach. diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17631342&form=6&db=m Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17631355&form=6&db=m Predictors of histological disease progression in untreated, localized prostate cancer. diagnostic usage,ongoing research,therapeutic application,unassigned 2,1,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17644122&form=6&db=m Prostate specific antigen only androgen independent prostate cancer: natural history, challenges in management and clinical trial design. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,3,3 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17644123&form=6&db=m Assessing and treating patients with increasing prostate specific antigen following radical prostatectomy. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17644125&form=6&db=m Contemporary trends in low risk prostate cancer: risk assessment and treatment. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17663247&form=6&db=m Peptide-nanoparticle hybrid SERS probes for optical detection of protease activity. diagnostic usage,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17674442&form=6&db=m Words of wisdom. Re: Age adjusted prostate specific antigen and prostate specific antigen velocity cut points in prostate cancer screening. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,3,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17682373&form=6&db=m Factors influencing prostate cancer screening decisions among African American men. diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17695453&form=6&db=m Serum tPSA, cPSA, related density parameters and chromogranin A as predictors of positive margins after radical prostatectomy. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17698101&form=6&db=m Rates of biochemical remission remain higher in black men compared to white men after radical prostatectomy despite similar trends in prostate specific antigen induced stage migration. diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17698107&form=6&db=m Lead time of prostate cancer detected in population based screening for prostate cancer in Japan. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17698131&form=6&db=m Predicting unilateral prostate cancer based on biopsy features: implications for focal ablative therapy--results from the SEARCH database. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17704405&form=6&db=m Assessing individual risk for prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17722004&form=6&db=m Identification of candidate prostate cancer biomarkers in prostate needle biopsy specimens using proteomic analysis. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17722872&form=6&db=m Pomegranate ellagitannin-derived metabolites inhibit prostate cancer growth and localize to the mouse prostate gland. diagnostic usage,therapeutic application,unassigned 2,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17767032&form=6&db=m [Hormone replacement Up-to-date. Clinical practice of androgen replacement therapy] causal interaction,diagnostic usage,therapeutic application,unassigned 1,3,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17868721&form=6&db=m Association of body mass index with response and survival in men with metastatic prostate cancer: Southwest Oncology Group trials 8894 and 9916. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17868724&form=6&db=m Current age and race adjusted prostate specific antigen threshold values delay diagnosis of high grade prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17868726&form=6&db=m Prostate cancer risk assessment program: a 10-year update of cancer detection. causal interaction,diagnostic usage,unassigned 2,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17885709&form=6&db=m Chemotherapy in the treatment of prostate cancer--is there a role? causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17894328&form=6&db=m Mechanistic insights into the inhibition of prostate specific antigen by beta-lactam class compounds. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17916259&form=6&db=m A randomised controlled trial of the effects of a web-based PSA decision aid, Prosdex. Protocol. causal interaction,diagnostic usage,unassigned 2,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17933704&form=6&db=m Impact of low prostate specific antigen on prostate cancer--a rare case report. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17936806&form=6&db=m Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience. diagnostic usage,ongoing research,unassigned 1,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17936815&form=6&db=m Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17936844&form=6&db=m Prostate specific antigen velocity in men with total prostate specific antigen less than 4 ng/ml. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,4 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17936845&form=6&db=m Biomarkers for prostate cancer detection. causal interaction,diagnostic usage,therapeutic application,unassigned 2,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17941930&form=6&db=m New blood-based biomarkers for the diagnosis, staging and prognosis of prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,3,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17947957&form=6&db=m Serum ceruloplasmin as a marker in prostate cancer. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17953381&form=6&db=m [Analysis of reference range responsible to normal percent value of free prostate specific antigen from men without prostate disease] diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17956937&form=6&db=m Oligosaccharide profiles of the prostate specific antigen in free and complexed forms from the prostate cancer patient serum and in seminal plasma: a glycopeptide approach. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,2,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17987231&form=6&db=m Efficacy of low-dose ketoconazole in hormone refractory prostate cancer patients at the National Cancer Centre and The Cancer Institute, Singapore. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17997422&form=6&db=m Percent free prostate specific antigen does not enhance the specificity of total prostate specific antigen for the detection of prostate cancer in Korean men 50 to 65 years old: a prospective multicenter study. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17997442&form=6&db=m Prediction of survival of metastatic prostate cancer based on early serial measurements of prostate specific antigen and alkaline phosphatase. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,3,4 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17998918&form=6&db=m New circulating biomarkers for prostate cancer. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18001801&form=6&db=m The natural history of men treated with deferred androgen deprivation therapy in whom metastatic prostate cancer developed following radical prostatectomy. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,1,4 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18006969&form=6&db=m Detection of prostate cancer in unselected young men: prospective cohort nested within a randomised controlled trial. diagnostic usage,therapeutic application,unassigned 4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18044088&form=6&db=m Is it necessary to cure prostate cancer when it is possible? (Understanding the role of prostate inflammation resolution to prostate cancer evolution). diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18062210&form=6&db=m [Clinical study on poor PSA response to initial endocrine therapy with MAB or estrogenic drugs for treatment of prostate cancer] causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18072496&form=6&db=m Realtime light dosimetry software tools for interstitial photodynamic therapy of the human prostate. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18076938&form=6&db=m The role of pelvic lymphadenectomy for prostate cancer--therapeutic? causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18076941&form=6&db=m CpG island hypermethylation profile in the serum of men with clinically localized and hormone refractory metastatic prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18097534&form=6&db=m Serum measurements of testosterone, insulin-like growth factor 1, and insulin-like growth factor binding protein-3 in the diagnosis of prostate cancer among Korean men. diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18163938&form=6&db=m Salvage options for biochemical recurrence after primary therapy for prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18174535&form=6&db=m Why men in the United Kingdom still want the prostate specific antigen test. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18180806&form=6&db=m Is there a role for positron emission tomography imaging in the early evaluation of prostate cancer relapse? causal interaction,diagnostic usage,ongoing research,therapeutic application 1,2,1,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18184186&form=6&db=m Willingness to pay for mass screening for prostate cancer: a contingent valuation survey. diagnostic usage,ongoing research,therapeutic application,unassigned 2,2,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18194186&form=6&db=m The role of BPH, lower urinary tract symptoms, and PSA levels on erectile function of Brazilian men who undergo prostate cancer screening. diagnostic usage,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18196551&form=6&db=m A novel transcript from the KLKP1 gene is androgen regulated, down-regulated during prostate cancer progression and encodes the first non-serine protease identified from the human kallikrein gene locus. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18214038&form=6&db=m Transrectal broadband-Doppler sonography with intravenous contrast medium administration for prostate imaging and biopsy in men with an elevated PSA value and previous negative biopsies. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18221963&form=6&db=m Prostate specific antigen kinetics in the management of prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,4 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18234062&form=6&db=m A pilot dose-escalation study of the effects of nordihydroguareacetic acid on hormone and prostate specific antigen levels in patients with relapsed prostate cancer. diagnostic usage,ongoing research,therapeutic application,unassigned 3,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18239761&form=6&db=m Abnormal PSA tests--delays in referral. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18250060&form=6&db=m [Analysis of the results of percent free prostate specific antigen detection among the men without prostate diseases in Xi'an.] diagnostic usage,ongoing research,therapeutic application,unassigned 4,1,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18273616&form=6&db=m Development of a Listeria monocytogenes based vaccine against prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18279918&form=6&db=m Prognostic significance of high-grade prostatic intraepithelial neoplasia (HGPIN): risk of prostatic cancer on repeat biopsies. causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18279939&form=6&db=m Does transurethral resection of prostate (TURP) affect outcome in patients who subsequently develop prostate cancer? causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18280514&form=6&db=m The rationale for inhibiting 5alpha-reductase isoenzymes in the prevention and treatment of prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,2,4 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18289590&form=6&db=m Comparison of prostate specific antigen velocity in screened versus referred patients with prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,4 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18304461&form=6&db=m Polymorphisms of GSTM1 and CYP1A1 genes and their genetic susceptibility to prostate cancer in Chinese men. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18343412&form=6&db=m Saturation technique does not decrease cancer detection during followup after initial prostate biopsy. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,1,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18343420&form=6&db=m The Ratio of Serum Testosterone-to-Prostate Specific Antigen Predicts Prostate Cancer in Hypogonadal Men. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,4 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18343425&form=6&db=m The performance of prostate specific antigen, prostate specific antigen density and transition zone density in the era of extended biopsy schemes. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,2,3 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18343434&form=6&db=m Limitations of Prostate Specific Antigen Doubling Time Following Biochemical Recurrence After Radical Prostatectomy: Results From the SEARCH Database. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18343439&form=6&db=m Prostate specific antigen versus prostate specific antigen density as a prognosticator of pathological characteristics and biochemical recurrence following radical prostatectomy. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18343442&form=6&db=m The arachidonic Acid pathway and its role in prostate cancer development and progression. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,3,4 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18394199&form=6&db=m Hypertrophic osteoarthropathy as the cause of a super scan of the bone in a patient with prostate cancer: a case report. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18398867&form=6&db=m Enterolactone restricts the proliferation of the LNCaP human prostate cancer cell line in vitro. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18404790&form=6&db=m Association between bone scintigraphy and serum levels of procollagen (I) and PSA in the detection of bone disease in prostate cancer patients. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,2,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18405753&form=6&db=m Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18411775&form=6&db=m [Five-year results of prostate specific antigen (PSA) screening in Yokosuka City--comparative study between PSA-screened group and non-screened group] diagnostic usage,ongoing research,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18411777&form=6&db=m [Histopathological characteristics of radical prostatectomy specimen and long-term PSA changes in men with PSA levels of 4.0 ng/ml or less] diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18415709&form=6&db=m Expression of p21(waf1/cip1), p27 (kip1), p63 and Androgen Receptor in Low and High Gleason Score Prostate Cancer. diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18422574&form=6&db=m Prediction of extraprostatic extension by prostate specific antigen velocity, endorectal MRI, and biopsy Gleason score in clinically localized prostate cancer. diagnostic usage,ongoing research,therapeutic application,unassigned 4,1,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18423715&form=6&db=m Interactive spaced education versus web based modules for teaching urology to medical students: a randomized controlled trial. therapeutic application,unassigned 1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18423725&form=6&db=m Circulating tumor cells in peripheral blood samples from patients with increased serum prostate specific antigen: initial results in early prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,1,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18423743&form=6&db=m Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18423746&form=6&db=m Change in prostate specific antigen following androgen stimulation is an independent predictor of prostate cancer diagnosis. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,3 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18425978&form=6&db=m Five-alpha-reductase Inhibitors for prostate cancer prevention. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18444145&form=6&db=m A combination of tomato and soy products for men with recurring prostate cancer and rising prostate specific antigen. causal interaction,diagnostic usage,therapeutic application,unassigned 2,3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18446367&form=6&db=m The use of prostate specific antigen (PSA) density in detecting prostate cancer in Chinese men with PSA levels of 4-10 ng/mL. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18452171&form=6&db=m Recent trends in prostate cancer mortality show a continuous decrease in several countries. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18452459&form=6&db=m Prediction of bone metastases by combination of tartrate-resistant acid phosphatase, alkaline phosphatase and prostate specific antigen in patients with prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,4,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18485383&form=6&db=m A novel nomogram to predict the probability of prostate cancer on repeat biopsy. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18535913&form=6&db=m Epithelial to mesenchymal transition (EMT) in human prostate cancer: lessons learned from ARCaP model. causal interaction,ongoing research,unassigned 2,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18542821&form=6&db=m Urinary PSA: a potential useful marker when serum PSA is between 2.5 ng/mL and 10 ng/mL. diagnostic usage,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18550097&form=6&db=m The performance of prostate specific antigen for predicting prostate cancer is maintained after a prior negative prostate biopsy. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,3,4 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18550118&form=6&db=m [-2]proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,3,3 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18552171&form=6&db=m Do patients with low volume prostate cancer have prostate specific antigen recurrence following radical prostatectomy? causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18554651&form=6&db=m Health risk behaviors and prostate specific antigen awareness among men in California. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,1,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18570713&form=6&db=m Outcome analysis of prostate cancer patients with pre-treatment PSA greater than 50 ng/ml. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18578523&form=6&db=m Proteomic analysis of conditioned media from the PC3, LNCaP, and 22Rv1 prostate cancer cell lines: discovery and validation of candidate prostate cancer biomarkers. diagnostic usage,therapeutic application,unassigned 4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18585845&form=6&db=m Prostate-specific antigen kinetics in clinical decision-making during active surveillance for early prostate cancer--a review. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18595241&form=6&db=m Stage T2 prostate cancer presented with high serum prostate specific antigen and nonspecific bone lesions. diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18595242&form=6&db=m Pelvic lymphadenectomy for localized prostate cancer. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18616419&form=6&db=m ZD4054: a specific endothelin A receptor antagonist with promising activity in metastatic castration-resistant prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18630475&form=6&db=m Accuracy of a new echographic method (RULES, radiofrequency ultrasonic local estimators) in prostate cancer diagnosis. diagnostic usage,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18630840&form=6&db=m Changes in prostate cancer at radical prostatectomy during the prostate specific antigen era: an Italian experience. causal interaction,diagnostic usage,therapeutic application,unassigned 2,1,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18635219&form=6&db=m Finnish multicenter study comparing intermittent to continuous androgen deprivation for advanced prostate cancer: interim analysis of prognostic markers affecting initial response to androgen deprivation. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18637139&form=6&db=m Evaluation of an Internet-Based Disease Trajectory Decision Tool for Prostate Cancer Screening. diagnostic usage,ongoing research,unassigned 3,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18642881&form=6&db=m Labeless immunosensor assay for prostate specific antigen with picogram per milliliter limits of detection based upon an ac impedance protocol. diagnostic usage,unassigned 2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18649741&form=6&db=m 25-Hydroxyvitamin D-1 alpha-hydroxylase (CYP27B1) is a new class of tumor suppressor in the prostate. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18668524&form=6&db=m Nonhuman primates as models for studies of prostate specific antigen and prostatic diseases. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18681353&form=6&db=m Prostate specific antigen (PSA) may be a poor marker for progression of prostate cancer after treatment with a combination of chemo-hormonal therapies. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18682773&form=6&db=m Recommendations by Canadian urologists and radiation oncologists for the treatment of clinically localized prostate cancer. therapeutic application,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18686378&form=6&db=m [Differentiation of prostate cancer from benign prostatic disease by total prostate specific antigen dynamic profiles after transrectal prostate biopsy] diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18697759&form=6&db=m Undetectable level of prostate specific antigen (PSA) nadir predicts PSA biochemical failure in local prostate cancer with delayed-combined androgen blockade. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,1,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18707695&form=6&db=m Evaluation of serum and urinary myeloid related protein-14 as a marker for early detection of prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18707696&form=6&db=m Outcomes following active surveillance of men with localized prostate cancer diagnosed in the prostate specific antigen era. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,2,1,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18707699&form=6&db=m Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18707706&form=6&db=m Prostate cancers diagnosed at repeat biopsy are smaller and less likely to be high grade. causal interaction,diagnostic usage,ongoing research,unassigned 3,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18707707&form=6&db=m It's time to abandon an upper limit of normal for prostate specific antigen: assessing the risk of prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18707710&form=6&db=m Racial variations in the performance of prostate specific antigen and prostate specific antigen density in the era of extended prostate biopsy schemes. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18707724&form=6&db=m Predicting prostate cancer risk through incorporation of prostate cancer gene 3. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18707733&form=6&db=m Does prostate growth confound prostate specific antigen velocity? Data from the Baltimore longitudinal study of aging. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,4,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18710743&form=6&db=m Testosterone recovery after prolonged androgen suppression in patients with prostate cancer. diagnostic usage,ongoing research,therapeutic application,unassigned 4,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18710761&form=6&db=m Prostate screening in patients with 46,XY disorders of sex development--is it necessary? causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18758115&form=6&db=m Coumarins from campylotropis hirtella (FRANCH.) SCHINDL. and their inhibitory activity on prostate specific antigen secreted from LNCaP cells. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,4,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18774466&form=6&db=m Local-regional prostate cancer. diagnostic usage,therapeutic application,unassigned 4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18774468&form=6&db=m Surgical management of high risk prostate cancer: the Mayo Clinic experience. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18783735&form=6&db=m The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18789607&form=6&db=m Peroxisome proliferator-activated receptor-gamma and growth inhibition by its ligands in prostate cancer. diagnostic usage,ongoing research,therapeutic application,unassigned 3,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18798614&form=6&db=m Toward a prostate specific antigen-based prostate cancer diagnostic assay: preparation of keyhole limpet hemocyanin-conjugated normal and transformed prostate specific antigen fragments. diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18801501&form=6&db=m Indications for preoperative prostate biopsy in patients undergoing radical cystoprostatectomy for bladder cancer. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18801505&form=6&db=m A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America. causal interaction,diagnostic usage,therapeutic application,unassigned 1,1,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18801519&form=6&db=m What are the factors associated with short prostate specific antigen doubling time after radical prostatectomy? A report from the SEARCH database group. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,4 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18801532&form=6&db=m Prostate specific antigen assay standardization bias could affect clinical decision making. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18804811&form=6&db=m The significance of monoamine oxidase-A expression in high grade prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18813934&form=6&db=m Active surveillance for prostate cancer: trials and tribulations. causal interaction,diagnostic usage,therapeutic application,unassigned 2,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18825504&form=6&db=m Changes in case mix and treatment patterns in prostate cancer in Saskatchewan during the prostate specific antigen testing era. causal interaction,unassigned 3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18927246&form=6&db=m Emerging biomarkers for the diagnosis and prognosis of prostate cancer. diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18930254&form=6&db=m Diet and dietary supplement intervention trials for the prevention of prostate cancer recurrence: a review of the randomized controlled trial evidence. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18930283&form=6&db=m Surveillance and deferred treatment for localized prostate cancer. Population based study in the National Prostate Cancer Register of Sweden. diagnostic usage,therapeutic application,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18930486&form=6&db=m A single microfocus (5% or less) of Gleason 6 prostate cancer at biopsy--can we predict adverse pathological outcomes? causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18959172&form=6&db=m [Disease relapses after radical radiotherapy of prostate cancer--analysis of prognostic factors] diagnostic usage,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18977589&form=6&db=m Suppression of androgen receptor signaling and prostate specific antigen expression by (-)-epigallocatechin-3-gallate in different progression stages of LNCaP prostate cancer cells. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,3,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19012907&form=6&db=m Effectiveness of antibiotics given to asymptomatic men for an increased prostate specific antigen. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,3,4 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19012915&form=6&db=m Defining increased future risk for prostate cancer: evidence from a population based screening cohort. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,3 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19021912&form=6&db=m The trends in prostate specific antigen usage amongst United Kingdom urologists--a questionnaire based study. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19035151&form=6&db=m [Epidemiology of prostate cancer from three centers and analysis of the first-line hormonal therapy for the advanced disease] diagnostic usage,therapeutic application,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19046489&form=6&db=m Screening for prostate cancer: an update. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19058905&form=6&db=m Screening for Prostate Cancer in 2008 II: The Importance of Molecular Subforms of Prostate-Specific Antigen and Tissue Kallikreins. causal interaction,diagnostic usage,ongoing research,unassigned 3,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19060997&form=6&db=m Pretreatment tumor volume estimation based on total serum psa in patients with localized prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,2,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19084862&form=6&db=m The role of prostate specific membrane antigen and pepsinogen C tissue expression as an adjunctive method to prostate cancer diagnosis. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19091352&form=6&db=m Risk factors for lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a community based population of healthy aging men: the Krimpen Study. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,3,3 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19093873&form=6&db=m 2D-DIGE as a strategy to identify serum markers for the progression of prostate cancer. diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19107370&form=6&db=m Inhibitory effect of matrine on the expression of PSA and AR in prostate cancer cell line LNCaP. diagnostic usage,ongoing research,therapeutic application,unassigned 3,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19116992&form=6&db=m Association of reported prostate cancer risk alleles with PSA levels among men without a diagnosis of prostate cancer. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19131636&form=6&db=m Multimarker circulating DNA assay for assessing blood of prostate cancer patients. causal interaction,diagnostic usage,unassigned 2,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19138385&form=6&db=m Factors prompting PSA-testing of asymptomatic men in a country with no guidelines: a national survey of general practitioners. causal interaction,diagnostic usage,unassigned 4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19150091&form=6&db=m Prognostic significance of circulating tumor cells in patients with hormone refractory prostate cancer. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19150546&form=6&db=m The number of cores positive for high grade prostatic intraepithelial neoplasia on initial biopsy is associated with prostate cancer on second biopsy. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19150547&form=6&db=m Testosterone therapy in men with prostate cancer: scientific and ethical considerations. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,1,4,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19152248&form=6&db=m Clinical utility of the interaction between lectin and serum prostate specific antigen in prostate cancer. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19157429&form=6&db=m Re: It's time to abandon an upper limit of normal for prostate specific antigen: assessing the risk of prostate cancer: I. M. Thompson, D. P. Ankerst, R. Etzioni and T. Wang J Urol 2008; 180: 1219-1222. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19157433&form=6&db=m Increased urokinase-type plasminogen activator receptor and epidermal growth factor receptor in serum of patients with prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19157448&form=6&db=m Predicting prostate cancer biochemical recurrence using a panel of serum proteomic biomarkers. causal interaction,diagnostic usage,therapeutic application,unassigned 1,2,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19167733&form=6&db=m A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablation. diagnostic usage,ongoing research,therapeutic application,unassigned 3,4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19189884&form=6&db=m [PSA kinetics after total prostatectomy] diagnostic usage,therapeutic application,unassigned 4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19193497&form=6&db=m Prostate cancer diagnosis: should patients with prostate specific antigen >10ng/mL have stratified prostate biopsy protocols? causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19202079&form=6&db=m Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues. causal interaction,diagnostic usage,unassigned 4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19222612&form=6&db=m Pitfalls of hormonal injection therapy in prostate cancer. diagnostic usage,ongoing research,therapeutic application,unassigned 4,1,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19227203&form=6&db=m [Clinical study of prostate specific antigen failure after radical prostatectomy for prostate cancer: a single center experience] causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,3,4 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19230915&form=6&db=m Phase II trial of neoadjuvant nab-paclitaxel in high risk patients with prostate cancer undergoing radical prostatectomy. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,3,3 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19230923&form=6&db=m Sociodemographic predictors of prostate cancer risk category at diagnosis: unique patterns of significant and insignificant disease. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19233404&form=6&db=m DNA methylation of the PITX2 gene promoter region is a strong independent prognostic marker of biochemical recurrence in patients with prostate cancer after radical prostatectomy. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19237173&form=6&db=m Bcl2 -938C/A polymorphism carries increased risk of biochemical recurrence after radical prostatectomy. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,2,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19241832&form=6&db=m [The density of prostate specific antigen of the transition zone as an early predictor of prostate cancer] causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19242073&form=6&db=m Detection rate of prostate cancer using prostate specific antigen in patients presenting with lower urinary tract symptoms: a retrospective study. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19246059&form=6&db=m Prostate specific antigen testing among the elderly--when to stop? causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,4 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19257827&form=6&db=m Activin A Enhances Prostate Cancer Cell Migration via Activation of Androgen Receptor and Is Overexpressed in Metastatic Prostate Cancer. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19286200&form=6&db=m Does transrectal ultrasound probe configuration really matter? End fire versus side fire probe prostate cancer detection rates. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19286210&form=6&db=m Association of nonsteroidal anti-inflammatory drugs, prostate specific antigen and prostate volume. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19293771&form=6&db=m PET-CT for treatment planning in prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 3,1,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19303084&form=6&db=m Re: The performance of prostate specific antigen for predicting prostate cancer is maintained after a prior negative prostate biopsy I. M. Thompson, C. M. Tangen, D. P. Ankerst, C. Chi, M. S. Lucia, P. Goodman, H. Parnes and C. A. Coltman, Jr. J Urol 2008; 180: 544-547. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19348246&form=6&db=m [Application of angiotensin II receptor blocker in prostate cancer] causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19355969&form=6&db=m A fresh prospect of extracellular matrix hydrolytic enzymes and their substrates. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19357018&form=6&db=m [Prognosis and predictive factors in prostate cancer.] diagnostic usage,ongoing research,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19364428&form=6&db=m Complexed prostate specific antigen: better test in the diagnosis of prostate cancer for the clinically relevant 2.5-4 ng/ml total PSA range. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19371879&form=6&db=m Characteristics of prostate cancers detected at prostate specific antigen levels less than 2.5 ng/ml. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19371894&form=6&db=m Prostate specific antigen half-time and prostate specific antigen doubling time as predictors of response to androgen deprivation therapy for metastatic prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,4 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19371911&form=6&db=m A duplex quantitative polymerase chain reaction assay based on quantification of alpha-methylacyl-CoA racemase transcripts and prostate cancer antigen 3 in urine sediments improved diagnostic accuracy for prostate cancer. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19375907&form=6&db=m Do the risk factors of age, family history of prostate cancer or a higher prostate specific antigen level raise anxiety at prostate biopsy? causal interaction,diagnostic usage,ongoing research,unassigned 3,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19415690&form=6&db=m Ubiquitous mitochondrial creatine kinase is overexpressed in the conditioned medium and the extract of LNCaP lineaged androgen independent cell lines and facilitates prostate cancer progression. causal interaction,diagnostic usage,ongoing research,unassigned 2,3,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19419125&form=6&db=m Values of prostate specific antigen in patients with operable prostate carcinoma. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,4 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19450837&form=6&db=m Effect of body mass index and waist circumference on prostate specific antigen and prostate volume in a generally healthy Korean population. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19450841&form=6&db=m Single nucleotide polymorphisms and the likelihood of prostate cancer at a given prostate specific antigen level. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19462822&form=6&db=m [The changes of prostate specific antigen (PSA) after treatment with alpha 1-adrenergic receptor antagonists in men with 4.0-9.9 ng/ml PSA level--a study for comparison of benign prostatic hyperplasia/lower urinary tract symptom (BPH/LUTS) and prostate cancer] causal interaction,diagnostic usage,ongoing research,therapeutic application 1,2,1,3 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19475654&form=6&db=m Regulation of PSA secretion and survival signaling by calcium-independent phopholipase A(2)beta in prostate cancer cells. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19483644&form=6&db=m Vaccination with agonist peptide PSA: 154-163 (155L) derived from prostate specific antigen induced CD8 T-cell response to the native peptide PSA: 154-163 but failed to induce the reactivity against tumor targets expressing PSA: a phase 2 study in patients with recurrent prostate cancer. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19486654&form=6&db=m Psychological Distress and Prostate Specific Antigen Levels in Men with and without Prostate Cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19507229&form=6&db=m Biomarkers for prostate cancer. diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19522868&form=6&db=m The effect of obesity and lower serum prostate-specific antigen levels on prostate-cancer screening results in American men. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19529978&form=6&db=m (18)F-choline PET/CT imaging of RECIST measurable lesions in hormone refractory prostate cancer. diagnostic usage,ongoing research,unassigned 2,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19549125&form=6&db=m Population-based prostate-specific antigen testing in the UK leads to a stage migration of prostate cancer. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19549601&form=6&db=m Substrate-guided design of a potent and selective kallikrein-related peptidase inhibitor for kallikrein 4. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19559380&form=6&db=m [Results and participation factors to the European Randomized study of Screening for Prostate Cancer (ERSPC) with Prostate Specific Antigen: French departments of Tarn and Hérault] diagnostic usage,therapeutic application,unassigned 2,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19561378&form=6&db=m Evaluation of plasma interleukin-8 concentration in patients with prostate cancer and benign prostate hyperplasia. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19562407&form=6&db=m Trends in prostate specific antigen testing in Ireland: lessons from a country without guidelines. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19615204&form=6&db=m [Mass screening prostate cancer and clinical comparison] diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19616226&form=6&db=m Primary cryoablation nadir prostate specific antigen and biochemical failure. causal interaction,diagnostic usage,ongoing research,unassigned 2,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19656762&form=6&db=m [PSA kinetics after radiotherapy] diagnostic usage,therapeutic application,unassigned 4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19662653&form=6&db=m The helix-loop-helix Id-1 inhibits PSA expression in prostate cancer cells. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19675860&form=6&db=m Prostate cancer incidence, mortality, total and free prostate specific antigen. diagnostic usage,ongoing research,unassigned 2,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19683287&form=6&db=m Hyaluronic acid and HYAL-1 in prostate biopsy specimens: predictors of biochemical recurrence. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,3,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19683310&form=6&db=m Extensive biopsies and transurethral prostate resection in men with previous negative biopsies and high or increasing prostate specific antigen. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19683745&form=6&db=m Electrical properties of prostatic tissues: I. Single frequency admittivity properties. diagnostic usage,ongoing research,therapeutic application,unassigned 4,1,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19688071&form=6&db=m Cancer of unknown primary finally revealed to be a metastatic prostate cancer: a case report. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19717042&form=6&db=m Prospective evaluation of prostate cancer risk in candidates for inguinal hernia repair. diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19751256&form=6&db=m Serum testosterone is associated with aggressive prostate cancer in older men: results from the Baltimore Longitudinal Study of Aging. diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19758616&form=6&db=m Men older than 70 years have higher risk prostate cancer and poorer survival in the early and late prostate specific antigen eras. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19758625&form=6&db=m A framework for the identification of men at increased risk for prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19759844&form=6&db=m Discovery and validation of urinary biomarkers for prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19778969&form=6&db=m Prostate specific antigen for early detection of prostate cancer: longitudinal study. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,2,4 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19778970&form=6&db=m Prostate specific antigen for detecting early prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19789132&form=6&db=m [Diagnosis and treatment of prostatitis: a case report] diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19795605&form=6&db=m Role of complexed PSA in the early detection of prostate cancer. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19795608&form=6&db=m Biochemical relapse after primary treatment for prostate cancer: studies on natural history and therapeutic considerations. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19823725&form=6&db=m Detection of prostate specific antigen with nanomechanical resonators. diagnostic usage,ongoing research,unassigned 3,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19836788&form=6&db=m Validation in a Multiple Urology Practice Cohort of the Prostate Cancer Prevention Trial Calculator for Predicting Prostate Cancer Detection. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19836806&form=6&db=m Should Prostate Specific Antigen be Adjusted for Body Mass Index? Data From the Baltimore Longitudinal Study of Aging. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19841273&form=6&db=m Nanoparticle-based bio-barcode assay redefines "undetectable" PSA and biochemical recurrence after radical prostatectomy. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19886716&form=6&db=m Current perspectives on the Gleason grading of prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19913246&form=6&db=m Validation of the partin nomogram for prostate cancer in a national sample. diagnostic usage,ongoing research,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19913252&form=6&db=m Men presenting for radical prostatectomy on preoperative statin therapy have reduced serum prostate specific antigen. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19913257&form=6&db=m Prostate specific antigen density to predict prostate cancer upgrading in a contemporary radical prostatectomy series: a single center experience. causal interaction,diagnostic usage,therapeutic application,unassigned 1,3,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19913814&form=6&db=m Can prostate specific antigen velocity thresholds decrease insignificant prostate cancer detection? causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19930176&form=6&db=m The Prostate Cancer gene 3 assay: indications for use in clinical practice. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19936334&form=6&db=m The prognostic value of serum chromogranin A and prostate specific antigen in prostate cancer patients for progression to the hormone resistance state. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19945309&form=6&db=m GREB1 tissue expression is associated with organ-confined prostate cancer. diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19950034&form=6&db=m Elevation of the serum total and free prostate specific antigen levels after stent implantation in patients with coronary artery disease. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19997837&form=6&db=m Prostate cancer in senior adults: over- or undertreated? causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20006859&form=6&db=m Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen. causal interaction,diagnostic usage,ongoing research,unassigned 3,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20006878&form=6&db=m An update of the Gleason grading system. diagnostic usage,therapeutic application,unassigned 4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20011088&form=6&db=m Does prostate specific antigen density correlates with aggressiveness of the prostate cancer? causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,4,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20021870&form=6&db=m [Clinical value of prostate specific antigen screening in early detection of prostate cancer] causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,3 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20022032&form=6&db=m Adaptive spaced education improves learning efficiency: a randomized controlled trial. unassigned - 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20036908&form=6&db=m Molecular markers for prostatic cancer. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20047017&form=6&db=m Preclinical evaluation of a monoclonal antibody (3C6) specific for prostate-specific membrane antigen. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,3,4 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20060331&form=6&db=m Prostate-specific antigen: An evolving role in diagnosis, monitoring, and treatment evaluation in prostate cancer. diagnostic usage,therapeutic application,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20067463&form=6&db=m Expression analysis and study of the KLK15 mRNA splice variants in prostate cancer and benign prostatic hyperplasia. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,4,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20078569&form=6&db=m A whole of population-based series of radical prostatectomy in Victoria, 1995 to 2000. diagnostic usage,therapeutic application,unassigned 3,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20083275&form=6&db=m Initial prostate specific antigen 1.5 ng/ml or greater in men 50 years old or younger predicts higher prostate cancer risk. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,1,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20088233&form=6&db=m A case study: ductal adenocarcinoma of the prostate. causal interaction,diagnostic usage,unassigned 3,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20089269&form=6&db=m Prostate specific antigen decrease and prostate cancer diagnosis: antibiotic versus placebo prospective randomized clinical trial. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,2,4 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20137723&form=6&db=m [The survival analysis of the advanced metastatic castration-resistant prostate cancer.] causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20155621&form=6&db=m Cancer chemoprevention by pomegranate: laboratory and clinical evidence. diagnostic usage,therapeutic application,unassigned 2,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20158074&form=6&db=m [Usefulness of screening for prostate cancer with prostate specific antigen (PSA) in the medical checkup ("human dock") at Onomichi Municipal Hospital: clinical significance of the cases diagnosed as prostate cancer] causal interaction,diagnostic usage,therapeutic application,unassigned 2,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20171670&form=6&db=m [-2]Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,3 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20204290&form=6&db=m Co-expression of the androgen receptor and the transcription factor ZNF652 is related to prostate cancer outcome. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,2,4,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20215859&form=6&db=m Assessing prostate cancer growth with mRNA of spermine metabolic enzymes. causal interaction,diagnostic usage,unassigned 3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20221315&form=6&db=m Malignant Ascites Associated with Carcinoma of the Prostate. causal interaction,diagnostic usage,therapeutic application,unassigned 2,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20223022&form=6&db=m The updated Swedish family-cancer database used to assess familial risks of prostate cancer during rapidly increasing incidence. diagnostic usage,ongoing research,unassigned 2,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20233430&form=6&db=m Molecular sampling of prostate cancer: a dilemma for predicting disease progression. diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20299064&form=6&db=m Do anxiety and distress increase during active surveillance for low risk prostate cancer? diagnostic usage,unassigned 2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20299498&form=6&db=m Trends of the Primary Therapy for Patients with Prostate Cancer in Nara Uro-oncological Research Group (NUORG): a Comparison Between the CaPSURE Data and the NUORG Data. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20300365&form=6&db=m Finasteride-its impact on sexual function and prostate cancer. causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20303104&form=6&db=m Preoperative prostate specific antigen doubling time is not a useful predictor of biochemical progression after radical prostatectomy. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,4 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20303520&form=6&db=m The EGFR polymorphism rs884419 is associated with freedom from recurrence in patients with resected prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20303538&form=6&db=m Clinical implications of TMPRSS2-ERG gene fusion expression in patients with prostate cancer treated with radical prostatectomy. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20336781&form=6&db=m Impact of recent screening on predicting the outcome of prostate cancer biopsy in men with elevated prostate-specific antigen: data from the European Randomized Study of Prostate Cancer Screening in Gothenburg, Sweden. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,3,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20367442&form=6&db=m Prostate Cancer: An Evolving Paradigm. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20369045&form=6&db=m Salvage Radiotherapy for Patients with PSA Relapse Following Radical Prostatectomy: Issues and Challenges. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20399465&form=6&db=m Association of Body Mass Index With Prostate Cancer Biochemical Failure. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20400522&form=6&db=m A Four-Kallikrein Panel Predicts Prostate Cancer in Men with Recent Screening: Data from the European Randomized Study of Prostate Cancer Screening, Rotterdam. diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20424135&form=6&db=m Blood biomarker levels to aid discovery of cancer-related single-nucleotide polymorphisms: kallikreins and prostate cancer. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20432434&form=6&db=m The chromatin remodeling factor SRCAP modulates expression of prostate specific antigen and cellular proliferation in prostate cancer cells. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,3,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20473923&form=6&db=m KLK15 is a prognostic marker for progression-free survival in patients with radical prostatectomy. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,4 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20478578&form=6&db=m Minimal impact of clinical stage on prostate cancer prognosis among contemporary patients with clinically localized disease. diagnostic usage,therapeutic application,unassigned 2,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20478579&form=6&db=m Multicenter clinical validation of PITX2 methylation as a prostate specific antigen recurrence predictor in patients with post-radical prostatectomy prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20478589&form=6&db=m Prostate cancer death of men treated with initial active surveillance: clinical and biochemical characteristics. diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20482314&form=6&db=m Tissue kallikrein promotes prostate cancer cell migration and invasion via a protease-activated receptor-1-dependent signaling pathway. unassigned - 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20506261&form=6&db=m Associations of aspirin, nonsteroidal anti-inflammatory drug and paracetamol use with PSA-detected prostate cancer: Findings from a large, population-based, case-control study (the ProtecT study). diagnostic usage,ongoing research,therapeutic application,unassigned 3,3,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20522448&form=6&db=m Dietary administration of mushroom mycelium extracts in patients with early stage prostate cancers managed expectantly: a phase II study. causal interaction,diagnostic usage,therapeutic application,unassigned 2,1,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20524513&form=6&db=m Clinical and imaging tools in the early diagnosis of prostate cancer, a review. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20571134&form=6&db=m Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20620404&form=6&db=m Prostate specific antigen mass ratio potential as a prostate cancer screening tool. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20620410&form=6&db=m Stage IV prostate cancer: survival differences in clinical T4, nodal and metastatic disease. causal interaction,diagnostic usage,therapeutic application,unassigned 2,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20643432&form=6&db=m Value of real-time elastography targeted biopsy for prostate cancer detection in men with prostate specific antigen 1.25 ng/ml or greater and 4.00 ng/ml or less. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,2,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20643434&form=6&db=m Prostate specific antigen velocity does not aid prostate cancer detection in men with prior negative biopsy. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20643445&form=6&db=m [11C]choline positron emission tomography/computerized tomography to restage prostate cancer cases with biochemical failure after radical prostatectomy and no disease evidence on conventional imaging. causal interaction,diagnostic usage,unassigned 4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20643452&form=6&db=m Lifelong yearly prostate specific antigen surveillance is not necessary for low risk prostate cancer treated with radical prostatectomy. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,3,3 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20665620&form=6&db=m Prostate specific antigen reduction following statin therapy: Mechanism of action and review of the literature. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20684321&form=6&db=m [Total PSA, PSA density and biopsy Gleason score in predicting the pathologic stage of prostate cancer] diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20693148&form=6&db=m Supporting informed decision making for prostate specific antigen (PSA) testing on the web: an online randomized controlled trial. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20705192&form=6&db=m Prostate-specific antigen testing and prostate cancer screening. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20708609&form=6&db=m A sensitive assay to measure biomarker glycosylation demonstrates increased fucosylation of prostate specific antigen (PSA) in patients with prostate cancer compared with benign prostatic hyperplasia. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20715498&form=6&db=m [Mass screening for prostate cancer at Ikeda City in Osaka Prefecture--results of screening with PSA alone between 2003 and 2007] causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20721252&form=6&db=m [Changes in clinical features of inpatients with prostate cancer in the past 11 years]. diagnostic usage,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20723930&form=6&db=m Gene based prediction of clinically localized prostate cancer progression after radical prostatectomy. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20800404&form=6&db=m Choline PET/CT for prostate cancer: Main clinical applications. diagnostic usage,therapeutic application,unassigned 1,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20800514&form=6&db=m Prostate specific antigen screening for prostate cancer: Knowledge of, attitudes towards, and utilization among primary care physicians. diagnostic usage,therapeutic application,unassigned 4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20825957&form=6&db=m [Quadrature coils for magnetic resonance spectroscopy in the detection of prostate cancer: Single voxel acquisition does not improve the diagnostic accuracy of multivoxel images.] diagnostic usage,ongoing research,unassigned 2,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20836318&form=6&db=m Knowledge of prostate cancer screening among native African urban population in Nigeria. diagnostic usage,unassigned 2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20843935&form=6&db=m Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,4,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20843937&form=6&db=m Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials. diagnostic usage,unassigned 2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20846422&form=6&db=m Normalization of prostate specific antigen in patients treated with intensity modulated radiotherapy for clinically localized prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,1,4 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20846681&form=6&db=m Comparing prostate specific antigen triggers for intervention in men with stable prostate cancer on active surveillance. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,3,4 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20846692&form=6&db=m Multifocal high grade prostatic intraepithelial neoplasia is a risk factor for subsequent prostate cancer. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20850153&form=6&db=m PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: validation in the placebo arm of the dutasteride REDUCE trial. diagnostic usage,therapeutic application,unassigned 2,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20854069&form=6&db=m Immunohistochemistry for p16, but not Rb or p21, is an independent predictor of prognosis in conservatively treated, clinically localised prostate cancer. causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20860009&form=6&db=m Prostate cancer risk alleles significantly improve disease detection and are associated with aggressive features in patients with a "normal" prostate specific antigen and digital rectal examination. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20864135&form=6&db=m Re: prostate specific antigen decrease and prostate cancer diagnosis: antibiotic versus placebo prospective randomized clinical trial: R. M. Stopiglia, U. Ferreira, M. M. Silva, W. E. Matheus, f. Denardi and L. O. Reis J Urol 2010; 183: 940-945. diagnostic usage,therapeutic application,unassigned 2,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20870581&form=6&db=m [Contribution of PSA and its density in the diagnosis and tracking of the prostate cancer]. causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20877758&form=6&db=m Prostate specific antigen - useful screening tool or potential liability? diagnostic usage,therapeutic application,unassigned 2,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20933446&form=6&db=m Prostate biopsy in patients with long-term use of indwelling bladder catheter: What is the rationale? diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20940693&form=6&db=m Personalized approach to prostate cancer prognosis. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20941824&form=6&db=m Comparison of methods for prediction of prostate cancer in Turkish men with PSA levels of 0-10 ng/mL. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,3,3 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20956725&form=6&db=m Mortality reductions produced by sustained prostate cancer screening have been underestimated. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20961582&form=6&db=m Establishment of a Urological Surgery Quality Collaborative. causal interaction,diagnostic usage,therapeutic application,unassigned 2,2,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20971627&form=6&db=m A miniature chip for protein detection based on magnetic relaxation switches. diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20976066&form=6&db=m Associations between an obesity related genetic variant (FTO rs9939609) and prostate cancer risk. causal interaction,diagnostic usage,ongoing research,unassigned 2,1,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20980650&form=6&db=m Rye Whole Grain and Bran Intake Compared with Refined Wheat Decreases Urinary C-Peptide, Plasma Insulin, and Prostate Specific Antigen in Men with Prostate Cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,2,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21031436&form=6&db=m Androgen-induced PSA expression requires not only activation of AR but also endogenous IGF-I or IGF-I/PI3K/Akt signaling in human prostate cancer epithelial cells. causal interaction,diagnostic usage,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21047591&form=6&db=m Interval cancers in the Antwerp European randomised study of screening for prostate cancer study, using a 6year screening interval. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21047592&form=6&db=m Latest results from the UK trials evaluating prostate cancer screening and treatment: The CAP and ProtecT studies. diagnostic usage,ongoing research,unassigned 3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21047593&form=6&db=m Lead-time in the European Randomised Study of Screening for Prostate Cancer. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21074193&form=6&db=m Prospective evaluation of operating characteristics of prostate cancer detection biomarkers. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21074214&form=6&db=m The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy: results from the REDUCE study. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,3,3 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21075385&form=6&db=m Inhibition of aberrant androgen receptor induction of prostate specific antigen gene expression, cell proliferation and tumor growth by 17?-estradiol in prostate cancer. causal interaction,ongoing research,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21093148&form=6&db=m PCA3: from basic molecular science to the clinical lab. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21132033&form=6&db=m Prognostic Significance of PSA, Gleason Score, Bone Metastases in Patients with Metastatic Prostate Cancer Under Palliative Androgen Deprivation Treatment. diagnostic usage,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21132070&form=6&db=m The Design and Evaluation of a Computerized and Physical Simulator for Training Clinical Prostate Exams. causal interaction,diagnostic usage,therapeutic application,unassigned 2,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21155038&form=6&db=m Nomogram to predict insignificant prostate cancer at radical prostatectomy in Korean men: a multi-center study. causal interaction,diagnostic usage,unassigned 2,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21156999&form=6&db=m The application of the RT-PCR method for the staging of the prostate cancer progression. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21163937&form=6&db=m Cost utility of prostate cancer chemoprevention with dutasteride in men with an elevated prostate specific antigen. causal interaction,diagnostic usage,unassigned 3,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21167519&form=6&db=m The prostate cancer risk calculator from the Prostate Cancer Prevention Trial underestimates the risk of high grade cancer in contemporary referral patients. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21167525&form=6&db=m Risk stratification and validation of prostate specific antigen density as independent predictor of progression in men with low risk prostate cancer during active surveillance. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21167529&form=6&db=m Role of prostate specific antigen and immediate confirmatory biopsy in predicting progression during active surveillance for low risk prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,2,1,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21190239&form=6&db=m Endothelial progenitor cells and circulating endothelial cells in early prostate cancer: A comparison with plasma vascular markers. causal interaction,diagnostic usage,ongoing research,unassigned 2,2,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21209527&form=6&db=m Correlation of serum free prostate-specific antigen level with histological findings in patients with prostatic disease. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21224094&form=6&db=m Evidence for the existence of an organ specific, androgen-independent pathway of progression in patients with metastatic prostate cancer. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21224096&form=6&db=m Radical prostatectomy in men less than 50 years old. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,3,3 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21224097&form=6&db=m Relative performance characteristics of prostate specific antigen and prostatic specific antigen density for the diagnosis of carcinoma of the prostate. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,3,4 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21224123&form=6&db=m Simultaneous detection of circulating prostate specific antigen (PSA)-expressing and prostate specific membrane antigen (PSM)-expressing cells by a multiplex reverse transcriptase polymerase chain reaction (RT-PCR) assay. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21224133&form=6&db=m Not all patients pursue prostate biopsy after abnormal prostate specific antigen results. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21227143&form=6&db=m Detection of prostate specific antigen messenger RNA from pelvic lymph node in prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,3,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21227198&form=6&db=m The utility of free to total PSA ratio for detecting prostate cancer in Japanese men with total PSA between 2.1 and 10 ng/ml. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21234867&form=6&db=m [Real-time elastography in the diagnosis of prostate cancer: personal experience]. diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21237611&form=6&db=m A community-based intervention to promote informed decision making for prostate cancer screening among Hispanic American men changed knowledge and role preferences: A cluster RCT. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21238998&form=6&db=m Evaluation of prostate specific antigen acceleration for prostate cancer diagnosis. diagnostic usage,ongoing research,therapeutic application,unassigned 4,1,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21239017&form=6&db=m Efficacy of a second line luteinizing hormone-releasing hormone agonist after advanced prostate cancer biochemical recurrence. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21239021&form=6&db=m Cost-effectiveness of prostate specific antigen screening in the United States: extrapolating from the European study of screening for prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21245843&form=6&db=m Tumour-initiating stem-like cells in human prostate cancer exhibit increased NF-?B signalling. diagnostic usage,ongoing research,therapeutic application,unassigned 1,3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21253471&form=6&db=m Long-term follow-up of HLA-A2+ patients with high-risk, hormone-sensitive prostate cancer vaccinated with the prostate specific antigen peptide homologue (PSA146-154). diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21256080&form=6&db=m Development and validation of health beliefs model scale for prostate cancer screenings (HBM-PCS): Evidence from exploratory and confirmatory factor analyses. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21272915&form=6&db=m Reversed association between levels of prostate specific antigen and levels of blood cadmium and urinary cadmium. diagnostic usage,unassigned 1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21300478&form=6&db=m Predicting Pelvic Lymph Node Involvement in Current-Era Prostate Cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21305738&form=6&db=m Transrectal sonography in prostate cancer detection--our 25 years experience of implementation. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21331774&form=6&db=m Stearoyl CoA desaturase (SCD) facilitates proliferation of prostate cancer cells through enhancement of androgen receptor transactivation. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,1,4,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21414880&form=6&db=m Re: prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study. diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21419438&form=6&db=m The Relationship Between Prostate Specific Antigen Change and Biopsy Progression in Patients With Prostate Cancer on Active Surveillance. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21419439&form=6&db=m A Multicenter Study of [-2]Pro-Prostate Specific Antigen Combined With Prostate Specific Antigen and Free Prostate Specific Antigen for Prostate Cancer Detection in the 2.0 to 10.0 ng/ml Prostate Specific Antigen Range. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,4 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21422628&form=6&db=m Utility of free prostate specific antigen serum level and its related parameters in the diagnosis of prostate cancer. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21446007&form=6&db=m Enzymatic activity of free-prostate-specific antigen (f-PSA) is not required for some of its physiological activities. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21446134&form=6&db=m [Influence of hormonal therapy on the level of prostate specific antigen in patients with advanced prostatic cancer]. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21472323&form=6&db=m Genetic variants in the distal enhancer region of the PSA gene and their implication in the occurrence of advanced prostate cancer. diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21504557&form=6&db=m A novel multiplex assay combining autoantibodies plus PSA has potential implications for classification of prostate cancer from non-malignant cases. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21510865&form=6&db=m Applying strategies from libertarian paternalism to decision making for prostate specific antigen (PSA) screening. diagnostic usage,therapeutic application,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21538426&form=6&db=m Characteristics of baseline PSA and PSA velocity in young men without prostate cancer: Racial differences. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21553390&form=6&db=m [Alternative tests to PSA for prostate cancer diagnosis.] causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21557269&form=6&db=m Endothelial progenitor cells and circulating endothelial cells in early prostate cancer: a comparison with plasma vascular markers. causal interaction,diagnostic usage,ongoing research,unassigned 2,2,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21557839&form=6&db=m Correlation of hepatitis C and prostate cancer, inverse correlation of basal cell hyperplasia or prostatitis and epidemic syphilis of unknown duration. diagnostic usage,ongoing research,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21604935&form=6&db=m The Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial: the prostate cancer screening results in context. diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21604943&form=6&db=m Tumor markers in prostate cancer I: blood-based markers. diagnostic usage,therapeutic application,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21604952&form=6&db=m When is active surveillance the appropriate treatment for prostate cancer? causal interaction,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21624609&form=6&db=m Lovastatin causes diminished PSA secretion by inhibiting AR expression and function in LNCaP prostate cancer cells. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,2,4,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21630551&form=6&db=m The analysis of some factors that influence on serum PSA level in localized prostate cancer patients: mathematical model. causal interaction,diagnostic usage,ongoing research,unassigned 3,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21664008&form=6&db=m Bone scan findings in a North African ethnic group and relation to PSA level and Gleason score of the biopsy. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21681779&form=6&db=m GPRC6A regulates prostate cancer progression. diagnostic usage,ongoing research,unassigned 1,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21717898&form=6&db=m Screening for prostate cancer with PSA testing: current status and future directions. diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21723425&form=6&db=m Bioinformatic strategies for unambiguous identification of prostate specific antigen in clinical samples. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21736692&form=6&db=m Effect of intra-observer variation in prostate volume measurement on prostate-specific antigen density calculations among prostate cancer active surveillance participants. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,2,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21753713&form=6&db=m Prostate specific antigen testing for the diagnosis of prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21756276&form=6&db=m Colour Doppler and microbubble contrast agent ultrasonography do not improve cancer detection rate in transrectal systematic prostate biopsy sampling. diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21761013&form=6&db=m Is bone scintigraphy necessary in initial staging of prostate cancer patients? diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21814469&form=6&db=m Survival of prostate cancer patients in central and northern Denmark, 1998-2009. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21816640&form=6&db=m A non-comparative randomized phase II study of 2 doses of ATN-224, a copper/zinc superoxide dismutase inhibitor, in patients with biochemically recurrent hormone-naïve prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,3,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21849186&form=6&db=m Dutasteride Reduces Prostatitis Symptoms Compared With Placebo in Men Enrolled in the REDUCE Study. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,3,4 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21855947&form=6&db=m High Incidence of Predominant Gleason Pattern 4 Localized Prostate Cancer is Associated With Low Serum Testosterone. diagnostic usage,therapeutic application,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21875267&form=6&db=m Factors affecting prostate cancer screening behaviour in a discrete population of doctors at the university hospital of the west indies, Jamaica. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21907706&form=6&db=m A novel steroidal antiandrogen targeting wild type and mutant androgen receptors. causal interaction,diagnostic usage,ongoing research,unassigned 2,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21920156&form=6&db=m Should baseline PSA testing be performed in men aged 40 to detect those aged 50 or less who are at risk of aggressive prostate cancer? causal interaction,diagnostic usage,therapeutic application,unassigned 3,2,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21934206&form=6&db=m Hepsin immunohistochemical expression in prostate cancer in relation to Gleason's grade and serum prostate specific antigen. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,3,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21944123&form=6&db=m Predicting prostate biopsy result in men with prostate specific antigen 2.0 to 10.0 ng/ml using an investigational prostate cancer methylation assay. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,4 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21949470&form=6&db=m Prostate size correlates with fasting blood glucose in non-diabetic benign prostatic hyperplasia patients with normal testosterone levels. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21955852&form=6&db=m Focal therapy for prostate cancer: opportunities and uncertainties. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21975078&form=6&db=m Detection and verification of glycosylation patterns of glycoproteins from clinical specimens using lectin microarrays and lectin-based immunosorbent assays. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21977157&form=6&db=m Routine screening by prostate specific antigen for prostate cancer seems unreasonable. causal interaction,diagnostic usage,therapeutic application,unassigned 2,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22008917&form=6&db=m Increased peripheral CD4+CD25high Treg in prostate cancer patients is correlated with PSA. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22018148&form=6&db=m Screening for prostate cancer: the current evidence and guidelines controversy. causal interaction,diagnostic usage,therapeutic application,unassigned 1,2,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22025344&form=6&db=m Knockdown of scavenger receptor class B Type I reduces prostate specific antigen secretion and viability of prostate cancer cells. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,2,4,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22048240&form=6&db=m NKX3.1 haploinsufficiency is prognostic for prostate cancer relapse following surgery or image-guided radiotherapy. diagnostic usage,therapeutic application,unassigned 4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22052759&form=6&db=m Personalized approach to prostate cancer prognosis. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22055461&form=6&db=m Histone H2A.Z prepares the prostate specific antigen (PSA) gene for androgen receptor-mediated transcription and is upregulated in a model of prostate cancer progression. diagnostic usage,ongoing research,therapeutic application,unassigned 2,2,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22057600&form=6&db=m Significance of serum total prostate specific antigen and digital rectal examination in the diagnosis of prostate cancer. diagnostic usage,ongoing research,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22077934&form=6&db=m Cost-effectiveness of Prostate Health Index for prostate cancer detection. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22081781&form=6&db=m Risk Prediction for Prostate Cancer Recurrence Through Regularized Estimation with Simultaneous Adjustment for Nonlinear Clinical Effects. diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22088695&form=6&db=m Re: prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study. diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22089607&form=6&db=m A pilot study on the use of serum glyoxalase as a supplemental biomarker to predict malignant cases of the prostate in the PSA range of 4-20 ng/ml. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22103356&form=6&db=m Involvment of IL-1 beta Mediated NF-Kappa B Signalling Payhways to Downregulate Prostate Specific Antigen And Cell Proliferation in LNCaP Prostate Cancer Cells. causal interaction,diagnostic usage,ongoing research,unassigned 1,2,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22117828&form=6&db=m High grade intraepithelial neoplasia of prostate is associated with values of prostate specific antigen related parameters intermediate between prostate cancer and normal levels. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22126493&form=6&db=m Metastasis on Bone Scan With Low Prostate Specific Antigen (? 20 ng/ml) and Gleason's Score (<8) in Newly Diagnosed Pakistani Males with Prostate Cancer: Should We Follow Western Guidelines? diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22126577&form=6&db=m Diagnostic and prognostic significance of prostate specific antigen and serum interleukin 18 and 10 in patients with locally advanced prostate cancer: a prospective study. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22127918&form=6&db=m Prospects in radionuclide imaging of prostate cancer. diagnostic usage,therapeutic application,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22132073&form=6&db=m Association between Prostinogen (KLK15) genetic variants and prostate cancer risk and aggressiveness in Australia and a meta-analysis of GWAS data. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22142521&form=6&db=m Preoperative prostate specific antigen and prostate volume are significant predictors of seminal vesicle invasion in patients with prostate cancer. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22146597&form=6&db=m Autoantibody signatures as biomarkers to distinguish prostate cancer from benign prostatic hyperplasia in patients with increased serum prostate specific antigen. causal interaction,diagnostic usage,ongoing research,unassigned 3,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22174166&form=6&db=m Assessment of atorvastatin effectiveness on serum PSA level in hypercholesterolemic males. diagnostic usage,therapeutic application,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22188439&form=6&db=m A Novel Lily-of-the-Valley Fragrance Contrast Agent for Magnetic Resonance and Fluorescence Imaging of Prostate Cancer Cells. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22189217&form=6&db=m [Pros and cons of active surveillance for low-risk prostate cancer]. causal interaction,diagnostic usage,therapeutic application,unassigned 3,2,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22198258&form=6&db=m Prostate cancer screening. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22228894&form=6&db=m Diagnostic performance of malignant prostatic cells detection in blood for early detection of prostate cancer: comparison to prostatic biopsy. diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22235671&form=6&db=m [Transrectal ultrasound-guided systematic 12-core biopsy of the prostate improves prostate cancer detection]. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22241581&form=6&db=m Mn-doped ZnSe d-dots-based ?-methylacyl-CoA racemase probe for human prostate cancer cell imaging. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22245323&form=6&db=m Molecular diagnosis of prostate cancer: PCA3 and TMPRSS2:ERG gene fusion. causal interaction,diagnostic usage,therapeutic application,unassigned 3,2,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22248277&form=6&db=m Evaluation ofalpha-methylacyl-CoA racemase, metallothionein and prostate specific antigen as prostate cancer prognostic markers. causal interaction,diagnostic usage,therapeutic application,unassigned 2,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22292649&form=6&db=m The lady with raised prostate specific antigen: do we need to worry? causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22296369&form=6&db=m Effects of the MTHFR C677T Polymorphism on Prostate Specific Antigen and Prostate Cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,4,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22314462&form=6&db=m Comparative study of total prostate specific antigen and free to total prostate specific antigen ratio in the diagnosis of prostate cancer. diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22318174&form=6&db=m [Biochemical recurrence criteria after radiotherapy (external beam, brachytherapy). Natural history of the disease after radiotherapy]. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22321153&form=6&db=m Tin Oxide Nanosheet Assembly for Hydrophobic/Hydrophilic Coating and Cancer Sensing. diagnostic usage,ongoing research,therapeutic application,unassigned 4,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22335862&form=6&db=m Detection of Prostate Cancer in an Ethnically Diverse, Disadvantaged Population With Multiple Prostate Specific Antigen Measurements Before Biopsy. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22335870&form=6&db=m Survival Among Men With Clinically Localized Prostate Cancer Treated With Radical Prostatectomy or Radiation Therapy in the Prostate Specific Antigen Era. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22336663&form=6&db=m Prostate cancer-specific mortality after definitive radiation therapy: Who dies of disease? diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22403723&form=6&db=m Inverse Relationship between PSA and IL-8 in Prostate Cancer: An Insight into a NF-?B-Mediated Mechanism. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22413117&form=6&db=m Incidental detection and monitoring of spontaneous recovery of sarcoidosis via fluorine-18-fluoroethyl-choline positron emission tomography/computed tomography. diagnostic usage,therapeutic application,unassigned 1,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22437089&form=6&db=m Diagnosis of prostate cancer with needle biopsy: should all cases be biopsied before treatment? diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22455307&form=6&db=m High-throughput quantitative analysis of total N-glycans by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. diagnostic usage,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22474344&form=6&db=m Microfluidic integration for automated targeted proteomic assays. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22482342&form=6&db=m Influence of the prostate volume, prostate specific antigen density and number of biopsy samples on prostate cancer detection. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22496589&form=6&db=m Identification of functionally active, low frequency copy number variants at 15q21.3 and 12q21.31 associated with prostate cancer risk. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,2,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22498212&form=6&db=m Posttreatment prostate specific antigen nadir predicts prostate cancer specific and all cause mortality. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,4,4 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22498219&form=6&db=m Prostate specific antigen levels and prostate cancer detection rates in patients with end stage renal disease. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22502673&form=6&db=m Elevated level of prostate specific antigen among prostate cancer patients and high prevalence in the Gangetic zone of Bihar, India. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22502733&form=6&db=m Prognostic significance of lymphovascular invasion in radical prostatectomy specimens. diagnostic usage,ongoing research,unassigned 2,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22502982&form=6&db=m Combined (18) F-fluorocholine and (18) F-fluoride positron emission tomography/computed tomography imaging for staging of high-risk prostate cancer. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22517270&form=6&db=m Joint latent class models for longitudinal and time-to-event data: A review. diagnostic usage,therapeutic application,unassigned 3,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22542926&form=6&db=m An aptamer based resonance light scattering assay of prostate specific antigen. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22552350&form=6&db=m Soluble E-cadherin and IL-6 serum levels in patients affected by prostate cancer before and after prostatectomy. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22589648&form=6&db=m A pilot study on percent free prostate specific antigen as an additional tool in prostate cancer screening. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,1,4 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22593492&form=6&db=m Surgical and oncological outcomes in patients with a preoperative PSA value <4 ng/ml undergoing robot-assisted radical prostatectomy. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22593494&form=6&db=m Surgical and oncological outcomes in patients with preoperative PSA >20 ng/ml undergoing robot-assisted radical prostatectomy. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22632629&form=6&db=m Streamlining immunoassays with immiscible filtrations assisted by surface tension. causal interaction,diagnostic usage,unassigned 3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22650049&form=6&db=m [Predicting prostate cancers using a logistic regression model with transrectal ultrasound characteristics, age and Serum PSA]. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22672199&form=6&db=m High-intensity focused ultrasound (HIFU) for definitive treatment of prostate cancer. diagnostic usage,therapeutic application,unassigned 3,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22679342&form=6&db=m Screening for prostate cancer using multivariate mixed-effects models. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,2,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22718641&form=6&db=m Rapid elimination kinetics of free PSA or human kallikrein-related peptidase 2 after initiation of gonadotropin-releasing hormone-antagonist treatment of prostate cancer: potential for rapid monitoring of treatment responses. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22722018&form=6&db=m Glycosylation of prostate specific antigen and its potential diagnostic applications. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22767278&form=6&db=m [Multiple myeloma diagnosed during hormonal therapy for prostate cancer: report of two cases]. causal interaction,diagnostic usage,therapeutic application,unassigned 2,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22799347&form=6&db=m Prostate specific antigen and Gleason score in men with prostate cancer at a private diagnostic radiology centre in Western Jamaica. diagnostic usage,ongoing research,therapeutic application,unassigned 4,1,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22807499&form=6&db=m Cut off value of time to prostate specific antigen nadir is inversely correlated with disease progression in advanced prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,1,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22818135&form=6&db=m Prostate Biopsy in Response to a Change in Nadir Prostate Specific Antigen of 0.4 ng/ml after Treatment with 5?-Reductase Inhibitors Markedly Enhances the Detection Rate of Prostate Cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,3,4 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22819489&form=6&db=m Prostate Specific Antigen Decrease and Prostate Cancer Diagnosis: Recognizing the Fundamental Previous Progresses and Moving Forward. causal interaction,diagnostic usage,therapeutic application,unassigned 1,3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22821767&form=6&db=m Urine TMPRSS2:ERG fusion transcript integrated with PCA3 score, genotyping, and biological features are correlated to the results of prostatic biopsies in men at risk of prostate cancer. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22831945&form=6&db=m Plasma sarcosine does not distinguish early and advanced stages of prostate cancer. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22847068&form=6&db=m Visual Loss from a Pituitary Mass: Collision Tumors of Prostatic Metastasis and Suprasellar Meningioma. causal interaction,diagnostic usage,unassigned 4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22901566&form=6&db=m Effectiveness of the Combined Evaluation of KLK3 Genetics and Free-to-Total Prostate Specific Antigen Ratio for Prostate Cancer Diagnosis. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,3,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22921015&form=6&db=m Improved Overall Survival Trends of Men with Newly Diagnosed M1 Prostate Cancer: A SWOG Phase III Trial Experience (S8494, S8894 and S9346). diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22924305&form=6&db=m Urinary PSA in monitoring of patients with prostate cancer. diagnostic usage,ongoing research,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22930290&form=6&db=m A dedicated clinic for HIV-positive individuals over 50 years of age: a multidisciplinary experience. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22954697&form=6&db=m Salvage radiotherapy for prostate cancer: Finding a way forward using radiobiological modeling. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22958940&form=6&db=m An examination of variations in the uptake of prostate cancer screening within and between the countries of the EU-27. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22960963&form=6&db=m Diagnostic value of lipids, total antioxidants, and trace metals in benign prostate hyperplasia and prostate cancer. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22987618&form=6&db=m Bias correction to secondary trait analysis with case-control design. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22998901&form=6&db=m Diagnostic performance of PCA3 to detect prostate cancer in men with increased prostate specific antigen: a prospective study of 1,962 cases. diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23012811&form=6&db=m [Renin-angiotensin system (RAS) as new molecular therapeutic targets in prostate cancer]. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23017522&form=6&db=m Toward the detection of prostate cancer in urine: a critical analysis. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,1,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23040007&form=6&db=m Transient therapy-related surge in serum tumor biomarkers: Characterizing behavior and postulating its biologic role. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23052263&form=6&db=m [Utility of diffusion-weighted magnetic resonance imaging and apparent diffusion coefficient in detection of prostate cancer and prediction of pathologic Gleason score]. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23070394&form=6&db=m [Long-term disease stabilization by Strontium 89 (89Sr) for castration and docetaxel-resistant prostate cancer : a case report]. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23071574&form=6&db=m Reproducibility, performance, and clinical utility of a genetic risk prediction model for prostate cancer in Japanese. diagnostic usage,therapeutic application,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23074113&form=6&db=m Practice patterns of Korean urologists for screening and managing prostate cancer according to PSA level. diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23083861&form=6&db=m Value of prostate specific antigen density and percent free prostate specific antigen for prostate cancer prognosis. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23088984&form=6&db=m Re: Survival among men with clinically localized prostate cancer treated with radical prostatectomy or radiation therapy in the prostate specific antigen era: A. S. Kibel, J. P. Ciezki, E. A. Klein, C. A. Reddy, J. D. Lubahn, J. Haslag-minoff, J. O. Deasy, J. M. Michalski, D. Kallogjeri, J. F. Piccirillo, D. M. Rabah, C. Yu, M. W. Kattan And A. J. Stephenson; J Urol 2012; 187: 1259-1265. therapeutic application,unassigned 1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23103235&form=6&db=m 25-Year disease-free survival rate after irradiation for prostate cancer calculated with the prostate specific antigen definition of recurrence used for radical prostatectomy. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23105429&form=6&db=m Early detection of prostate cancer: evaluating the diagnostic performance of prostate specific antigen by comparing with histological technique among africans. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23123372&form=6&db=m Operational Characteristics of (11)C-Choline Positron Emission Tomography/Computerized Tomography for Prostate Cancer with Biochemical Recurrence After Initial Treatment. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23164385&form=6&db=m [11C]choline positron emission tomography/computerized tomography for early detection of prostate cancer recurrence in patients with low increasing prostate specific antigen. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23164392&form=6&db=m Clinically significant prostate cancer is rarely missed by ablative procedures of the prostate in men with prostate specific antigen less than 4 ng/ml. causal interaction,diagnostic usage,unassigned 4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23206426&form=6&db=m Prospective Multicenter Evaluation of the Beckman Coulter Prostate Health Index Using WHO Calibration. diagnostic usage,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23246478&form=6&db=m Personalized Prostate Specific Antigen Testing Using Genetic Variants May Reduce Unnecessary Prostate Biopsies. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,3,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23268329&form=6&db=m High grade prostate intraepithelial neoplasia (PIN) is a PSA-independent risk factor for prostate cancer in African American men: Results from a pilot study. causal interaction,diagnostic usage,therapeutic application,unassigned 2,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23379600&form=6&db=m Real-Time Individual Predictions of Prostate Cancer Recurrence Using Joint Models. diagnostic usage,therapeutic application,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23391636&form=6&db=m Association of transcript levels of 10 established or candidate-biomarker gene targets with cancerous versus non-cancerous prostate tissue from radical prostatectomy specimens. diagnostic usage,ongoing research,unassigned 3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23395803&form=6&db=m Testosterone Replacement Therapy in Patients with Prostate Cancer After Radical Prostatectomy. causal interaction,diagnostic usage,therapeutic application,unassigned 3,1,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23448270&form=6&db=m Can one blood draw replace transrectal ultrasonography-estimated prostate volume to predict prostate cancer risk? diagnostic usage,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23459235&form=6&db=m A Cancer-Indicative microRNA Pattern in Normal Prostate Tissue. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23464439&form=6&db=m Estimation of Time Trends of Incidence of Prostate Cancer -an Indian Scenario. causal interaction,diagnostic usage,unassigned 3,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23499583&form=6&db=m Clinical significance of kallikrein-related peptidase (KLK10) mRNA expression in colorectal cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,4 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23506962&form=6&db=m Do racial disparities exist in the use of prostate cancer screening and detection tools in veterans? diagnostic usage,therapeutic application,unassigned 4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23526145&form=6&db=m The relationship between Agent Orange and prostate specific antigen: a comparison of a hotspot and a non-sprayed area in Vietnam. diagnostic usage,ongoing research,unassigned 2,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23536554&form=6&db=m Interleukin-1? promotes skeletal colonization and progression of metastatic prostate cancer cells with neuroendocrine features. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,1,4,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23540183&form=6&db=m Efficacy of lower cut off value of serum prostate specific antigen in diagnosis of prostate cancer. diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23544270&form=6&db=m DPP4 genetic variants influence baseline prostate-specific antigen levels: the J-MICC study. diagnostic usage,ongoing research,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23576029&form=6&db=m Perceptions of Prostate Cancer Fatalism and Screening Behavior Between United States-Born and Caribbean-Born Black Males. diagnostic usage,ongoing research,unassigned 2,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23596126&form=6&db=m Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23608675&form=6&db=m Socioeconomic variation and prostate specific antigen testing in the community: a United kingdom based population study. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23613288&form=6&db=m An evaluation of usefulness of prostate specific antigen and digital rectal examination in the diagnosis of prostate cancer in an unscreened population:experience in a nigerian teaching hospital. diagnostic usage,ongoing research,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23619589&form=6&db=m Prostate specific antigen testing: age-related interpretation in early prostate cancer detection. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23620432&form=6&db=m Quantified KLK15 gene expression levels discriminate prostate cancer from benign tumors and constitute a novel independent predictor of disease progression. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23633630&form=6&db=m [Socioeconomic advantages of longer screening intervals for men with low prostate-specific antigen levels in prostate cancer mass screening]. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23636138&form=6&db=m Mitochondria, prostate cancer, and biopsy sampling error. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23676536&form=6&db=m A performance analysis of the presence of malignant circulating prostate cells as a predictive factor for the detection of prostate cancer in the first, second and third prostate biopsy. diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23679906&form=6&db=m Differences in prostate cancer detection rates according to the level of glomerular filtration rate in patients with prostate specific antigen levels of 4.0-10.0 ng/ml. causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23716281&form=6&db=m The "PROCAINA (PROstate CAncer INdication Attitudes) Project" (Part II) - A survey among Italian radiation oncologists on radical radiotherapy in prostate cancer. diagnostic usage,therapeutic application,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23723577&form=6&db=m Predictive value of serum prostate specific antigen in detecting bone metastasis in prostate cancer patients using bone scintigraphy. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23789290&form=6&db=m Optimal use of prostate specific antigen for prostate cancer screening. diagnostic usage,therapeutic application,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23826311&form=6&db=m Seminal plasma as a source of prostate cancer peptide biomarker candidates for detection of indolent and advanced disease. causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23831327&form=6&db=m DNA vaccine coding for the rhesus prostate specific antigen delivered by intradermal electroporation in patients with relapsed prostate cancer. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23874588&form=6&db=m Short-term soy isoflavone intervention in patients with localized prostate cancer: a randomized, double-blind, placebo-controlled trial. diagnostic usage,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23884959&form=6&db=m Hypoxia enhances the expression of prostate-specific antigen by modifying the quantity and catalytic activity of Jumonji C domain-containing histone demethylases. ongoing research,unassigned 2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23918570&form=6&db=m Role of prostate volume in the early detection of prostate cancer in a cohort with slowly increasing prostate specific antigen. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23992417&form=6&db=m Proteomics of human prostate cancer biospecimens: the global, systems-wide perspective for Protein markers with potential clinical utility. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23998499&form=6&db=m Re: Strategy for Detection of Prostate Cancer Based on Relation Between Prostate Specific Antigen at Age 40-55 and Long Term Risk of Metastasis: Case-control Study. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24026658&form=6&db=m Time to prostate specific antigen (PSA) nadir may predict rapid relapse in men with metastatic castration-resistant prostate cancer (CRPC) receiving docetaxel chemotherapy. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24032176&form=6&db=m Carbon-11-acetate positron emission tomography (PET), versus fluorine- 18 fluorodeoxyglucose PET and CT for the diagnosis of recurrent prostate cancer after radical prostatectomy in cases of prostate specific antigen of more than 1 to 3ng/mL. causal interaction,diagnostic usage,therapeutic application,unassigned 2,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24038200&form=6&db=m The utility of PSA velocity in prediction of prostate cancer and high grade cancer after an initially negative prostate biopsy. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24054394&form=6&db=m Editor's Comment. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,3,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24072433&form=6&db=m The number of tPSA tests continues to rise and variation in testing practices persists: a survey of laboratory services in Ireland 2008-2010. causal interaction,diagnostic usage,therapeutic application,unassigned 2,2,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24078345&form=6&db=m Exploring Prostate Cancer Literacy and Family Cancer Awareness in College Students: Getting Ahead of the Curve in Cancer Education. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24123045&form=6&db=m Biopsy and radical prostatectomy pathological patterns influence Prostate cancer gene 3 (PCA3) score. diagnostic usage,ongoing research,therapeutic application,unassigned 4,1,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24174942&form=6&db=m Effect of ejaculation on serum prostate specific antigen level in screening and non-screening population. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24175761&form=6&db=m Correlation between low Gleason score and prostate specific antigen levels with incidence of bone metastases in prostate cancer patients: when to omit bone scans? diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24180518&form=6&db=m Metabolic Atrophy and 3T 1H - MR Spectroscopy Correlation After Radiation Therapy for Prostate Cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24213318&form=6&db=m Immune response to sipuleucel-T in prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,2,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24246211&form=6&db=m Adding Cyclooxygenase-2 inhibitor to alpha blocker for patients with benign prostate hyperplasia and elevated serum prostate specific antigen could not improve prostate biopsy detection rate but improve lower urinary tract symptoms. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24255735&form=6&db=m Prevalence and characteristics of prostate cancer among participants of a community-based screening in Nigeria using serum prostate specific antigen and digital rectal examination. diagnostic usage,ongoing research,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24270797&form=6&db=m Genetic variation in KLK2 and KLK3 is associated with concentrations of hK2 and PSA in serum and seminal plasma in young men. causal interaction,diagnostic usage,unassigned 3,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24281110&form=6&db=m Markers for detection of prostate cancer. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24333515&form=6&db=m Improving Detection of Clinically Significant Prostate Cancer: Magnetic Resonance Imaging/Transrectal Ultrasound Fusion Guided Prostate Biopsy. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24336421&form=6&db=m Fluorescent immunosensor based on CuS nanoparticles for sensitive detection of cancer biomarker. diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24344022&form=6&db=m Neoadjuvant hormonal therapy in prostate cancer - impact of PSA level before radiotherapy. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,2,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24345439&form=6&db=m Prostate Cancer Risk Alleles Are Associated with Prostate Cancer Volume and Prostate Size. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24381428&form=6&db=m Changes in Serum PSA During Normal Menstrual Cycle. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24392440&form=6&db=m Can microfocal prostate cancer be regarded as low-risk prostate cancer? causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24426697&form=6&db=m Unresolving / progressive skin lesions in cancer patients: be aware of carcinoma cutis. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24453387&form=6&db=m Modeling Disease Progression with Longitudinal Markers. diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24455582&form=6&db=m Prostate specific antigen change after administration of nimotuzumab in prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,3,3 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24472071&form=6&db=m The fluctuation of PCA3 score in men undergoing first or repeat prostate biopsies. diagnostic usage,ongoing research,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24531776&form=6&db=m Screening for Prostate Cancer: Current Status of ERSPC and Screening-Related Issues. diagnostic usage,therapeutic application,unassigned 2,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24531778&form=6&db=m ERSPC, PLCO Studies and Critique of Cochrane Review 2013. diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24531789&form=6&db=m Management of Low Risk and Low PSA Prostate Cancer: Long Term Results from the Prostate Cancer Intervention Versus Observation Trial. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24579688&form=6&db=m Positive correlation of serum parathormone and prostate specific antigen levels in prostate cancer. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24603597&form=6&db=m A novel three serum phospholipid panel differentiates normal individuals from those with prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 2,2,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24616581&form=6&db=m Nomogram for Prediction of Prostate Cancer with Serum Prostate Specific Antigen Less than 10 ng/mL. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24646125&form=6&db=m Prostate Cancer and Its Mimics at Multiparametric Prostate MRI. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24661660&form=6&db=m The impact of definitive local therapy for lymph node-positive prostate cancer: a population-based study. diagnostic usage,therapeutic application,unassigned 2,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24682399&form=6&db=m Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,3,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24701353&form=6&db=m Natural history of untreated prostate specific antigen radiorecurrent prostate cancer in men with favorable prognostic indicators. diagnostic usage,ongoing research,therapeutic application,unassigned 4,1,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24727321&form=6&db=m Aggressive Variants of Castration Resistant Prostate Cancer. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24747751&form=6&db=m Pharmacologic profiles of investigational kisspeptin/metastin analogues, TAK-448 and TAK-683, in adult male rats in comparison to the GnRH analogue leuprolide. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,3,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24785255&form=6&db=m Targeted BikDD expression kills androgen-dependent and castration-resistant prostate cancer cells. diagnostic usage,ongoing research,therapeutic application,unassigned 2,3,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24793632&form=6&db=m [Abiraterone acetate (AA): current guidelines of prescription of abiraterone]. causal interaction,ongoing research,therapeutic application,unassigned 3,3,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24809052&form=6&db=m Kallikreins as biomarkers for prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24814705&form=6&db=m Measurement of aberrant glycosylation of prostate specific antigen can improve specificity in early detection of prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24815452&form=6&db=m Utility of digital rectal examination, serum prostate specific antigen, and transrectal ultrasound in the detection of prostate cancer: a developing country perspective. diagnostic usage,ongoing research,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24820830&form=6&db=m Contribution of allelic variability in prostate specific antigen (PSA) & androgen receptor (AR) genes to serum PSA levels in men with prostate cancer. causal interaction,diagnostic usage,ongoing research,unassigned 3,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24853012&form=6&db=m The Chance of Small Interfering RNAs as Eligible Candidates for a Personalized Treatment of Prostate Cancer. causal interaction,diagnostic usage,ongoing research,unassigned 2,3,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24870726&form=6&db=m Economic evaluation of prostate cancer screening test as a National Cancer Screening Program in South Korea. unassigned - 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24881167&form=6&db=m Optimising the management of early prostate cancer. causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24917739&form=6&db=m Prostate specific antigen: the past, present and future. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,3,4 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24918412&form=6&db=m Tendencies of mortality by prostate cancer in the states of the Central-West Region of Brazil, 1980-2011. unassigned - 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24932281&form=6&db=m Diagnostic role of fluorodeoxyglucose positron emission tomography-computed tomography in prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,3,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24938184&form=6&db=m Prostate specific antigen testing is associated with men's psychological and physical health and their healthcare utilisation in a nationally representative sample: a cross-sectional study. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24973540&form=6&db=m Rapid aptasensor capable of simply diagnosing prostate cancer. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24981574&form=6&db=m Cisplatin modulates B-cell translocation gene 2 to attenuate cell proliferation of prostate carcinoma cells in both p53-dependent and p53-independent pathways. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,4,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24998102&form=6&db=m The complexity of PSA interpretation in clinical practice. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25016713&form=6&db=m Serum lactate dehydrogenase in combination with free-to-total serum prostate specific antigen ratio for diagnosis of prostate cancer. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25065587&form=6&db=m Targeting thapsigargin towards tumors. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25066872&form=6&db=m Impact of family history on prostate cancer mortality in white men undergoing prostate specific antigen based screening. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,2,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25091355&form=6&db=m Hypogonadal obese men with and without diabetes mellitus type 2 lose weight and show improvement in cardiovascular risk factors when treated with testosterone: an observational study. diagnostic usage,therapeutic application,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25117476&form=6&db=m Identification of threshold prostate specific antigen levels to optimize the detection of clinically significant prostate cancer by magnetic resonance imaging/ultrasound fusion guided biopsy. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25137886&form=6&db=m Paget's disease of bone in ethnic Thai presented with urologic symptoms and misleading as metastatic prostate cancer: report of a case with a review of the literature. diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25150640&form=6&db=m Salvage lymph node dissection for prostate cancer nodal recurrence detected by 11C-choline positron emission tomography/computerized tomography. causal interaction,diagnostic usage,therapeutic application,unassigned 2,2,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25150936&form=6&db=m 3D label-free prostate specific antigen (PSA) immunosensor based on graphene-gold composites. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25153383&form=6&db=m Kallikreins are involved in an miRNA network that contributes to prostate cancer progression. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,1,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25158234&form=6&db=m Pomegranate and its components as alternative treatment for prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 2,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25164550&form=6&db=m The impact of PSA and digital rectal examination on the risk of prostate cancer specific mortality in men with a PSA level <2.5 ng/ml. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25199875&form=6&db=m Circulating tumor cells in prostate cancer: a better predictor of survival than prostate specific antigen? causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,3,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25205025&form=6&db=m Image-guided focal therapy for prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25218922&form=6&db=m Poor glycemic control is associated with reduced prostate specific antigen concentrations in men with type 1 diabetes. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25221428&form=6&db=m Knowledge, attitudes and practices of Ugandan men regarding prostate cancer. diagnostic usage,unassigned 2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25232413&form=6&db=m The role of empiric antibiotic treatment in preventing unnecessary prostate biopsies in asymptomatic patients with PSA levels between 4 and 10 ng/ml. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25242417&form=6&db=m Relationships between times to testosterone and prostate-specific antigen rises during the first off-treatment interval of intermittent androgen deprivation are prognostic for castration resistance in men with nonmetastatic prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,2,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25250323&form=6&db=m Multiparametric MRI in the PSA screening era. causal interaction,diagnostic usage,unassigned 2,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25254935&form=6&db=m Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case-control study. diagnostic usage,unassigned 3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25264336&form=6&db=m Quality of life improvement in patients treated with degarelix versus leuprorelin for advanced prostate cancer. causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25293802&form=6&db=m [Giant subcutaneous hematoma with hemorrhagic shock induced by goserelin acetate injection for prostate cancer : report of a case]. diagnostic usage,therapeutic application,unassigned 2,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25327667&form=6&db=m Glycoproteomics: identifying the glycosylation of prostate specific antigen at normal and high isoelectric points by LC-MS/MS. causal interaction,diagnostic usage,therapeutic application,unassigned 2,4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25328681&form=6&db=m Elucidating immunologic mechanisms of PROSTVAC cancer immunotherapy. ongoing research,therapeutic application,unassigned 1,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25337254&form=6&db=m Ratio of prostate specific antigen to the outer gland volume of prostrate as a predictor for prostate cancer. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25362477&form=6&db=m Detection of cancer biomarkers in serum using a hybrid mechanical and optoplasmonic nanosensor. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25366976&form=6&db=m A novel aptamer-functionalized MoS2 nanosheet fluorescent biosensor for sensitive detection of prostate specific antigen. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25399914&form=6&db=m Economic evaluation of diagnostic localization following biochemical prostate cancer recurrence. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25427836&form=6&db=m Quantitative analysis of prostate specific antigen isoforms using immunoprecipitation and stable isotope labeling mass spectrometry. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25444984&form=6&db=m 5?-Reductase Inhibition Coupled with Short Off Cycles Increases Survival in the LNCaP Xenograft Prostate Tumor Model on Intermittent Androgen Deprivation Therapy. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25458043&form=6&db=m The cutoff level of free/total prostate specific antigen (f/t PSA) ratios in the diagnosis of prostate cancer: a validation study on a Turkish patient population in different age categories. diagnostic usage,ongoing research,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25467965&form=6&db=m Prostate specific antigen kinetics following robotic stereotactic body radiotherapy for localized prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 2,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25476113&form=6&db=m Re: Relative Value of Race, Family History and Prostate Specific Antigen as Indications for Early Initiation of Prostate Cancer Screening: E. A. Vertosick, B. Y. Poon and A. J. Vickers J Urol 2014;192:724-729. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25483747&form=6&db=m CCL2 Chemokine as a Potential Biomarker for Prostate Cancer: A Pilot Study. diagnostic usage,unassigned 2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25518358&form=6&db=m [Screening for prostate cancer: present status and future perspectives]. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25520115&form=6&db=m Significant association of metabolic indices, lipid profile, and androgen levels with prostate cancer. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25528940&form=6&db=m Prostate cancer in patients from rural and suburban areas--PSA value, Gleason score and presence of metastases in bone scan. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25551447&form=6&db=m Meta-analysis of prostate cancer gene expression data identifies a novel discriminatory signature enriched for glycosylating enzymes. causal interaction,diagnostic usage,ongoing research,unassigned 2,1,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25569713&form=6&db=m Technological aspects of delivering cryotherapy for prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 3,2,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25646042&form=6&db=m Serum Testosterone, 17?-Estradiol and PSA Levels in Subjects with Prostate Disorders. diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25653573&form=6&db=m Proteomics analysis of urine reveals acute phase response proteins as candidate diagnostic biomarkers for prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25655628&form=6&db=m Intratherapeutic biokinetic measurements, dosimetry parameter estimates, and monitoring of treatment efficacy using cerenkov luminescence imaging in preclinical radionuclide therapy. diagnostic usage,ongoing research,therapeutic application,unassigned 3,3,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25682698&form=6&db=m p,p'-Dichlorodiphenyltrichloroethane (p,p'-DDT) and p,p'-dichlorodiphenyldichloroethylene (p,p'-DDE) repress prostate specific antigen levels in human prostate cancer cell lines. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,3,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25734645&form=6&db=m The Utility and Limitations of Contrast-Enhanced Ultrasound for the Diagnosis and Treatment of Prostate Cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25761834&form=6&db=m Combined tests of prostate specific antigen and testosterone will improve diagnosis and monitoring the progression of prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25773442&form=6&db=m Epidemiological evidences on overdiagnosis of prostate and kidney cancers in Korean. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25818705&form=6&db=m The percentage of prostate-specific antigen (PSA) isoform [-2]proPSA and the Prostate Health Index improve the diagnostic accuracy for clinically relevant prostate cancer at initial and repeat biopsy compared with total PSA and percentage free PSA in men aged ?65 years. diagnostic usage,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25821749&form=6&db=m Transition zone prostate specific antigen density improves prostate cancer detection in Iranian men. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,2,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25835063&form=6&db=m A narrowing range of bone scan in newly diagnosed prostate cancer patients: A retrospective comparative study. diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25849602&form=6&db=m Gleason 6 Prostate Cancer: Translating Biology into Population Health. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25862824&form=6&db=m Efficacy and safety of docetaxel and prednisolone for castration-resistant prostate cancer: a multi-institutional retrospective study in Japan. diagnostic usage,unassigned 2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25867450&form=6&db=m Mass-tag enhanced immuno-laser desorption/ionization mass spectrometry for sensitive detection of intact protein antigens. diagnostic usage,ongoing research,therapeutic application,unassigned 3,3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25883418&form=6&db=m Reconnoitring the status of prostate specific antigen and its role in women. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25889751&form=6&db=m Phage display aided improvement of a unique prostate-specific antigen (PSA) antibody unreactive with Lys(145)-Lys(146) internally cleaved forms. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25894226&form=6&db=m VEGFR-1 overexpression identifies a small subgroup of aggressive prostate cancers in patients treated by prostatectomy. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25926946&form=6&db=m Production and Characterization of Monoclonal Antibodies against Human Prostate Specific Antigen. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25948796&form=6&db=m [Non- PSA serum markers for the diagnosis of PCa]. diagnostic usage,therapeutic application,unassigned 4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25948798&form=6&db=m [Role of tissue markers on diagnosis, prognosis and monitoring of prostate cancer]. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25969144&form=6&db=m miR-145 suppress the androgen receptor in prostate cancer cells and correlates to prostate cancer prognosis. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25979635&form=6&db=m Experiences of Uncertainty in Men With an Elevated PSA. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,1,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25983194&form=6&db=m Patterns of Local Failure following Radiation Therapy for Prostate Cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25988518&form=6&db=m Baseline Perineural Invasion is Associated with Shorter Time to Progression in Men with Prostate Cancer Undergoing Active Surveillance: Results from the REDEEM Study. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,1,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26017879&form=6&db=m Augmented immunoexpression of survivin correlates with parameters of aggressiveness in prostate cancer. diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26022737&form=6&db=m Characterization of the Glycosylation Site of Human PSA Prompted by Missense Mutation using LC-MS/MS. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26025500&form=6&db=m Testosterone Therapy after Radiation Therapy for Low, Intermediate and High Risk Prostate Cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26044924&form=6&db=m Cancer surveillance using registry data: Results and recommendations for the Lithuanian national prostate cancer early detection programme. causal interaction,diagnostic usage,unassigned 2,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26087383&form=6&db=m The Effect of the USPSTF Grade D Recommendation against Screening for Prostate Cancer on Incident Prostate Cancer Diagnoses in the United States. diagnostic usage,unassigned 2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26100327&form=6&db=m Magnetic Resonance Imaging-Ultrasound Fusion Targeted Prostate Biopsy in a Consecutive Cohort of Men with No Previous Biopsy: Reduction of Over Detection through Improved Risk Stratification. diagnostic usage,ongoing research,unassigned 1,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26116115&form=6&db=m Preclinical imaging of kallikrein-related peptidase 2 (hK2) in prostate cancer with a (111)In-radiolabelled monoclonal antibody, 11B6. diagnostic usage,ongoing research,therapeutic application,unassigned 2,2,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26131282&form=6&db=m Transrectal real-time elastography-guided transperineal prostate biopsy as an improved tool for prostate cancer diagnosis. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26157519&form=6&db=m Prostate-Specific Antigen (PSA) and Prostate Volume: Better Predictor of Prostate Cancer for Bosnian and Herzegovina Men. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26162485&form=6&db=m Prostate health index and prostate cancer gene 3 score but not percent-free Prostate Specific Antigen have a predictive role in differentiating histological prostatitis from PCa and other nonneoplastic lesions (BPH and HG-PIN) at repeat biopsy. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26164541&form=6&db=m Prostate-specific antigen velocity is not better than total prostate-specific antigen in predicting prostate biopsy diagnosis. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26165588&form=6&db=m Baseline Prostate Atrophy is Associated with Reduced Risk of Prostate Cancer in Men Undergoing Repeat Prostate Biopsy. diagnostic usage,ongoing research,therapeutic application,unassigned 2,2,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26187217&form=6&db=m Incidental possible diagnosis by 18F-fluorocholine PET/CT of Meckel's diverticulum and potential pitfalls. causal interaction,diagnostic usage,therapeutic application,unassigned 1,1,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26192253&form=6&db=m The Risk of Distant Metastases and Cancer Specific Survival in Men with Serum Prostate Specific Antigen Values above 100 ng/ml. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,3,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26225663&form=6&db=m Diagnostic Role of Serum Free-to-Total Prostate Specific Antigen (PSA) Ratio in Prostate Cancer with Serum Total Concentration of PSA below 4 ng/mL. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26234360&form=6&db=m Design, synthesis and biological evaluation of thiohydantoin derivatives as novel anti-prostate cancer agents. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,2,4,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26239148&form=6&db=m Transrectal ultrasound-guided prostate biopsy in Taiwan: A nationwide database study. diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26239337&form=6&db=m No Detrimental Effect of a Positive Family History on Long-Term Outcomes Following Radical Prostatectomy. causal interaction,diagnostic usage,therapeutic application,unassigned 2,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26254378&form=6&db=m PHI in the Early Detection of Prostate Cancer. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26254722&form=6&db=m Prostate Needle Biopsy Outcomes in the Era of the U.S. Preventive Services Task Force Recommendation against Prostate Specific Antigen Based Screening. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26269155&form=6&db=m [Epidemiology of prostate cancer in China: an overview and clinical implication]. diagnostic usage,unassigned 3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26269156&form=6&db=m [The focus and prospect of prostate cancer research]. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26307160&form=6&db=m Do Ultrasensitive Prostate Specific Antigen Measurements Have a Role in Predicting Long-Term Biochemical Recurrence-Free Survival in Men after Radical Prostatectomy? causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,4,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26325671&form=6&db=m Validation of International Society of Urological Pathology (ISUP) grading for prostatic adenocarcinoma in thin core biopsies using TROG 03.04 'RADAR' trial clinical data. diagnostic usage,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26328140&form=6&db=m The impact of educational sessions provided on prostate cancer, and its screening tests on the knowledge level, and participation behavior of the individuals in questionnaire surveys. diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26341575&form=6&db=m African-American Men with Gleason Score 3+3=6 Prostate Cancer Produce Less Prostate Specific Antigen than Caucasian Men: A Potential Impact on Active Surveillance. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26371515&form=6&db=m Splicing Factor Prp8 Interacts With NES(AR) and Regulates Androgen Receptor in Prostate Cancer Cells. diagnostic usage,ongoing research,therapeutic application,unassigned 4,1,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26388370&form=6&db=m Real-time prostate-specific antigen detection with prostate-specific antigen imprinted capacitive biosensors. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26406460&form=6&db=m 3D-printed supercapacitor-powered electrochemiluminescent protein immunoarray. diagnostic usage,ongoing research,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26429715&form=6&db=m Thapsigargin, Origin, Chemistry, Structure-Activity Relationships and Prodrug Development. diagnostic usage,therapeutic application,unassigned 4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26506115&form=6&db=m Clinical impact of prostate specific antigen (PSA) inter-assay variability on management of prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,3,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26513282&form=6&db=m Detection of prostate specific antigen based on electrocatalytic platinum nanoparticles conjugated to a recombinant scFv antibody. diagnostic usage,ongoing research,therapeutic application,unassigned 4,1,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26514494&form=6&db=m Human Kallikrein-2, Prostate Specific Antigen and Free- Prostate Specific Antigen in Combination to Discriminate Prostate Cancer from Benign Diseases in Syrian Patients. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26519653&form=6&db=m Comorbid Disease Burden is Independently Associated with Higher Risk Disease at Prostatectomy in Patients Eligible for Active Surveillance. causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26528342&form=6&db=m A pilot study of the association of manganese superoxide dismutase and glutathione peroxidase 1 single gene polymorphisms with prostate cancer and serum prostate specific antigen levels. diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26530362&form=6&db=m Prostate Specific Antigen as a Tumor Marker in Prostate Cancer: Biochemical and Clinical Aspects. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,3 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26545398&form=6&db=m Integration of Metabolomics and Transcriptomics Reveals Major Metabolic Pathways and Potential Biomarker Involved in Prostate Cancer. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26558056&form=6&db=m The value of percentage free prostate specific antigen (PSA) in the detection of prostate cancer among patients with intermediate levels of total PSA (4.0-10.0 ng/mL) in Nigeria. diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26582203&form=6&db=m A Single Glycan at the 99-Loop of Human Kallikrein-related Peptidase 2 Regulates Activation and Enzymatic Activity. diagnostic usage,unassigned 1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26592690&form=6&db=m Prostate cancer screening practices and diagnoses in patients age 50 and older, Southeastern Michigan, pre/post 2012. causal interaction,diagnostic usage,therapeutic application,unassigned 1,2,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26594035&form=6&db=m Mode of prostate cancer detection is associated with the psychological wellbeing of survivors: results from the PiCTure study. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26598427&form=6&db=m Determinants of Prostate Specific Antigen Screening among Black Men in the United States in the Contemporary Era. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26608903&form=6&db=m Pathological Outcome following Radical Prostatectomy in Men with Prostate Specific Antigen Greater than 10 ng/ml and Histologically Favorable Risk Prostate Cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,3,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26626216&form=6&db=m Validation of a Genomic Classifier for Predicting Post-Prostatectomy Recurrence in a Community Based Health Care Setting. diagnostic usage,ongoing research,therapeutic application,unassigned 4,1,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26652466&form=6&db=m Testing the variability of PSA expression by different human prostate cancer cell lines by means of a new potentiometric device employing molecularly antibody assembled on graphene surface. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26656266&form=6&db=m Trade-Off between Treatment of Early Prostate Cancer and Incidence of Advanced Prostate Cancer in the Prostate Screening Era. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26665686&form=6&db=m [Related biomarkers in the diagnosis of prostate cancer]. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26666105&form=6&db=m LOW RISK PROSTATE CANCER: ACTIVE TREATMENT OR ACTIVE SURVEILLANCE? causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26678954&form=6&db=m The Effect of Start and Stop Age at Screening on the Risk of Being Diagnosed with Prostate Cancer. diagnostic usage,therapeutic application,unassigned 2,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26726317&form=6&db=m Positron Emission Tomography in Prostate Cancer: Summary of Systematic Reviews and Meta-Analysis. causal interaction,diagnostic usage,unassigned 3,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26746834&form=6&db=m A large, benign prostatic cyst presented with an extremely high serum prostate-specific antigen level. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26779889&form=6&db=m Endogenous and exogenous testosterone and the risk of prostate cancer and increased prostate specific antigen (PSA): a meta-analysis. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,3,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26784243&form=6&db=m Cancer-Cells on Chip for Label-Free Detection of Secreted Molecules. diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26784645&form=6&db=m A Parallel Randomized Clinical Trial Examining the Return of Urinary Continence after Robot-Assisted Radical Prostatectomy with or without a Small Intestinal Submucosa Bladder Neck Sling. diagnostic usage,unassigned 3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26785797&form=6&db=m Assessment of a new point-of-care system for detection of prostate specific antigen. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26790837&form=6&db=m Demographic, Social Support, and Community Differences in Predictors of African-American and White Men Receiving Prostate Cancer Screening in the United States. diagnostic usage,ongoing research,unassigned 3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26799945&form=6&db=m Prostate specific antigen patterns in US and European populations: comparison of six diverse cohorts. diagnostic usage,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26813414&form=6&db=m Protein Counting in Single Cancer Cells. causal interaction,diagnostic usage,ongoing research,unassigned 1,3,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26839521&form=6&db=m The 4Kscore® Test Reduces Prostate Biopsy Rates in Community and Academic Urology Practices. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26840176&form=6&db=m Development of glycan specific lectin based immunoassay for detection of prostate specific antigen. diagnostic usage,ongoing research,therapeutic application,unassigned 4,1,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26870272&form=6&db=m Solitary recurrence of castration-resistant prostate cancer with low or undetectable levels of prostate specific antigen salvaged with local ablative radiation therapy: A case report. causal interaction,diagnostic usage,therapeutic application,unassigned 4,1,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26893749&form=6&db=m (99m)Tc-MDP uptake in SPECT/CT by a bladder hernia simulating inguinal metastasis: A case report. diagnostic usage,unassigned 1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26935594&form=6&db=m Combination of PI-RADS score and PSA density predicts biopsy outcome in biopsy naïve patients. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26945657&form=6&db=m Evaluation of Vitronectin Expression in Prostate Cancer and the Clinical Significance of the Association of Vitronectin Expression with Prostate Specific Antigen in Detecting Prostate Cancer. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26958088&form=6&db=m Immunochemical Assays and Nucleic-Acid Detection Techniques for Clinical Diagnosis of Prostate Cancer. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26960506&form=6&db=m Outcome of radical prostatectomy as primary treatment for high-risk prostate cancer patients. diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26963936&form=6&db=m Predicting Prostate Biopsy Outcomes: A Preliminary Investigation on Screening with Ultrahigh B-Value Diffusion-Weighted Imaging as an Innovative Diagnostic Biomarker. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26966043&form=6&db=m Diagnostic Value of Guided Biopsies: Fusion and Cognitive-registration Magnetic Resonance Imaging Versus Conventional Ultrasound Biopsy of the Prostate. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,1,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26983637&form=6&db=m Radioimmunotherapy of prostate cancer targeting human kallikrein-related peptidase 2. causal interaction,diagnostic usage,ongoing research,unassigned 1,2,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26985061&form=6&db=m 18F-choline PET/MRI: the Additional Value of PET for MRI-guided Transrectal Prostate Biopsies. diagnostic usage,ongoing research,therapeutic application,unassigned 4,1,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26996553&form=6&db=m Visually Estimated MRI Targeted Prostate Biopsy Could Improve the Detection of Significant Prostate Cancer in Patients with a PSA Level <10 ng/mL. diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27013850&form=6&db=m Age-specific Serum Prostate Specific Antigen Ranges Among Apparently Healthy Nigerian Men Without Clinical Evidence of Prostate Cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,3,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27018191&form=6&db=m Impact of capillary conditioning and background electrolyte composition on capillary electrophoresis analysis of prostate specific antigen isoforms. diagnostic usage,ongoing research,therapeutic application,unassigned 4,1,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27036218&form=6&db=m Use of mpMRI in active surveillance for localized prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27050101&form=6&db=m The Role of Personalised Choice in Decision Support: A Randomized Controlled Trial of an Online Decision Aid for Prostate Cancer Screening. diagnostic usage,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27060052&form=6&db=m Decline in Prostate Cancer Screening by Primary Care Physicians: An Analysis of Trends in the Use of Digital Rectal Examination and Prostate Specific Antigen Testing. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27060053&form=6&db=m The Association between Phosphodiesterase Type 5 Inhibitors and Prostate Cancer: Results from the REDUCE Study. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,4 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27062787&form=6&db=m [Diagnosis Values of Back Propagation Neural Network Integrating Age, Transrectal Ultrasound Characteristics and Serum PSA for Prostate Cancer]. diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27072171&form=6&db=m The preoperative serum ratio of total prostate specific antigen (PSA) to free testosterone (FT), PSA/FT index ratio, and prostate cancer. Results in 220 patients undergoing radical prostatectomy. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27140073&form=6&db=m Clinical Use of PCA3 and TMPRSS2:ERG Urinary Biomarkers in African-American Men Undergoing Prostate Biopsy. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27148956&form=6&db=m Using the SAEM algorithm for mechanistic joint models characterizing the relationship between nonlinear PSA kinetics and survival in prostate cancer patients. diagnostic usage,therapeutic application,unassigned 1,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27221926&form=6&db=m Incidentally Detected Adenocarcinoma Prostate in Transurethral Resection of Prostate Specimens: a Hospital Based Study from India. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27264113&form=6&db=m Is it time to abandon the digital rectal examination? Lessons from the PLCO Cancer Screening Trial and peer-reviewed literature. diagnostic usage,therapeutic application,unassigned 2,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27323113&form=6&db=m Serum levels of PSA, ALP, ICTP, and BSP in prostate cancer patients and the significance of ROC curve in the diagnosis of prostate cancer bone metastases. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27337755&form=6&db=m The role of PSA in detection and management of prostate cancer. diagnostic usage,therapeutic application,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27343801&form=6&db=m Do Black NonHispanic Men Produce Less Prostate Specific Antigen in Benign Prostate Tissue or Cancer Compared to White NonHispanic Men with Gleason Score 6 Prostate Cancer? causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,3,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27375789&form=6&db=m Colorimetric TMPRSS2-ERG Gene Fusion Detection in Prostate Cancer Urinary Samples via Recombinase Polymerase Amplification. diagnostic usage,unassigned 1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27406859&form=6&db=m Tomato-based randomized controlled trial in prostate cancer patients: Effect on PSA. diagnostic usage,ongoing research,therapeutic application,unassigned 4,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27416673&form=6&db=m [Updated treatments of castration-resistant prostate cancer]. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27431530&form=6&db=m Prostate-specific antigen testing for prostate cancer: Depleting a limited pool of susceptible individuals? causal interaction,diagnostic usage,therapeutic application,unassigned 2,3,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27452492&form=6&db=m [Efficacy and Prognostic Factors of Estracyt ® in Patients with Castration-Resistant Prostate Cancer (CRPC) : From the Data Analysis of Estracyt ® Special Drug Use Investigation]. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,1,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27452497&form=6&db=m [Management of High-Risk Prostate Cancer and Left Ectopic Ureter Inserting into Seminal Vesicle with Ipsilateral Hypoplastic Kidney of a Young Patient : A Case Report]. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27453983&form=6&db=m Discovery of prostate specific antigen pattern to predict castration resistant prostate cancer of androgen deprivation therapy. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27482127&form=6&db=m Usefulness of Total PSA Value in Prostate Diseases Diagnosis. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27483413&form=6&db=m Prostate cancer incidence and mortality in Portugal: trends, projections and regional differences. causal interaction,diagnostic usage,therapeutic application,unassigned 2,3,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27489290&form=6&db=m Association of AR-V7 and prostate specific antigen RNA levels in blood with efficacy of abiraterone acetate and enzalutamide treatment in men with prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 1,2,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27493956&form=6&db=m Efficacy of Immediate Switching from Bicalutamide to Flutamide as Second-Line Combined Androgen Blockade. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,3,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27509056&form=6&db=m XB130 is overexpressed in prostate cancer and involved in cell growth and invasion. causal interaction,diagnostic usage,unassigned 4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27531267&form=6&db=m [Value of prostate volume, PSAD and F/T in the detection of prostate cancer in males with PSA 4-10 ?g/L]. causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27532102&form=6&db=m The Cuban Institute of Oncology and Radiobiology experience on the beliefs and opinions about digital rectal exam in urological patients. unassigned - 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27547287&form=6&db=m Weight Management to Reduce Prostate Cancer Risk: A Survey of Men's Needs and Interests. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27555663&form=6&db=m ANNALS EXPRESS: Frequency of KLK3 gene deletions in the general population. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27562331&form=6&db=m [Current aspects of prostate cancer screening]. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27597096&form=6&db=m Re: Endogenous and Exogenous Testosterone and the Risk of Prostate Cancer and Increased Prostate Specific Antigen (PSA): A Meta-Analysis. causal interaction,diagnostic usage,therapeutic application,unassigned 2,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27610197&form=6&db=m Outcome of radical prostatectomy in primary circulating prostate cell negative prostate cancer. diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27618028&form=6&db=m Early Prediction of Therapy Response to Abiraterone Acetate Using PSA Subforms in Patients with Castration Resistant Prostate Cancer. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27652058&form=6&db=m Developing a new score system for patients with PSA ranging from 4 to 20 ng/mL to improve the accuracy of PCa detection. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27672001&form=6&db=m Clarifying the PSA grey zone: The management of patients with a borderline PSA. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27683474&form=6&db=m Kallikrein-Related Peptidases in Prostate Cancer: From Molecular Function to Clinical Application. causal interaction,diagnostic usage,therapeutic application,unassigned 2,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27699819&form=6&db=m Prostate Specific Antigen-Growth Curve Model to Predict High-Risk Prostate Cancer. diagnostic usage,ongoing research,therapeutic application,unassigned 4,1,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27703291&form=6&db=m Actual Contribution of Free to Total PSA Ratio in Prostate Diseases Differentiation. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27741512&form=6&db=m Positive associations between galectin-3 and PSA levels in prostate cancer patients: a prospective clinical study-I. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27746282&form=6&db=m Multisite Experience of the Safety, Detection Rate and Diagnostic Performance of Fluciclovine ((18)F) Positron Emission Tomography/Computerized Tomography Imaging in the Staging of Biochemically Recurrent Prostate Cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 1,1,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27747294&form=6&db=m High-Throughput Electrochemical Microfluidic Immunoarray for Multiplexed Detection of Cancer Biomarker Proteins. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27749139&form=6&db=m Proportion and characteristics of men with unknown risk category in the National Prostate Cancer Register of Sweden. diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27768220&form=6&db=m GNRH-agonist or antagonist in the treatment of prostate cancer: a comparision based on oncological results. causal interaction,diagnostic usage,unassigned 2,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27769214&form=6&db=m INNOVATE: A prospective cohort study combining serum and urinary biomarkers with novel diffusion-weighted magnetic resonance imaging for the prediction and characterization of prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27784553&form=6&db=m Testosterone Replacement in Men with Treated and Untreated Prostate Cancer. diagnostic usage,ongoing research,unassigned 1,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27792187&form=6&db=m Prostate Cancer Detection and Prognosis: From Prostate Specific Antigen (PSA) to Exosomal Biomarkers. diagnostic usage,ongoing research,therapeutic application,unassigned 4,2,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27810449&form=6&db=m Detection of High Grade Prostate Cancer among PLCO Participants Using a Prespecified 4-Kallikrein Marker Panel. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27833172&form=6&db=m Cranberry intervention in patients with prostate cancer prior to radical prostatectomy. Clinical, pathological and laboratory findings. diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27834929&form=6&db=m Prostate Specific Antigen (PSA) as Predicting Marker for Clinical Outcome and Evaluation of Early Toxicity Rate after High-Dose Rate Brachytherapy (HDR-BT) in Combination with Additional External Beam Radiation Therapy (EBRT) for High Risk Prostate Cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,2,4 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27841465&form=6&db=m Dielectrophoretic label-free immunoassay for rare-analyte quantification in biological samples. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27893926&form=6&db=m Estimation of the optimal regime in treatment of prostate cancer recurrence from observational data using flexible weighting models. diagnostic usage,therapeutic application,unassigned 2,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27903863&form=6&db=m Internalization of secreted antigen-targeted antibodies by the neonatal Fc receptor for precision imaging of the androgen receptor axis. diagnostic usage,ongoing research,unassigned 2,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27904688&form=6&db=m Molecular mechanism of prostate cancer cell apoptosis induced by busulfan via adjustment of androgen receptor phosphatization. ongoing research,therapeutic application,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27909617&form=6&db=m Diagnostic value of microRNAs in prostate cancer patients with prostate specific antigen (PSA) levels between 2, and 10 ng/mL. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27910903&form=6&db=m Prostate Cancer Patients-Negative Biopsy Controls Discrimination by Untargeted Metabolomics Analysis of Urine by LC-QTOF: Upstream Information on Other Omics. causal interaction,diagnostic usage,unassigned 2,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27918991&form=6&db=m Sample preparation of serum to allow capillary electrophoresis analysis of prostate specific antigen isoforms. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27941343&form=6&db=m Detection of Prostate Cancer Metastasis by Whole Body Magnetic Resonance Imaging Combined with Bone Scintigraphy and PSA Levels. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27943512&form=6&db=m Trajectories of quality of life, life satisfaction, and psychological adjustment after prostate cancer. diagnostic usage,therapeutic application,unassigned 2,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28007467&form=6&db=m Mortality and Androgen Deprivation Therapy as Salvage Treatment for Biochemical Recurrence after Primary Therapy for Clinically Localized Prostate Cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,4 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28008272&form=6&db=m Different levels of serum microRNAs in prostate cancer and benign prostatic hyperplasia: evaluation of potential diagnostic and prognostic role. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28012442&form=6&db=m Lower use of prostate specific antigen testing by cigarette smokers-Another possible explanation for the unfavorable prostate cancer (PCA) specific prognosis in smokers? diagnostic usage,therapeutic application,unassigned 4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28012755&form=6&db=m Comparison of Digital Rectal Examination and Serum Prostate Specific Antigen in the Early Detection of Prostate Cancer: Results of a Multicenter Clinical Trial of 6,630 Men. causal interaction,diagnostic usage,ongoing research,unassigned 2,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28042138&form=6&db=m The efficacy and safety of docetaxel-based chemotherapy combined with dexamethasone 1 mg daily oral administration: JMTO Pca 10-01 phase II trial. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28054089&form=6&db=m Separation and dual detection of prostate cancer cells and protein biomarkers using a microchip device. diagnostic usage,ongoing research,therapeutic application,unassigned 3,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28067370&form=6&db=m Automated 3D-printed unibody immunoarray for chemiluminescence detection of cancer biomarker proteins. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28078896&form=6&db=m [The incidence, mortality and risk factors of prostate cancer]. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28098061&form=6&db=m Prostate cancer immunotherapy, particularly in combination with androgen deprivation or radiation treatment. Customized pharmacogenomic approaches to overcome immunotherapy cancer resistance. therapeutic application,unassigned 2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28104375&form=6&db=m Estimate of Opportunistic Prostate Specific Antigen Testing in the Finnish Randomized Study of Screening for Prostate Cancer. diagnostic usage,ongoing research,therapeutic application,unassigned 4,1,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28121355&form=6&db=m Serum BSP, PSADT, and Spondin-2 levels in prostate cancer and the diagnostic significance of their ROC curves in bone metastasis. diagnostic usage,ongoing research,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28124526&form=6&db=m Predictive value of [-2]propsa (p2psa) and its derivatives for the prostate cancer detection in the 2.0 to 10.0ng/mL PSA range. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28143433&form=6&db=m Developing a nomogram based on multiparametric magnetic resonance imaging for forecasting high-grade prostate cancer to reduce unnecessary biopsies within the prostate-specific antigen gray zone. diagnostic usage,ongoing research,therapeutic application,unassigned 3,1,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28168057&form=6&db=m Biomarkers of Prostatic Cancer: An Attempt to Categorize Patients into Prostatic Carcinoma, Benign Prostatic Hyperplasia, or Prostatitis Based on Serum Prostate Specific Antigen, Prostatic Acid Phosphatase, Calcium, and Phosphorus. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28199985&form=6&db=m FOXM1 promotes the progression of prostate cancer by regulating PSA gene transcription. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28217016&form=6&db=m Prostate-specific Antigen as a Risk Factor for Skeletal Metastasis in Native Ethnic African Men with Prostate Cancer: A Case-control Study. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28259216&form=6&db=m The Relationship of Baseline Prostate Specific Antigen and Risk of Future Prostate Cancer and Its Variance by Race. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28270948&form=6&db=m Neutrophil gelatinase-associated lipocalin as a screening test in prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28272245&form=6&db=m Single-nucleotide polymorphism rs1058205 of KLK3 is associated with the risk of prostate cancer: A case-control study of Han Chinese men in Northeast China. diagnostic usage,ongoing research,unassigned 3,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28338305&form=6&db=m Prostate cancer in renal transplant recipients. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28343840&form=6&db=m Prostate Cancer Screening. diagnostic usage,unassigned 2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28396511&form=6&db=m Database-augmented Mass Spectrometry Analysis of Exosomes Identifies Claudin 3 as a Putative Prostate Cancer Biomarker. diagnostic usage,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28417057&form=6&db=m Evaluation of sHLA-G levels in serum of patients with prostate cancer identify as a potential of tumor marker. diagnostic usage,therapeutic application,unassigned 4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28420168&form=6&db=m Comparative Study of Blood-Based Biomarkers, ?2,3-Sialic Acid PSA and PHI, for High-Risk Prostate Cancer Detection. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28422738&form=6&db=m Peripheral zone volume ratio (PZ-ratio) is relevant with biopsy results and can increase the accuracy of current diagnostic modality. causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28426464&form=6&db=m Comparative effectiveness in urology: a state of the art review utilizing a systematic approach. causal interaction,diagnostic usage,therapeutic application,unassigned 3,2,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28428110&form=6&db=m Does Peak Urine Flow Rate Predict the Development of Incident Lower Urinary Tract Symptoms in Men with Mild to No Current Symptoms? Results from REDUCE. causal interaction,diagnostic usage,therapeutic application,unassigned 3,2,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28441008&form=6&db=m Simultaneous Detection of Dual Prostate Specific Antigens Using Surface-Enhanced Raman Scattering-Based Immunoassay for Accurate Diagnosis of Prostate Cancer. diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28484728&form=6&db=m Pretreatment prostate specific antigen doubling time as prognostic factor in prostate cancer patients. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28495148&form=6&db=m Analysis of urinary PSA glycosylation is not indicative of high-risk prostate cancer. diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28517325&form=6&db=m SU-E-T-227: Re-Evaluation of Dose Distribution and Margins for IMRT Prostate Plans. causal interaction,diagnostic usage,therapeutic application,unassigned 3,2,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28552708&form=6&db=m Recent Changes in Prostate Cancer Screening Practices and Epidemiology. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,3,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28552710&form=6&db=m Clinical Outcomes and Testosterone Levels Following Continuous Androgen Deprivation in Patients with Relapsing or Locally Advanced Prostate Cancer: A Post Hoc Analysis of the ICELAND Study. causal interaction,diagnostic usage,unassigned 1,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28555048&form=6&db=m Sensitivity of HOXB13 as a Diagnostic Immunohistochemical Marker of Prostatic Origin in Prostate Cancer Metastases: Comparison to PSA, Prostein, Androgen Receptor, ERG, NKX3.1, PSAP, and PSMA. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28637799&form=6&db=m (68)Ga-PSMA PET/CT and volumetric morphology of PET-positive lymph nodes stratified by tumor differentiation of prostate cancer. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28669765&form=6&db=m Independent Validation of the American Joint Committee on Cancer 8th Edition Prostate Cancer Staging Classification. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28685078&form=6&db=m (68)Ga-PSMA PET/CT for the detection of bone metastasis in recurrent prostate cancer and a PSA level <2 ng/ml: Two case reports and a literature review. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28694142&form=6&db=m Increased PSA expression on prostate cancer exosomes in in vitro condition and in cancer patients. diagnostic usage,therapeutic application,unassigned 4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28714919&form=6&db=m Overcoming Oncogenic Mediated Tumor Immunity in Prostate Cancer. diagnostic usage,unassigned 3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28716650&form=6&db=m The Use of Prostate Specific Antigen Screening in Purchased versus Direct Care Settings: Data from the TRICARE® Military Database. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28725582&form=6&db=m Co-registration of MRI and ultrasound: accuracy of targeting based on radiology-pathology correlation. diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28730787&form=6&db=m Association of ferritin with prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28736322&form=6&db=m Clinical Outcomes of Chemotherapy Naïve Men with Metastatic Castration Resistant Prostate Cancer and Low Baseline Prostate Specific Antigen Treated with Enzalutamide vs Placebo. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28743526&form=6&db=m Change in Prostate Specific Antigen Concentration in Men with Prostate Specific Antigen Less than 2.5 ng/ml Taking Low Dose Finasteride or Dutasteride for Male Androgenetic Alopecia. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,3,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28801291&form=6&db=m [Value of PI-RADS v2 scores combined with prostate specific antigen in diagnosis of peripheral zone prostate cancer: a logistic regression analysis]. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28811834&form=6&db=m High risk human papilloma viruses (HPVs) are present in benign prostate tissues before development of HPV associated prostate cancer. diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28818527&form=6&db=m Prostate specific antigen testing after radical prostatectomy: can we stop at 20 years? causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28861591&form=6&db=m Multianalyte quantitative competitive PCR on optically encoded microspheres for an eight-gene panel related to prostate cancer. diagnostic usage,ongoing research,unassigned 2,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28869684&form=6&db=m Prevalence and associations of general practitioners' ordering of "non-symptomatic" prostate-specific antigen tests: A cross-sectional analysis. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28878597&form=6&db=m The Advantages of Transurethral Resection of the Prostate in Patients with an Elevated or Rising Prostate Specific Antigen, Mild or Moderate Lower Urinary Tract Symptoms, Bladder Outlet Obstruction and Negative Prostate Cancer Imaging or Prostate Biopsies: A Prospective Analysis in 105 Consecutive Patients. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28878603&form=6&db=m Abdominal Mass After Robotic Assisted Laparoscopic Prostatectomy: Spigelian Type Trocar Hernia. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28957842&form=6&db=m Comparison of 68Ga-PSMA PET/CT and multiparametric MRI for staging of high-risk prostate cancer68Ga-PSMA PET and MRI in prostate cancer. diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28965781&form=6&db=m Trends in Prostate Cancer Incidence Rates and Prevalence of Prostate Specific Antigen Screening by Socioeconomic Status and Regions in the United States, 2004 to 2013. causal interaction,diagnostic usage,unassigned 4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28969413&form=6&db=m The eternal enigma in prostatic biopsy access route. diagnostic usage,ongoing research,unassigned 1,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29032014&form=6&db=m High-intermediate prostate cancer treated with low-dose-rate brachytherapy with or without androgen deprivation therapy. diagnostic usage,unassigned 1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29061540&form=6&db=m Use of Digital Rectal Examination as an Adjunct to Prostate Specific Antigen in the Detection of Clinically Significant Prostate Cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29100363&form=6&db=m Alterations in expressed prostate secretion-urine PSA N-glycosylation discriminate prostate cancer from benign prostate hyperplasia. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29104305&form=6&db=m Full-length antibodies versus single-chain antibody fragments for a selective impedimetric lectin-based glycoprofiling of prostate specific antigen. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29109592&form=6&db=m Nanomaterial-based biosensors for detection of prostate specific antigen. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29137895&form=6&db=m A Four-kallikrein Panel and ?-Microseminoprotein in Predicting High-grade Prostate Cancer on Biopsy: An Independent Replication from the Finnish Section of the European Randomized Study of Screening for Prostate Cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,2,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29138196&form=6&db=m Cross-sectional study evaluating data quality of the National Cancer Registration and Analysis Service (NCRAS) prostate cancer registry data using the Cluster randomised trial of PSA testing for Prostate cancer (CAP). diagnostic usage,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29145267&form=6&db=m Osteoblastic bone metastases from neuroendocrine tumor (NET) of unknown origin detected by 18fluorocholine PET/CT and its comparison with 68gallium-DOTATOC PET/CT: Case report and review of the literature. causal interaction,diagnostic usage,unassigned 1,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29153623&form=6&db=m Abiraterone acetate + prednisolone treatment beyond prostate specific antigen and radiographic progression in metastatic castration-resistant prostate cancer patients. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,2,1,4 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29172142&form=6&db=m Detection of early stage prostate cancer by using a simple carbon nanotube@paper biosensor. diagnostic usage,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29173037&form=6&db=m Can Women Facilitate Men's Prostate Cancer Screening Informed Decision-Making? The M-PACT Trial. causal interaction,diagnostic usage,therapeutic application,unassigned 3,2,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29175542&form=6&db=m Defining a Cohort that May Not Require Repeat Prostate Biopsy Based on PCA3 Score and Magnetic Resonance Imaging: The Dual Negative Effect. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29181269&form=6&db=m Diagnostic test accuracy study of causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,2,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29182649&form=6&db=m Men's perspectives of prostate cancer screening: A systematic review of qualitative studies. diagnostic usage,therapeutic application,unassigned 2,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29190897&form=6&db=m Biomarkers identified for prostate cancer patients through genome-scale screening. diagnostic usage,therapeutic application,unassigned 4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29222595&form=6&db=m 'Prostate Cancer Risk Calculator' mobile applications (Apps): a systematic review and scoring using the validated user version of the Mobile Application Rating Scale (uMARS). diagnostic usage,therapeutic application,unassigned 2,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29223389&form=6&db=m A Multi-Institutional Prospective Trial in the Veterans Affairs Health System Confirms Noninvasive Blood Test Maintains Predictive Value in African American Men. diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29225057&form=6&db=m Comparison of Pathological and Oncologic Outcomes of Favorable Risk Gleason Score 3 + 4 and Low Risk Gleason Score 6 Prostate Cancer: Considerations for Active Surveillance. causal interaction,diagnostic usage,therapeutic application,unassigned 3,2,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29234265&form=6&db=m The Benefit of a Surgical Resection of a Solitary Pulmonary Metastasis of Prostate Cancer after Radical Prostatectomy. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,1,1,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29248716&form=6&db=m Visual electrochemiluminescence ratiometry on bipolar electrode for bioanalysis. diagnostic usage,ongoing research,therapeutic application,unassigned 2,3,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29264144&form=6&db=m Contemporary outcomes in the detection of prostate cancer using transrectal ultrasound-guided 12-core biopsy in Singaporean men with elevated prostate specific antigen and/or abnormal digital rectal examination. diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29264209&form=6&db=m Role of multi-parametric MRI of the prostate for screening and staging: Experience with over 1500 cases. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29288120&form=6&db=m National Comprehensive Cancer Network® Favorable Intermediate Risk Prostate Cancer-Is Active Surveillance Appropriate? causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29337395&form=6&db=m Testosterone Suppression with Luteinizing Hormone-Releasing Hormone (LHRH) Agonists in Patients Receiving Radiotherapy for Prostate Cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,1,2,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29358783&form=6&db=m Prostate cancer incidence and mortality in Navarre (Spain). causal interaction,diagnostic usage,therapeutic application,unassigned 2,4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29360504&form=6&db=m New biomarkers for diagnosis and prognosis of localized prostate cancer. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29366641&form=6&db=m Subcutaneous Fat Distribution Is a Prognostic Biomarker for Men with Castration Resistant Prostate Cancer. diagnostic usage,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29370662&form=6&db=m [Availability of Local Therapy to Castration-Resistant Prostate Cancer for M0 Patients with Initial Prostate Specific Antigen 100 ng/ml or Higher]. diagnostic usage,therapeutic application,unassigned 3,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29408619&form=6&db=m Long-Term Outcome of a Single Intervention Population Based Prostate Cancer Screening Study. diagnostic usage,therapeutic application,unassigned 4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29434658&form=6&db=m Healthy living and cancer: evidence from UK Biobank. causal interaction,diagnostic usage,unassigned 3,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29464091&form=6&db=m Boolean analysis identifies CD38 as a biomarker of aggressive localized prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29484232&form=6&db=m Supraclavicular lymph node as the first presentation and late skin metastasis: an unusual clinical course for prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 2,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29520847&form=6&db=m Detectable end of radiation prostate specific antigen assists in identifying men with unfavorable intermediate-risk prostate cancer at high risk of distant recurrence and cancer-specific mortality. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,1,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29523809&form=6&db=m Factors associated with prostate specific antigen testing in Australians: Analysis of the New South Wales 45 and Up Study. causal interaction,diagnostic usage,therapeutic application,unassigned 2,2,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29524974&form=6&db=m African-American men with prostate cancer have larger tumor volume than Caucasian men despite no difference in serum prostate specific antigen. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29549234&form=6&db=m Age-Related Prostate Specific Antigen Reference Ranges in Healthy Northern Iranian Men. causal interaction,diagnostic usage,unassigned 2,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29552150&form=6&db=m Potential use of chymotrypsin-like proteasomal activity as a biomarker for prostate cancer. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29577356&form=6&db=m Ser-486/491 phosphorylation and inhibition of AMPK? activity is positively associated with Gleason score, metastasis, and castration-resistance in prostate cancer: A retrospective clinical study. diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29580043&form=6&db=m Prostate Specific Antigen, Mean Platelet Volume, and Platelet Distribution Width in Combination to Discriminate Prostate Cancer from Benign Prostate Hyperplasia causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29594032&form=6&db=m Being on active surveillance: the patient perspective. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,1,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29594398&form=6&db=m Impedimetric PSA aptasensor based on the use of a glassy carbon electrode modified with titanium oxide nanoparticles and silk fibroin nanofibers. diagnostic usage,ongoing research,therapeutic application,unassigned 2,2,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29596802&form=6&db=m Re: Trends in Prostate Cancer Incidence Rates and Prevalence of Prostate Specific Antigen Screening by Socioeconomic Status and Regions in the United States, 2004 to 2013: K. A. Houston, J. King, J. Li and A. Jemal J Urol 2018;199:676-682. diagnostic usage,unassigned 1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29602039&form=6&db=m Potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitors based on the benzoisoxazole moiety: application of a bioisosteric scaffold hopping approach to flufenamic acid. causal interaction,diagnostic usage,therapeutic application,unassigned 3,2,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29616296&form=6&db=m PSMA-PET guided hook-wire localization of nodal metastases in prostate cancer: a targeted approach. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29630978&form=6&db=m The IMAAGEN Study: Effect of Abiraterone Acetate and Prednisone on Prostate Specific Antigen and Radiographic Disease Progression in Patients with Nonmetastatic Castration Resistant Prostate Cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,3,4 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29630980&form=6&db=m The Research Implications of Prostate Specific Antigen Registry Errors: Data from the Veterans Health Administration. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29650035&form=6&db=m Image-guided radiotherapy reduces the risk of under-dosing high-risk prostate cancer extra-capsular disease and improves biochemical control. diagnostic usage,therapeutic application,unassigned 4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29657651&form=6&db=m Role of Magnetic Resonance Imaging, Magnetic Resonance Spectroscopy and Transrectal Ultrasound in Evaluation of Prostatic Pathologies with Focus on Prostate Cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29672570&form=6&db=m Detection of glypican-1 (GPC-1) expression in urine cell sediments in prostate cancer. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29689502&form=6&db=m A robust electrochemical immunosensor based on hydroxyl pillar[5]arene@AuNPs@g-C3N4 hybrid nanomaterial for ultrasensitive detection of prostate specific antigen. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29696431&form=6&db=m Magnetic resonance guided focused high frequency ultrasound ablation for focal therapy in prostate cancer - phase 1 trial. diagnostic usage,ongoing research,therapeutic application,unassigned 4,2,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29732203&form=6&db=m Is magnetic resonance imaging helpful in detecting significant prostate cancer in patients with haematospermia, normal prostate specific antigen level and digital rectal examination. A single institution, observational, and retrospective study in a United Kingdom hospital. causal interaction,diagnostic usage,unassigned 3,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29755696&form=6&db=m The use of long non-coding RNAs as prognostic biomarkers and therapeutic targets in prostate cancer. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29758219&form=6&db=m Prostate Specific Antigen Density as a Predictor of Clinically Significant Prostate Cancer When the Prostate Specific Antigen is in the Diagnostic Gray Zone: Defining the Optimum Cutoff Point Stratified by Race and Body Mass Index. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,4,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29758220&form=6&db=m Evaluation of an Aggressive Prostate Biopsy Strategy in Men Younger than 50 Years. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,2 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29807949&form=6&db=m Outcomes of salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29854284&form=6&db=m Development of a reliable assay to measure glypican-1 in plasma and serum reveals circulating glypican-1 as a novel prostate cancer biomarker. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29885274&form=6&db=m Overview of tissue kallikrein and kallikrein-related peptidases in breast cancer. causal interaction,diagnostic usage,ongoing research,unassigned 1,2,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29901677&form=6&db=m Silver nanoparticles deposited on graphene oxide for ultrasensitive surface-enhanced Raman scattering immunoassay of cancer biomarker. causal interaction,diagnostic usage,therapeutic application,unassigned 3,2,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29904592&form=6&db=m Prostate specific antigen (PSA) kinetic as a prognostic factor in metastatic prostate cancer receiving androgen deprivation therapy: systematic review and meta-analysis. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29928903&form=6&db=m Biochemical characterization of human tissue kallikrein 15 and examination of its potential role in cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,4,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29929902&form=6&db=m Prostate sparing cystectomy for bladder cancer: A two-center study. diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29958881&form=6&db=m Expression profile of human tissue kallikrein 15 provides preliminary insights into its roles in the prostate and testis. causal interaction,diagnostic usage,ongoing research,unassigned 1,1,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29991835&form=6&db=m One-year experience with 68Ga-PSMA PET/CT: applications and results in biochemical recurrence of prostate cancer. diagnostic usage,unassigned 3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30038817&form=6&db=m Comparison of serum uric acid levels between prostate cancer patients and a control group. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,1,1 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30042207&form=6&db=m The Proteome of Prostate Cancer Bone Metastasis Reveals Heterogeneity with Prognostic Implications. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30063887&form=6&db=m Biological variation estimates for prostate specific antigen from the European Biological Variation Study; consequences for diagnosis and monitoring of prostate cancer. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30077749&form=6&db=m Fluciclovine, Anti-1-amino-3-[18F]-fluorocyclobutane-1-carboxylic acid: A Novel Radiotracer for Meningioma. causal interaction,diagnostic usage,unassigned 3,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30104809&form=6&db=m Netrin 1 and Alpha-Methyl Acylcoenzim-A Racemase in diagnosis of prostate cancer. diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30178257&form=6&db=m Methylation and MicroRNA Profiling to Understand Racial Disparities of Prostate Cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30179618&form=6&db=m The Impact of Positron Emission Tomography with 18F-Fluciclovine on the Treatment of Biochemical Recurrence of Prostate Cancer: Results from the LOCATE Trial. causal interaction,diagnostic usage,therapeutic application,unassigned 1,2,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30189186&form=6&db=m Which Patients with Negative Magnetic Resonance Imaging Can Safely Avoid Biopsy for Prostate Cancer? causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30196046&form=6&db=m Graphene nanocomposites modified electrochemical aptamer sensor for rapid and highly sensitive detection of prostate specific antigen. causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30197761&form=6&db=m Approaches to the discovery of non-invasive urinary biomarkers of prostate cancer. diagnostic usage,therapeutic application,unassigned 4,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30215331&form=6&db=m Novel diagnostic biomarkers of prostate cancer: an update. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30220139&form=6&db=m [Developing a Chinese PI-RADS v2-based nomogram for predicting clinically significant prostate cancer in patients with a prior negative biopsy]. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30229547&form=6&db=m Novel Biomarkers for Prostate Cancer Detection and Prognosis. diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30237853&form=6&db=m Distinct urinary glycoprotein signatures in prostate cancer patients. causal interaction,diagnostic usage,therapeutic application,unassigned 2,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30240688&form=6&db=m Defining Intermediate Risk Prostate Cancer Suitable for Active Surveillance. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30246213&form=6&db=m Is cryosurgery a feasible local therapy for bone metastatic prostate cancer? diagnostic usage,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30260630&form=6&db=m "Mix-to-Go" Silver Colloidal Strategy for Prostate Cancer Molecular Profiling and Risk Prediction. diagnostic usage,therapeutic application,unassigned 3,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30292801&form=6&db=m Parameter identification of a model for prostate cancer treated by intermittent therapy. diagnostic usage,unassigned 3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30298710&form=6&db=m Prostate specific antigen levels and proportion of biopsy positive cores are independent predictors of upgrading patterns in low risk prostate cancer. diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30324348&form=6&db=m Evaluation of Prostate Needle Biopsies. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,3,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30367880&form=6&db=m A chemiluminescent dual-aptasensor capable of simultaneously quantifying prostate specific antigen and vascular endothelial growth factor. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30369229&form=6&db=m [A Case of Rectum-Infiltrating Prostate Cancer Mimicking Prostate-Infiltrating Rectal Cancer]. diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30374275&form=6&db=m Detecting Novel Urine Biomarkers for the Early Diagnosis of Prostate Cancer: Platelet Derived Growth Factor-BB as a Possible New Target. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30452625&form=6&db=m Circulating microRNAs combined with PSA for accurate and non-invasive prostate cancer detection. diagnostic usage,therapeutic application,unassigned 4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30472220&form=6&db=m A molecularly imprinted electrochemical nanobiosensor for prostate specific antigen determination. diagnostic usage,therapeutic application,unassigned 4,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30510970&form=6&db=m NKX3.1 and PSMA are sensitive diagnostic markers for prostatic carcinoma in bone metastasis after decalcification of specimens. diagnostic usage,ongoing research,therapeutic application,unassigned 4,1,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30522147&form=6&db=m The Effect of Vitamin D Supplementation on Prostate Cancer: A Systematic Review and Meta-Analysis of Clinical Trials. diagnostic usage,ongoing research,therapeutic application,unassigned 3,4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30528698&form=6&db=m Reducing unnecessary biopsies while detecting clinically significant prostate cancer including cribriform growth with the ERSPC Rotterdam risk calculator and 4Kscore. diagnostic usage,ongoing research,therapeutic application,unassigned 3,2,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30546938&form=6&db=m Genetic associations of T cell cancer immune response with tumor aggressiveness in localized prostate cancer patients and disease reclassification in an active surveillance cohort. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30547158&form=6&db=m Energy Dispersive X-Ray Fluorescence Zn/Fe Ratiometric Determination of Zinc Levels in Expressed Prostatic Fluid: A Direct, Non-Invasive and Highly Accurate Screening for Prostate Cancer. diagnostic usage,therapeutic application,unassigned 2,2,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30570843&form=6&db=m Screening for prostate cancer: moving forward in the molecular era. diagnostic usage,unassigned 4,0 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30577404&form=6&db=m Evaluation of Cancer Specific Mortality with Surgery versus Radiation as Primary Therapy for Localized High Grade Prostate Cancer in Men Younger Than 60 Years. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,1,4 3.4.21.35 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30631911&form=6&db=m 11C-choline PET/CT predicts survival in prostate cancer patients with PSA?